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ABSTRACT 
The development and application of a partial composite S. aureus virulence-associated 
gene micro array is described. Epidemic, pandemic and sporadic lineages of healthcare-
associated (HA-) and community-associated (CA-) S. aureus were compared. The clonal 
population structure was supported but further evidence for large-scale recombination 
events was obtained. Phage structural genes linked with the CA phenotype were identified 
and in silico analysis revealed these to be correlated with phage serogroup. CA strains 
generally carried a PVL-associated phage either of the A or Fb serogroup, whilst the HA 
strains predominantly carried serogroup B phage. It is proposed that carriage of PVL-
associated phage rather than the specific pvl genes is correlated with the CA phenotype. 
These findings further support the role of the accessory genome in shaping the 
epidemiology of S. aureus. 
The microarray was used to study gene expression in isogenic strains differing by a 
deletion in the agr locus. Microarray analysis revealed significant differences between the 
levels of expression of several genes of the normal and mutant strains. However, RNAIII 
levels in the non-mutant strain were found to be cell density independent, indicating that 
the expected quorum sensing mechanism was not functional. 
Expression profiles of cells grown under biofilm simulating conditions were compared to 
their planktonic counterparts. Biofilm cells displayed a typical expression profile that was 
different from both the actively growing planktonic exponential cells and the planktonic 
stationary cells. The strongest feature of the biofilm state was high level expression of the 
haemolysin genes. This model therefore is amenable to exploitation in studies designed to 
improve our understanding of the mechanisms underlining biofilm survival and regulation 
after long periods of growth. 
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CHAPTER 1.0 INTRODUCTION 
1.1 THE STAPHYLOCOCCI 
Staphylococci belong to the Order Bacillales, Bacterial family Staphylococcaceae, genus 
Staphylococcus. They are characteristically non-motile, Gram positive, non sporulating 
facultative anaerobes, which generate energy from respiration and fermentation. They are 
also catalase positive. Variations in colony pigmentation are common, ranging from 
opaque to orange (Ho It, 1994). The genus Staphylococcus has been studied extensively 
and contains at least 41 recognised species and 24 subspecies (January 2009 entry at 
http://www.bacterio.cict.fr/s/staphylococcus.html). The genus can also be sub divided into 
two broad groups based on ability to coagulate blood plasma. Coagulase-positive species 
are primarily represented by S. aureus, but also include S. intermedius and S. delphini. 
Coagulase-negative species include S. epidermidis (Kloos, 1990). 
Based on their ability to divide in several planes, S. aureus display a cluster appearance on 
microscopic examination; a property first-described by Sir Alexander Ogston in 1880. 
Ogston observed these organisms in pus from human abscesses. On microscopic 
examination, the appearance of the organisms was described as similar to grapes (Greek 
name staphyle) and berries (kokkos). Shortly after in 1884, staphylococci isolated from a 
wound were grown for the first time in pure culture by Rosenbach (Baird-Parker, 1990). 
Staphylococci form part of the normal flora of the human nasopharynx, other musocal 
surfaces and skin. Infections associated with staphylococci are generally the result of 
breaches in the host's innate immunity, such as damage to mucosal and cutaneous 
membranes (through trauma, surgery or indwelling medical devices) (Lowy, 1998). It is 
for this reason staphylococci are referred to as opportunistic pathogens (Kloos 1980, 
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Massey et al. 2006). S. aureus is the most clinically significant member of this genus 
(Holt, 1994) and has been studied extensively. It can be distinguished from other species 
based on its gold colony pigmentation, positive coagulase reaction, ability to ferment 
mannitol and deoxyribonuclease activity. S. epidermidis (the most common species of 
coagulase-negative staphylococci from clinical disease), is responsible for infections 
associated with medical devices e.g. implanted prosthetics or intravascular devices (von 
Eiff, 2002). Prior to the use of these devices in modem medicine, S. epidermidis was 
rarely considered pathogenic. Conversely, S. aureus is more aggressive in causing 
infection, both acute and chronic in nature. 
1.2 TilE STAPHYLOCOCCUS GENUS 
1.2.1 Staphylococcus aureus 
S. aureus is a highly adapted and extremely successful coloniser of the moist squamous 
epithelium of the anterior nares in humans (30-70% of the population), other mucosal 
surfaces and skin. It is also occasionally found as part of the flora of the digestive and 
vaginal tracts (Smith et al. 1982, Enright 2008). The innate and adaptive components of 
the nasal associated lymphoid tissue (NAL n protect the nares from microbial infection. 
NALT organs (tonsils and adenoids) and mucosal membranes both consist of single-layers 
of epithelial cells which are continually washed in mucus. Mucus contains further 
protective elements including antimicrobial proteins and peptides, proteoglycans, 
specialized immune cells and secretory immunoglobulins (Fokkens and Scheeren 2000, 
Massey et al. 2006). S. aureus is able to maintain its colonist status by producing a 
variety of virulence-associated factors that interact with host cell components. Several of 
the virulence factors described for S. aureus permit immune evasion whilst others are 
toxins enabling the spread of infection (discussed further in section 1.3). These virulence 
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factors facilitate its survival as a commensal in this niche. However, S. aureus is also able 
to infect any tissue of the body via a breach in the skin or mucous membranes. Infections 
which then develop locally can potentially disseminate; diseases range in severity from 
minor skin infections to systemic life threatening conditions. Most individuals (if not all) 
will succumb to infection with S. aureus during their lifetime. The most common of the 
uncomplicated infections include pimples, boils, styes and conjunctivitis. More severe 
infections include endocarditis, osteomyelitis, haemorrhagic pneumonia and other 
metastatic complications. S. aureus has also been noted for causing toxin-mediated 
diseases such as toxic-shock syndrome, food poisoning and scalded skin syndrome 
(Lindsay et al. 2004, Kuroda et al. 2001). However, invasive disease and infection of 
normally sterile body sites are very rare in previously healthy individuals (Enright, 2008). 
1.2.1.1 S. aureus genomics 
S. aureus is unsurpassed among human pathogens in the versatility of its pathogenic 
strategies, number of virulence factors, and ability to survive and multiply in a wide range 
of environments (Oliveira et al., 2002). The impact on human health of S. aureus 
infections in community and hospital settings has led to intensive investigation of this 
organism over recent years (Holden et al., 2004). Incremental changes in the gene 
complement have resulted in the emergence of strains that are antibiotic-resistant, 
transmissible and successful in causing disease (Holden et al., 2004). 
With the advent of molecular biology techniques, a greater understanding of the 
mechanisms governing these aspects has been elucidated. In particular, genome 
sequencing in recent years has advanced our understanding of the biology and genetics of 
this species. To date, 19 staphylococcal genomes (NCBI) have been sequenced (publicly 
available). of which 14 are S. aureus genomes (Table 1.1). The main aim of these projects 
21 
has been to understand the nature of staphylococcal pathogenicity, and why certain 
strains/species are more successful than others. In general, these initiatives have shown the 
genomes of staphylococci share a common core set of genes, in addition to accessory 
genes. In S. aureus, these accessory components are horizontally acquired and are 
composed of genomic islands, transposons, plasmids, insertion sequences and 
bacteriophage-derived segments. Encoded on these components are many virulence 
factors and antibiotic resistance genes thought to contribute to the pathogenic potential of 
this organism. In particular, a prominent concern with respect to S. aureus is the rate at 
which it acquires antibiotic resistance, due to the accumulation of mobile genetic elements 
encoding resistance genes from other species (or within the species). The complexity of 
the regulation of virulence factors (discussed further in section 1.3) provides S. aureus with 
the adaptability to interact with its host in such a diverse manner to colonise, spread and 
cause disease (whether toxin-mediated, pyogenic or invasive). 
22 
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Table 1.1 The fourteen completely sequenc:ed Staphylococcus Qureus strains. 
Strain CC· Source First Comments· isolated 
N315 5 Pharynx, Japan 1982 Hospital-acquired MRSA. 
Mu50 5 Wound,Japan 1997 Hospital-acquired VISA, related to N315. 
Fatal paediatric 
MW2 1 bacteraemia, 1998 Typical USA community-acquired MRSA, PVL-positive. 
North Dakota, USA 
MRSA252 30 Fatal bacteraemia, 1997 Typical UK hospital-acquired epidemic MRSA Oxford, UK (EMRSA-16). 
MSSA476 1 Osteomyelitis, 1998 Community-acquired MSSA. I Oxford, UK ! 
I 
COL 8 Colindale, UK 1961 EarlyMRSA. 
NCTC8325 8 Colindale, UK <1949 Laboratory strain, parent of non-lysogenic 8325-4, 
can be genetically manipulated. 
USA300-FPR3 757 8 USA 2000 Community associated MRSA, PVL-positive. 
USA300- 8 Severe sepsis, USA 2007 Community associated MRSA, PVL-positive. TCH1516 
RF122 151 Ireland 2006 Associated with bovine mastitis 
Mu3 5 Pneumonia, Japan 1996 Hetero-VISA 
ill 1 5 Endocarditis, USA 2000 MRSA 
JH9 5 Endocarditis, USA 2000 In vivo VISA derivative of JHl 
Newman 8 UK <1941 MS SA, clumping factor over-producer 
• Abbreviations: CC, clonal complex; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; PVL, Panton-Valentine leukocidin; 
VISA, vancomycin intermediate-level-resistant S. aureus. (Adapted from Lindsay and Holden., 2004, Holden and Lindsay 2008) 
1.2.1.2 Antimicrobial resistance in S. aureus 
1.2.1.2.1 Molecular basis of antimicrobial resistance 
S. aureus is a leading cause of nosocomial infections and it is also becoming of increasing 
concern in the community. This is due to its transmissibility, intrinsic virulence, ability to 
cause a diverse array of life-threatening infections, and capacity to adapt to different 
environmental conditions (Lowy, 2003). The vast genetic repertoire of this bacterium 
allows it to adapt rapidly to change in hostile environments. This ability is repeatedly 
demonstrated by the emergence of strains that have acquired resistance to virtually all 
antimicrobial agents shortly after their introduction into clinical practice. 
The introduction of large numbers of structurally diverse antimicrobial agents into human 
use over the past 60 years has presented a new set of challenges to bacterial pathogens such 
as S. aureus. Successful lineages of contemporary pathogens have excelled in their ability 
to acquire resistance genes and to construct regulatory mechanisms that can survive 
following exposure to increasing concentrations of the antimicrobial agent. Furthermore, 
these resistant strains have the propensity to spread, establish ecological reservoirs, 
colonise, and cause disease (Oliveira et al., 2002). The ever increasing emergence of 
antimicrobial resistant bacterial species can be attributed to a multitude of factors that 
include the widespread and sometimes inappropriate use of antimicrobials, their extensive 
use as growth enhancers in animal feed, an increase in regional and international travel and 
the relative ease with which these organisms cross geographic barriers (Lowy, 2003). 
In the post-antibiotic era, staphylococci have developed efficient mechanisms to neutralise 
each new antibiotic introduced. Antimicrobial resistance can occur by the mutation of 
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chromosomal loci (e.g. for streptomycin, rifampin, fusidic acid, mupirocin and novobiocin) 
(Wichelhaus et al. 200 I, O'Neil et al. 2006, Vickers et al. 2007). However, the primary 
mechanism driving multiple antimicrobial resistance in staphylococci is through horizontal 
gene transfer of pre-formed resistance detenninants carried on accessory genetic elements 
including plasmids, transposable elements (insertion sequences and transposons) and 
genomic islands (Lyon and Skurray 1987, Jensen and Lyon 2009). Understanding the 
mechanisms by which S. aureus resists antirnicrobials is a pre-requisite to developing more 
robust therapeutics. Such research has highlighted a few key mechanisms used by S. 
aureus (Table 1.2; reproduced from Lowy 2003). A recent review (Jensen and Lyon, 
2009) highlights several examples of antimicrobial resistance determinants in S. aureus 
and the mechanisms of resistance. 
Table 1.2 Mechanisms of S. aUI'eus resistance to antimicrobials. Taken from Lowy, 
2003. 
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1.2.1.2.2 Resistance to fJ-lactam antimicrobials 
1.2.1.2.2.1 Penicillin resistance 
Penicillin, the first ~-lactam antibimicrobial, was introduced in the early 1940s. Prior to its 
introduction, the mortality of patients with S. aureus bacteraemia was greater than 80% 
(Skinner and Keefer, 1941) and over 70% developed metastatic infections. The 
introduction of penicillin heralded a dramatic improvement in prognosis for these patients. 
However, by the late 1960s, greater than 80% of both hospital- and community-associated 
staphylococci were penicillin-resistant (Lowy, 2003). 
The mechanism of staphylococcal resistance to penicillin was later shown to be due to the 
effects of the p-Iactamase enzyme. Staphylococci synthesize p-Iactamase when exposed to 
~-lactam antibiotics (fig. 1.1; reproduced from Lowy 2003). Synthesis of p-Iactamase 
permits inactivation of penicillin (and other p-Iactam antimicrobials e.g. ampicillin and 
amoxicillin) via hydrolysis of the p-Iactam ring. The gene that encodes p-Iactamase, blaZ, 
is part of a transposable element located on a large plasmid, which often carries additional 
antimicrobial resistance genes (e.g. to erythromycin and gentamicin) (Lowy, 2003). 
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Figure 1.1 Induction of staphylococcal p-Iactamase synthesis in the presence of the p-
lactam antibiotic penicillin. The blaZ gene is controlled by two adjacent regulatory genes, 
the anti-repressor blaRl and the repressor blaJ (I) The DNA-binding protein Bla! binds to 
the operator region, thus repressing RNA transcription from both blaZ and blaRl-blaI. In 
the absence of penicillin, p-Iactamase is expressed at low levels. (11) Binding of penicillin 
to the transmembrane sensor-transducer BlaR! stimulates BlaR! autocatalytic activation. 
(Ill- IV) Active BlaR! either directly or indirectly (via a second protein, BlaR2) cleaves 
Bla! into inactive fragments, allowing transcription of both blaZ and blaRl-blaI to 
commence. V- VII. p-Lactarnase, the extracellular enzyme encoded by blaZ (V), 
hydrolyzes the p-Iactam ring of penicillin (VI), thereby rendering it inactive (VII). Taken 
from Lowy, 2003 . 
1.2.1.2.2.2 Methicillin resistance 
Methicillin (or meticillin), a penicillin derivative introduced in 1959, was the fIrst of the 
semi-synthetic penicillinase-resistant penicillins. Originally called celbenine, methicillin 
was the fust mechanism-based antimicrobial agent. As a semi-synthetic derivative of 
penicillin, it was chemically modifIed to withstand the degradative action of penicillinase 
(Oliveira et al. , 2002). The introduction of methicillin and other semi-synthetic penicillins 
(e.g. oxacillin, cloxacillin, flucloxacillin) and penicillinase-resistant methicillin represented 
a significant advancement in anti-staphylococcal therapy; these agents were non 
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susceptible to the activity of ~-lactamases (Rolinson, 1998). However, reports of 
methicillin-resistant S. aureus (MRSA) rapidly followed its introduction. The first report 
of resistance occurred in a British hospital in 1960 (Jevons et al., 1961). Successful MRSA 
clones have since spread rapidly across international borders. 
Resistance to methicillin is mediated by the presence of the chromosomally located mecA 
gene. mecA encodes the penicillin-binding protein 2a (pBP2a, also known as PBP2' and 
mecA) (Ubukata et al., 1989). Like the blaZ gene, mecA is also controlled by two 
regulatory proteins, MecRl and Mecl. In the presence of ~-lactam antibiotics, MecRl 
protein (signal transducer) directly or indirectly cleaves the MecI repressor which is bound 
to the me cA operator. Cleavage of MecI allows transcription of mecA to occur, and thus 
synthesis of PBP2a (Katayama et al., 2001). PBP2a has been shown to have a reduced 
affmity for methicillin, and was proposed to permit cell wall synthesis (normally blocked 
by ~-lactams) in the presence of ~-lactam antibiotics. Synthesis of the peptidoglycan layer 
is a critical function necessary for cell homeostasis and thus growth of MRSA (Hartman 
and Tomasz 1984, Chambers et al. 1985, Lowy 1998, Berger-Bachi and Roher 2002). 
Although mecA confers resistance to most p-Iactam antibiotics, not all mecA-positive 
strains are equally resistant to methicillin. The overall level of resistance in an MRSA 
population depends on the interplay between several chromosomal determinants affecting 
the expression of PBP2a. For this reason, MRSA resistance levels vary from 
phenotypically susceptible (MICs as low as 1 J.1g1ml) to highly resistant (MIC >500J.1g1ml) 
(Berger-Bachi and Rohrer, 2002). The genomic factors controlling resistance levels, 
termed fem/faux factors, include genes involved in peptidoglycan precursor formation, 
composition and turnover, teichoic acid synthesis, and several genes of uncharacterised (or 
poorly characterised) function (de Lencastre et al. 1994, de Lencastre et al. 1999; Berger-
Bachi and Rohrer 2002, Rohrer and Berger-Bachi 2003). Several regulatory loci have also 
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been shown to influence resistance levels. These include regulators of metabolism e.g. 
catabolite control protein A (CcpA) (Seidl et al., 2006), global regulators of virulence 
factors such as the agr and sarA systems and the alternative sigma factor aB (Piriz Duran et 
al. 1996, Wu et al. 1996) and the VraSR loci, responsible for cell wall stress response 
induced upon antibiotic challenge (Kuroda et al., 2003). SA1665, a recently characterised 
DNA binding protein, is amongst the latest implicated in modulating ~-lactam resistance 
(Ender et al., 2009). SA1665, which has a negative impact on methicillin resistance, has 
been proposed to modulate ~-lactam resistance in a mecA-independent manner by 
controlling genomic factors or cellular functions necessary for methicillin resistance 
(Ender et al., 2009). 
Studies on the evolution of methicillin resistance in S. aureus have shown that this 
occurred in a stepwise manner. Pre-MRSA strains carried the me cA gene along with the 
regulatory gene mecI and mecRl, but displayed no resistance. Hetero-MRSA strains 
displayed a mutation in mecI causing release of repression effects of mecI; strains then 
showed low level resistance to minimal concentrations of methicillin but remained 
susceptible to high dosages. Subsequently, homo-MRSA displayed homogeneously high 
resistance to methicillin (Hiramatsu, 2004). 
MRSA have been noted for their accumulation of resistance determinants within the mec 
region (section 1.2.1.3.2), an integration hotspot for plasmids and transposons. thus giving 
rise to multi-drug resistance (lto et al., 1999). It is this ability of S. aureus to rapidly 
acquire resistance to antibiotics that has led to its classification as a major pathogen or 
"superbug" . 
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1.2.1.2.2.3 Vancomycin resistance 
MRSA infections are generally treated with glycopeptides including vancomycIn. 
Vancomycin is frequently administered for empirical therapy in patients displaying signs 
of infection, prior to MRSA diagnosis that can take up to 48 hours. Increased use of 
vancomycin has led to the emergence of two types of glycopeptides-resistant S. aureus; 
vancomycin intermediate-resistant S. aureus (VISA) and vancomycin-resistant S. aureus 
(VRSA). The first VISA (Mu50), isolated in Japan, was described in 1997, and has since 
spread world-wide (Tenover, 1998). Glycopeptides inhibit cell wall synthesis in Gram 
positive bacteria. VISA strains synthesise a thicker cell wall that absorbs the vancomycin 
and allows sufficient cross-linking of newly synthesised cell wall (Pereira et al., 2007). 
VISA strains are generally unfit and slow-growing, arising through spontaneous mutations 
in patients undergoing long-term glycopeptide therapy (Mwangi et al., 2007). In contrast, 
high level resistant strains, VRSA, arise by acquisition of the vanA operon (carried on 
transposon Tn1546 on a conjugative plasmid) from vancomycin-resistant enterococci 
(VRE) (reviewed in Perichon and Courvalin, 2009) To date, 11 VRSA strains have been 
described, the first of which was isolated in the USA in 2002 (Zhu et aI., 2008). Of these 
11 isolates, 9 have been characterised in the USA (7 in Michigan state), and the remainder 
in Iran and India (Zhu et al. 2008, Saha et al. 2008, Aligholi et al. 2008, Perichon and 
Courvalin 2009). 
Interestingly, MRSA and VRE are frequently associated in the hospital environment. 
Several studies have reported co-colonisation and co-infection in of MRSA and VRE in 
patients (Sigurdardottir et al. 2006, Han et al. 2009, Milstone et al. 2008). However, 
Severin and colleagues (2004a) showed that in S. aureus isolates resistant to both 
methicillin and vancomycin, treatment with both antibiotics rendered these strains non-
viable. This is because PBP2a (induced in the presence of methicillin) cannot cross-link 
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muropeptides in the cell wall that have the D-ala-D-Iac group necessary for VRSA to 
prevent the action of vancomycin (Severin et al. 2004b). Nevertheless, although this 
indicates a short-term mechanism by which MRSANRSA infections can be treated, this 
can easily become complicated in the future by spontaneous mutations preventing this 
mechanism of control. S. aureus with reduced susceptibility to quinolones, tetracyclines, 
macrolides and aminoglycosides have also been documented (Hiramatsu et al., 1997). 
1.2.1.3 The Staphylococcal Chromosome Cassette mec (SCCmec) element 
1.2.1.3.1 The SCCmec gene complex 
mecA, a 2.1 kb gene, is embedded into a larger 21-67kb mobile genetic element termed the 
mec element or staphylococcal chromosomal cassette (SCCmec). SCCmec is incorporated 
into the S. aureus chromosome at a site-specific location (attBscc) downstream of the orjX 
gene of unknown function, located near the origin of replication (Hiramatsu et al. 2001, 
Hiramatsu et al. 2002. Holden et al. 2004, Kuroda et al. 2001. Oliveira et al. 2002, Ho et 
al. 1999). It has been characterized as a mobile genetic element, separate from 
bacteriophage and transposons that renders the organism resistant to methicillin (Ho et al. 
1999, Katayama et al. 2000. Hiramatsu 2001. Berger-Bachi and Rohrer 2002). 
The SCCmec gene complex is essentially composed of three primary elements; 
i. a mec element containing mecA, mecR, IS/mecI, IS431 
H. a ccr complex containing recombinase genes ccrA/ccrB or cere 
111. three joining regions (J regions; previously known as junkyard) consisting of 15-
base direct and/or inverted core repeat sequences (Highuchi et al., 2008). 
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Thus SCCrnec can be summarised as: J3-rnec-J2-ccr-JI (Deurenberg and Stobberingh 
2008, De Lencastre et al. 2007) . 
1.2.1.3.2 Classification of SCCmec 
To date, five major classes (A-E) of rnec complex have been characterised and are 
summarised in Table 1.3 (Taken from Deurenberg and Stobberingh ,2008). 
Table 1.3 The major classes of mec complexes. Taken from Deurenberg and 
Stobberingh, 2008. 
Class 
A 
B 
C 
D 
E 
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The ccr gene complex encodes recombinases of the invertase/resolvase class and are 
located on all SCCrnec elements. By mediating the integration of the SCCrnec element 
from the recipient chromosome at the SCCrnec attachment site (attBScc) , these enzymes 
control the mobility of the SCCrnec element (Zhang et al., 2009). Three ccr genes (ccrA, 
ccrB and ccrC) have been documented, of which five allotypes have been described; four 
allotypes for the cerAB genes (1 , 2, 3, 4) and one for the cerC gene. It is the different 
combinations of the rnee and cer complexes that comprise various SCCmec types. Further 
sub-types are classified according to variations in the J region DNA; although these are 
non-essential components of SCCrnec element, additional antimicrobial resistance 
determinants (and genes encoding heavy metal resistance) may be carried in this region 
(Ito et al. , 2003). The drug resistance genes encoded by SCCmec elements are listed in 
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Table 1.4 (Ito et al. 2001, Ito et al.2003, Leclercq 2002, Oliveira et al. 2006, Deurenberg 
and Stobberingh 2008). 
Table 1.4 Non p-Iactamase resistance genes encoded by elements integrated into 
SCCmec 
Element Encoded Confers resistance to gene 
Plasmid pUB110 ant (4 ') Aminoglycosides e.g. kanamycin, tobramycin, 
bleomycin 
Plasmid pT258 Penicillins and heavy metals (e.g. mercury) 
Plasmid pT181 Tetracycline 
Transposon 
ermA Macrolide, lincosamide and streprogramin (MLS) Tn554 resistance 
. 'I'Tn554 Cadmium 
Presently, eight SCCmec subtypes and variants have been described (Zhang et al. 2009, Ito 
et al. 2004, Derensinsk 2005, Shore et al. 2005, Qi et al. 2005, Jansen et al. 2006, 
Milheirico et al. 2007, Heusser et al. 2007, Kondo et al. 2007). In the original 
classification, these subtypes were designated roman numerals to determine type and were 
thus designated I -VIII. Figure 1.2 provides a schematic representation of SCCmec types 1-
VII (taken from Deurenberg and Stobberingh, 2008). SCCmec type IV is the most variable 
type, for which 8 subtypes (IVa-h) have been described, differing predominantly in the J1 
region (Ma et al. 2002, Ito et al. 2003, Kwon et al. 2005, Shore et al. 2005). As the 
smallest of the SCCmec types, its enhanced mobility could be the cause for its variability 
(De Lencastre et al. 2007). Recently, the SCCmec III element initially described as 66.9kb 
in size, has been shown to be a composite of two SCCmec elements, SCCmec III (35.2kb) 
and SCCmercury (31.8) harbouring ccrC, pI1258 and Tn554 (Chongtrakool et al., 2006). 
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Figure 1.2 A schematic drawing of SCCmec types I to VD in MRSA. The major 
elements of the seven main SCCmec types (ccr genes, IS 431, IS 1272, mecA, mecJ IR1, 
orfX, p1258, pT181, pUB101 and Tn554) are presented (taken from Deurenberg and 
Stobberingh, 2008). 
In comparison to the larger types (11 and Ill), the smaller types (I, IV-VII) encode only p-
lactam resistance (Deresinski, 2005). SCCmec types II and III also contain multiple 
determinants integrated into SCCmec for resistance to non-p lactam antibiotics and have 
been found to be responsible for the multi drug resistance commonly found in nosocomial 
MRSAs (Hiramatsu et al. 2001, Oliveira et al. 2002, Zetola et al. 2005). 
Recently, a new nomenclature has been proposed for SCCmec types; defined by the 
combination of mec gene class and ccr allotype (Chongtrakool et al., 2006). Based on this, 
the eight recognised SCCmec types are as follows (proposed names in parentheses): Type I 
(combination of the typel ccr and the class B mec gene complex; IB); type 11 (2A), III 
(3A), IV (2B), V (5C2), VI (4B), VII (5Cl) and the latest, type VIII (4A). Table 1.5 
compares the SCCmec allotypes (taken from Chambers and DeL eo, 2009). 
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Table 1.5 Comparison of staphylococcal chromosome cassette allotypes. Taken from 
Chambers and DeLeo, 2009. 
featu 're* SCCmec allotype 
11 III IV V VI vu VIII 
Size (kb) 34 53 67 21-24 28 24 '11-~9 32 
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1.2.1.3.3 Origins of the SCCmec element 
Analysis of other staphylococcal species has shown that mecA is not native to S. aureus, 
and must therefore have been acquired horizontally, probably from methicillin-resistant 
coagulase-negative staphylococci (MRCNS) (Wielders et a/. 2001, Berger-Bachi and 
Rohrer 2002, Katayama et al. 2003, Wisplinghoff et al. 2003, Hansenn et al. 2004). 
Investigations of methicillin-resistant S. epidermidis (MRSE) and other MRCNS have 
detected the presence of SCCmec types I-V, as well as novel SCCmec elements (Hanssen 
et al. 2004, Hanssen and Sollid 2007, Wisplinghoff et al. 2003, Miragaia et al. 2007). It 
has been suggested that these novel SCCmec elements in MRCNs could act as an SCCmec 
pool for S. aureus (Corkill et al. 2004, Mongkolrattanothai et al. 2004). Zhang and 
colleagues (2009) in their recent classification of SCCmec type VIII, suggest this unique 
element could be the product of homologous recombination between two S. epidermidis 
strains, acquired by horizontal transfer into S. aureus. Other studies suggest mecA 
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descended from a close homologue ubiquitous in both ~-lactam-susceptible and -resistant 
isolates of the animal commensal species S. sciuri (Antignac and Tomasz 2009, Couto et 
al. 1996, Couto et al. 2000, Wu et al. 2001, Oliveira et al. 2002). The pdpD gene, encoding 
PBP4, has been shown to be highly structurally similar to the mecA gene. In a recent 
study, Antignac and Tomasz (2009) showed that replacement of SCCmec from MS SA 
strain COL-S (an MRSA strain from which SCCmec was excised) with the S. sciuri pdpD 
gene restored the typical MRSA phenotype of the original MRSA strain COL. 
In contrast to the common theory that MRSA emerged (over a very short period) under the 
selective pressure of ~-lactamase-resistant antibiotics, the complexity of the mecA 
resistance mechanism prompted the proposal of alternative theories. De Lencastre and 
colleagues (2007) postulate the evolution of me cA resistance mechanisms occurred over a 
long time span, in a penicillinase-free staphylococcal species, under the selective pressure 
of penicillin. They propose this species to be S. sciuri, which is free of a penicillinase 
plasmid. Penicillin was used extensively in veterinary medicine as a prophylactic agent in 
1949, very soon after its introduction and use in clinical medicine. Prophylactic use of 
penicillin could have been the selective pressure promoting the emergence of the S. sciuri 
mecA homologue (De Lencastre et al., 2007). Others have proposed an element in 
Maccrococcus caseolyticus (formally Staphylococcus caseolyticus; Schleifer et al. 1982) to 
be the ancestral precursor to SCCmec (Baba et al., 2009). Additional studies are necessary 
to determine the source of this genetic element. 
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1.2.1.3.4 Non-mec SCC elements 
The SCC element, defmed as the "mobile chromosomal cassette with dedicated 
recombinase genes (ccr) and characteristic flanking short sequence repeats" (De 
Lencastre et al. 2007) is not limited to dissemination of mecA. Several non-mec SCC and 
",SCC (lacking ccr genes, or possessing non-functional ones) carrying other genetic 
elements have been documented. Genes encoded on these elements could contribute to the 
fitness/pathogenic potential of the genus. These are summarised in Table 1.6 (data from 
De Lencastre et al., 2007). Several of these non-mec SCC and ",SCC have been found in 
coagulase negative staphylococci (CNS), further supporting for the importance of this 
group in the dissemination of SCC elements. 
Recent whole genome sequencing of S. haemolyticus strain JCSC1435, and its 
comparative analysis with S. aureus and S. epidermidis species highlighted a chromosomal 
region downstream of the origin of replication (designated the "oriC environ") as important 
in the diversification and evolution of these clinically significant staphylococcal species 
(Takeuchi et al., 2005). The analysis showed that although the oriC environ did not 
harbour genes essential for bacterial viability, species-specific genes were evident. The 
authors propose that SCCs were the driving vehicle for the introduction of exogenous 
genes into the oriC environ. Furthermore, it is postulated that other recombinases and IS 
elements may have served to remove non-beneficial genes, thus leaving only those species-
specific genes which survived selection. 
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Table 1.6 Non-mec SCC elements. 
Some of these elements encode putative virulence factors that may contribute to the 
fitness- or pathogenic-potential of the bacterium (information from De Lencastre et al., 
2007). 
SCC element Function Reference 
SCCmer Heavy metal resistance Chongtrakool et al., 2006 
Heavy metal resistance; Mongkolrattanothai et SCCCl DNA protection by restriction 
modification systems al., 2004 
SCCMSSA476 Fusidic acid resistance Holden et al., 2004 
SCCcapl Capsule biosynthesis Luong et al., 2002 
SCC 15305cap Capsule biosynthesis Kuroda et al., 2005 
",SCC hl Potassium transport Takeuchi et al., 2005 
SCCpbp4 Cell wall cross linking Mongkolrattanothai et 
al., 2004 
",SCCACME Arginine deaminase and oligopeptide Diep et al., 2006 permease 
1.2.1.4 Epidemiological typing of S. aureus 
1.2.1.4.1 Molecular epidemiology 
MRSA remain among the most challenging pathogens, responsible for a huge burden of 
disease in healthcare facilities worldwide. The global spread of MRSA seems to be 
primarily due to the dissemination of a few pandemic clones in which the SCCmec element 
was acquired by a genetic background with potential for epidemic spread (Oliveira et al., 
2002). The prevalence of MRSA varies among different countries throughout Europe. 
This is monitored by a European national surveillance network (EARSS; European 
antimicrobial resistance surveillance system) coordinated by the Dutch National Institute 
of Public Health and the Environment (RIVM). Surveillance data show the lowest 
incidence of methicillin resistance «1%) among S. aureus isolates is reported by the 
Nordic countries, whilst Southern European countries report high incidences of MRSA of 
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between 30-40%. Figure 1.3 illustrates MRSA prevalence data reported for 2007 and 
2008. 
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Figure 1.3 MRSA prevalence in Europe (EARSS data) reported in 2007 and 2008. 
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Molecular-based techniques greatly improve the capacity of hospitals to track the source 
and transmission dynamics of bacterial pathogens during outbreaks (Oliveira et aI., 2002). 
Characterisation of isolates of S. aureus enables scientists to gain a better understanding of 
the origins, spread, and relatedness of geographically and clinically different MRSA clones 
(Enright et al., 2000). Essentially, characterisation of strains addresses two important 
epidemiological points: (i) whether isolates recovered from a localised outbreak of disease 
are the same or different (local epidemiology), and (ii) how the strains causing disease in 
one geographic area are related to those occurring world-wide (global epidemiology) 
(Maiden et al., 1998). 
Molecular characterization techniques can be exploited to determine the inter-relatedness 
of isolates to assess clonal relationships. The possible outcomes of determining strain 
relatedness include identifying the source of infection (environmentaV personnel) and 
delineating transmission dynamics. Furthermore, these approaches help distinguish re-
infection (caused by an isolate independent from that causing the initial infection) from 
relapse of infection (caused by the same strain) (Singh et al., 2006). Understanding the 
distribution and relatedness of strains is a prerequisite to understanding the pattern of 
transmission and thus establishing appropriate intervention and infection control measures. 
Therefore, during an outbreak, the results of molecular typing methods focus the effects of 
infection control teams on more targeted intervention strategies. 
To help monitor and limit intra- and inter-hospital spread of MRSA, typing techniques 
must allow discrimination between unrelated isolates as well as recognition of those 
descending from a common ancestor (Aires de Sousa and De Lencastre, 2004). The 
suitability of any particular typing system is dependent on a number of factors. In 
particular, the needs. skill level and resources of the typing laboratory. as well as the goal 
of the analysis (long-term or short-term analysis) may all influence the system used. An 
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ideal typing system needs to be capable of high typeability, adequate stability, display high 
technical reproducibility and high discriminatory power. Furthermore, it should be rapid, 
easy to perform and interpret, accessible, and cost-effective (Struelens, 1996). Key criteria 
can be defined as follows: 
• Typeability requires the technique to unambiguously assign a result (type) to each 
isolate. 
• Reproducibility refers to yielding the same result for an isolate upon repeat testing. 
• Discriminatory power reflects ability to discriminate epidemiologically unrelated 
isolates, ideally assigning each isolate to a type. 
1.2.1.4.2 Laboratory procedures for epidemiological analysis 
Traditional phenotypic characterization methods for S. aureus include biotyping, 
serotyping, phage typing and antimicrobial susceptibility testing. However, genotypic 
identification methods (based on molecular analysis) have become more established over 
the last two decades; these provide in-depth information regarding strain relatedness 
(Singh et al. 2006). Techniques include pulsed-field gel electrophoresis (pFGE), other 
restriction-based methods, plasmid analysis, PeR-based typing methods and microarrays. 
1.2.1.4.2.1 Phenotypic characterization methods for S. aureus 
Biotyping (biochemical typing), a species (and sub-species) identification method, can be 
used to differentiate strains based on properties such as differences in biochemical 
reactions and morphological appearance. Biotyping systems (e.g. API and Vitek) have 
now become automated and are used in some routine laboratories for species identification. 
However, strain resolution of S. aureus and coagulase-negative staphylococci is sub-
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optimal, with poor reproducibility and weak discriminatory power (Low, 1997). As many 
of the phenotypic methods depend on the expression of metabolic or morphological 
features which may vary between strains, reproducibility may be limited (Becker et al., 
2004). Therefore, with respect to comparisons of S. aureus, such methods may not be ideal 
(Aires de Sousa and De Lencastre, 2004). 
Antimicrobial susceptibility testing (e.g. broth! agar dilution or disk diffusion methods) can 
be used to determine the resistance or susceptibility of an organism to a panel of 
antimicrobial agents. Although these methods are generally standardised and reproducible 
within and between laboratories, antibiogram data have limited value for epidemiological 
investigations because of their limited discriminatory power i.e. clonally unrelated isolates 
can have the same susceptibility patterns. Furthermore, the loss or acquisition of mobile 
genetic elements may confound results; the instability of these elements can adversely 
affect the interpretation of data. Genotypic methods can be used to monitor antimicrobial 
resistance genotypes as an alternative to (or to augment) phenotypic testing. 
Serotyping of S. aureus is based on the detection of capsular polysaccharide proteins. 
Several serotypes of capsular polysaccharides have been reported to date, however, only 2 
serotypes (types 5 and 8) are expressed by the vast majority (90%) of S. aureus clinical 
isolates. Capsular typing therefore has very poor discriminatory power as a strain typing 
system. 
Phage typing has been used to distinguish bacteria according to their pattern of 
susceptibility/ resistance profiles to a defined set of bacteriophage (Holmberg et al. 1984, 
Lina et al. 1993, Schlichting et al. 1993). Generally, isolates of the same strain are lysed 
by the same phage(s). Consequently, phage typing is useful for strain identification and 
differentiation. Whilst the technique is fairly rapid, cost-effective and lends itself to high-
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throughput, it is difficult to set up and maintain. In addition, reliable interpretation is 
subjective and non-typability of some isolates can limit its utility. 
Overall for S. aureus, the discriminatory power and strain typeability properties of the 
phenotypic methods tend to be lower than can be achieved using genotypic methods (Table 
1.7 compares the characteristics of the phenotypic and genotypic typing systems). Where 
the control of costs has a high priority, the introduction of new molecular methods may be 
difficult. However. costly material and equipment for molecular identification may be 
balanced by labour and other costs associated with traditional methods. Savings may also 
accrue over time as molecular identification protocols are often applicable to a variety of 
species while phenotypic typing schemes are restricted to one or a few species (Singh et 
al., 2006). 
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Table 1.7 Characteristics ofphenotypic and genotypic typing systems. Taken from Arbeit, 1997. 
Typing System 
Biotyping 
Antimicrobial 
susceptibility testing 
Serotyping 
Phage typing 
Plasmid analysis 
Ribotyping 
PFGE 
peR analysis 
Nucleotide sequence 
analysis 
~ 
Vl 
Proportion Of 
Strains Typeable 
All 
All 
Most 
Most 
Most 
All 
All 
All 
All 
Reproducibility Discriminatory Ease Of Power Interpretation 
Poor Poor Good 
Fair Poor Excellent 
Good Poor Good 
Fair Fair Fair 
Good Fair Good 
Excellent Fair Good 
Excellent Excellent Excellent 
Excellent Good Excellent 
Excellent Excellent Excellent 
Ease Of Extent Of Use Performance 
Excellent Moderate 
Excellent Widespread 
Fair Rare 
Poor Limited 
Excellent Moderate 
Good Moderate 
Good Widespread 
Good Limited 
Fair Limited 
1.2.1.4.2.2 Genotypic identification techniques 
1.2.1.4.2.2.1 Genotypic characterization 
The advent of molecular-based typing methods has overcome the shortcomings of 
phenotypic typing methods, in particular, improving strain typeability, standardization and 
reproducibility. The increased number of sequenced microbial genomes has enabled the 
development of several molecular typing systems to target single or multiple chromosomal 
loci. A principle of all molecular detection methods is that isolates with greater numbers 
of genetic differences are less likely to be epidemiologically related. Those molecular 
methods used for S. aureus typing can be characterised as follows (Aires de Sousa and De 
Lencastre, 2004): 
• Plasmid analysis 
• Pulsed-field gel electrophoresis (PFGE) 
• Southern hybridisation analysis of digested DNA e.g. ribotyping 
• PCR-based methods e.g. amplified fragment length polymorphism (AFLP) and 
SCCmec typing 
• DNA sequence typing techniques e.g. spa typing and multilocus sequence typing 
(MLST) 
Plasmid analysis 
Plasmid analysis was the first molecular typing method used for bacterial analysis and the 
first DNA based typing system applied to S. aureus (McGowan et al. 1979, Archer et al. 
1984, Meyers et al. 1976, Schaberg et al. 1981, Tenover 1985). Plasmids are self-
replicating, mobile extra-chromosomal DNA elements found in the prokaryote cytoplasm. 
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Plasmid analysis as a typing tool involves isolation of plasmid DNA and comparison of 
the numbers and sizes by agarose gel electrophoresis. Where plasmids are large (e.g. 100-
150kb), restriction digestion is incorporated into the method after plasmid isolation. 
Plasmid analysis of S. aureus was shown to be useful only in typing MRSA (>90% carry 
plasmid), but not for typing methicillin sensitive S. aureus (MSSA) since approximately 
50% lack plasmids, thus rendering some MSSA non-typeable (Coia et al., 1988). 
Additionally, plasmid profiling has limited technical reproducibility due to features 
inherent to plasmid biology. Plasmids can exist in different molecular isofonns, for 
example supercoiled (closed circle), nicked (open circle), linear, and oligomeric. These 
isoforms will migrate at different rates during agarose gel electrophoresis, confounding the 
results and making the analysis difficult. Finally, epidemiologically unrelated isolates may 
have the same plasmid content whilst related isolates may have different plasmid content. 
Collectively, these problems demonstrate the limited reproducibility and discriminatory 
power of this system. Its usefulness is most probably effective only in the evaluation of 
isolates in a restricted time and place, e.g. during (suspected) acute outbreaks within a 
single hospital where it is expected that epidemiologically related isolates will have three 
or more plasmids in common (Mayer 1988, Schaberg and Zervos 1986). However, outside 
this scope, plasmid content evaluation has limited value in delineation of strain relatedness 
(Singh et aI, 2006). 
Pulsed-field gel electrophoresis (pFGE) 
PFGE is generally accepted as the 'gold standard' for MRSA typing as it provides a high 
discriminatory index for microepidemiological (local outbreak) investigations. PFGE 
relies on the separation of restriction fragments of chromosomal DNA in a switching 
electric field to yield a banding pattern or 'fingerprint' following separation of bands on an 
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agarose gel. It provides a relative global overview of the chromosome, covering 90% of 
the genome (sum of the restriction fragment sizes). The banding pattern reflects the 
distance between infrequent restriction sites around the chromosome. Chromosomal 
variation (as occurs between unrelated isolates) will affect the restriction sites and/or the 
distances between them. 
PFGE was first used for the analysis of S. aureus isolates in an intensive care unit (Prevost 
et al., 1991). It has since proven to be a very popular epidemiological tool with high 
discriminatory power. It is ideally used for studying local outbreak isolates but, although 
used, is less appropriate for large scale analysis or long-term epidemiology studies since 
small genetic changes are capable of radically changing PFGE banding fingerprints 
(Enright, 2008). In short, PFGE can identify small differences between isolates that are 
generally quite similar as occurs in a local outbreak (e.g. random genetic polymorphisms 
that may occur over the time of an outbreak; van Belkum et al., 2007). However, 
comparing large numbers of isolates is more problematic. In such a case, there is no 
reference from which to determine the degree of similarity that constitutes members of an 
outbreak strain that may change slightly over time. Clonal relationships may be difficult to 
define since minor sequence changes may result in significant pattern variation. 
Although PFGE can be technically challenging, tedious and costly to perform, the biggest 
advantage is its ability to detect the movement of chromosomal mobile genetic elements. 
The greatest limitation of this technique is the difficulty of comparing complex fmgerprints 
generated on different gels, especially when comparing between laboratories (Enright, 
2008). Inter-laboratory standardisation methodologies in Europe (Murchan et al. 2004, 
Cookson et al. 2007) have only proved partially successful. The widespread use of PFGE 
has necessitated method standardisation, primarily to enable inter-laboratory comparisons 
(Murchan et al. 2003. van Belkum et al. 1998). Interpretation of fmgerprints is not an 
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automated process and is therefore subject to variation according to the interpretation of 
the analyst locally. Guidelines have been proposed in an attempt to standardise the number 
of mismatches allowed in judging whether isolates are outbreak associated or non-outbreak 
associated (Tenover et al., 1995). However, these guidelines are somewhat arbitrary, and 
therefore scientifically unsatisfactory. 
Southern hybridisation analysis - Ribotyping 
Some typing techniques are based on the use of restriction enzymes and electrophoresis to 
generate a DNA fingerprint (e.g. PFGE). Often the number of bands (DNA fragments) 
that can be resolved is limited. Southern hybridisation makes band resolution more 
manageable; chromatogram interpretation is simplified and conclusions about strain 
relatedness can be drawn more easily. During Southern blotting, the bands separated by 
electrophoresis are blotted (transferred) onto a nylon or nitrocellulose membrane. A 
labelled piece of DNA is then used to probe the membrane. Hybridisation of the probe to 
complementary sequences and subsequent probe detection enables the banding patterns to 
be resolved. As a typing method, the discriminatory power of this technique relies on the 
size and copy number as well as the positions of restriction sites on the targeted genomic 
sequence. The targeting of ribosomal RNA genes during Southern blotting is referred to as 
ribotyping. 
Ribotyping has been used for species (and subspecies) identification as well as for strain 
typing. However, the discriminatory power of ribotyping has been shown to be lower than 
that of PFGE and some PeR-based methods (described below). lzard and colleagues 
(1992) described ribotyping as poor quality for differentiating coagulase-negative 
staphylococci. However, ribotyping can be highly automated, thus reducing human error 
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and limiting variation; the RiboPrinter microbial characterization system (Qualicon, Inc., 
Wilmington, DE) is an example of an automated ribotyping system (Singh et al., 2006). 
PeR-based methods 
PCR based methods rely on the amplification of targeted nucleic acid sequences so that 
only selected sequences are detected. It requires template DNA, complementary primers 
for each gene of interest and a heat stable DNA polymerase. Under optimal conditions, the 
primers bind to the target genes, serving as starting points for the polymerase to produce a 
complementary strand by the addition of nucleotide bases. Of those PeR-based methods 
used routinely for S. aureus typing, single-locus sequence typing (SLST) and multi- locus 
sequence typing (MLST, described further in the DNA sequence based typing section 
below) represent two of the most frequently used, targeting single and multiple genes 
respectively. Amplified fragment length polymorphism (AFLP) analysis based on linker-
mediated amplification of selected restriction fragments is also used (Vos et al., 1995) . 
• AFLP 
AFLP (Vos et al., 1995) combines restriction digestion with PCR amplification. Several 
reports have documented the use of AFLP for typing S. aureus isolates (Grady et al. 2001, 
Cuteri et al. 2004, Melles et al. 2007, Savelkoul et al. 2007, MeIles et al. 2009). Surgi and 
colleagues (2009) found AFLP to have a higher resolution in discriminating between 
MSSA populations compared with MRSA, due to the higher degree of clonality of the 
later. By combining AFLP with multiplex PCR, increased resolution of MRSAs was 
achieved. The technique is relatively easy to perform and the profiles are relatively easy to 
interpret for comparative analyses; software programs such as BioNumerics™ may be 
used to interpret the results. As a fingerprinting tool, it is comparable to PFGE, although 
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PFGE represents a greater portion of the genome sequence. AFLP is more reproducible 
than PFGE. and is therefore regarded to be more useful for epidemiological surveillance 
(Me lIes et al. 2007). However, as with PFGE, inter-laboratory reproducibility is sub-
optimal, particularly when different electrophoresis platforms are employed (van Belkum 
et al., 2007). 
• SCCmec typing 
Detection of the mecA gene (carried on the SCCmec element) in S. aureus has been 
recognised as the 'gold standard' for determining methicillin resistance (Murakami et al., 
1991). With the increased knowledge of the variation that occurs within the SCCmec 
element (section 1.2.1.3), typing methods to detect the mecA gene as well classify the type 
of SCCmec element have been developed. Resistance genes for antibiotics and heavy 
metals present on insertion sequences, transposons and plasmids within SCCmec elements 
can also be detected (Enright, 2008). Compared with methods that only recognise mecA 
(which are not specific to just MRSA, but also coagulase-negative species that carry 
mecA), the SCCmec typing system represents a sensitive and rapid approach for obtaining 
results. Furthermore, mecA and SCCmec organisation are important epidemiological 
indicators of strain origin (Naimi et al. 2003, Dufour et al. 2002). 
DNA sequence-based typing techniques 
Sequence typing techniques can be divided into those that target a single locus (single-
locus sequence typing; SLST) and those that target multiple loci (multi-locus sequence 
typing; MLST). 
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• SLST (spa typing) 
The frequently employed SLST method for the analysis of S. aureus is spa typing; this 
involves the analysis of the polymorphic X or short sequence repeat region of the 
staphylococcal protein A gene (spaA). The polymorphic X region consists of 24-bp 
nucleotide repeat sequences that can vary in the number of repeats, due to deletions and 
multiplications of the units, as well as variations in the overall sequence due to point 
mutations (Koreen et al., 2004). This method, although less discriminatory than PFGE 
(Strommenger et al. 2006, Cookson et al. 2007), benefits from high throughput, ease of use 
and interpretation. Furthermore, it is valuable tool for multicentre studies since DNA 
sequence data can be controlled and checked, and the results curated digitally on online 
databases (www.spa.ridom.de) that can be queried remotely (Harmsen et al. 2003, Enright 
et al. 2008) . 
• MLST 
MLST, based on the same principles as multi-locus enzyme electrophoresis (MLEE), was 
first developed in 1998 (Maiden et al. 1998) for the identification ofhypervirulent lineages 
of Neisseria meningitidis. It subsequently became popular as a means of studying bacterial 
population structure of other pathogenic bacteria including S. aureus (Enright, 2000). 
MLST involves amplification and sequencing of amplicons (450-500bp in length) of 
several genes (7 for S. aureus) encoding conserved metabolic compounds and comparing 
the results to an international database (www.mlst.net) (Francoise and Schrenzel, 2008). 
Compared with SLST, MLST probes a larger portion of the genome. The targets ofMLST 
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are typically the internal regions of a series of housekeeping genes present in all isolates 
of a given species. Genetic polymorphism within these fragments is representative of a 
distinct allele. Isolates are thus defined by the alleles of all the target genes, which 
together comprise the allelic profile (sequence type) for that isolate. The basic principle of 
the typing profile is that individual allelic profiles do not occur by chance, and the potential 
alleles at each locus are many. Therefore, where isolates have the same allelic profile, they 
are considered as members of the same clone. 
The target housekeeping genes are chosen to allow sufficient chance for evolutionary 
diversification in the absence of selective pressure. This technique is therefore well suited 
for epidemiological studies. However, as a method focused on conserved loci and not 
mobile genetic elements, MLST is limited in its discriminatory power for strain resolution. 
Additionally. the turnaround time may not be rapid enough for clinical surveillance for 
diagnostic purposes. MLST is relatively expensive and labour intensive compared with 
SLST due to the need to survey multiple genes. Sequence-based typing systems such as 
SLST and MLST are reproducible methods that are highly applicable to standardisation 
and database cataloguing. thus facilitating an internationally agreed nomenclature. As 
sequence data are unambiguous, quality control measures can easily be implemented to 
ensure accurate nucleotide assignment. Furthermore. sequence traces, allelic data and 
information about the organism can be collated over the internet to moderate the accuracy 
of information in the database (Enright, 2008). 
1.2.1.4.2.2.2 Advanced molecular typing 
1.2.1.4.2.2.2.1 Combining genotypic typing techniques 
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Based on MLST data the S. aureus New York/Japan clone and the Paediatric clone both 
belong to ST5. The combination of SCCmec analysis with MLST provides more useful 
information. Pairing these techniques can distinguish the New York/Japan clone (ST5-II) 
from the Paediatric clone (ST5-IV). In general, combining different typing techniques 
provides broader insights into the organism under investigation. Spa typing and PFGE are 
useful for fine strain typing e.g. microepidemiological investigations. MLST, spa and 
SCCmec typing can be used to relate isolates to information held on databases as well as 
published literature (Enright, 2008). PFGE, spa typing and MLST each display 
approximately comparable levels of resolution and congruency for clonal grouping 
(Cookson et al. 2007, Enright 2008). The approach taken by an individual laboratory is 
highly dependent on the cost and availability of resources. 
1.2.1.4.2.2.2.2 Complete genome analysis 
Many current genotyping methods only identify lineage without addressing the presence of 
individual genes or various mobile genetic elements that carry virulence and resistance 
genes. Thus none of the techniques discussed thus far extensively define the genes that 
constitute the organism(s) under investigation (Dunman et al., 2004). Molecular methods 
such as sequencing and/or multi-strain microarray analysis are now available for 
completely determining the gene content of individual strains. 
The extensive work undertaken in sequencing the genomes of S. aureus isolates has led to 
the publication of 14 complete genomes to date. These resources have given researchers 
an unprecedented glimpse into the genetics and biology of S. aureus. Such information 
can be used to better understand and identify the evolutionary potential of S. aureus 
(Lindsayand Holden, 2004). However, the cost of whole genome sequencing still remains 
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its biggest constraint. Additionally, genome sequencing is unsuitable for rapid diagnostics 
or epidemiological applications. 
1.2.1.5 MRSA 
1.2.1.5.1 The epidemiology of MRSA 
Molecular epidemiology studies have shown the population structure of S. aureus to be 
clonal with some dominant lineages that have evolved independently. The population 
structure of S. aureus was first proposed several decades ago in studies by Rountree 
(Rountree and Freeman 1955, Rountree and Beard 1958) using bacteriophage typing. 
During the 1950s, a particular type of penicillin-resistant S. aureus caused severe disease 
in both the hospital environment as well as the community. This strain (first found in 
Australia and Canada) was lysed by 'phages 80 and 81 (Rountree and Beard, 1958), and 
became known as the 80/81 strain. This strain spread globally during the 1950s and 
acquired resistance to several antibiotics. Furthermore, its enhanced virulence was noted 
to be due to the production of an unusual leukocidin (Donahue and Baldwin, 1966), later 
identified as Panton-Valentine leukocidin (PVL) (Robinson et al .• 2005). Strain 80/81 
spread rapidly in the UK where it was the causative agent of more than 60% of 
staphylococcal infections in England and Wales (Anonymous, 1959) in 1957 compared to 
13% in 1954 (Staphylococcal Reference Laboratory, Colindale, UK). Subsequent studies 
on staphylococcal population structure borne out of the analysis of nosocomial isolates 
have added further to our understanding of this organism. 
One of the earliest explanations relating to the molecular evolution of MRSA proposed the 
single clone theory. in which was suggested all MRSA clones descended from a common 
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ancestor and that SCCmec was introduced only once into the S. aureus genome 
(Kreiswirth et al. 1993). However, subsequent studies favour the multi-clone theory, 
which suggests that SCCmec was introduced into various S. aureus lineages on several 
occasions (Enright et al. 2002, Qi et al. 2005, Fitzgerald et al. 2001, Gomes et al. 2006). 
Robinson and Enright (2003) in their analysis of an international panel of 147 diverse 
MRSA isolates, proposed that MRSA emerged at least 20 times via acquisition of 
SCCmec. They also observed that acquisition of SCCmec by S. aureus was a more 
common occurrence (by a factor of 4) than the replacement of an SCCmec element of one 
type with another type. 
Retrospective studies of the first MRSA clone (ST8) using MLST revealed it to be closely 
related to 1950s isolates of methicillin-susceptible S. aureus (MS SA) that were prevalent 
in Denmark and possibly also seen elsewhere in Europe (Crisostomo et al., 2001); the only 
difference identified was mecA and SCCmec in the MRSA strain (Katayama et al., 2000). 
A pioneering study by Enright and colleagues in 2002 investigating the evolutionary 
history of MRSA using MLST and PCR analysis, collated these results using a novel 
algorithm, based upon repeat sequence type (BURST). The study analysed 912 globally 
distributed S. aureus isolates (both MS SA and MRSA). BURST grouped together similar 
allelic profiles (~ 5 allele commonality with at least one other isolate), and showed that 
five lineages (clonal complexes; CC) dominate for nosocomial MRSA (CC5, 8,22,30 and 
45). This algorithm later became the publicly available online tool eBURST (Feil et al., 
2004). eBURST is capable of predicting an ancestral progenitor (sequence type; ST) for 
each CC, determined by the genotype with the highest number of single-locus variants 
(SLVs), or in the case of a tie, double-locus variants (DLVs) (Enright et al., 200S). These 
(and similar) studies concluded that the MRSA clones stem from genetically similar MSSA 
that had acquired SCCmec elements, possibly on multiple occasions. In particular, 
Enright's study (2002) showed that STS-MSSA (CCS) was the ancestor of the first MRSA 
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clone (ST250-MRSA-I); a single point mutation in yqiL locus in ST250 was the primary 
difference in the core genome. Schematic diagrams have been generated and illustrate the 
evolutionary descent of some of the major MRSA clones (fig. 1.4). 
Figure 1.4 The evolutionary origins of the major MRSA clones and the possible 
relation between CA-MRSA and HA-MRSA. The arrows indicating either (1) the 
acquisition of SCCmec, (2) a change of SCCmec, (3) a change of ST, or (4) the acquisition 
ofPVL. The grey coloured circles represent the MRSA clones from CC30, while the white 
circles represent the MRSA clones from CC8. ST239-MRSA-III from CC8 has evolved by 
the transfer ofa 557-kb fragment from the chromosome ofST30 into a ST8 background. 
Katayama and colleagues (2005) showed the dominant nosocomial MRSA lineages (CC1, 
5, 8, 22, 30 and 45) were easier to transform with mecA-expressing plasmids compared 
with strains of other lineages. They therefore highlighted the fact that the genetic 
background of S. aureus as an important determinant for SCCmec stability. Furthermore, 
Noto and co-workers (2008) showed the genomic region around atlBscc (site of integration 
of SCCmec) was variable, permitting SCCmec integration only in certain isolates. 
Collectively, these studies suggest the spread of a limited number ofMRSA clones may be 
attributed to genetic backgrounds that favour integration and maintenance of SCCmec. 
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Further, Lindsay and co-workers (2006) have proposed the S. aureus restriction 
modification system determines the reception/rejection of SCCmec into these lineages. 
1.2.1.5.2 MRSA in humans 
Epidemiologically, MRSA in humans can be separated into two broad groups: community-
associated (CA-) MRSA and healthcare-associated (HA-) MRSA. Both present with 
varied disease spectI1lIl1, and are acquired (in most cases) from different origins. The 
division of these two classes, initially based on these epidemiological features, is becoming 
increasingly problematic. HA-MRSA originating in healthcare facilities can be detected in 
the community, and thus appear to arise here (Tacconelli et al., 2004). Similarly, CA-
MRSA are no longer confined to the community as their transmission into the healthcare 
setting has been documented (HP A 2006, David et al. 2006, Otter and French 2006). 
1.2.1.5.2.1 Healthcare-associated MRSA (HA-MRSA) 
Acquisition of HA-MRSA is generally associated with recent hospitalisation, surgery, 
outpatient visit, nursing home admission, chronic illness, recent antibiotic exposure, 
injection drug use, and/or close contact with a person with risk factors for MRSA 
acquisition (Salgado et al. 2003, Aires de Sousa and De Lencastre 2004). With respect to 
the healthcare setting, the widespread use of broad-spectrum antibiotics and 
immunosuppressive drugs, and more adventurous surgery in an aging population are all 
factors that have favoured the rise in MRSA infections over recent years (Enright, 2008). 
Table 1.8 lists some of the internationally recognised HA-MRSA clones (discussed further 
in a recent review by Deurenberg and Stobberingh 2009). 
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Table 1.8 An overview of the major HA-MRSA clones. Taken from Deurenberg and 
Stobberingh, 2008. 
3-3-1- 1-4·-.- 16 
10- 14-8-6- 10-3-2 
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250 8 
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239 8 II I 
247 8 
8 8 11 
5 5 11 
5 5 IV 
228 5 I 
8 8 IV 
5 5 
22 22 IV 
36 3 11 
Limiting MRSA spread within healthcare settings has proved challenging in many 
countries. Implementation of infection control policies and procedures are time-
consuming and can be difficult to enforce. Some of the complications of limiting MRSA 
spread stem from the presence of unknown (hidden) reservoirs of carriers, as well as the 
emergence of highly epidemic clonotypes e.g. UK EMRSA-15 and EMRSA-16 (Auken et 
al. 2002, Cox et al. 1995, Richardson and Reith 1993, O'Neil et al. 2001). Screening high 
risk patients for MRSA colonisation has been suggested as a cost-effective measure for 
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limiting the spread of MRSA (Papia et al., 1999). Early and reliable detection of MRSA 
carriage is crucial for infection control strategies. In this way. over prescription oflast-line 
antibiotics (such as glycopeptides and oxazolidinones) can be prevented. The most recent 
Department of Health guidelines (published April 2009) requires all elective admissions 
(including surgical and medical day cases. except ophthalmic day cases) but not children. 
to be screened for MRSA. A decolonisation regime can then be prescribed for MRSA-
positive patients prior to surgery. It is anticipated that this screening policy will be 
extended to all admissions, including emergencies, by 2010/11. 
1.2.1.5.2.2 Community-associated MRSA (CA-M RSA) 
1.2.1.5.2.2.1 Emergence of CA-MRSA 
Until the 1990s, MRSA clones endemic within hospitals were rarely associated with 
healthy individuals who had no previous exposure to a healthcare environment. However, 
at that time. cases were reported in Australia and the United States (Okuma et al., 2002). 
CA-MRSA was first reported in Western Australia in 1993 from hospitalised patients who 
resided in remote communities (Udo et al., 1993). Interest in the prevalence of CA-MRSA 
gathered pace following the 1999 report of four paediatric deaths in Minnesota and North 
Dakota, USA (CDC report 1999). Compared to nosocomial isolates, these MRSA had a 
relatively simple antibiotic susceptibility profile. They were resistant only to J3-lactam 
antibiotics, possibly due to the carriage of SCCmec type IV which carries only the 
resistance gene to mecA. Furthermore. these isolates produced PVL toxin (Anonymous, 
1999), 
It is thought that MRSA colonisation within 'closed communities' such as the Australian 
aboriginals (Udo et al. 1993) and Native Americans (Groom et al .• 2001) is likely to be 
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due to factors associated with spread in the community e.g. overcrowding and high rates 
of skin infections, as well as frequent use of broad-spectrum antibiotics (Maguire et a/., 
1998). The earliest reports of serious CA-MRSA infections (particularly in the United 
States) occurred in populations of intravenous drug users, men who have sex with men, 
members of contact sports teams and prison inmates. However, increasing occurrences of 
infections in the general population have been reported (Moran et al., 2006). Community-
associated isolates have been associated with disease in younger healthier individuals with 
no previous risk associated with nosocomial disease (Chambers, 2001). These MRSAs 
often cause skin and soft-tissue infections, although cases of necrotising pneumonia are 
also reported with high fatality rates in young (median age 14 years), previously healthy 
individuals (Lina et al. 1999, Gillet et al. 2002). More recent studies have identified 
additional factors known as phenol-soluble modulins (PSM) which some workers suggest 
are important co-factors contributing to the enhanced virulence of CA-MRSA (Wang et al. 
2007). 
Many studies have focussed on CA-MRSA, however, no standard definition exists, with at 
least 8 different classifications available for describing MRSA infections as community-
associated (Salgado et al. 2003). The Centre for Disease Control and Prevention (CDC) 
defme CA-MRSA as strains isolated in an outpatient setting, or from patients within 48hrs 
of hospital admission. Other criteria include lack of a medical history of MRSA infection 
or colonization or history of recent (past year) of either hospitalisation (e.g. surgery), 
admission to a nursing home or dialysis, permanent indwelling devices e.g. catheters or 
other devices that pass through the skin (Deurenberg and Stobberingh 2009). Genetic 
markers such as SCCmec type, presence of the PVL genes and genetic background 
(lineage) have also been used to define CA-MRSA (Tristan et al., 2007b). 
1.2.1.5.2.2.2 Origins of CA-M RSA 
61 
Several groups have explored the origins of CA-M RSA. Some suggest SCCmec was 
acquired by pvl-positive MSSAs (which have a highly diverse genetic background) 
prevalent in the community (Ma et al. 2006, Taneike et al. 2006, Monecke et al. 2007). 
Conversely, Aires de Sousa and De Lencastre (2003) in their study on the evolution of HA-
MRSA and CA-MRSA observed strong similarities between sporadic HA-M RSA isolates 
and CA-MRSA. They suggested that some MRSA described as community associated may 
have originated from hospitals. Robinson and colleagues (2005) propose the possibility of 
a common ancestor of HA-MRSA and CA-MRSA from their analyses of ST30 isolates; 
they propose ST30-MSSA as the ancestor. Phage type 80/81, apvl-harbouring ST30 clone 
(penicillin resistant) emerged in the 1940s but disappeared following the introduction of 
penicillinase-resistant f3-lactam antibiotics in the 1960s. It later re-emerged and acquired 
SCCmecIV to become the CA-MRSA SouthWest Pacific clone, ST30-MRSA-IV. 
Furthermore, it was also proposed that PVL-negative ST30-MSSA acquired type 11 
SCCmec, possibly through transitional step including acquisition of SCCmec 11, to become 
ST36-MRSA-II (the pandemic HA-MRSA, EMRSA-16). In contrast, other studies have 
shown CA-MRSA are clearly distinct from any of the major nosocomial MRSA clones 
(Okuma et al. 2002, Dufour et al. 2002), suggesting de novo evolution of CA-MRSA via 
horizontal acquisition of the mecA gene into different S. aureus genetic backgrounds 
(Slamenlinna et al., 2002). Hallin and colleagues (2008) suggest the sporadic isolates may 
have originated in the community and subsequently moved into the hospital environment. 
but remained sporadic due to inept adaptation to this hostile environment. Vandenesch and 
colleagues (2003) showed the pvl-producing CA-MRSA carrying SCCmec IV belonged to 
six dominant lineages (STI, 8, 30, 59, 80, and 93), which were (in most cases) distinct 
from those of nosocomial isolates (Table 1.9). In countries where international exchanges 
are frequent (e.g. Singapore), more diverse set of CA-MRSA have been documented 
(Deurenberg and Stobberingh 2009). 
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Table 1.9 An overview of the major PVL-positive CA-MRSA clones. 
Taken from Deurenberg and Stobberingh, 2008. 
Sf cc<' SCCrnl!C" 
B 80 rv 
So 11 wc I 2-2-2-2-&-3-2 30 30 rv 
,PaCI le ( Si\l IOO) 
US/VIOl) 1- 1- 1- 1- 1-1- \ IV 
USl\300 3-3- 1-1-11-4-3 8 8 rv 
59 59 rv OT VlI 
1.2.1.5.2.2.3 Success and virulence of CA-MRSA 
One of the most successful CA-MRSA to date is the so-called USA300 strain (pvl-positive 
ST8-IV, named according to its characteristic PFGE pulsotype), which was first reported in 
the USA in 2000. It spread rapidly across the USA causing outbreaks in Native American 
populations, military recruits, prison inmates, children in day care centres and among men 
who have sex with men. The appearance ofUSA300 (fig. 1.5) is thought to have arisen via 
the acquisition of SCCmec type IV by ST8-MSSA leading to the intermediate lineage 
USA500 (an ST8-SCCmec IV HA-MRSA strain), and subsequently led to the emergence 
of USA300 via acquisition of at least 20 genes, predominantly mobile genetic elements (Li 
et al. 2009, Tenover and Goering 2009, Enright et al. 2002, Deurenberg and Stobberingh 
2008, Tenover et al. 2006). 
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Figure I.S Evolutionary model of MRSA in CC8 leading to the emergence of USA300 
and other pandemic clones ofthis lineage. Taken from Tenover and Goering, 2009. 
At the time of the first report of USA300, another pulsotype USA100 (i.e. the New 
Yorlc/Japan clone, ST5-II) was the predominant clone recovered from HA infections. The 
rapid displacement of USA100 by USA300 led to intensive investigation and sequencing 
of the latter to determine factors implicated in its success (Diep et al., 2006). Comparative 
genomics highlighted several unique mobile genetic elements carried by USA300, in 
particular pvl and the arginine catabolic mobile element (ACME) genes. In early reports, 
these mobile genetic elements were implicated in the increased transmissibility and 
virulence of this clone. ACME I found in USA300, is characterized by two gene clusters, 
arc and opp-3. The ACME-arc cluster (which differ from the native arc cluster found in 
all S. aureus isolates) encodes a complete arginine deaminase pathway involved at low pH 
and inhibition of the immune response against bacterial infections (Pi et al., 2009). The 
ACME opp-3 cluster, on the other hand, encodes a member of the ABC transporter family, 
with functions associated with peptide nutrient uptake, quorum sensing, pheromone 
transport, chemotaxis, eukaryotic cell adhesion, binding of serum components and 
expression of virulence determinants (Podbielski et aI. , 1996). ACME is carried on a non-
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mec SCC element known as SCCACME. More recently, Li and colleagues (2009) speculate 
core genomic virulence determinants (e.g. a toxin and phenol-soluble modulators which 
lyse human neutrophils) rather than accessory factors govern the virulence of USA300. 
This minor contribution of mobile genetic elements to the virulence of CA-MRSA is 
further supported by reports of CA-MRSA infections caused by pvl-negative strains (Diep 
and Otto 2008, Zhang et al. 2008). 
Kennedy and colleagues (2008) conducted a study of the genomic sequences of 10 
USA300 isolates recovered from across the USA from invasive MRSA infections spanning 
the clinical spectrum of diseases (uncomplicated bacteraemia to more invasive infections 
such as necrotising pneumonia, endocarditis, and osteomyelitis). They identified several 
single nucleotide polymorphisms (SNPs), of which the ratio of non-synonymous to 
synonymous mutations was 3:1. This study highlighted that the success of this clone could 
be due to its ability to acquire mutations (increasing its disease spectrum) rather than 
success due to the acquisition of additional virulence factors since genetic homogeneity 
(other than the SNPs) was evident in the isolates (Kennedy et al. 2008, Tenover and 
Goering 2009). Other studies support a key role for the accessory genome regulator, agr 
(the global regulator and quorum sensing element) in the enhanced virulence potential of 
USA300. Lougbman and colleagues (2009) show that the USA300 clone harbours a 
highly active agr system. Montgomery and colleagues (2008) suggest this may have 
contributed to causing USA300 to displace USA400 as the predominant CA-MRSA strain 
in the USA. However, others refute the implication agr is responsible for differential 
virulence of USA300 and USA400 (Wang et al. 2007, Voyich et al. 2005). Tenover and 
Goering (2009) in their recent review of the origin and epidemiology of USA300 
concluded that "our mobile society, when coupled with the cramped and unsanitary living 
conditions of various populations, and the reluctance to culture wounds in emergency 
departments in the late 1990s and early 2000s probably led to the dramatic spread of this 
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organism before it was recognised as a medical and public health problem". In summary, 
the success of the USA300 clone is attributable to a combination of several factors, 
including enhanced virulence, efficient colonization and host-to-host transmissibility (Li et 
al. 2009). 
1.2.1.5.2.3 Classification: HA- versus CA-M RSA 
The confusion with regard to classification lies in distinguishing true acquisition of MRSA 
infection in the community from MRSA detected in the community whose origin may be 
nosocomial. In recent years, CA-MRSA have started to displace HA-M RSA within 
healthcare institutions, particularly in areas of high prevalence of CA-MRSA e.g. 
USAffaiwan (Otter and French 2006, Seybold et al. 2006, Klevens et al. 2006, Maree et 
al. 2007, Moran et al. 2006). An Australian study by O'Brien and colleagues (1999) 
reported introduction of an MRSA strain originating in the community into the hospital 
environment. However, the true origin of acquisition is difficult to determine since prior 
colonisation can persist from months to years, and the acquisition of MRSA may pass 
undetected unless clinical infection develops (Salgado et al. 2003). Therefore, one of the 
main criteria for distinguishing HA-MRSA from CA-MRSA lies in their phenotypic and 
genotypic characteristics. In contrast to HA-MRSA, CA-MRSA are (usually) susceptible 
to several non ~-lactam antibiotics. MLST and PFGE analyses have highlighted 
differences in the genetic lineages of HA- and CA-MRSA (Groom et al. 2001. Naimi et al. 
2001). CA-MRSA have been noted for their larger clonal diversity, suggesting that many 
S. aureus lineages have the potential to acquire smaller SCCmec elements and emerge as 
CA-MRSA (Enright et al. 2002, Okuma et al. 2002. Francois et al. 2008. Feng et al. 2008). 
Strain characteristics such as SCCmec type carriage, are also key to differentiating between 
HA-MRSA and CA-MRSA. The latter are primarily associated with the smaller SCCmec 
types (IV. V-VII). However. CA-MRSA associated with SCCmec types I. 11 or III have 
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been documented rarely (Cheung et al., 2004). The high prevalence of pvl genes in CA-
MRSA strains has also led to it being proposed as an epidemiological marker (Vandenesch 
et al., 2003). A simplified summary of some of the main differences between these two 
groups is shown in Table 1.10. 
Table 1.10 Differences between HA and CA-MRSA 
HA-M RSA Characteristics CA-M RSA 
Primarily healthcare Epidemiological Primarily community 
(can overspill into community) setting (some infiltration into healthcare) 
Vulnerable patients particularly Individuals Young, previously healthy 
elderly or immunocompromised affected individuals 
Wound infections to Clinical SSTI to fatal necrotising 
bacteraemia presentation pneumonia 
Pandemic lineages Genetic Diverse lineages back~round 
Various SCCmec Genetic SCCmec IV N NIl 
traits 
Multi-resistant Antibiotic Resistant to J3-lactams 
resistance profile 
. SSTI, skin and soft tIssue mfectIons . 
CA-MRSA have been shown to have a faster growth rate compared with HA-MRSA. As 
an important determinant of bacterial fitness, research into this area has recently led to the 
identification of the 'fudoh' gene carried on SCCmec. Identified by a group in Japan 
(Kaito et al., 2008), thefudoh gene (translation "spreading") was shown to suppress colony 
spreading, a property normally observed when S. aureus are spread on soft agar plates. 
Furthermore, S. aureus carrying the fudoh gene also displayed decreased exotoxin 
production and were less virulence in mice models. Kaito and colleagues showed fudoh to 
be associated with SCCmec 11 and III (typically found in HA-MRSA), the larger SCCmec 
elements, but missing from the smaller SCCmec IV and V elements. In strains lacking 
fudoh, high colony spreading ability was observed. Thus, this novel gene points to mobile 
genetic elements as possibly being the key to the success and international dissemination 
ofMRSA carrying SCCmec types IV and V (predominantly CA-MRSA). 
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1.2.1.5.3 Livestock-associated MRSA: an emerging reservoir for CA-M RSA 
Worldwide, there have been reports that livestock have become a reservoir of CA-MRSA. 
In the Netherlands (which typically report MRSA rates of <1%), a specific lineage of 
MRSA is shared by farm animals (in particular pigs and veal calves) and their handlers 
(Witte et 01,. 2007). This was highlighted in 2003, when several unexpected cases of 
MRSA colonisation of humans in contact (direct/indirect) with pigs in the Netherlands 
were identified (Voss, 2005). Isolates of this particular lineage could not be typed by 
PFGE following SmaI digestion of genomic DNA, likely attributed to an unknown change 
in the DNA methylation system (Bens et al., 2006). MLST analysis identified these 
isolates as belonging to sequence type ST398, an unusual lineage in humans. van Loo and 
colleagues (2007) in a retrospective case-control analysis, found a strong correlation 
between MRSA carriage and contact with either pigs or veal calves. Interestingly, 
although pig strains of ST398 are pvl-negative, documentation of pvl-positive human 
isolates highlight the ability of ST398 to acquire additional virulence determinants. Thus, 
unless adequately contained. ST398 has the potential to pose serious healthcare problems 
(Deurenberg and Stobbering, 2009). 
The origin and emergence of this lineage within the animal population and subsequently in 
humans remains unclear. Some suggest ST398 was a highly prevalent MSSA strain in pigs 
which then acquired mecA from other staphylococci in pigs or their handlers (Wulf and 
Voss, 2008). Various SCCmec types have been found in the ST398 lineage, suggesting 
SCCmec may have been acquired on several occasions (van Duijkeren et al., 2008). 
The presence of an extensive network of pig farms within the relatively small country of 
the Netherlands could have facilitated the spread of ST398 (Wulf and Voss, 2008). This 
zoonotic MRSA has become a major problem in the Netherlands where a search-and-
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destroy infection control strategy has been key to reducing MRSA rates. In particular. 
constant exposure of farmers to MRSA has made the 'destroy' part of the strategy (i.e. 
decolonisation) virtually impossible. The solution to the control of MRSA therefore lies in 
tackling the source of the problem, that is, MRSA in livestock. Revising policies for the 
use of antibiotics in livestock is a pressing issue. It is possible that the current animal 
husbandry regimes select for ST398 MRSA. With the potential to colonise and infect 
humans, further spread of this novel MRSA must be prevented; an effort involving 
clinicians. veterinarians and infection control practitioners (Wulf and Voss. 2008). 
1.2.1.5.4 International surveillance of MRSA 
The need for international surveillance systems with harmonized methodologies was 
recognised with the emergence and international spread of antibiotic resistance pathogens. 
One such system created in 1995 was the Centre for Molecular Epidemiology and 
International Network (CEMlNET) (De Lencastre. 2000). It was created to monitor and 
identify reservoirs of major multidrug-resistant S. aureus clones (and other Gram-positive 
pathogens). Several typing techniques were used for strain identification including PFGE, 
SCCmec typing, spa typing and MLST (Aires de Sousa and De Lencastre, 2004). The 
CEMlNET initiative analysed over 3000 MRSA isolates from Europe. Latin Americ~ 
North America and Asia. Six lineages were identified as being particularly significant: 
Iberian, ST247-I; Brazilian, ST239-III; Hungarian. ST239-III; New York/Japan. ST5-II; 
Paediatric. ST5-VI and EMRSA-16, ST36-II. Such fmdings were recognised as evidence 
of the existence of only a few key pandemic clones which had spread worldwide (Oliveira 
et al., 2002). Comparative genomics studies of staphylococcal genomes have led to 
several theories regarding the limited number of these pandemic clones. These have either 
supported intrinsic genetic determinants (i.e. the genetic background; De Lencastre et al. 
,2007) or extrinsic environmental and host-associated determinants (Hallin et al., 2008) as 
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factors promoting pandemic success. Some have suggested that epidemic lineages of 
MRSA are good colonisers. highly transmissible and virulent (Lipsitch 2001, Martinez and 
Baquero 2002). However, although these major MRSA clones have spread internationally, 
several reports have documented shifts in these MRSA clones over time. For example, Ma 
and colleagues (2006) showed that in Japanese hospitals between 1979-1985, the pvl-
positive ST30-MRSA-IV clone was the dominant lineage, but was replaced by pvl-
negative ST5-MRSA-U in the early 1990s. 
In addition to the major epidemic clones, other lineages are also recognised; those that 
predominate in particular healthcare establishments but are not seen in others have been 
classed as minor clones. Furthermore, isolates recovered from an individual (or a few 
patients) in a single hospital have been termed sporadic isolates (Aires de Sousa and De 
Lencastre, 2004) to differentiate them from the highly successful lineages which have 
disseminated internationally. 
In summary, rapid identification ofMRSA in addition to knowledge about the evolutionary 
pathways (through studies of historic and extant collections) will greatly facilitate the 
overall aim of limiting the emergence and spread of MRSA. Furthermore, understanding 
MRCNS (implicated as a source for horizontal transfer of genetic elements in S. aureus) 
could provide insights into MRSA which may emerge in the future. This may be 
facilitated by micro array-based genome comparisons. With the readily available resource 
of sequence data on the internet (and as new isolates are sequenced), microarrays represent 
a powerful platform for analysing and comparing bacterial genotypes. Rather than 
comparing sequences base by base, as in traditional sequencing methods, genomes are 
compared gene by gene. This approach greatly reduces the cost of genome sequencing, 
whilst still providing data comparable with that of sequencing in terms of the presence or 
absence of genes (van Ijperen & Saunders, 2004). Gene arrays for bacterial genome 
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analysis have proven to be of great value in helping elucidate the genomic diversity and 
evolutionary relationship within species (Saunders et al .• 2004). Finally, elucidating the 
spectrum of virulence factors encoded by each isolate analysed will enable prediction of 
the disease potential of a particular strain (Li et al., 2009). 
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1.3 REGULATION OF VIRULENCE 
1.3.1 The staphylococcal virulence factor regulatory network 
S. aureus strains possess genes encoding a wide variety of potential virulence factors, 
which are located either on the core chromosome or on mobile genetic elements. 
Virulence factors encompass bacterial surface proteins and secreted exoproteins whose 
biological activities include mediating host colonization, invasion of and damage to the 
skin and mucosa, dissemination through the body, and evasion of host defence mechanisms 
(Table 1.11). Other, potent factors have superantigenic properties (Projan et al. 1997, 
Dunman et al. 2001, Ferry et al. 2005). 
The complex repertoire and regulatory network of S. aureus virulence factors is consistent 
with its ability to adapt to the human host in causing a wide array of infections (Bronner et 
al., 2004). Research into the virulence mechanisms of S. aureus has concluded that with 
the exception of toxin-mediated diseases (e.g. toxic shock syndrome and staphylococcal 
scalded-skin syndrome). staphylococcal pathogenicity is generally not due to single 
virulence factors. Non-toxin mediated infections occur in a stepwise manner, involving a 
multiplicity of bacterial virulence and host factors (Jarraud et al. 2002, Ferry et al. 2005). 
The genes that encode the majority of these virulence factors belong to an extensive 
regulon that is co-ordinately regulated in response to a variety of both intra- and 
extracellular signals (Dunman et al., 2001). Virulence factor production can be stimulated 
by changes in bacterial cell density, energy availability, environmental signals (pH, CO2, 
O2) and superantigens (Bronner et al., 2004) and are carefully controlled so that they are 
only produced when required. 
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Table 1.11 Selected S. aureus virulence factors. Taken from Gordon and Lowy, 2008. 
T) IK' ohirulrncl' factors 
In\ oln-d in persi. tener 
Invol ed in eVlldinl' 
destroying ho. t defen. 
'111\ olvl-d in ti sue 
inva. tonfpenetr:llion 
Involved in toxin· 
m dinted di. en: e and/or 
se'psis 
With poorly definl-d role in 
virulen e 
Selected factors" 
MSCRAMMs (e.g., 
dumping factoTS. 
fibronectin-binding 
proteins. collagen. and 
bone sialoprotein·bindillg 
proteins) 
Iliolihn accl1l11 ulation 
le.g .. polysaccharid.: 
intercellular adhesion,. 
sm:lll- olony vari. nlS. 
and intracellular 
persistence 
Leukocidins (e.g., PVL 
and y-toxin). capsular 
poly.a charide. (e.g .. 5 
and R). protein A. ellll'S. 
Eap, :\Od phenol·. oluble 
modulin. 
PrOtl"aSl'S. lipascs. 
lIucle:1ses. hyaluronate 
Iya. e. phoSI)Il(l lipasc C. 
and metalloprotea. 
(elast:lse) 
Enter to ins, toxi . hock 
. yndrome tDxin- l. 
exfolimh toxins A and 
n. Cl-toxin, 
peptidoglyclln. find 
lipoteichoic acid 
('0:: gul. ,e. A(, ,"IE. and 
oocteriocin 
Genes 
cljif, djB,jilM, 
/hhB, ('/la, . tlr. 
bhp 
{ea locus. ltt!mB 
nHIt.tion 
(II~S·PV, (lIkF-
P V, "~J;, cap 5 and 
K gene clusters. 
. pa. chp, "up. 
p.m/-agene 
dwter 
1', . fly .• A, hili, plc. 
.,pp!l 
• ('(/-(1 (no ~eJ). 
IMH. eta. ",b. Ma 
/11 ', ' c l ust~ r. "pp.] 
clIL~ter. "-la 
ssociated cliniclll ~'ndrfllnes 
Endocorditi . . osteomyelitis. septic 
arthriti .. and prosthetic-ill-ice and 
t:ltheter infeC1iolls 
Relapsing infections. cystic tibros i . . 
and syndromes as described abow lor 
allachmellt 
Invasive in infections and 
necrotizing pneumonb (C -MRSA 
stmins that cause these ar~ often 
ll.'5OCiated \\ilh PYL) abscesses 
(associated \\ it h t-apsular 
polysaccharide.) 
Ti. sue destruction. nd met, Slatic 
int1 ti ns 
Food poisoning. to. ie shOCK 
.yndrome. scalded skin syndrome. 
bullous impetigo. and psi- s ndrome 
a Several factors may have > 1 role in S. aureus pathogenesis. ACME, arginine catabolic 
mobile element; CA-MRSA, community-acquired methicillin-resistant S. aureus; CHIPS, 
chemotaxis inhibitory protein of staphylococci; Eap, extracellular adherence protein; 
MSCRAMMs, microbial surface components recognizing adhesive matrix molecules; 
PVL, Panton-Valentine leukocidin 
In the laboratory setting, expressIOn of many S. aureus virulence factors follows a 
predictable pattern. Cell wall associated adhesins (e.g. microbial surface components 
recognising adhesive matrix molecules, MSCRAMMs) are expressed during the early 
exponential growth phase when bacterial cell density is low. Conversely, haemolysins, 
toxins, and enzymes facilitating tissue destruction and dissemination (secreted extracellular 
proteins) are expressed at the end of the exponential phase and during the stationary phase 
(projan et al., 1997); figure 1.6. 
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Figure 1.6 Growtb pbase dependant production of cellular components. Taken from 
Lowy 1998. 
A. Growth-phase dependent synthesis of S. aureus virulence factors. Illustrated are 
the most recognized surface and secreted proteins. 
B and C. Cross sections of the cell envelope. The structural organisations of many of 
the surface proteins are similar to that of clumping factor (TSST-l , toxic shock 
syndrome toxin). 
In their review of the regulation of virulence in staphylococci Dunman and Projan (2001) 
posit that the purpose of virulence factors is to enhance the survival of the bacterium in 
adverse environments, rather than to cause disease. As such, the infected host represents 
an environment to which the bacterium must adapt for its survival and success. Few (if 
any) virulence factors have been shown to be essential for bacterial proliferation in vitro. 
However, many factors have been recognised as essential during infection (Dunman and 
Projan, 2001). Therefore, in vitro studies coupled with in vivo experimentation will be 
necessary to give more precise understanding of disease causation. Dunman and Projan 
also observed that cell wall-associated virulence factors require ongoing cell wall assembly 
to become embedded into the cell wall. Therefore, the exponential phase during which cell 
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division and proliferation occurs is the optimum time for production of these factors. 
Conversely, the effects of extracellular proteins are most pronounced when the bacterial 
cells are localised and in enough concentration to produce a "beneficial effect". Thus, the 
optimum time for production of extracellular proteins is during the post-exponential phase 
(Dunman and Projan, 2001). 
Extensive research has revealed the significance of global regulators, such as the much 
studied Agr system (discussed further in section 1.3.2.1), in contributing to the regulatory 
network. The more research is conducted in this area, the more the complexity of this 
network has become apparent. Analysis of changes in gene expression, initially in culture, 
in vitro, and subsequently in animal models in vivo, has helped to delineate known and 
putative pathways of virulence regulation. This knowledge of the global regulatory 
network is continually being refined and reviewed (Novick et al. 1993, Founier et al. 2001, 
Dunman and Projan 2001, Baba et al. 2002, Garvis et al. 2002, Novick and Jiang 2003, 
Bronner et al. 2004, Ferry et al. 2005, Fournier 2008). 
Several two-component regulatory systems that are sensitive to environmental signals have 
been identified within S. aureus. These systems generally consist of two proteins: a 
histidine kinase sensor and a response regulator. The sensor can be either associated with a 
receptor, or it can bind to an extracellular ligand. Upon binding of the extracellular ligand 
to the receptor, autophoshorylation occurs in which there is a transfer of a phosphate 
residue from AIP to a histidine residue of the cytoplasmic domain of the sensor kinase. 
This phosphate residue is then transferred to an aspartate residue on the response regulator. 
The end result of this cascade is the binding of the response regulator to specific DNA 
target sequences, permitting transcription-regulating functions to initiate. The effector 
molecules of the two-component systems can then be transcribed. 
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1.3.2 Global regulators of virulence gene expression 
The main global regulators of S. aureus can be classed into 4 groups, the details of which 
are discussed below: (0 the Agr system, (ii) the SarA system and its homologues, (Ui) the 
Sae system, and (iv) the Arl system. 
1.3.2.1 The Agr system 
1.3.2.1.1 Overview of the Agr system 
The Agr locus was first discovered in the early 1980s when a mutant strain (carrying a 
Tn551 insertion at this locus) displaying a hla-negative phenotype was identified 
(Mallonee et al., 1982). Later work suggested this locus probably encoded a regulator of 
the virulence genes tsst, spa, hla, hlb and hid (encoding toxic shock syndrome toxin, 
protein ~ alpha toxin, beta toxin and delta toxin respectively) (Recsei et al., 1986). 
Subsequently, Agr has been studied in extensive detail, and its mechanisms of action have 
been well characterized. Cloning and sequencing revealed a two-component regulatory 
system (peng et al.,1988). However, further work highlighted the complexity of this 
system compared with that of classical two-component systems. The Agr locus is now 
known to consist of a four gene operon, agrBDCA. Transcription in the forward direction 
produces one RNA molecule, RNAII, whereas transcription in the opposite direction 
(overlapping the hid gene encoding delta toxin) produces another RNA molecule, RNAIII 
(Novick et al. 1993, Morfeldt et al. 1995). These two transcripts (initiated from two 
promoters, P2 and P3, respectively) are essential to agr mediated regulation. RNAIII, the 
main effector molecule of the Agr locus (Novick et al., 1993), is produced in response to 
quorum sensing and functions to regulate mainly gene translation (although it is also 
known to act at the transcription level; Novick et al. 1993). Remarkably, it acts both as a 
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repressor and activator. It is positively regulated by the gene products of the agrBDCA 
operon. increasing its level during growth and reaching a maximum in the post-exponential 
phase (Vandenesch et al., 1991). 
As well as acting on other global regulators, agr activates the virulence factor hla 
(representing the classic secreted extracellular protein), but also suppresses spa (encoding 
protein A, the classic cell wall-associated protein) via RNAlII (Novick et al. 1993, Benito 
et al. 1998, Benito et al. 2000). This modulation of gene expression by RNAlII has been 
shown to operate based on conformational changes in the secondary structures of RNA 
molecules. It is the regulation of these two proteins that have been studied in detail with 
respect to the agr locus and its effects; it is for this reason that hla and spa are almost 
always depicted in the diagrammatical representation of the S. aureus virulence regulatory 
network. 
The agr locus has been shown to be modulated via autocatalytic feedback (Novick et al., 
1995). AgrA and AgrC have been classified as the response regulator and histidine kinase 
components, respectively, in this complex two-component system (Novick et al. 1995, 
Lina et al. 1998). During the exponential growth phase, AgrD (a propeptide which is 
proteolytically digested and matured by AgrB) is secreted into the extracellular 
environment; the result is a mature auto inducing peptide (AlP). The concentration of AlP 
is linked directly to cell density. Once AlP concentration reaches a specific threshold, the 
Agr locus is able to regulate itself further; a process defined as quorum sensing. Binding 
of AlP to its receptor AgrC, causes AgrC to become phosphorylated and activates the 
response regulator AgrA by a second phosphorylation step. Activated AgrA is then able to 
stimulate transcription of the agr P2 and P3 promoters and thus the transcription of 
RNAlII, the major effector molecule of the agr response. Therefore, the AgrC protein is 
the receptor/sensor of AlP and AgrA is the response regulator in this signal transduction 
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pathway (fig. 1.7). The Agr system has two recognised functions effected via RNAIII, 
first it activates the transcription of several extracellular proteins and second it represses 
the transcription of several cell-wall associated proteins in a cell-density dependent manner 
(Janzon et al. 1986, Recsei et al. 1986, Gaskill and Khan 1988, Mahamood and Khan 
1990, Cheung et al. 1992, Patel et al. 1992, Sheehan et al. 1992, Dassy et al. 1993, 
Daugherty and Low 1993, Tremain et al. 1993, Chamberlain and Imanoel 1996, Saravia-
Otten et al. 1997, Arvidson 2000, Bronner et al. 2000, Novick 2000, Arvidson and 
Tegmark 2001, Dunman et al. 2001, Reed et al. 2001, Luong and Lee 2002, Schmidt et al. 
2004, Xiong et al. 2004, Rooijakkers et al. 2006). Dunman and colleagues (2004) in their 
analysis of agr-controlled genes identified 104 upregulated and 34-downregulated genes. 
Furthermore, Zeibandt and colleagues (2004) showed similar up- and down-regulation of 
most of these virulence factors at the protein level. Interestingly, some studies have noted 
that agr mediated regulation of virulence factors depends on the strain used and also 
therefore on genetic background (Blevins et al. 2002, Cassatt et al. 2006). 
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Figure 1.7 Schematic diagram illustrating autoregulation of the Agr locus, and its 
interactions with the TRAP (target of RNAIII activating protein) system (see text; 
taken from Bronner et aI. , 2004). 
Furthermore, strain variation in the Agr locus has been the basis for defining 3 allelic 
groups (agr types I, Il and Ill). Ji and colleagues (1997) in their analysis of the Agr locus 
noted that in the laboratory strain RN6390B the Agr locus was either activated or inhibited 
by the culture supematant of other strains. From this they deduced three groups of 
Staphylococci based on AlP cross-inhibition of the Agr response. Within groups, the AlP 
activated the Agr locus but AlP from outside the group inhibits the agr signal pathway. S. 
aureus AlPs also inhibit the agr pathways of other Staphylococcal species. Thus, each 
group is defined by inter-group inhibition of the agr response via AlP peptides (Ji et al .. 
1997). A fourth agr group was later defined by Jarraud and co-workers (2000). 
Sequencing of Agr loci showed a high degree of conservation between strains of the same 
Agr group. The variation observed between groups was observed in the B-D-C region (Ji 
et al. 1997, Otto et al. 1999, Jarraud et al. 2000). 
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It has been noted that some agr groups preferentially produce specific toxins e.g. 
menstrual toxic shock strains mainly belong to agr group III (Ji et al., 1997) and 
epidermolysin A producing strains mainly belong to agr group IV (Jarraud et al., 2000). It 
has been suggested that agr group may be involved in colonization by inhibiting the spread 
and growth of other strains via inhibition of agr and therefore virulence factors required for 
spread and survival. Studies favouring this view have depended on evidence from the 
distribution of particular groups in vivo (Papakyriacou et al. 2000, van Leeuwen et al. 
2000, Peacock et al. 2002, Goerke et al. 2003, Lina et 01. 2003, Shopsin et al. 2003, Gilot 
and van Leeuwen 2004). However, others have reported no such correlation (Lina et al., 
2003). Furthermore, other studies have presented evidence against a close relationship 
between agr group and virulence (Peacock et al. 2002, Goerke et 01. 2003, Kahl et al. 
2003, Gilot and van Leeuwen 2004). 
1.3.2.1.2 Activation of Agr via the RAPrrRAP system 
An alternative mechanism for the activation of the Agr locus through an auto inducing 
peptide has been recognised and named the RAPffRAP two component system. RNAlIl-
activating protein (RAP), the auto inducer, which is constitutively secreted (Balaban And 
Novick 1995) has been proposed to activate the phosphorylation of Target of RAP 
(TRAP), which binds to a membrane associated protein putatively identified as the 
staphylococcal virulence regulator (SvrA; Gillot et al. 2002, Balaban et al. 2001). 
Phosphorylated TRAP is able to activate agr P21P3 promoters (Garvis et al., 2002); see 
figure 1.7. Balaban and co-workers (2001) in their study of TRAP regulation suggested 
that AlP, produced during mid-exponential growth, inhibits TRAP phosphorylation by 
causing the activation of a phosphatase. They further suggested that RAP and AlP may 
both activate the Agr locus temporarily. That is, AlP (the mature, processed product of the 
agrD transcript) activates the Agr locus via phosphorylation of AgrC and activation of 
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AgrA, whilst RAP activates the Agr locus via phosphorylation of TRAP. Finally, an 
RNAIII-inhibiting peptide (RIP) has been recognised as an inhibitor of the Agr locus in 
coagulase negative Staphylococcus species S. warnerii and S. xylosus (Balaban et al., 
2001). It was proposed that RAP and RIP compete as agonist-antagonist in their binding 
for the same receptor for RNAIII activation. 
1.3.2.1.3 Control of the Agr locus via other global regulators 
Expression of the Agr locus has been shown to be under the control of other global 
regulators, e.g. staphylococcal accessory regulator (Sar; discussed below). Deletion of the 
sarA gene (in strains RN450 and RN6390) results in dramatically reduced synthesis of 
RNAII and RNAIII, demonstrating that SarA protein up-regulates agr expression (Cheung 
and Projan 1994, Morfeldt et al. 1996). Regulation occurs via binding of SarA to the P2-
P3 promoter region (Heinrichs et al. 1996, Morfeldt et al. 1996, Cheung et al. 1997, Chien 
and Cheung 1998, Rechtin et al. 1999). Indeed at least four regulators (SarA, SarR, SarX 
and SarU) are known to bind to P2-P3, highlighting the complexity of the regulation of this 
locus (Manna and Cheung 2006a and 2006b). In addition, RNAIII transcription is under 
the indirect control of many other regulators. Examples include aB which down regulates 
RNAIII production (Bischoff et al. 2001, Horsburgh et al. 2002). RNAIII acts mainly by 
modulating target gene transcription. This can occur directly by binding to the promoters 
of target genes or indirectly by regulation of other transcriptional regulators e.g. SarT and 
SarS (Tegmark et al. 2000, McNamara et al. 2000, Schmidt et al. 2001). 
1.3.2.2 The Sar system 
The staphylococcal accessory regulator (Sar) locus generates three overlapping transcripts 
(sarABC) synthesised from three promoters (PI. 2 and 3 respectively). all of which 
81 
terminate at the same stem-loop sequence. All three transcripts of the Sar locus encode 
the message for SarA (fig. 1.8). SarA modifies expression of virulence genes either 
directly by binding to conserved DNA regions (Sar boxes) within promoter sequences e.g. 
hla, spa, fnb, sec or indirectly via suppression of RNAIII transcription by binding to the 
Agr P3 promoter (Novick et al. 1993, Saravia-Otten et al. 1997, Chien et al. 1999, Rechtin 
et al. 1999, Dunman et al. 2001). 
0.56 kb 
0.8 kb 
1.2 kb P2 (sarB) 
Figure 1.8 The SarA locus. The three transcripts, sarABC, are synthesised from the three 
promoters PI, 2, 3 respectively. 
Unlike the Agr system (RNAIII) which up-regulates extracellular proteins and down-
regulates cell wall-associated proteins during the post-exponential growth phase (Janzon et 
al. 1990, Komblum et al. 1990, Morfeldt et al. 1995, Novick et al. 1993), SarA up-
regulates both surface-bound and extracellular proteins (Cheung et al. 1992). The level of 
SarA protein produced during all growth phases remains constant, whereas the levels of 
SarB and sarC depends on growth phase (Blevins et al. , 1999). SarB is more prominent in 
the mid- to late-exponential phase whilst SarC is prevalent in the late-exponential to 
stationary phase (Bayer et al. 1996, Manna et al. 1998). Like Agr, the SarA locus is 
autoregulatory (Chien and Cheung 1998, Manna et al. 1998) since deletion of the sarA 
gene attenuates transcription of the other transcripts of this locus. 
The regulation of SarA occurs by means of SarR, the regulatory protein that binds the sarA 
promoter (PI). Expression of SarR peaks during the post-exponential phase and it 
decreases the transcription of sarA during the late exponential and stationary growth 
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phases (Manna et al., 2001). SarA has been shown to be a strong regulator of protease 
genes such as serine protease (sspA), cystein protease (scpA) and aureolysin (aur), as well 
as fibronectin binding protein (fnbp) and protein A (spa) (Cheung et a!. 1992, Lindsayand 
Foster 1999, Wolz et a!. 2000, Karlsson et al. 2001, Karlsson and Arvidson 2002). 
Furthennore, SarA has been recognised as an important regulator of biofilm fonnation. It 
induces the intracellular adhesin (ica) operon (Beenken et al. 2003, Valle et al. 2003), as 
well as regulating bap expression, both of which are important in biofilm fonnation 
(Cucarella et al., 2001). SarA is thought to regulate transcription by binding to DNA 
(Rechtin et al., 1999), although the protein structure has not revealed a classic DNA-
binding motif. Some have proposed that this regulation is mediated by confonnational 
changes in DNA and DNA supercoiling (Schumacher et al. 2001, Roberts et al. 2006). 
1.3.2.3 Sar Homologues 
Sar homologues belong to the MarR winged helix family of transcriptional regulators 
(Ellison and Miller, 2006), comprising two subgroups based on protein size. Group-l 
comprises the smaller size proteins (13-16kDa) which bind DNA as dimers; these include 
SarA, SarR, 8arT and 8arX. The second group comprising the larger proteins (29-30kDa) 
include Rot, Sar8, 8arT, SarU, SarV, MgrA and TcaR; these proteins also bind DNA but 
have N- and C-tenninal regions similar to SarA (Liu et al. 2001, Schumacher et al. 2001, 
Li et al. 2003). Of these homologues, one of the most studied is the repressor of toxins 
(Rot). 
Rot has been reported to regulate many virulence factors. This has been shown 
particularly in agr-negative mutants (Said-8alim et al., 2003); since agr represses rot, 
these studies have shown the effects of rot excluding the agr effect. Agr has been reported 
to display an opposite pattern of virulence gene regulation to Rot possibly due to the 
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negative regulation of rot mRNA by RNAIII. However, the Rot-Agr relationship is more 
complex than this implies (Said-Salim et al., 2003). It has been suggested that the 
regulation of Rot by Agr occurs at the post-transcriptional level (McNamara et al. 2000, 
Said-Salim et al. 2003, Geisinger et al. 2006). It is therefore thought that Rot is one of the 
transcriptional regulators used by Agr to control virulence gene expression. Furthermore, 
SarA has been reported to bind directly to the promoter region of rot modulating its 
transcription (Manna and Ray, 2007). The relationship between the Sar family members 
and their interaction with virulence factors is summarised in figure 1.9. 
TeaR SarS* 
SarT 
T 
SarA* 
T 
SarR 
MgrA 
Figure 1.9 Interactions of the Sar homologues with each other and with virulence 
genes spa and hla. Arrows indicate positive regulation, perpendicular lines represent 
negative regulation, and * indicates positive regulation by aB. Adapted from Fourmer, 
2008. 
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1.3.2.4 The Sae system 
The staphylococcal accessory element (Sae), also described as a S. aureus exoprotein 
expression locus, constitutes four genes (A-D) encoding SaeRSPQ generated from three 
promoters (P A-C) ; figure 1.10. Of these four transcripts, only the functions of SaeRS are 
known; these two components encode the classical histidine kinase and response regulator 
of a two-component system. 
PB~~~~~~~~~~~vv~~~vv~~~vv~~~~ Pc~~~vv~~~vv~~~vv~~~~~~~vv~~~vv~~~~ 
Vv'vv'vVV' 0 
Figure 1.10 The Sae locus. Four transcripts encoding saePQRS are synthesised from 
three promoter, P A-C. 
The genes of this locus are also differentially expressed during growth phase; T3 is 
prevalent in the exponential phase, whilst the others are produced later. Agr and Sar are 
also required for full production of these transcripts (Novick and Jiang, 2003). The Sae 
system has been shown to be essential for the transcription of hla, hlb and coa, 
independently of Agr and Sar, supporting its recognition as a major regulatory system 
(Giraudo et al. , 1997). Sae upregulates hId, seb, ejb, eap, lukF, lukM, hlgACB, chp, scn, 
fnbA and fnbB and represses plc, sspA, aur and spa. 
1.3.2.5 The Arl system 
Autolysins are required to facilitate cell division and separation through their role in 
splitting the cell wall. Furthermore, as they are involved in peptidoglycan turnover and cell 
suicide co-ordinated control is essential. In S. aureus, the autolysis related (Arl) locus, 
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another two-component system (Fournier and Hooper, 2000) appears to be responsible for 
controlling expression of these enzymes. The precise mechanisms by which this system 
modulates virulence gene expression have not been fully elucidated and it is supposed that 
other regulators may be involved (Fournier et al. 2001, Luong and Lee 2006). As with 
SarA, the Arl system has also been reported to modulate DNA supercoiling and this has 
therefore been proposed as a mechanism for transcription regulation (Fournier and Klier, 
2004). 
The Arl system transcripts are expressed during the exponential and post exponential 
growth phases. It is thought that the targets of ArIR could be the sar A regulatory factors 
SarR, SarA and crB (sigma factor B) (Fournier et al., 2001). In addition Arl may affect agr 
targeted genes by reducing agr expression by down-regulating RNAIII transcription and 
thus AlP concentration. Expression of this locus is highest during the post-exponential 
phase. However, autoregulation is not thought to occur. SarA and Agr have been reported 
as positive regulators (Fournier et al., 2001). In addition, MgrA (multiple global regulator, 
also known as NorA and Rat) and fI1 may upregulate expression but this has been reported 
as strain dependent (Ingavale et al. 2003, Luong and Lee 2006). Finally, Arl has been 
reported to modulate biofilm formation, although the mechanisms by which this occurs are 
not fully understood (Fournier and Hooper 2000, Toledo-Arana et al. 2005). 
1.3.3 Other recognised regulatory systems 
Other global regulators of virulence gene expression include OB (Sigma B), SrrAB 
(staphylococcal respiratory response, also known as SrhSR system), and LytRS. 
OB is an alternative sigma factor that is generally activated directly within the cell rather 
than through signal transduction (Novick et al., 2003). OB has been recognised for its role 
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in regulating stress responses and intermediary metabolism (Chan and Foster 1998, Kullik 
et al. 1998, Zeibandt et al. 2001, Bischoff et al. 2004). aB has been shown to be activated 
by environmental stress and energy depletion (reduced ATP/ ADP ratio), ethanol and 
salicylic acid (Chan and Foster, 1998). Regulation of aB occurs via a complex post-
translational pathway involving rsbU, rsbV and rsbW(Scott et al., 1999). RsbW is an anti-
sigma factor that phosphorylates RsbV, an anti-anti-sigma factor. Under environmental 
stress, phosphorylated Rsb V (Rsbv-P) is dephosphorylated by either RsbU or RsbP 
(phosphatases), and it is then able to bind RsbW; the result is release of aB and thus its 
activation. 
The SrrAB system has been recognised as having a role in regulation influenced by 
environmental oxygen conditions (Throup et al. 2001, Yarwood et al. 2001). This is 
significant at focal points of infection (especially deep infection) where oxygen levels 
becomes limiting. It has therefore been proposed that SrrAB could be the link between 
respiratory metabolism and the expression of virulence factors (Yarwood et al., 2001). 
A further system, the LytRS system is involved in autolysis (Brunskill et al., 1996). LytR 
and LytS control the expression of two transcripts LrgA and LrgB (immediately 
downstream of their locus) which inhibit the extracellular activity of murein hydrolases. 
These are enzymes which catalyse the cleavage of bacterial structural cell wall 
components. Thus, inhibition of these autolysins prevents cell division. 
Finally, virulence factors whose primary role is not regulation have been reported to 
function as regulators. Included in this group are several Clp proteins such as ClpX (Frees 
et al. 2003, Frees et al. 2005), ClpP (Frees et aI. 2003, Frees et al. 2005, Michel et al. 
2006), ClpC (Frees et al. 2004, Becker et al. 2001), SvrA (staphylococcal virulence 
regulator; Garvis et al. 2002), Msr (methionine sulfoxide reductase; Rossi et al .• 2003), 
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CvfAB (conserved virulence factors; Matsumoto et al., 2007), CcpA (catabolite control 
protein A; Warner and Lolkema 2003. Seidl et al., 2006), Aconitase (Somerville et al., 
2002) and Msa (modulator of SarA; Sambanthamoorthy et al., 2006). This list is expanding 
continually. 
In conclusion, knowledge of this complex network has helped our understanding of the co-
ordinated manner in which genes are temporally expressed. It is thought that it is the 
complexity of the pathways involved and the specificity of the interactions that facilitate 
survival of this organism since they enable accurate and pleotropic regulation of the 
expression of virulence factors in response to environmental signals. 
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1.4 M ICROARRA Y TECHNOLOGY 
1.4.1 Background and principles 
Microarrays are essentially a large scale dot blot, used for multiplex reactions to define the 
genome compositions of samples (Wildsmith and Elcock, 2001). They represent a 
continuation of molecular biology hybridisation methods, but in a format that allows a 
huge increase in the number of probes available for parallel testing. The principle of all 
'arrays', as recognised in different technological platforms, is the composition of a set of 
pre-defined nucleic acid probes, immobilised at specific X, Y coordinates on a surface of 
choice. When used for typing purposes, labelled (target) nucleic acids are exposed to the 
probes, resulting in hybridisation in the presence of complementary sequences. This 
method of comparing genomes using arrays has been classified as Genomotyping 
(Lucchini et al., 2001). 
The key part of all microarray processes is the hybridisation step. This property of 
exploiting the preferential binding of complementary single-stranded nucleic acid 
sequences was first exploited experimentally during the 1960s, and became well accepted 
with the technique of Southern blotting (Gillespie and Spiegelman 1965, Southern 1975). 
However, with the development of sequencing projects, advances in miniaturisation and 
high density synthesis of nucleic acids on solid support, the principle of microarrays and 
microchip technologies emerged (Causton et al., 2003). Microarrays were first developed 
in the pioneering laboratories of Schena and Brown (Schena et al., 1995). Shortly after, the 
first gene expression study using microarray technology was used in 1997 (DeRisi et al., 
1997). Microarray technology has changed the experimental landscape of expression 
analysis from low throughput (typically by northern blot analysis) to high throughput 
parallel analysis, where many genes can be simultaneously interrogated. 
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With the sequencing of several complete genomes, a vast amount of information has 
become available. However, the value of this information will only be fully realised when 
the function and expression of individual genes has been elucidated. Microarrays are 
greatly facilitating this process. Analysis of genomic content by microarrays provides an 
additional means to determine the functions of uncharacterised open reading frames. The 
ability to use partially characterised sequences and the flexibility of microarray design 
have advanced the utility of arrays for understanding many biological entities (Nubel et al. 
2004, Troesch et al. 1999, Khodakov et al. 2008, You et al. 2008, B0ving et al. 2009). 
The identity of the probe sequences determines the information obtained from the array 
experiments, which in turn is completely dependent on genome sequencing information. 
Therefore, obtaining accurate information is crucial, as any deficiencies in this will impact 
on all downstream processes. 
1.4.2 Technological overview 
1.4.2.1 Microarray Production 
Each feature on an array represents a nucleic acid sequence called a spot or probe. Probes 
can be produced from cDNA, PCR products, or from pre-synthesised or in situ synthesised 
oligonucleotides (single-stranded DNA segments). Several different platforms are 
available for the accurate deposition of probes onto solid support. Standard robotic 
arrayers are capable of spotting >20,000 probes on standard low-fluorescence microscope 
slides. This process is highly automated. Probes (either synthetic oligonucleotides or PCR 
amplicons) are spotted onto glass slides usually in a grid format using either a pin-based 
robotic arrayer or an ink jet microdispensing liquid handling system (Hardiman. 2004). 
The pin based arrayers deposit the DNA solution (picolitre quantities) by direct contact 
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between the pins and the solid support. Available contact printing robots use either split-
or solid-pins. Split pins have a reservoir that can hold nanolitre quantities of spotting 
solution, allowing many spots to be printed without refilling. Solid pins can produce only 
a single spot before refilling unless used in the 'pin and ring' format. Non-contact printing 
is said to more accurately produce even spots and uses technology based on that found in 
ink jet printers. However, it has been reported that cross contamination is more of an issue 
with non-contact printing. 
Spotted arrays can be fabricated on site using equipment that is now available within most 
medium to large size research establishments. The advantages of these platforms are that 
the arrays may be printed at a relatively low cost, and provide the flexibility to enable 
fabrication of arrays with many different designs. Unlike the commercially available 
microarrays comprised of oligonucleotides synthesised in situ (Le. Affymetrix™ and 
NimbleGenTM) which often accommodate only one sample per array, spotted arrays are 
generally used to compare two samples, each labelled with a different fluorescent dye and 
hybridised in parallel (Hardiman, 2004). 
Very high density microarrays (Causton et al., 2003) comprise oligonucleotides assembled 
in situ and are often referred to as 'chips', the term coined by the leader in the field, 
AffymetrixTM. Synthesis involves photodependent deprotection, and physical masks (four 
per nucleotide position making 80 for an array of 20mers) are needed to direct light to 
specific areas of the chip (Lipshutz et al., 1999). 
The microarray market production has matured over recent years and several competing 
platforms are commercially available. The pioneering platform amongst these was the 
Affymetrix™ GeneChip. Probes consist of short oligos (-25-mers) built up by chemical 
synthesis by a combination of photolithography and solid-phase DNA synthesis (Chee et 
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al., 2004). These arrays are supplied pre-fabricated, therefore reducing the time 
associated with producing and optimising an in-house system. They have become well 
established in the field of transcription profiling due to their extensive genetic content and 
high reproducibility. Furthermore, the quality control measures already in place by the 
manufacturers provide an increased level of assurance for the user. This type of system is 
very useful for small scale experiments where flexibility in chip design is not necessary. 
Presently, it represents the most cost effective way of screening the genome of interest. 
One of the major advantages of the AffymetrixTM GeneChips is probe redundancy. Several 
independent oligos binding to different regions of the same RNA are included in the 
design. This minimises cross-hybridisation effects, improving signal-to-noise ratio, as well 
as the dynamic range of detection. Up to 400,000 oligos can be supplied on a single array 
representing up to 10,000 genes, with 40 oligo features per gene. Recent advances in this 
platform have limited the probes per gene to 11 probe pairs, while at the same time 
reducing the feature size to as small as 18J.Ull. Furthermore, mismatch control probes-
(which contain a single base difference in a central location) are also employed to control 
for non-specific hybridisation. These are used to subtract background and cross-
hybridisation (Hardiman, 2004). 
Agilent™, a competitor of AffymetrixTM, also synthesise probes in situ but using ink jet 
printing via phosphoramidite chemistry (Agilent™ additionally produce spotted cDNA 
arrays from peR amplicons). The oligos consist of 60-mers which are more than double 
the size of the 25-mers used by AffymetrixTM. These longer oligos are used to overcome 
the poor hybridisation problem associated with shorter probe sequences. That is, larger 
probes provide a greater surface area for hybridisation, which subsequently provide better 
sensitivity. In addition, the longer probes are better able to tolerate mismatches, providing 
a better system for the analysis of highly polymorphic regions (Hardiman, 2004). 
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Compared with the Affymetrix™ GeneChips, the Agilent™ system only requires one 60-
mer per gene or transcript. Finally, although both AgileneM and Affymetrix™ also both 
offer user-defined custom arrays, the cost is still much higher than producing custom 
arrays using a standard arrayer. 
The CodeLinkTM Bioarray platform produced by Amersham Biosciences provides yet 
another commercial array. Short oligonucleotide probes (30-mers) are applied to a three-
dimensional polyacrylamide gel matrix. The idea behind this technology is that the 
hydrophobic surface favours only specific binding, thereby minimising background noise. 
In addition, as with the Agilent™ system, only one oligo probe per gene is used. This oligo 
is empirically selected from similar probes on the basis of the signal intensity and 
specificity achieved with a panel of tissues (Hardiman, 2004). 
Alternatives to in situ array fabrication (not based on conventional photolithography 
masks) are provided by NimbleGen™ and FebieM, which use digital mirror devices (DMD) 
and digital light processors (DLP) respectively. The DMD technology used by 
NimbleGen™ enables rapid production of custom high-density arrays in a cost effective 
manner. In contrast, the FebieM system (DLP) uses a benchtop instrument to generate 
arrays within a three-dimensional microstructure. Four individual channel-like chambers 
within the 3D microstructure allow four array experiments to be run in parallel (Hardiman, 
2004). The list of commercially available platforms is extensive and it seems likely that 
3D arrays represent the next trend in rnicroarray platforms. The main features of the above 
mentioned platforms have been summarised in Table 1.12. 
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Table 1.12 Comparison of microarray platforms. Taken from Hardiman. 2004. 
CodeLinkTM Affymetrix ™ Agilent™ NimbleGen™ Febit™ Spotted Arrays 
Array format 30-mer 25-mer 60-mer 24-mer 25- to 30-mer Variable 
Hybridisation time 18h 16h 17h 16h 16h 17h 
Hybridisation 37°C 45°C 60°C 45°C 45°C 60°C temperature 
Sensitivity 1:900,000 1:100,000 1:100,000 
-
1:100,000 1:300,000 
Sensitivity; 3D surface; Inexpensive; can 
liquid hybridisation Reproducibility; Reproducibility; be utilized with 
Advantages kinetics; can be utilised content; mature content; mature Customization Customization any mlcroarray 
with any microarray platform; platform; scanner; 
scanner; customization is customization custornization customization is 
possible possible 
Two-colour dye 
bias and ozone-
Non-contact printing: Short Two-colour dye Short Short related 
Disadvantages printing-related issue, oligonucleotides: bias and ozone- oligonucleotides: oligonucleotides: degradation; 
such as poor spot . less sensitive related less sensitive less specific poor 
morphology degradation reproducibility; 
reporter feature 
identity errors 
'£ 
1.4.2.2 Experimental process 
Fluorescent dyes have been adopted as the pnmary labelling method in rmcroarray 
analysis. This approach offers the advantage of simultaneous detection of two or more 
signals in one experiment, enabling microarray users to subject two differentially labelled 
samples to the same array for comparative analysis (whether mRNA for expression studies, 
or DNA for genomic analysis). As such, the throughput of arrays has increased over filter-
based macroarrays where only one radioactively labelled sample could be analysed at any 
one time. However, for some experimental designs, the hybridisation of a "single-labelled 
population of nucleic acids" to the array is still the preferred method. Here comparisons 
between samples are obtained from different arrays. 
During the hybridisation reactions, duplexes are formed between the single-stranded 
immobilised probes and the denatured targets. The probes are immobilised in excess so as 
not to limit the kinetics of hybridisation. Equal amounts of labelled sample are combined 
and hybridised to the array. The fluorescence level of each spot is measured independently 
for each dye, post hybridisation. The most frequently used dyes for two-colour analyses 
are the cyanine dyes Cy3 and Cy5 which, when scanned in false colour, appear green and 
red respectively. Therefore, if the nucleic acid from sample 1 (labelled with Cy3) is present 
on an array, the probes fluoresce green. Similarly if the nucleic acids from sample 2 
(labelled with Cy5) are present, the probes fluoresce red. However, if the nucleic acid 
from both samples are present on the same array, the probes fluoresce yellow, and if 
neither are present, the probes do not fluoresce (appear black when scanned). A detection 
system quantifies these fluorescence signals. Since each gene can be identified by its 
location on the slide, an output file from the scanner is generated for the relative signal 
abundance of each gene. 
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The complexity of the hybridisation process is greater than that encountered in any other 
molecular biology technique. The quality of data obtained from microarrays is highly 
dependent on the specificity of the system, as determined by the stringency of 
hybridisation and washing conditions. Stringent hybridisation conditions should ensure 
that only sequences with high homology bind to the probes on the array. Computerised 
data processing is a pre-requisite in all microarray data analyses due to the large amount of 
data generated. Often micro array scanners come with specialised software packages to 
extract primary information from the scanned image. Other packages may then be used for 
more downstream manipulation and analysis, such as normalisation and extraction of 
biologically meaningful conclusions. It is this process of extracting biologically 
meaningful data from the experiments that presents the greatest challenge in microarray 
analysis. Several factors can affect the outcome of this process including, in particular, the 
experimental design. A biologically sound and statistically robust experiment will 
facilitate extraction of useful information. For this reason, and to enable the organized 
compilation of microarray data, the Microarray Gene Expression Database (MGED) group 
have defined the minimal information about a microarray experiment (MAIME) guidelines 
for data submission (gene expression data). With the increased use of microarray 
technology, scientific research journals are becoming more concerned with conformance to 
MAIME guidelines. Additionally, post-hybridisation confirmatory studies (e.g. Northern 
blot and/or RT-PCR analysis) are also being proposed, necessitating the need for 
guidelines here. Yet, the main issues with confirmatory studies lie in the 'subjective' 
manner in which researchers select the genes to confirm. Furthermore, certain techniques 
(e.g. biopsy or laser-captured micro dissection material) produce insufficient RNA extracts 
for both array analysis and confirmatory studies. However, the issues raised here are 
concerns of whether confirmatory studies are necessary for such experiments (Rocket, 
2003). 
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1.4.3 Advantages and disadvantages of microarrays 
The rapid emergence of microarrays as a general microbiology analytical tool is reflective 
of its versatility. This technique has been used in a diverse range of biomedical disciplines 
to understand the biology of host pathogen interactions. Microarrays therefore provide 
insights into the dynamics of the genome being studied, as well as genomic shifts, an area 
recognised as functional genomics. 
Microarrays primarily provide a screening tool to identify putative genes of interest. The 
main advantage of this technology is the ability to obtain information on many hundreds 
(or thousands) of data points simultaneously. With respect to gene expression studies, all 
the data are obtained under the same experimental conditions, eliminating this source of 
error in the analysis (Bunney et al., 2003). At the genomic level, microarrays provide a 
method of differentiating strains by genotypic characterisation. Yet, since probe sequences 
represent specific phenotypic characteristics, microarrays also provide a link between 
genotypic and phenotypic characterisation (van Ijperen and Saunders, 2004). Furthermore, 
as advances in biological understanding come as much from DNA sequence data as well as 
gene annotation, microarrays provide a means to understand the function of non-annotated 
sequences by functional analysis. Since the principle of gene expression is that genes up-
and down-regulated in the same way could have similar functions, by analysing gene 
expression under different conditions, the pathways in which these hypothetical genes 
associate may be better understood. That is, microarrays help fill in the information gap in 
sequencing data. Importantly, due to the high cost associated with more advanced 
techniques such as genome sequencing, arrays provide a rapid, cost-effective alternative. 
Although arrays are very much dependant on the information provided by sequencing 
projects, in practical terms, they provide a shortcut to whole genome comparisons. 
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Genomes are compared gene by gene rather than base by base, undercutting the cost 
associated with sequencing. 
In contrast to the many advantages of using microarrays, there are also several limitations. 
Some of these limitations, together with possible solutions are as follows. Initial 
microarray setup (within a laboratory) requires a considerable amount of hands-on-time. 
Sample preparation can also be time consuming. However, commercial companies have 
realised this and some automated platforms are available. The most time consuming aspect 
of this technique remains data analysis (van Ijperen and Saunders, 2004). Additionally, 
micro array results can easily be confounded by the process of cross-hybridisation due to 
sequence similarities in either probes or genes (e.g. gene families). This can be limited 
somewhat during probe design by selecting gene sequences that are unique between family 
members (Le. probe sequences based on regions that differ between closely related genes; 
Bunney et al., 2003). Finally, as with all technologies, there is a limit of detection. With 
expression studies (often where obtaining large amounts of mRNA can be the limiting 
factor) low abundance genes may not be easily detected. To overcome this, commercial 
companies have developed RNA amplification techniques. However. many presently on 
the market cater for eukaryotic RNA amplification rather than that of prokaryotic origin. 
1.4.4 Applications of microarray analysis: Comparative genome hybridisation (CGH) 
versus transcription profiling 
CGH studies are used to detect DNA sequences in a genome, and thus the presence of 
genes similar to the strains used for probe design. This method of analysis is useful for 
detecting genomic shift between strains. CGH comparisons enable the identification of 
'interesting genes' by comparing two or more different phenotypes. The aim: to provide a 
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possible correlation between gene carriage and disease transmission/presentation (van 
Ijperen and Saunders, 2004). 
The sequencing projects of many bacterial pathogens have illustrated the commonalty in 
all genomes; that is, the presence of a core set of genes, together with the variable 
'divergent' genes which are present only in some strains. Indeed what is shown is the 
variation in the degree of genomic plasticity. The divergent genes which are generally 
either located on or very close to chromosomal elements (e.g. transposons, bacteriophage, 
insertion sequences, or genomic islands) are lost or acquired as a unit. In more recent 
years, some of the more informative arrays have been composite arrays comprising probes 
from the 'divergent' genes in various key strains rather than strain specific probes (Witney 
et al., 2005, Saunders et al., 2004). Since all array comparisons are relative to strain 
specific probes used, composite probes provide greater insights and thus a more 
informative genotype (van Ijperen and Saunders. 2004). 
Gene expression studies (transcriptomics) identify mRNA transcripts (sometimes 
represented as cDNA) in a genome. Transcription studies provide insights into the 
functional behaviour of the genome (genome dynamics) by determining which genes are 
induced or repressed in response to an environmental stimulus. The underlying hypothesis 
with such studies is that genes with similar expression levels (under the same conditions) 
are likely to have similar biological functions. 
Traditional methods of analysing gene expreSSlOn include Northern blotting, reverse 
transcriptase peR and nuclease protection assays. However, these methods are only suited 
to analysing a small number of genes and samples at anyone time. Essentially microarray 
methodology represents the reverse of Northern blotting principles. The target is derived 
from the mRNA and the probe sequences are immobilised onto the solid support. Between 
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Northern blotting and microarrays, filter-based gene expression developed. However, the 
filters were large in size, and often had the associated problem of auto-fluorescence, 
limiting the efficiency of this multiplex reaction. 
During typical expression analysis, two samples are compared. One of these is the control, 
whilst the other is derived from cells subjected to a different stimulus. The presence of 
mRNA serves as an indicator for gene expression. Furthermore, the amount of mRNA is 
used as a measure for expression level. All expression levels are relative, and not absolute. 
This is because the intensity of the fluorescence signals not only reflects the number of 
hybridised fragments, but also the labelling density of each fragment, and the length of the 
fragments. Since the labels are incorporated during reverse transcription, a longer 
transcript could easily contain more labels than a shorter fragment. Thus, a strong 
hybridisation signal does not necessarily represent a highly expressed gene. Normalisation 
controls for this variation. 
It has been noted that many genes are constitutively expressed, and their regulation takes 
place at the translational or post-translational level. The relationship between transcription 
and translation is not as simple as originally perceived by the 'central dogma' theory. 
Indeed the correlation between gene and protein expression is relatively poor. For this 
reason, global proteome analysis may be more informative on the phenotype than 
transcription analysis (Wildsmith and Elcock, 2001). 
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1.5 THESIS AIMS AND OBJECTIVES 
1. S. aureus microarray and protocol development (Chapter 3.0) 
1. To update the existing microarray to include further virulence-associated genes. 
The microarray will be used to investigate the natural population structure of S. 
aureus strains and better understand their potential to cause disease. 
The microarray will be used for two main types of studies, (i) comparative genome 
hybridisation (CGH), and (ii) transcription profiling. CGH involves analysis of 
samples at the level of DNA, and therefore provides a profile of the presence and 
absence of genes on the array. Effectively, this highlights genetic differences between 
the strains under investigation. Transcription profiling, however, consists of analysis at 
the level of RNA and provides valuable information (implicitly) about the function of 
genes through analysis of their pattern of expression or regulation under particular 
conditions. 
11. To develop protocols for CGH and transcription profiling studies. 
2. CGH studies (Chapter 4.0) 
The underlying aim of this project is to use the virulence-associated microarray for 
comparative studies of a panel of internationally recognised healthcare-associated (HA-) 
and community-associated (CA-) strains. The objectives are: 
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1. To study variation amongst lineages ofMRSA. 
The array data will be used to explore genotypic differences that may explain 
variations in epidemiology and pathogenicity of recognised successfuV epidemic! 
pandemic strains. The predominance of certain lineages (e.g. epidemic MRSA-15!-
16) suggests a greater pathogenic potential. The search for differential markers will 
provide insights into traits which may be important in the success, transmission and 
pathogenicity of different lineages. 
11. To provide evidence for recombination events to gain insights into the evolutionary 
history of S. aureus via this mechanism. 
CGH will be used to find strains that are closely related to the ancestral clones that 
we hypothesise recombined to produce the lineage EMRSA-15 (ST22-SCCmecIV). 
the most prevalent epidemic HA-M RSA in the UK. The data will be examined to 
identify other large-scale recombination events that may have taken place. The 
hypothesis is that large-scale recombination events may have had an impact on the 
way epidemic strains survive in hospital environments and colonise the human 
nasopharynx. 
lll. To explore genotypic differences that may explain variations in phenotypes. In 
particular, patterns of genotypic variation that might account for differences in 
epidemiology and pathogenicity of the CA and HA S. aureus. 
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3. Transcriptosome profiling: gene expression studies (Chapter 5.0) 
i. The agr locus of S. aureus encodes a regulatory RNA molecule (RNAIII) known to 
influence the transcription of many virulence-associated genes. In studies using an 
agr mutant, the virulence gene expression profiles of cells of strain SHl 00 1 will be 
compared during exponential and stationary phases of growth. The agr mutant will 
be tested in parallel with the unmodified parental strain (SHlOOO) to determine the 
effect of this mutation on virulence gene regulation. The hypothesis is that the 
ability of the knock-out mutants to alter their transcriptional activity in response to 
stress or quorum sensing signals will be impaired. 
H. Compare expression profiles of cells grown under biofilm simulating conditions to 
their planktonic counterparts in order to determine putative biofilm-associated 
virulence genes. 
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2.0 MATERIALS AND METHODS 
2.1 Description of S. aureus strains 
Forty three strains (26 healthcare-associated and 17 community-associated strains) were 
provided by the Laboratory of Healthcare-Associated Infections (LHCAI). Centre for 
Infections, Colindale. All strains were typed by MLST and PFGE, and SCCmec type was 
defined by PCR Additional information (agr type, spa type, and toxin profile) was 
provided for some of the strains (Table 2.1). Isolates were classified as healthcare-
associated or community associated from molecular and epidemiological data. In addition, 
a collection of 17 epidemic MRSA (EMRSA) isolates were received from the National 
Collection of Type Cultures (NCTC) via LHCAI. Strains were provided on nutrient agar 
by LHCAI, and later stored on beads (Pro-lab diagnostics). In addition, two isogenic 
strains, one carrying a mutation in the agr (accessory gene regulator) locus and its parental 
progenitor, were provided by Professor Simon Foster's laboratory, University of Sheffield. 
Finally, one S. aureus strain isolated from a chronic wound at Heath Hospital (Cardiff) was 
used in a collaborative study with the Department of Dral Surgery, Medicine and Dentistry 
(School of Dentistry, Cardiff University). 
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Table 2.1 Strains used in this project. All strains were provided by LHCAI, unless otherwise stated (see text). Replicates indicated by ' *' . 
Isolates were classified as healthcare-associated or community associated from molecular and epidemiological data. 
MLSTI MLST 
Strain Identifier SCCmecType CC PVL Toxin gene profile sp_a agr HIC 
Berlin ST45-IV 45 enterotoxins G & I H 
Iberian ST247-I 8 enterotoxin B H 
N Y /Japan ST5-II 5 enterotoxins G & I H 
Paediatric (USA800) ST5-IV 5 enterotoxins G & I H 
South German ST228-I 5 enterotoxins G & I H 
Veterinary Strain ST398 398 none detected H 
lrish-l (var) ST8-II 8 enterotoxin A H 
Irish-2 (var) ST8-IV 8 none detected H 
EMRSA 15 var B3 (0412) ST22-IV 22 enterotoxins G & I 1 H i ! 
EMRSA 15 var B3 (0414) ST22-IV 22 enterotoxins G & I 1 H 
EMRSA 15 var B3 (0415) ST22-IV 22 enterotoxins G & I 1 H 
USA400 STI-IVa 1 + enterotoxins A & H, PVL t127 3 C 
ST5-IV PVL STS-IVc S + enterotoxins D,G,I &J, PVL t002 2 C 
USA300 ST8-IVa 8 + PVL t008 1 C 
S.W. Pacific clone ST30-IVc 30 + 
(USAlI00) enterotoxins G & I, PVL t019 3 C 
S.E. Asia clone (USAlOOO) STS9-V 59 + enterotoxin B, PVL t437 1 C 
European Clone ST80-IVc 80 + enterotoxin H, exfol D & PVL t044 3 C 
MRSA252 ST36-II 30 H 
MSSA476 STl 1 C 
NCTC 8325 ST8 8 C 
COL ST250-I 8 H 
MuSO STS-II S H 
N315 ST5-II 5 H 
MLSTI MLST 
Strain Identifier SCCmecType CC PVL Toxin gene profile spa agr WC 
WA-MRSA STI-Iva 1 enterotoxins A & H t127 3 C 
ST772-VI Bengal-Bay_ clone ST8S1-V 1 + enterotoxins A, G & I, PVL C 
Queensland clone ST93-?IV 93 + PVL C 
enterotoxins A, C, G & I, PVL, 
ST866-IV ST866-IV S + TSST C 
ST88-IV ST88-IVa 88 + PVL t690 3 C 
ST97 ST97-V 97 enterotoxins D & J C 
STS-IV neg STS-IV S enterotoxins C,D, G, I & J, TSST-l C 
ST22-IV ST22-IVe 22 + enterotoxins G & I, PVL tOOS 1 C 
EMRSA -15 variant B 1 ST22-IV 22 enterotoxins C, G & I H 
EMRSA-15 variant B3 ST22-IV 22 enterotoxins G & I H 
EMRSA-15 variant B5 ST22-IV 22 H 
EMRSA-15 variant B7 ST22-IV 22 H 
EMRSA-15 variant B27 ST22-IV 22 H 
EMRSA -16 variant Al ST36-II 30 enterotoxins A, G & I, TSST-l H 
EMRSA-16 variant A2 ST36-II 30 enterotoxins A, G & I, TSST-l H , 
EMRSA -16 variant A 14 ST36-II 30 enterotoxins A, G & I, TSST-l H i 
EMRSA -16 variant A 16 ST36-II 30 enterotoxins A, G & I, TSST-l H 
EMRSA-16 variant 29 (r1) * ST36-II 30 enterotoxins A, G & I, TSST-1 H 
EMRSA-16 variant 29 (r21 * ST36-II 30 enterotoxins A, G & I, TSST-1 H 
EMRSA-1 ST239-III 8 enterotoxin A t037 1 H 
EMRSA-2 ST8-IV 8 enterotoxin A (variable} t190 1 H 
EMRSA-3 STS-I 5 enterotoxins G & I tOOl 2 H 
EMRSA-4 ST239-III 8 enterotoxin A t037 1 H 
EMRSA-5IIberian clone ST247-I 8 enterotoxins A & B t051 1 H 
EMRSA-6 ST8-IV 8 enterotoxin A (variable) t190 1 H 
EMRSA-7 ST239-II1 8 enterotoxin A t037 1 H 
EMRSA-8 ST250-I 8 none detected t194 1 H 
-- - -
-o 0"1 
MLSTI MLST 
Strain Identifier SCCmecType CC PVL Toxin gene profIle spa agr WC 
EMRSA-9 ST240-III 8 none detected t037 1 H 
EMRSA -1 OlHannover clone ST254-IV 8 enterotoxins A & B t009 1 H I 
EMRSA-11 ST239-III 8 enterotoxin A t037 1 H 
EMRSA-12 ST8-IV 8 enterotoxin A (variable) t190 1 H 
EMRSA-13 ST8-IV 8 enterotoxin A (variable) t190 1 H 
EMRSA-14 ST8-IV 8 enterotoxin A (variable) t190 1 H 
EMRSA-15 ST22-IV 22 enterotoxins C, G & I t022 1 H 
EMRSA-16 (Tkl) * ST36-II 30 enterotoxins A, G, I & tsst t018 3 H 
EMRSA-16 (Tk2) * ST36-II 30 enterotoxins C, G & I t018 3 H 
EMRSA-17 ST247-1 8 enterotoxin A t051 1 H 
ST779-IV ST779-IV exfoliative D H 
ST39-II ST39-II 30 enterotoxins C, G and TSST-l H 
MW2 STI-IV 1 + C 
D76 
Agr 
Agr-
-o 
-....l 
2.2 Transcription profiling 
2.2.1 Culture of S. aureus cells for transcription profiling analysis 
2.2.1.1 Standard liquid culture 
Isolates were recovered from frozen beads by sub-culturing onto nutrient agar overnight at 
37°C. A single colony was inoculated directly into lOml LB broth (HPA) and incubated 
(37°C) overnight with shaking. An aliquot of the culture was used to make a fresh 
suspension with an OD6oo reading of 0.005 (50ml final volume) and grown with shaking at 
120rpm (37°C). The purity of the inoculum was tested by plating out a loopful of the 
starter culture. Cells were removed at different time points determined by growth curve 
analysis (section 3.1.2.1.2). Samples of the culture were stabilised in two volumes of 
RNAprotect bacteria reagent (Qiagen), and collected by centrifugation (lSmin, 3,000 x g). 
Cell pellets were either used for RNA extraction immediately or stored (-20°C) until later 
use. 
2.2.1.2 Biofilm study: constant depth film fermenter 
Biofilms were grown aerobically at 37°C in a constant depth film fermenter (CDFF) by the 
Department of Oral Surgery, Medicine and Dentistry. The CDFF instrument provides a 
simplistic, reproducible model to grow biofilms of fixed thickness. The instrument 
consists of a glass vessel housing a turntable containing 15 polytetrafluoroethylene (PTFE) 
pans. Each pan contains five recessed PTFE plugs (5mm diameter) on which the biofilms 
form. After inoculation, sterile media flows over the biofilms, which are maintained at a 
constant depth of IS microns. Excess growth is removed by rotating PTFE scraper blades. 
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Cells from five to seven pans were stabilized in two volumes RNAprotect (Qiagen), and 
transported to the Centre for Infections (HP A) on dry ice. 
2.2.2 Growth curves of S. aureus strains 
Growth curves were used to estimate growth phases and determine the best time points for 
RNA extraction. One millilitre samples were removed from liquid broth cultures at 
prescribed times (Oh, lh, 2h, 3.Sh, 4.Sh, S.Sh, 6.Sh, 7.Sh, l6h) for quantification. In a 
sterile microtitre plate, serial 10 fold dilutions (down to 10-7) were made in PBS containing 
0.1 % triton X100 (Severn Biotechnology, UK). Twenty microlitre aliquots of each dilution 
were transferred onto nutrient agar plates (HP A) in triplicate as described by Miles and 
Misra (1938). Plates were incubated overnight at 37°C and counted on the following day. 
Growth curves were drawn in Microsoft Excel. 
2.2.3 Quantification of cells in culture 
To estimate cell numbers rapidly, one millilitre cell suspensions were analysed using the 
Densimat (Biomerieux), a photometric reader that counts cells on the McFarland standard 
scale. 
2.2.4 RNA isolation 
2.2.4.1 RNeasy mini (Qiagen) 
Cell pellets were resuspended in 100J.lI of lysozyme/lysostaphin solution containing 2X TE 
(Sigma, UK), O.3mg/ml lysozyme (Sigma UK), 0.03mg/ml recombinant lysostaphin 
(Sigma UK) and 1.2% Triton X100 (Severn Biotechnology, UK) then incubated at 37°C 
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for 30-40min. RNA was then extracted using the RNeasy mini kit (Qiagen) from the lysis 
step onward. 
Briefly, cells were lysed in 350JlI RL T Buffer containing ~-mercaptoethanol, with 
thorough mixing by vortexing. Two hundred and fifty micro litres of ethanol (Sigma) was 
added to the lysate and mixed by gentle pipetting, before applying to an RNeasy mini 
column. RNA was bound to the column by a brief spin (15sec, 10,000 x g), followed by a 
wash step with 350JlI Buffer RWl. DNA was removed by the recommended on-column 
digestion step; 10JlI DNase! and 80JlI RDD Buffer mix was incubated on the column for 
15min at room temperature. The enzyme was removed by a further wash step with 350JlI 
Buffer RWI with brief centrifugation (l5sec, 10,000 rpm). The column was washed twice 
more in 500JlI each of Buffer RPE, and the column dried by centrifuging for 2min at full 
speed. Finally, the RNA was eluted in a sterile tube with 30-50JlI RNase-free water. RNA 
(from all protocols) was stored at -20°C. 
2.2.4.2 RNeasy Midi (Qiagen) 
The RNeasy Midi protocol was identical to the mini protocol except that larger volumes 
were used enabling more cells to be extracted from a larger culture. The RL T buffer and 
ethanol volumes were increased by 5.7 and 5.6 times respectively, and the Buffer RPE by a 
factor of 5. The volume of DNase solution was doubled, and finally the elution volume 
was increased to 150Jll. 
2.2.4.3 PureYield RNA Midi (Promega) 
Cell pellets that had been collected from RNAprotect solution were resuspended in 100JlI 
lysozyme/lysostaphin solution for 30min at 37°C. Cells were lysed in Iml Lysis Solution 
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containing p-mercaptoethanol, mixed thoroughly and incubated on ice for 10min. Two 
millilitres of the lysate were transferred to a sterile 1.5m1 tube, diluted in RNA Dilution 
Buffer, and mixed immediately by inverting the tube several times. One millilitre of 
Clearing Agent was added to the tube, and again mixed by inversion. The tube was then 
incubated at 70°C for 5min, cooled to room temperature, homogenized with shaking and 
applied to the Clearing Column. Sample impurities were bound to the column by 
centrifuging for 10min (2,000 x g), and the cleared lysate (flow-through) transferred to a 
sterile 50ml falcon tube. Isopropanol (4ml) was added to the cleared lysate. mixed by 
inversion, applied to the Binding Column and centrifuged for 10min. The flow-through 
from this column was discarded and the column was washed twice in 20ml and 10ml 
volumes of RNA Wash Solution (5min, 2,000 x g). The column was dried by 
centrifugation (5min, 2,000 x g). Finally, the RNA was eluted in Iml nuclease-free water. 
2.2.4.4 PureLink Micro to Midi (lnvitrogen) 
Cell pellets were resuspended in 100J.1llysozyme/lysostaphin solution (see Section 2.2.4.1) 
and mixed with 0.5J.11 of 10% SDS (Gibco). The mixture was incubated for 5min at room 
temperature then 350J.11 RNA Lysis Solution (containing p-mercaptoethanol) was added. 
The tube was mixed thoroughly by vortexing to ensure complete lysis. Two hundred and 
fifty microlitres of 100% ethanol (Sigma) was added and mixed thoroughly. The sample 
was then transferred to the RNA Spin Cartridge and centrifuged briefly (l5sec, 12,000 x g) 
at room temperature. At this point DNase treatment was performed. This involved an 
initial wash step with 350J.11 Wash Buffer I, brief centrifugation (5min, 12,000 x g) and 
incubation (15min at room temperature) with IOU DNasel in DNase buffer (80J.11 volume). 
Finally, the cartridge was washed with a further 350J.11 Wash Buffer I to remove the DNase. 
Following DNase treatment, the cartridge was washed twice in 500J.11 of Wash Buffer 11 
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containing ethanol, centrifuged briefly (15sec, 12,000 x g), and dried with a final spin. 
RNA was eluted in 30-50JlI RNase-free water. 
2.2.4.5 RNAspin Mini (GE Healthcare) 
Cell pellets containing 5 x 109 cells (prepared from a quantified liquid culture) were lysed 
by the addition of 350111 Buffer RAl and 3.5ll1 p-mercaptoethanol, with thorough mixing. 
Each lysate was applied to an RNAspin Mini Filter and centrifuged for 1 min at 11,000 x g. 
The filtrate was transferred to a sterile 1.5ml tube to which 70% (v/v) ethanol (350lll) was 
added. The preparation was vortexed and applied to an RNAspin Mini column. The 
mixture was pipetted 2-3 times and centrifuged briefly (30sec, 8,000 x g) to bind RNA. 
Three hundred and fifty micro litres Membrane Desalting Buffer was then applied to the 
membrane and spun for 1 min. According to the manufacturer, this step improves the 
efficiency of DNase digestion. 
A DNase reaction mixture was prepared by adding IOll1 reconstituted DNaseI to 90111 
DNase reaction buffer. Of this mixture, 95jll was applied directly to the silica membrane 
and incubated at room temperature for 15min. The column was then washed three times in 
200J..lI, 600J..lI and 250J..lI each of Buffer RA2 and twice Buffer RA3 respectively, with Imin 
centrifugations (11,000 x g). The column was dried with a further 2min centrifugation, 
and finally eluted in two successive volumes of 50111 RNase-free water. 
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2.2.5 RNA enrichment 
Ribominus® Bacteria Transcriptosome Isolation Kit (Invitrogen) for the removal of 
rRNA 
The Ribominus® kit is based on the principle of removing ribosomal RNA (rRNA) from 
total RNA using specific probes which bind to magnetic beads. During the initial step, the 
beads are prepared for hybridization. This is followed by the hybridization of the rRNA 
specific probes with their target in the sample. Finally, the rRNA probe complex is 
separated from the sample using the magnetic beads. The concentration module is then 
used to concentrate the remaining sample into a small volume. The details of this method 
are as follows. 
The Ribominus® Magnetic beads were prepared by mixing the beads thoroughly in their 
bottle, prior to aliquoting a 250111 suspension into a sterile 1.5ml tube. The beads were 
separated from their solution on a magnetic stand and the supematant discarded. The 
beads were then washed twice in 250111 RNase-free water, each time discarding the 
suspension solution by pelIeting the beads using the magnetic stand for aided separation. 
This was repeated for 250111 Hybridization Buffer B 1 0, before finally re-suspending the 
beads in 100111 Hybridization Buffer B 10. The suspension was kept at room temperature 
during sample preparation. 
For hybridization, total RNA (2-10Jlg) was combined with 400pmol Ribominus™ probe, 
and lOOJlI Hybridization Buffer BlO. up to a final volume of 124111. The mixture was 
incubated for 5min at 37°C and snap cooled on ice. Next, the 124111 sample mix was 
combined with the bead suspension, mixed by thoroughly vortexing and incubated at 37°C 
for 15min, with occasional gentle mixing. The tube was then placed on a magnetic stand 
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to pellet the rRNA-probe complex. The supematant containing the Ribominus™ RNA 
fraction was then transferred to a sterile tube for concentration using the Ribominus™ 
concentration module. 
For RNA concentration, 250J,l1 Binding Buffer (L3) and 125,.u ethanol (100%) were mixed 
thoroughly with the supematant, and applied to a column. The column was centrifuged 
(12,000 x g) for lmin and the flow through discarded. The column was washed twice in 
200J,l1 each of Wash Buffer B5 and centrifuged (12, 000 x g) for lmin each and a further 2-
3min to dry the column. Finally, the column was placed in a sterile 2ml collection tube 
and the RNA eluted in 1O-15J,l1 RNase-free water. RNA was stored at -20°C. 
2.2.6 RNA quality check 
2.2.6.1 Standard agarose gel electrophoresis 
The integrity of the RNA and/or DNA samples was checked by horizontal gel 
electrophoresis on a 1 % (w/v) agarose gel in TBE buffer. Agarose gels (lnvitrogen) were 
prepared in Ultrapure 1 X TBE buffer (Invitrogen), heated in a microwave for 30sec (or 
until dissolved) and cast into a mould. One microlitre of sample mixed with 0.5,.u 5X 
Loading Buffer (Bioline, OK) or 5J.ll of the DNA Hyperladder (Bioline, UK) were loaded 
into wells. Samples were electrophoresed at 120V for 20-30min, or until the dye had 
migrated three quarters of the way down the gel. Gels were then stained in ethidium 
bromide (lJ,lg/ml) in distilled water. Finally, the gel was visualised under UV light (570-
640nm) using a CCD camera on an AutoChemi Imaging System (UVP). 
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2.2.6.2 Denaturing agarose gel electrophoresis 
Briefly, RNA was dissolved in loading buffer consisting of 10111 formamide, 2!ll 
fonnaldehyde, 2111 10X TBE, 4111 RNase-free water, and 2111 bromophenol blue. Samples 
were denatured at 65°C for 2min and cooled on ice. Products were separated on a 1 % (w/v) 
denaturing agarose gel in 0.5X TBE buffer. After staining with ethidium bromide the 
separated bands were examined under UV light as described (section 2.2.6.1). 
An alternative to this method was the use of a urea buffer for denaturing RNA instead of 
the fonnamide-fonnaldehyde buffer. The urea buffer consisted of 7M Urea, 13% FicoIl, 
0.0 I % bromophenol blue, and 10X TBE, up to a final volume of 18!ll. 
2.2.6.3 Qubit quantification system (lnvitrogen) 
For DNAlRNA quantification, samples were diluted 200-fold in a Quant-iT master mix 
solution comprised of 199 volumes of Quant-iT (dsDNA or RNA) buffer and I volume of 
Quant-iT (dsDNA or RNA) reagent. Pre-prepared standards (Ong and lOng) were diluted 
IO-fold in the master mix solution, and were used to calibrate the instrument. Calibration 
values were measured using the Qubit Fluorimeter (Invitrogen) by measuring the 
fluorescence of the standards. Using these values, the fluorimeter quantifies the 
concentration of dsDNA or RNA in the sample. 
2.2.7 In vitro transcription (IVT), amplification and labelling 
For transcription profiling, RNA was converted to cDNA by IVT, and labelled with 
fluorescent dyes. A number of protocols were tested, involving IVT alone (with a later 
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labelling step) or IVT with labelling all in one step. Amplification of cDNA was also 
included in some of the protocols. 
2.2.7.1 IVT: First strand cDNA synthesis 
2.2.7.1.1 Random Primer method with MMuLV enzyme 
Reverse transcriptase reactions consisted of total RNA (5 Jlg), 400U MMuL V reverse 
transcriptase (New England Biolabs, NEB, UK), IOX MMuLV buffer (NEB, UK), 3Jlg 
Random Primer 9 (NEB, UK), 40U RNase inhibitor (NEB), dNTP mix (20mM each of 
dATP, dCTP, dGTP and dTTP; Invitrogen) and nuclease-free water in a fmal volume of 
30Jll. Reaction mixes were incubated at 42°C for 2.5h and cooled to 4°C for 2min. The 
RNA (in RNA:cDNA heteroduplex structures) was then digested by the addition of 5U 
RNase H in IOX RNase H buffer (NEB, UK). Complementary DNA (cDNA) was purified 
from the reaction mixtures using the MinElute Cleanup Kit (Qiagen, UK) with an 
optimised protocol. 
Briefly, 300JlI of buffer ERC and 30JlI 3M sodium acetate (PH 5) were applied to the 
columns. The samples were added to the mixture on the column, mixed and centrifuged 
for lmin at IO,OOOrpm. The columns were washed in 750J!l buffer PE and spun to dry. 
Finally, the cDNA was eluted twice in IOJlI IOmM sodium-phosphate (PH 8.5). The 
eluates were pooled, dried in a heating block at 65°C and then re suspended in 5Jll O.1M 
carbonate coupling buffer pH9 (2: 1 NaC03:NaHC03, v/v) and coupled with either Cy3 or 
Cy5 monoreactive dye (NHS ester, Amersham) in DMSO (2~1 DMSO per sample with one 
dye pack split for up to 3 samples). Samples were mixed thoroughly, wrapped in foil and 
incubated at room temperature for up t090min in the dark. Uncoupled dyes were removed 
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by MinElute purification (according to the manufacturers' instructions) and cDNA was 
recovered in elution buffer (10J,tl). 
2.2.7.1.2 CMV-tailed nonamer method with MMuLV enzyme 
This method involved a modification of the random primer method in which 3Jlg CMV-
tailed nonamer-F (Table 2.2) was used instead of the 3Jlg random primer. All other 
reagents and conditions remained the same. The strategy was to produce first- and second-
strand cDNA using the tailed-nonamers, followed by amplification using CMV -primers. 
2.2.7.2 Second strand cDNA synthesis and amplification 
2.2.7.2.1 CMV-tailed nonamer method (Taq polymerase enzyme) and amplification 
The second strand was produced using CMV tailed-nonamer-R (Table 22) in a reaction 
volume of 30JJ1. consisting of 3J,tl lOX Taq polymerase buffer (Invitrogen). 1 J,ll of 6mM 
dNTP mix, 2JlI MgCh (50mM), 3Jll CMV taiIed-nonamer-R (3Jlg), and 0.4J,ll (2U) Taq 
polymerase (Invitrogen). The reaction mixture was incubated for 3 min at ambient 
temperature, followed by 30 min incubation at 42°C, and 5 min at 72°C. The cDNA was 
then amplified using the non-tailed CMV primers (Table 2.2). Briefly, 2Jll of 2mM dNTP 
mix was added to the cDNA, as along with 5J,ll each of CMV-F and CMV-R primers 
(5pmollJ,ll each). The cycle parameters were 93°C lOsec, 65°C lOsec, and 74°C 30sec. 
Amplified products were purified using the MinElute reaction cleanup kit (Qiagen). 
117 
2.2.7.2.2 CMV-tailed nonamer method with exo- KIenow enzyme 
This method was a slight adaptation of the Taq polymerase method (section 2.2.7.2.1). 
Five units exo- Klenow enzyme (NEB) was used, along with its IOX buffer. Additionally, 
the dNTPs were at a final concentration of 2mM. 
2.2.7.2.3 CMV-tailed nonamer method with Superscript enzyme 
This method follows the exo- Klenow method (section 2.2.7.2.2), except that the first 
strand was transcribed using Superscript enzyme (400U) in 5X Superscript buffer. 
2.2.7.3 IVT (Random Primer 9) and direct labelling 
A mixture of2~g total RNA and 3~g Random Primer 9 (NEB) in a fmal volume of21~ 
was heated to 70°C for 5min and cooled to 20°C. An IVT labelling mixture (9~1) 
consisting of IOX MMuLV buffer (3J.ll; NEB), 400U MMuLV (2~; NEB), 40U RNase 
inhibitor (lJ.lI; NEB), 2J.lI dNTP mix (2mM each of dATP, dCTP, dGTP, and ImM dTTP; 
Invitrogen) and I ~l Cy3-dUTP or Cy5-dUTP (GE Healthcare, UK» was added to the 
RNA/random primer mix,. The reaction was incubated at 42°C for 2.5h to generate 
fluorescently labelled DNA. The RNA template was removed by adding 5U RNase H and 
IOX RNase H buffer (fmal volume 20J.ll) and incubating at 37°C for 20min. The labelled 
samples were again purified using the MinElute Reaction Cleanup kit (Qiagen) and eluted 
inl0~. 
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2.2.7.4 IVT and indirect labelling 
2.2.7.4.1 Random Primer method 
The initial part of the protocol for amino-allyl indirect labelling was the same as the direct 
labelling of cDNA (section 2.2.7.3), except that the dNTP mix included 5-
aminohexylacrylamide-dUTP (aha-dUTP, Invitrogen). A 20X working stock of aha-dUTP 
mix was prepared containing 22.22mM each of dATP, dCTP, dGTP and aha-dUTP, and 
11.1lmM dTIP. Aha-dUTP is a dTIP derivative which is incorporated into cDNA and 
subsequently labelled with the NHS-ester derivative of a fluorescent dye (indirect method). 
Unincorporated nucleotides were removed using the MinElute Reaction Cleanup kit. 
2.2.7.4.2 CMV-tailed nonamer method with indirect labelling 
In this variation of the Random Primer method using MMuLV (section 2.2.7.1.1), the 
20mM dNTP mix was replaced with 2JJ.l of 20X aha-dUTP mix, 5X MMuL V buffer was 
used instead of the original lOX buffer and 3JJ.l O.lM DIT was added to the mixture 
giving a final volume of 291l1. 
2.2.7.4.3 Supencript method 
This method was similar to the CMV-tailed nonamer method (section 2.2.7.4.2) except that 
the enzyme was SuperScript III (Invitrogen) was used along with its corresponding 5X 
SuperScript buffer. Additionally, the concentration of the aha-dNTP mixture was 
increased to 2X. 
119 
2.2.7.5 Promega Chipshot kit 
'b d and labelled using the ChipShot Indirect Labelling kit RNA was reverse transcn e 
, t 1 (with the exception of the RNA (Promega) according to the manufacturer s pro oco 
A (2 5 . t d of 5 11 g) was reverse transcribed starting concentration). Briefly, total RN . llg lOS ea r 
to cDNA by random priming in the presence of amino-allyl dNTP. The initial RNA 
DNA un·fied The synthesized template was then degraded, and the remaining c was p . 
cDNA was then coupled with Cy3 or Cy5 mono-functional dye (NHS-ester). Finally, the 
labelled samples were purified to remove excess dye. 
2.2.8 Real-time peR 
Real-time polymerase chain reaction (RT-PCR) was carried out in a total volume of 101ll 
containing 1111 sample (genomic DNA! cDNA), O.5pmol of each primer (Table 2.2) and 
2JlI LightCycler FastStart DNA MasterPLUS SYBR Green I (Roche Diagnostics). The 
reaction was performed as follows: HotStart Taq polymerase was activated at 95°C for 
10min, followed by 50 cycles of denaturation at 92°C for Osec, annealing at 55°C for Osec 
and 58°C for Osec, and extension at 74°C for lOsec. The ramp rate between annealing 
temperatures was 3°C/sec and all other ramp rates were at maximum. For quantification, 
the fluorescence signal associated with the binding of SYBR Green I to the double-
stranded PCR product was recorded at the end of each cycle. After the PCR reaction, the 
temperature was decreased to 50°C and then gradually raised to 92°C at a ramp rate of 
O.loC/sec. Fluorescence was continuously monitored during this process for melting curve 
analysis. A negative control (water as sample) was included in each run. Primer pairs 
were synthesised by MWG-biotech AG (UK). 
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Table 2.2 Sequences of tailed random nonamers and primers (5'-3') used in the 
methods. 
Oligonucleotide Sequence Use 
RT-PCR; to 
16S rRNA GGA TCG T AA AAC TCT GTI A TT detect forward primer chromosomal 
DNA 
RT-PCR; to 
16SrRNA 
TIC ACA TCA GAC TTA AAA AAC detect 
reverse primer chromosomal 
DNA 
CMVforward RT-PCR; to 
(CMV-F) GAG GAC AAC GAA ATC CTG TIG GGC produce & 
J'rimer quantify cDNA 
CMV(CMV-R) RT-PCR; to 
GTC GAC GGT GGA GAT ACT GCT GAGG produce & reverse primer 
quantify cDNA 
CMV -F tailed [(AGCT)x9] GAG GAC AAC GAA ATC CTG random cDNA synthesis 
nonamers TIGGGC 
CMV -R tailed [(AGCT)x9] GTC GAC GGT GGA GAT ACT random cDNA synthesis GCTGAGG nonamer 
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2.3 Comparative genome hybridization 
2.3.1 Culture of S. aureus cells 
Bacterial cells were plated onto nutrient agar (HP A, Colindale UK) and incubated 
overnight for 16-18 h at 37°C. The following day a single colony was spread onto a fresh 
nutrient agar plate to fonn a dense layer for DNA extraction after overnight culture. All 
isolates were stored on Microbank beads (Pro-lab diagnostics) at -20°C. 
2.3.2 Genomic DNA extraction 
2.3.2.1 DNeasy kit (Qiagen) 
Cells were harvested from nutrient agar plates with a 1 J.11 culture loop and resuspended in 
1001l1lysozyme/lysostaphin solution (Section 2.2.4.1) and incubated for 30-40min at 37°C. 
DNA was then extracted according to the manufacturers' protocol. 
Briefly, cells were lysed by the addition of 25J.Ll Proteinase K (Qiagen, UK) and 200J.11 
buffer AL, with vortexing to ensure complete mixing. The mixture was incubated at 70°C 
for 30min to complete lysis. DNA was precipitated by the addition of 100% ethanol 
(200JlI) and applied to the DNeasy column for binding. The column was centrifuged for 
lmin (8,000 x g), and washed twice in 500JlI each of buffer AWl and A W2. The column 
was then dried by a further centrifugation (3min, full speed) before finally eluting the DNA 
in 200J.Ll buffer AE. 
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2.3.2.2. Pitcher method (adapted) 
This method was an adaptation of a DNA extraction method described by Pitcher and 
Saunders (1989). 
An inoculation loop of bacterial cells taken from a nutrient agar culture plate were 
resuspended in a 12Sll1 mixture of lysozyme/ lysostaphin as before, and incubated at 37°C 
for 30min. Cells were then lysed by gentle pipetting in 2 volumes of L2 buffer containing 
guanidine isothiocyanate and EDTA (Severn Biotechnology, Kidderminster, UK). Half the 
volume of 7.SM ammonium acetate was added, with mixing. A further 450111 
chloroform:isoamyl alcohol (24:1) was added and the mixture was vortexed thoroughly. 
The phases were separated by centrifugation (10,000 x g) for 2min, and the supernatant 
transferred to a fresh tube. DNA was precipitated by the addition of 0.54 volumes of ice 
cold propan-2-o1, with mixing by inversion of the tube several times. The fibrous DNA 
was then removed using a pipette tip into a sterile I.Sml tube and washed twice in 1 ml 
80% ethanol and air dried overnight. Finally, the DNA was resuspended in SOlll sterile 
deionised water (Sigma). 
2.3.3 DNA amplification 
2.3.3.1 GenomiPhi DNA Amplification Kit (GE HeaIthcare) 
DNA (Sng) in sample buffer, up to a final volume of 10J.l.l, was denatured at 95°C for 3min 
and snap cooled on ice. Single-stranded DNA was then combined with 10lll of the 
amplification mixture (containing IJ.l.l enzyme and 9111 reaction buffer), and incubated at 
30°C for 16-18h. The enzyme was heat inactivated for lOmin at 65°C, and the sample 
cooled at room temperature before purification. 
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To purify the amplified DNA, 1 volume water and 0.1 volume sodium acetatelEDTA 
buffer was mixed with the sample. This was followed by ethanol precipitation with 100J,Ll 
100% ethanol and centrifugation at 12,000 x g for 15min. The supematant was removed 
by aspiration, and the pellet washed in a large volume of 70% ethanol. DNA pellets were 
centrifuged (12,000 x g) again for lmin to ensure that they were adhered to the tube wall 
before the supematant was removed by aspiration. Pellets were air-dried and then 
re suspended in TE. 
2.3.3.2 Whole genome amplification with Phi29 
5ng DNA in a volume of 10J,Ll was denatured at 98°C for 30sec and snap cooled on ice. A 
40J.t1 amplification reaction was added. consisting of Snmoles hexanucleotide primers 
(NEB), 10X Phi buffer (NEB), 1 O~g BSA (NEB), dNTP mix (10mM each; Invitrogen), 
0.005U inorganic pyrophosphatase (Roche Diagnostics) and 1 unit Phi 29 DNA 
polymerase (NEB). The sample was mixed and then incubated at 30°C for 16-18h. The 
amplified products were then purified as described for the GenomiPhi DNA Amplification 
method (section 2.3.3.1). 
2.3.4 DNA labelling methods 
2.3.4.1 Direct labelling 
2.3.4.1.1 Bioprime® Array CGH Genomic Labeling System (Invitrogen) 
A mixture of 2~g genomic DNA and 10,.u of 2.SX random primer solution, to a fmal 
volume of211l1, was heated to 9SoC for Smin and snap cooled on ice for Smin. A labelling 
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mixture of 3.5J.tl was then added, consisting of 2.5~1 lOX dUTP Nucleotide Mix, O.5~1 
Cy3- or CyS-dUTP and O.S~l exo-Klenow fragment. Tubes were wrapped in foil and 
incubated for 2h at 37°C. The reaction was stopped by the addition of 2.5~1 Stop buffer, 
and the samples purified using the MinElute Reaction Cleanup kit (Qiagen). 
2.3.4.2 Indirect labelling 
2.3.4.2.1 Bioprime® Plus Array CGH Indirect Genomic Labeling System (Invitrogen) 
A mixture of 4~g genomic DNA and 20~1 of 2.SX random primer solution, to a final 
volume of 44~1. was heated to 95°C for 5min and snap cooled on ice for 5min. An indirect 
labelling mixture of 5~1 of lOX nucleotide mix with amino-allyl dUTP and lJ.tl exo-
Klenow fragment was added. Reaction tubes were wrapped in foil and incubated for 2h at 
37°Cin the dark. The reaction was stopped by the addition of 2.5J.tl stop buffer, and the 
samples purified using the MinElute reaction cleanup kit (Qiagen). The purified DNA was 
precipitated with lOJlI 3M sodium acetate, 2Jll glycogen and 300JlI ice cold 70% ethanol 
and incubated for 30min at -20°C. The DNA was centrifuged (4°C) at maximum speed for 
20min, and the pellet washed in 250~1 of ice cold 70% ethanol. Finally, the pellet was air 
dried. 
For the coupling reaction, 5J.tl of2X Coupling buffer and 3~1 water first re suspended with 
the dried pellet. To this was added 2JlI Alexa Fluor dye resuspended in DMSO. The tubes 
were mixed thoroughly, wrapped in foil, and incubated at room temperature for Ih in the 
dark. Finally, the labelled DNA was purified using the MinElute Reaction Cleanup kit 
(Qiagen). 
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2.3.4.2.2 Adaptation of the DeRisi cDNA labelling protocol to label genomic DNA 
Genomic DNA (lJlg) and random primer mixture (6Jlg final of8, 9, lOmers; Invitrogen), in 
a final volume of 16JlI, were heated to 95°C for 30sec and then snap cooled on ice. 
Labelling mixture consisting of 10X exo-Klenow buffer (NEB), dNTP mix (20mM dATP, 
dCTP, dGTP each, and 10mM dTIP and aha-dUTP; Invitrogen) and 5U exo-Klenow 
fragment enzyme (4J.l.I total; NEB) were added and incubated at ambient temperature for 
30min, followed by a further incubation at 37°C for Ih. Nucleic acid was purified using 
the optimised MinElute protocol (section 2.2.7.1.1) and labelled as described above 
(2.3.4.2.1 ). 
2.4 Microarray development 
2.4.1 Array design and printing 
2.4.1.1 Oligonucleotide probe design 
The selection of oligonucleotide probes for the array was described by Saunders et al. 
(2004). Briefly. the design of the array was intended to include S. aureus genes that have a 
potential virulence association with the intent of investigating the virulence repertoire of 
clinical strains. A genome browser containing the complete annotations of the S. aureus 
sequenced strains MW2, Mu50 and N315 was developed and used to search for user-
defined keywords to select genes for probe design. The keywords used for this array were 
toxin, leukocidin, coagulase, adhesion, protease, nuclease, lipoprotein, lipase, capsular 
polysaccharide, binding, regulatory and iron. The probes were designed using the 
OligoArray program (Rouillard et al., 2002), a program that computes gene specific and 
secondary structure free oligonucleotides for genome-scale oligonucleotide microarray 
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construction. Each probe on the array consisted on 50 bases, with a calculated melting 
temperature (T m) of approximately 80°C and with minimal internal structure. Probe 
specificity was verified through a local BLAST database containing the complete 
sequences ofMW2, Mu50 and N315. 
The unannotated genome of S. aureus strain MRSA252 (which has since been annotated) 
was also used to identify additional virulence-associated genes by searching for protein 
motifs associated with virulence. Potential genes encoding toxins and adhesins were 
selected using this method. Additional virulence-associated genes that were not present in 
the genomes of the four sequenced strains (e.g. staphylococcal enterotoxin E), selected 
from the literature, were also included. Finally, the seven house-keeping genes used in 
MLST together with the 16S and 23S rRNA subunits were included as positive controls. 
The complete array included probes for 384 genes. 
During this project, the original design of the array has since been extended to include an 
additional 337 S. aureus virulence-associated genes whose sequences have been obtained 
from more recently sequenced strains such as the USAJOO strain. The new genes were 
selected using the methods described above. New keywords used in the genome browser 
included proteinase, peptidase and SCC. A further 30 E. coli gene probes were also added 
as negative controls. These provide a system of calculating background hybridisation 
noise, and therefore enable elimination of noise from real positive results in the data 
analysis. The revised array comprises probes for a total of 751 genes. Gene descriptions 
were updated as new information became available; all annotation descriptions here are 
based on the June-2008 revision (see CD for complete gene list). 
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2.4.1.2 Printing 
2.4.1.2.1 Glass slides 
Oligonucleotide probes were printed onto epoxy coated glass slides (Schott, Nexterion E 
slides). The original probes were 5'-amino-linked, to enable covalent binding of the free 
amino group to the glass surface during micro array preparation. However, it was found 
that non-amino linked probes bind to the epoxy surface efficiently with no observable 
difference in hybridisation so the majority of probes used were of the non-amino linked 
type. 
2.4.1.2.2 Printing platform 
2.4.1.2.2.1 Biorobotics Microgrid 11 
The Biorobotics system is able to print up to 108 slides from up to 20 microtitre plates held 
in a cooled storage rack in an unattended run. Probes were printed at a concentration of 
25pmoVJJ.l in ArrayIT spotting solution (Molecular Solutions Europe Ltd), using tungsten 
split pins (Biorobotics) at ambient temperature and humidity. Slides were printed with 16 
pins to give a 4 by 4 array grid, each block contained 16 rows and 16 columns giving a 
potential total of 4096 features. Four replicate spots were made for each probe. This 
system suffered from the generally low ambient humidity in the laboratory which 
adversely affected spot morphology and caused drying and subsequent blocking of the 
print tips. Later microarray printing was done on the Genetix Qarray mini. 
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2.4.1.2.2.2 Qarray mini (Genetix) 
The Qarray mini proved efficient and reproducible for array printing. The humidity was 
controlled at 50%, Stainless steel TeleChem SMP4 split pins (TeleChem) were used. The 
layout of the arrays was changed to include five replicates, printed at random positions 
within the grid. In this way, the maximum information about a particular gene can be 
gained even in the likely event of spatial artefacts post hybridization. This was a problem 
seen in the previous layout, where sometimes the information for all replicates was lost. 
2.4.2 Hybridization, scanning and preliminary data generation 
2.4.2.1 Hybridization 
Hybridisation (7b) was performed using the Lucidea SlidePro instrument (GE Healthcare). 
Mixed target samples (Cy3 and Cy5 labelled cDNA or DNA) in GenHyb buffer (100!!1; 
Genetix, UK) were denatured (95°C, 3min) and injected into the hybridization chambers of 
the Lucidea SlidePro. The targets usually represented approximately 50% of the total 
eluate from the MinElute clean-up for either DNA or cDNA labelling. Following 
hybridization, slides were washed sequentially (under non-stringent conditions) with IX 
SSCI 0.2% SDS, 0.1 X SSCI 0·2 % SDS, O.IX SSC and propan-2-ol then finally air dried. 
2.4.2.2 Scanning 
In the beginning of the project, arrays were scanned using the Affymetrix™ 428 array 
confocal microscope scanner. This was later replaced by the Genetix aQuire scanner. 
Fluorescence intensity for the Genetix aQuire confocal laser scanner was measured 
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concurrently at 532nm (Cy3) and 639nm (Cy5) using a resolution of 10J.lM. The images 
were then analysed using QScan software (Genetix), which superimposes the two images. 
2.4.2.3 Image processing 
For each array, the process of spot finding begins by positioning the grid (defined by the 
gal file) which indicates by an array of circular areas the expected size and position of each 
spot. The grid is placed over the scanned spots and resized if necessary so that the spots 
fall within the circles as much as possible. Individual circles on the grid may be adjusted 
manually where necessary. Circle areas may also be adjusted to increase or decrease the 
number of pixe1s included in the spot to more clearly define the signal and reduce the 
background intensities. 
2.4.2.4 Generating data statistics 
The gene IDs (associated with each spot) were loaded from a formatted list. The mean, 
mode, median intensities and standard deviations for pixels in both the spots (defined 
areas) and their associated backgrounds were measured. The data was exported as a CSV 
file for more detailed analysis in Microsoft Excel. 
2.4.3 Further data analysis (Microsoft Excel) 
2.4.3.1 Background subtraction 
Initially, for each defined spot on the array, the background intensity (mean intensity of 
pixels within a doughnut shaped area surrounding the spot) was subtracted from signal 
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intensity (mean intensity of pixels within the circle defining the spot). The ratios of the 
background-subtracted two colour intensities were also calculated. 
Median values were calculated for all replicates of each probe, and henceforth used to 
represent that gene. 
2.4.3.2 Normalization, logarithmic transformation and cut-off determination 
Individual probe spot ratios were normalised by dividing by the ratio of the means of all 
spots so that the ratios clustered around a value of one. This method performs a crude 
adjustment for the variable specific activities of the target preparations (including different 
dye incorporation rates) and corrects for different scanner settings used for the two dyes. 
Signals that were greater than the mean plus four standard deviations of the negative 
controls (E. coli specific probes) were considered positive except when the lo~ ratios of 
fluorescence values (Cy3/Cy5) were outside of the normal distribution. The cut-offvalues 
on either side of the normal distribution oflog2 ratios were selected automatically from the 
Minimum Kernel Density algorithm. Similarly signals that were greater than the mean plus 
two standard deviations of the negative controls were considered equivocal. 
2.4.3.3 Data filtering 
Spots that were defined as 'bad' from the raw image (due to poor morphology or spatial 
artefacts) were excluded from the analysis. Furthermore, if 4 of the 5 replicates ofa gene 
were defined as 'bad', the result for that gene was considered equivocal. In addition, each 
probe result for the control strain was checked against the known sequence of MW2 and if 
found to be incorrect the test strain result was discarded. Using these methods, low quality 
and/or questionable data were flagged for further analysis or discarded directly. 
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2.4.3.4 Heat-map generation 
Heat maps were generated in Excel. Initially, the data for all the strains were collated into 
an Excel spreadsheet, where each column contained the full CGH result (positive or 
negative) of one strain. Positive results were coloured red, negative green and the 
equivocal remained white (see CD for complete data set in colour). For those results 
presented in this thesis (unless otherwise stated), positive results are coloured black, 
negative grey and the equivocal remained white. 
2.4.3.5 Cluster analysis 
Cluster analysis was performed in BioNumerics™ (Applied Maths), using the simple 
matching coefficient and UPGMA dendogram type. The heatmap data was converted into 
binary digits, and saved as a comma-delimited text file, which could then be exported into 
BioNumerics TM to produce the clusters. 
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CHAPTER 3.0 S. AUREUS MICROARRA Y DEVELOPMENT AND 
EVALUATION 
3.1 S. aureus microarray development 
The methods often used to delineate the diversity and/or relatedness of S. aureus strains 
circulating within both healthcare institutions and community settings include spa typing, 
ribotyping, PFGE, VNTR, MLST and SCCmec typing. However, none of these techniques 
extensively defines the genes that constitute the organism(s) under investigation. This 
requires further evaluation of the genes of interest within an individual isolate. This is 
currently achieved by PCR amplification of the particular loci of interest followed by 
restriction enzyme analysis or sequencing (Dunman et al., 2004). 
A microarray was designed to provide an alternative method of characterizing S. aureus 
strains, using array features (probes) to differentiate sub-types while concurrently 
providing enhanced information concerning the genetic composition of strains. The 
design also allowed the array to be used as a tool to investigate the natural population 
dynamics of S. aureus strains and to better understand their potential to cause disease. 
The earlier stages of this project focussed on method development, both for CGH and 
transcription profiling. The methods evaluated were detailed extensively in the previous 
section (chapter 2.0). Here the methods leading to the final protocol, used to generate the 
results, are presented and discussed. 
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3.1.1Array Design 
3.1.1.1.Array Layout 
The original probe layout printed on the BioRobotics instrument included four replicates 
for each probe spotted in adjacent positions (fig. 3.1 a). The limitation of this design was 
apparent post-hybridisation where local artefacts occasionally affected all replicates for a 
particular probe. This design layout was improved by printing probes at random positions 
within each sub-grid (fig. 3.1b). In addition, the complete arrays were also printed in 
duplicate on each slide, which significantly reduced the loss of data. 
a 
eeeeddd 
dccccbb 
bbaaaa 
b 
abecdaeb 
dacaedbcd 
ecb 
abecdaeb 
dacaedbcd 
ecb 
duplicate 
arrays 
Figure 3.1 Array layout (a) previous design (b) adapted design layout. 
In the original array design, replicate probes (represented by letters) were printed side by 
side. In the adapted array layout, probes were printed in random order. 
3.1.1.2 Negative control probes 
Escherichia coli probes were spotted onto the arrays for use as negative controls during 
data analysis. These probes provided a system for calculating background hybridisation 
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noise, and therefore enabled its subtraction from the signal. This is important because 
background may be generated by the scanner as well as by non-specific binding. The 
former is apparent within the statistics collected by the scanner software and can be 
eliminated later, whilst the latter can be estimated by means of negative controls such as 
these. This is detailed further in the data analysis section (section 3.1.3). 
3.1.1.3 Printing 
The order of the source plates (used for printing) was rearranged to ensure printing of the 
E. coli negative controls first. and the ribosomal RNA probes (rRNA) (which generated the 
most signal in studies of the transcriptosome) last. This arrangement was chosen to prevent 
possible contamination of the negative controls and other probes by the rRNA, which 
occurred on one occasion where there was an error in setting up the printing robot. 
Contamination was only evident in hybridisations to total RNA when, for example, probes 
printed immediately after the rRNA probes were unexpectedly positive. 
3.1.1.4 Probe design 
All additional probes (n=337) were ordered as 50mers, to match the primary batch. 
Previous research conducted on establishing the optimal length for probes have suggested 
70mers as the best compromise between specificity and sensitivity. However the array 
described here includes many genes that belong to families. Consequently, the selection of 
70mers with high specificity was problematic. Besides the advantage of high specificity (in 
the context of this study). 50mers are significantly less costly than 70mers (approximately 
25% of the 70mer cost) since cartridge purification is unnecessary. 
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3.2 Protocol evaluation 
The microarray was designed for two main types of study (i) CGH, and (ii) transcription 
profiling. CGH involves the analysis of samples at the level of DNA, and therefore 
provides a profile for the presence or absence of genes on the array. Effectively, this 
highlights genetic differences between the strains under investigation. Transcription 
profiling, however, consists of analysis at the level of RNA and provides information 
implicitly about the function of genes through analysis of their pattern of expression or 
regulation. However, as RNA has a very short half life, it can be converted into more 
stable cDNA through reverse transcription. Protocols for converting RNA to cDNA that 
maintain the in vivo gene expression profile were developed during this project. 
3.2.1 Development of a protocol for S. aureus transcription profiling 
An important aspect of this project was to establish a cost-effective and reproducible 
protocol for transcription profiling of S. aureus strains. The biggest limitation of 
transcription profiling protocols is the requirement for relatively large amounts of RNA 
(20-100Jlg total RNA) to produce an adequate signal over background noise. This is 
particularly important for detecting low abundance transcripts. Where the RNA yield is 
low, such as in clinical samples, there are two possible approaches to reduce the quantity 
of RNA required; signal amplification and sample amplification. 
Signal amplification involves improving the labelling efficiency in order to produce a 
greater number of signal molecules per transcript. Conventional labelling methods involve 
the direct incorporation of dye molecules in a reverse transcription reaction. However, this 
approach suffers from several limitations including a high cost for the dyes and inefficient 
incorporation of dye molecules due to their bulky structure. Furthermore, the dye 
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molecules may be incorporated at different rates in different transcripts, a factor that will 
affect the amount of signal generated from these transcripts. More recently. indirect 
labelling techniques have been developed to overcome some of the labelling issues of the 
direct method. In this project, indirect labelling via aa-dUTP and aha-dUTP were tested 
(section 2.2.7.4). The amino-allyl and aha groups are small compared with the standard 
bulky fluorescent dyes and have a minimal impact on incorporation of the nucleotide in a 
reverse transcription reaction. 
The second strategy. sample amplification, involves global amplification of the sample. 
Here the most important issue is the conservation of relative transcript abundance. In 
recent years, many methods for RNA amplification have been developed. These have 
included in vitro transcription using the Eberwine protocol, single primer amplification, 
SMART technology (Clontech). Ribo-SPIA TM RNA amplification (NuGEN), amplification 
using terminal continuation, and others. However. the majority of protocols are tailored 
towards the amplification of eukaryotic RNA by exploiting their characteristic poly-A tail 
sequences. The limited availability of a protocol targeting prokaryotic sources necessitated 
the pursuit of an in-house sample amplification protocol. This section details protocols 
developed to investigate the transcription profiles of S. aureus strains. 
3.2.1.1 RNA isolation and concentration: optimising the RNA yield 
3.2.1.1.1 Optimising the RNeasy protocol 
The primary method used for the isolation of RNA from cells grown on solid and liquid 
agar was the Qiagen RNeasy mini kit. Good RNA yields (O.2Jlg/Jll) were reproducible 
after optimization. Most significantly, the initial RNA stabilisation step implemented prior 
to RNA extraction improved the RNA yield considerably (figure 3.2). RNA stabilisation 
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was initially performed using RNAlater (Qiagen), but later exchanged with RNAprotect 
(Qiagen) which proved more efficient as it is targeted towards use in bacterial samples. 
RNAprotect stabilises RNA prior to cell lysis in order to maintain the gene expression 
profile during the extraction process. These RNA stabilisation products (Ambion patent, 
6.528.641) are buffered salt solutions (e.g. ammonium sulphate) that act by rapidly salting 
out nucleases present within target cells. 
In the early stages of the project, the RNeasy kit provided a yield of 0.1 ~g/~l in 
comparison to the maximum 1 ~g/~l quoted by the manufacturer. As a means of increasing 
the RNA yield, various methods of optimizing the protocol were explored. These included 
using a larger number of cells for RNA extraction, incorporating SDS to break any RNA-
protein bonds that may potentially prevent the RNA from sticking to (or eluting from) the 
Qiagen column membrane, growing cells in liquid culture instead of on solid agar (since 
actively growing cells contain larger quantities of mRNA) and finally optimizing the RNA 
elution step (discussed below). The 16S primers were used to detect the presence of 
chromosomal DNA remaining post- DNase treatment during the RNA isolation procedure. 
DNA-free-RNA samples are essential during subsequent cDNA synthesis to ensure the 
results on the array are representative of gene expression and not contaminating 
chromosomal DNA. In particular, since the array was designed to detect both DNA and 
cDNA targets, there would be no way of differentiating these post-hybridisation based on 
signal alone. 
Figure 3.2 shows RNA extracts (using the RNeasy kit) taken from strain NCTC 8325, 
obtained using different amount of starting material, pre- and post-DNase treatment. Cells 
were extracted from plate cultures. The gel image shows increasing amounts of harvested 
cells (except lane 2 which was part of another test). These same preparations were DNase 
treated and shown also in the figure. In general, the RNA eluted post DNase treatment 
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produced roughly the same yield. Presumably the binding capacity of the clean-up kit 
played some factor in this. However, lane 7 (which contained 2JlI cells) produced the 
largest RNA yield post-DNase treatment (lane 8). Although this particular preparation 
appears degraded in the gel image (a problem experienced initially), it nevertheless showed 
that that using optimised cell numbers was effective in obtaining higher RNA yields. 
Consequently, larger cell numbers (than the initial protocol) were used for harvesting cells 
from plate cultures. The limitation of this method was that it was not reproducible since 
the exact number of cells used was unknown. This could have been overcome by 
resuspending cells in solution and measuring the OD of the suspension, but this method 
was replaced with quantified liquid cultures (described below). 
* * * * 
DNA 
235 RNA 
16SRNA 
Figure 3.2 RNA extractions from strain NCTC 8325-4; evaluating the optimal size for 
cells harvested from plate culture. Lane 1, DNA Hyperladder II; lane 2, part of a 
separate experiment; lane 3, O.5JlI cell harvest; lane 4, DNase treated preparation of lane 3; 
lane 5, O.75JlI cell harvest; lane 6, DNase treated preparation of lane 5; lane 7, 2JlI cell 
harvest; lane 8, DNase treated preparation of lane 7; lane 9, 5JlI cell harvest; lane 10, 
DNase treated preparation oflane 9. DNase digested preparations are marked (*). 
A possible reason for the sub-optimal RNA yields was that RNA was either not sticking to 
the column membrane or it was not eluting efficiently, possibly due to the formation of 
RNA-protein complexes. SDS, which tends to disassociate RNA-protein complexes, was 
included in the lysis buffer but did not significantly improve the RNA yield. It was 
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therefore concluded that RNA-protein complexes were not a persistent problem, and the 
SDS step omitted from the final protocol. 
A further variation of the original protocol was the extraction of RNA from exponentially 
growing cells in liquid culture. This was consistent in providing high yields of RNA. It 
was hypothesised that this was due to the extraction of messenger RNA (mRNA) that is 
present in greater amounts during exponential growth than in stationary phase (as is the 
case with overnight plate cultures). Therefore, RNA was extracted from liquid culture, 
quantified and stabilized in RNAprotect. The RNeasy instruction recommendation of 1 x 
109 cells as an optimal amount of starting material proved sufficient. 
Aside from the starting material volumes and using liquid culture, the most significant 
factor in improving the RNA yield was increasing the RNA elution volume to two 
successive steps (Le. two lots of 50J.11 elutions performed one after the other), instead to a 
single 50J.11 elution. All these modifications improved the yield obtained from the RNeasy 
kit from 0.1 J.1g/J.11 to 0.2J.1g/, .. L1. At one point, pooling cell pellets to increase the RNA yield 
was evaluated, but this did not provide a significant improvement. The limitation here was 
the binding capacity of the column membrane used for extraction and purification. 
3.2.1.1.2 Comparison of different RNA isolation kits 
The RNA yield obtained from the RNeasy kit did not reach the manufacturer's quoted 
yield even with the protocol adaptations described above. To achieve higher yields, a 
number of different kits (both small- and large-scale) were evaluated for the quality and 
quantity of RNA produced. Kits were obtained from several suppliers (Qiagen, Promega, 
Invitrogen and GE Healthcare) and compared with the RNeasy mini kit. 
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In this study the least efficient kit was the Promega Pure Yield kit, which gave a very low 
RNA yield (in a single test. <100ng was obtained at a concentration below 2Ong/I.ll). The 
GE Healthcare kit gave RNA depleted of small RNA when analysed on an agarose gel (not 
shown). Although this is favourable towards concentrating RNA, it was unclear whether 
other RNA transcripts were also being lost. This kit was therefore not pursued. 
Of the large scale extraction kits, the Qiagen RNeasy midi kit was the most successful. 
However, although providing a good yield (40J.lg), the concentration was similar to that 
obtained from the RNeasy mini kit. Furthermore, the midi kit was more time consuming 
and labour intensive than the mini kit, a limitation when extracting from many samples. It 
was therefore not pursued for these reasons. It was concluded that none of the alternative 
kits provided consistent advantages over the RNeasy mini kit used with the modified 
protocol and this kit was retained as the standard method for RNA extraction. 
3.2.1.1.3 RNA concentration 
Methods for concentrating RNA were also investigated. This was important because the 
subsequent cDNA synthesis reactions were limited to a maximum sample input volume of 
20J.lI containing at least 5J.lg RNA. Standard RNA precipitation and vacuum evaporation 
(i.e. Spin-Vac) concentration methods were evaluated. These allowed testing of input RNA 
concentration of O.8J.lg/J.lI (50J.lI reaction mix) in the cDNA synthesis protocols. However, 
concentrated RNA gave poor results in the transcription reactions as judged by poor signal 
intensities on the post-hybridisation array images. Furthermore the vacuum concentration 
method resulted in RNA degradation as judged by gel analysis (not shown). For these 
reasons, these methods were not included in the routine protocol. 
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An alternative method for RNA concentration was the Ribominus kit (Invitrogen) which 
removes rRNA from total RNA. Since rRNA competes with mRNA in reactions dependent 
on random primers it was thought that the presence of large amounts of rRNA might 
reduce mRNA transcription and labelling significantly. Therefore, reducing the levels of 
rRNA should result in more mRNA transcripts being produced. However, gel analysis of 
RNA post Ribominus treatment (not shown) failed to show any material on the gel image 
indicating that no (or very little) mRNA was extracted from cells, or that both the mRNA 
and rRNA were being removed by the Ribominus method or finally that the mRNA was 
not recovered from the binding column used in the kit . 
3.2.1.1.4 RNA quantification 
In the initial stages of the project, RNA integrity was determined by standard gel 
electrophoresis analysis and the yield estimated by comparison to molecular standards on 
the gel. Denaturing gel electrophoresis did not provide a significant improvement in the 
analysis of RNA, and required more toxic reagents. It was therefore not used routinely. In 
later stages, the Qubit quantification system (Invitrogen) was used post-extraction to 
provide a more accurate and faster method of quantifying the RNA yield. 
3.2.1.2 Growth curves 
The growth kinetics of the test isolates were monitored by taking aliquots and measuring 
OD6oo readings and performing viable counts. The objective of this work was to monitor 
the time points of growth to estimate lag-, log- and stationary-phases of growth. Cells 
extracted from log- and stationary-phases would be subsequently used for transcription 
profiling. The logarithmic phase is assumed to be the stage where the greatest amounts of 
mRNA is being produced, reflecting the transcription of genes necessary for growth and 
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other metabolic processes. At the stationary phase, the rates of cell-division and of many 
other processes is reduced although expression of key genes associated with survival under 
adverse conditions is likely to be enhanced. 
The growth patterns for the agr + strain consisted of a short lag phase, followed by an 
exponential phase, then a period of stable cell numbers (possibly even a small decline) 
before the cells resumed growth. In addition, the data suggest that the cells were still 
growing after 23h (fig. 3.3). 
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Figure 3.3 Agr+ growth kinetics over a 23h period. 
The growth curve for the agr- strain was very similar to that of its isogenic partner except 
that the period of stability following exponential growth was less clearly defined (fig. 3.4). 
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Figure 3.4 Agr- growth kinetics over a 23h period. 
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From these data, and similar work (Sabersheikh, 2003), it seems that S. aureus rarely 
display the classic sigmoidal growth curve and often show more than one phase of rapid 
growth. It seems likely that the rapid depletion of glucose and other readily available 
nutrients occurs during the exponential growth phase and that this is followed by a period 
of re-adjustment followed by sustained non-exponential growth over a longer period 
during which there is greater competition for the available resources. 
For the transcription profiling study of the agr mutant strains, the expression profiles for 
early-log (Sh). late-log (7.Sh) and overnight cells (23h) were analysed. As expected log 
phase gave the most heterogeneous mRNA (most spots seen on the post hybridisation 
microarray images). The overnight cultured cells were transcriptionally active but fewer 
transcripts were found at detectable levels. The results of this study are detailed in chapter 
5.0. 
3.2.1.3 cDNA synthesis: signal amplification and sample amplification 
Several parameters of standard cDNA synthesis protocols were evaluated. These methods 
may also include amplification and labelling steps (both direct and indirect). Primarily, 
since prokaryotic mRNAs lack polyA of sufficient length for efficient oligodT priming, 
only random priming was viable in these protocols. The biggest challenge observed 
during cDNA synthesis was the production of the second-strand in the pursuit of indirectly 
labelled cDNA. It appears that the indirect label incorporated into the first cDNA strand 
may have interfered with the production of the second cDNA strand. Consequently, 
reverse transcriptase variants were tested with these protocols to overcome any steric 
effects that may prevent any particular enzyme transcribing the modified nucleotides 
incorporated into the cDNA. 
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Initially, the Bioprime kit (Invitrogen) for the direct labelling of DNAlcDNA was 
evaluated. This method, which depends upon random primers and direct incorporation of 
Cy-dye labelled dUTP by reverse transcriptase, worked well for some samples but was not 
sufficiently robust to provide good fluorescent signals when the input RNA was of lower 
quality. Since good signals are essential for accurate transcript quantification, alternative 
protocols were sought. The problem of inefficient Cy-dye labelled nucleotide incorporation 
has been recognized by the commercial market and alternative and cheaper indirect 
labelling methods have been developed using amine-modified dNIPs (section 2.3.4.2). 
The smaller structure of these modified nucleotides (compared with the relatively large Cy 
groups) enables them to be incorporated into the target nucleic acid at a rate similar to that 
of unmodified nucleotides. The Cy-dye (or Alexa-dye) can then be bound to the target 
DNA post-synthesis by ester bonding. 
In order to overcome the problems associated with limited mRNA yields, experiments 
were performed to adapt PCR for generic amplification of cDNA. Initially, first strand 
cDNA synthesis using commercial Random Primer 9 (NEB) was compared to that 
obtained with an in-house primer comprised of a random nonamer with a cytomegalovirus 
(CMV) specific 5'-tail. Custom synthesised oligonucleotides are less expensive than ofT-
the-shelf nonamers (Random Primer 9). For the second strand synthesis, a random 
nonamer with a complementary CMV primer tail was used. The use of CMV -tailed 
random nonamers (CMV-forward and CM V-reverse) for the first and the second strands of 
cDNA synthesis was designed to generate template cDNAs that should be efficiently 
amplified using non-tailed CMV primers. A previously developed RI-PCR using the CMV 
primers (Kearns et al., 2002) showed their reproducibility in detecting their targets. The 
melt curves, used to confirm PCR product identity, have been shown to be reproducible at 
68°C. For this reason, these primers were incorporated into cDNA synthesis via the tailed 
nonamers. 
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The reverse transcriptase enzyme MMuL V was used with the tailed nonamers to 
incorporate aha-dUTP into first strand cDNA, an adaptation of the DeRisi cDNA synthesis 
and indirect-labelling protocol. During second strand synthesis, two protocol variants 
using either exo- Klenow or Taq polymerase were evaluated. Priming with the untailed 
primer was compared with that achieved using the tailed primers. The cDNA produced 
was analysed by real-time PCR (using either the primers complementary to the CMV tail, 
or SYBR Green). It was shown that cDNA amplification occurred and different yields 
were obtained when different enzymes were used to produce the cDNA i.e. Toq 
polymerase and exo- Klenow fragment (data not shown). The yields were generally low, 
indicating these protocol variants were relatively inefficient (data not shown). However, 
the tailed nonamers were found to be slightly more efficient at producing intact cDNA 
(data not shown). Successful cDNA synthesis was confirmed by a logarithmic 
amplification curve and by a defmed melt peak at 68°C. In all cases with the different 
enzymes, post-hybridisation signals were low, indicating inefficient incorporation. The 
possibility remains that this was due to inadequate RNA extraction and labelling. However, 
gel analysis of the RNA showed relatively good yields and direct labelling protocols 
showed more spots on the array. The results of the different protocols were as follows 
(data not shown). 
The PCR methods were not found to be reproducible with either aha-dUTP or aminO-allyl 
dUTP (used in the original DeRisi protocol). Optimisation of the aha-dUTP:dTTP ratio and 
using a lower aha-dUTP concentration were found to give higher yields of product as 
judged by crossing thresholds during PCR analysis. Yet, by reducing the aha-dUTP 
concentration, fewer Cy-dye molecules would subsequently label to the cDNA, 
confounding the purpose for pursuing indirect labelling techniques. Direct dye 
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incorporation of dUTPs modified with Cy3, Cy5, or the alternatives Alexa-555 and 
Alexa-647 were tested, but these materials also adversely affected the PCR. 
As an alternative to PCR amplification, whole genome amplification methods (originally 
designed for the amplification of DNA) were tested for their ability to produce and amplify 
cDNA. The first protocol tested used random nonamers (N9) for first strand cDNA 
synthesis followed by whole genome amplification using the GenomiPhi (GPhi) kit (GE 
Healthcare). GPhi was used to produce the second cDNA strand, whilst at the same time 
amplifying the two strands (under isothermal conditions). Real-time (RT-) PCR was 
employed for analysis of the products. Primers specific for 16S RNA sequences were used 
in the RT-PCR. Successful whole genome amplification should produce a large number of 
copies of each component sequence recognised by a small number of cycles before the 
crossing threshold is reached. However, the PCR showed that the reaction products of this 
protocol contained low cDNA levels. Examination of the product of whole genome 
amplification revealed that non-specific amplification had occurred since all negative 
controls showed a high molecular size amplification product. This phenomenon has been 
acknowledged by the manufacturer and a second version of the GPhi enzyme is now 
available. 
An alternative in-house whole genome amplification protocol similar to the GPhi kit 
(which utilises Phi29 enzyme) was evaluated so that Phi29 from an alternative source 
(NEB) could be tested. It was hoped that the NEB enzyme would contain lower levels of 
contaminating DNA. This in-house method gave higher yields of high molecular weight 
DNA compared with the GPhi kit but unfortunately was not efficient at amplifying the 
relatively short cDNA sequences that were the intended targets in the reaction (revealed by 
RT-PCR). Generally, it was noted that the use of whole genome amplification with cDNA 
targets did not give significant amplification of the short sequences. One possibility for this 
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low finding is that the whole genome amplification process is relatively inefficient for 
short sequences (Le. cDNA) compared with long sequences (Le. chromosomal DNA). 
Concatenation of cDNA may be a solution to this problem but this was not evaluated in 
this study. 
Gel analysis of cDNA generally showed the presence of residual rRNA (not shown). This 
indicated that the RNaseH hydrolysis was not efficient. RNaseH degrades RNA in 
RNA:DNA heteroduplex complexes. Where cDNA synthesis was inefficient, less 
heteroduplexes will have formed and therefore less RNA will have been degraded. To 
remove residual RNA. alkaline hydrolysis (NaOH) and final neutralisation (HCI) steps 
were added to the protocol resulting in the production of cDNA containing no RNA. 
The inefficiency of the second-strand synthesis and amplification methods when applied to 
S. aureus mRNA greatly reduces the potential advantages of using these methods. 
Furthermore, the addition of manipulations increases the possibility that the final cDNA 
product will not be representative of the cellular mRNA. Consequently, it was decided that 
these steps would not be used in subsequent studies. First strand cDNA indirectly labelled 
with the fluorescent dyes by random priming can generally give reproducible signals in 
microarray work. Additionally, random priming by some reverse transcriptases (with 
DNA properties) can produce the second cDNA strand during the first strand synthesis, the 
evidence for which can be observed post-hybridisation. That is, the design of the 
oIigonucleotides of the virulence-associated micro array was such that they were 
synthesised to capture cDNA in opposite reading orientations (3'-5' and 5'-3'), as is the 
case for the two strands of cDNA. It was observed that the transcripts produced using the 
reverse transcriptase MMuL V for first strand synthesis produced signals in some of the 
oligonucleotides designed to recognise the second strand (data not shown). However, the 
intensity of most of the probes remained weak. The ChipShot kit (Promega) was therefore 
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used in subsequent studies. This kit employs amino-allyl dUTP incorporation via a 
reverse transcriptase (unspecified). The ChipShot kit successfully and reproducibly 
produce indirectly labelled cDNA from S. aureus RNA. The only limitation of this method 
was the requirement of at least 2.5Jlg of total RNA to produce a high quality array image. 
This was achievable with the optimised RNeasy protocol. 
3.2.2 Development of a protocol for comparative genome hybridisation 
3.2.2.1 DNA extraction 
DNA extraction with the Qiagen DNeasy kit was optimised. The manufacturer's 
recommended lysis conditions were sub-optimal and the lysis step described for RNA 
extraction (section 2.2.4.1) was used. During protocol evaluation, the Pitcher method 
(Pitcher and Saunders, 1989) was also evaluated but this was not as convenient as the 
Qiagen kit and the purification of DNA from RNA was less efficient. The DNeasy kit was 
therefore used routinely for DNA extraction. 
3.2.2.2 DNA labelling: signal amplification and sample amplification 
The attempts to produce indirectly-labelled cDNA led to the development of a protocol for 
indirect labelling of DNA via aminohexyl tagged (from aha dUTP) intermediates. 
Primarily, a commercial kit (Bioprime kit) was used. The kit generated good quality 
labelled DNA and spots of good intensity (bright signal) were seen on the post-
hybridisation images. 
The quality of microarray data generated is determined by the quantity and label density of 
the target DNA. These, in turn, are determined by the quality of the DNA extract, the ratio 
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of modified to native nucleotides and the efficiency of coupling with the NHS-ester. 
However. during optimisation of the labelling protocol it was noted that the colour 
intensity (absorbance) of the product eluted from the MinElute clean-up column following 
the NHS-ester reaction was strongly correlated with microarray signal intensity. That is, a 
brightly coloured sample (prior to hybridisation) would give a strong signal on the array. 
whereas a sample with no colour (or with a slight tint) did not produce a good quality array 
signal. Thus colour intensity was used as surrogate for effective labelling. 
The kit protocol has been optimised for a defmed quantity of DNA. However, due to inter-
strain variation, DNA extracts were occasionally of low yield. Furthermore. it was 
considered desirable to be able to store an archive of DNA preparations, therefore, the 
whole genome amplification (WGA) method was evaluated. The GPhi kit (described 
previously. section 2.3.3.1) was tested with chromosomal DNA, and produced amplified 
DNA of large molecular weight. However, the negative controls always showed an 
amplified product (as discussed above). The NEB Phi29 protocol also suffered from 
similar limitations. It was considered likely that the DNA amplified in the negative 
controls was of bacterial origin (i.e. a contaminant of the Phi29 enzyme) and consequently 
that it may influence array results. Thus, WGA was not used to generate DNA for use in 
array studies. Instead in order to overcome the occasional problem of low DNA 
concentrations from the DNeasy columns, diluted solutions were dried on a heating block 
set at 65°C and resuspended in a suitable volume of water. This simple yet effective 
method overcame the possible contamination, time and cost associated with DNA 
amplification techniques. 
The protocol adopted for DNA labelling was an adaptation of the DeRisi cDNA labelling 
protocol (http://cmgm.stanford.edulpbrownlprotocolsJamino-allyI.htm). The adaptations 
made were as follows. The random primer was a cocktail (equal weights) of 8, 9 and 
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IOmers (rather than 9mers). Furthermore, a single dye pack (intended for one sample) was 
used to label three samples without any apparent reduction in the labelling efficiency of the 
DNA. This measure significantly reduced the cost of performing microarray experiments. 
Finally, the MinElute cleanup kit (optimised in the DeRisi protocol) worked efficiently for 
intermediate and final cleanup steps in the protocol. 
3.3 Microarray analysis and data mining 
3.3.1 Pre-analysis 
For each spot on the array, the mean intensities and standard deviations for pixels in both 
the spots and their surrounding local background areas were measured. The local 
background and non-specific background (E. coli mean values) were subtracted from the 
mean value of each spot. Several tests of the data were performed to distinguish between 
positive signals, low signals representing cross-reactivity and background noise. 
Abnormal spots either marked as 'bad' manually (prior to quantification) or automatically 
by discarding spots with high pixel to pixel variation were excluded from the analysis. If 
all four replicates of a spot were marked as 'bad' spots, or if only one good value 
remained, the result was highlighted and classified equivocal. The ratio between the mean 
(or median. see below) signal intensities in the red (Cy3) and green (Cy5) channels were 
then calculated for the remaining replicate spots. Individual spot ratios were normalised by 
dividing by the ratio of the means (or medians) of all spots so that the ratios clustered 
around a value of one. This method performs a crude adjustment for the variable specific 
activities of the target preparations (including different dye incorporation rates) and 
corrects for different scanner settings used for the two dyes. 
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3.3.2 Further analysis 
3.3.2.1 CGH data 
For the CGH arrays, data were analysed relatively conservatively. A reaction was only 
considered positive if, following the elimination of poor spots, there was a minimum of 
two replicates with signals above background. Hybridisation results were categorized as 
positive or negative based on the mean or median spot intensities. Signals that were 
greater than the median plus four standard deviations of the negative controls (E. coli 
specific probes) were considered positive when the fluorescence ratio was in the range 
approximately lo~ ±2. When the ratio was outside this range, the target giving the lower 
signal was considered negative. The purpose of this correction was to eliminate 
hybridisation reactions from similar but non-identical sequences. The precise range of 
ratios was determined from the position of the minima on either side of the major peak 
around zero on a Minimum Kernel density plot as described by Carter and colleagues 
(2008) (minima were usually at approximately +2 and -2 on the lo~ scale). Intensity ratios 
for probes reacting with both strains (i.e. strains being tested on any individual array) were 
always in the range lo~ ±2. These manipulations of the data were performed 
automatically in Microsoft excel using a workbook formatted for the microarray so that it 
was only necessary to paste the raw data and run the Kernel density module. Ratio cut-ofTs 
determined for each array using the kernel density plots provided a robust and dynamic 
way of identifying cross-reactions. By avoiding a fixed cut-off, genes were more likely to 
be classified correctly under the conditions of each particular experiment, therefore 
reducing the number of false-positives. 
As the mean for replicate spots may be skewed by any abnormally high fluorescence 
values (e.g. dust fluorescence), the medians and an estimate of the standard deviation based 
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on the median absolute deviation (MAD) were also used as criterions to determine 
significance. Median values were calculated from all valid replicates of each probe. The 
advantage of using a method based on medians is that outliers were automatically 
eliminated. Furthermore, since the final results obtained are governed by the stringency of 
the analysis, and in particular, the cut-off threshold, genes which hybridise poorly may 
drift in and out of significance. It is therefore important to determine the threshold 
carefully. Signals that were greater than the median plus two standard deviations were 
considered equivocal, and those greater than the median plus four standard deviations were 
considered positive. 
Finally, the data for each array feature was designated positive, negative, weak positive or 
equivocal for both the experimental strain and the control strain. MW2. The results 
obtained for the MW2 strain could be validated against the published genome sequence 
(Baba et al .• 2002), and a consensus result generated for all MW2 replicates. Using this 
approach. discrepancies between individual MW2 probe results with the consensus result 
for that probe highlighted a possible erroneous test result, i.e. results were partially 
corrected by reference to the MW2 data. In this way, the test strain result was flagged for 
further analysis or discarded. The final data set was used for determining similarities! 
differences between isolates and for heat map generation (chapter 4.0). 
3.3.2.2 Transcription profiling data 
Data analysis for the transcription profiling experiments was similar to the CGH data 
analysis. However, the output results were quantitative (to indicate fold change in 
expression) rather than qualitative (gene presence or absence). Briefly, as with the CGH 
experiments, background subtraction (using the E. coli probes) and crude normalisation 
(using the ratio of the mean of all spots) were performed. Scatter plots, in the form of M 
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versus A (MvA) plots were used as a rapid, visual indication of variation within data. 
MvA plots were applied to the data before and after any pre-processing procedure 
(background subtraction, normalisation, etc). These plots show the variability of the data 
(M [minus] = log2 R -log2 G, where Rand G represent the red and green dye channels) as a 
function of the mean (A [average] = Y2 (lo~ R + lo~ G)). Figure 3.5 shows an MvA plot 
for one of the arrays used to generate the agr results (section 5.1) before and after 
normalisation. As with most two colour arrays, the raw data generally show dye bias at 
high and low signal intensities, which is partially corrected by normalisation techniques. 
Normalisation reduces this variability by centering the data. Following normalisation, 
signals greater than the median plus three MAD standard deviations of the negative control 
probes (E. coli) were considered to be significant when the fluorescence ratio was greater 
than lo~ +2 (up-regulated) or lo~ -2 (down-regulated). Additionally, total probe signal 
intensity had to be greater than 900 fluorescence units, indicating sufficient signal was 
detected in both channels. Outside this range, no change in expression was considered. 
Genes were ranked according to fold change in expression. 
154 
~ 
U) 
'<t 
<'l 
<'l 
I 
'1 
U) 
I 
lfl 
I 
-. 
6 8 
6 8 
" . 
12 
A 
. " 
-,,04 
1",,1, 
• I ''. ' , 
..... : t " 
.' 
. " 
14 
Sllbtl',,('tiou "ud Norm:.liS"ltioll 
.... 
,'" ' . 
. '., " , 
. , .... . 
.' 
10 12 4 
A 
.~ . 
.. 
16 
, . . 
Figure 3.5 Typical MvA plot for array data. The top panel displays the raw data before 
any pre-processing. The bottom panel shows the spread of the data following background 
subtraction and normalisation. 
3.4 In silico validation for selected probes: confirmation of microarray results 
3.4.1 Array reproducibility 
3.4.1.1 CGH data set 
The data for all strains used in the CGH study were collated on an excel spreadsheet. The 
reproducibility of the array was assessed in two ways. First by comparing replicates of test 
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strains and second by the degree of matching of the MW2 control strain replicates (n=61). 
Technical replicates provide an indication of the contribution of technical variation in an 
imperfect reaction. Technical replicates were initially performed, but it was found that the 
results were highly reproducible (not shown). Several control measures were included in 
the array design such that only good quality arrays, which produced bright fluorescence 
intensities post-hybridisation, were analysed. Due to consistency between replicates, it 
was not deemed necessary to perform technical replicates for all strains analysed. Instead, 
the level of reproducibility afforded by the array was calculated to provide an overall 
indication of variation, described below. 
Several factors may cause incorrect calling of an array result. The degree of matching 
between probe and target has an impact on the relative fluorescence ratio. In general it was 
found that 1-3 nucleotide differences had little influence on relative fluorescence intensity 
but 4 or more mismatches could have a significant effect on the signal leading to observed 
ratios of >4:1. The significance of a ratio >4:1 is that the sample giving the lower 
fluorescence is automatically called as negative even when the signal is above the cut-off 
(E. coli probe median + two (weak positive) or four standard deviations}. Results may also 
vary for probe/target pairs that routinely give low signals or when probes are missing due 
to printing errors. To reduce the occurrence of errors, the called data were automatically 
screened to eliminate results where the control strain (MW2) gave a non-consensus (Le. 
incorrect) result. This process results in a loss of information but eliminates poor quality 
data. 
A subset (n=80) of probes were chosen to calculate reproducibility and error rates. Sixty 
probes were originally designed using MW2 gene sequences and the remainder from 
MRSA252 genes. The underlying assumptions in these analyses were as follows. The 
probes designed to hybridise to MW2 genes were a useful set since they were all expected 
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to hybridise to the control strain (MW2). However, the estimate of reproducibility based 
on these reactions does not include the effect of variability due to an imperfect match. The 
MRSA252 genome represents the most divergent genome of the sequenced S. aureus 
strains compared with MW2. Furthermore, the probes from this strain were selected 
because a corresponding gene was not identified in strain MW2. It is therefore assumed 
that many of these genes will not have homologues to MW2 (or will have imperfect 
matches that may not result in hybridisation). Probes from MRSA252 should therefore 
show some variability in their reactions with MW2. Table 3.1 displays the error rates 
determined from this data. 
Table 3.1 Array reproducibility. In silico prediction versus experimental array result 
based on a subset of probes (n=80) from the MW2 and MRSA252 genome. Part A gives 
the results for the complete subset of probes, whilst part B shows how these results were 
derived. 
A 
Experimental array 
result 
+ 
-
B 
Correct 
negative 
MRSA252 
probes 767 
n=20 
MW2probes 0 
n=60 
Total 767 
l"l' d' f n SIICO pre lC IOn 
+ -
3842 18 
(82.370/11} (0.38%) 
37 767 
(0.79%) 116.45%) 
False Correct False 
positive positive negative 
18 266 23 
0 3576 14 
18 3842 37 
These results show a 98.82% (true positive + true negative) correct calling rate for the 
experimental results based on the in silico prediction. As discussed above, the MW2 
probes could only give true positive or false negative results. The results obtained from the 
MRSA252 probes, however, could provide estimates of true negative and false positive 
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rates. Analysis showed that the vast majority of MW2 reactions to probes from the 
MRSA252 genome. classified as false positive (n=18). were due to low levels reactions 
between the probes and a similar sequence in MW2 (fig. 3.6). As discussed, a negative 
result from the test strain coupled with a low but significant level of fluorescence due to 
the similar MW2 sequence will result in a positive call, whilst positive hybridisation by the 
test strain leads to the low level MW2 signal being called as negative. Most of the false 
positives were derived from four probes encoding exotoxins which have somewhat 
conserved sequences. With respect to the false negatives, the 23 recorded results were 
derived from only 2 probes (E16-0472, n=13; E16-1208c, n=10) indicating poor probe 
design since the results were not reproducible due to low signal levels. The true positives 
recorded between MW2 and the MRSA252 probes were confirmed for 5 probes. In these 
cases, in silico analysis showed matching between the probes and similar sequences (small 
number of mismatches, fig 3.7) in MW2. However, often the matching was not observed 
over the complete probe, i.e. sequences either side of the probe were not homologous in 
strains other than the MRSA252 genome. Finally, the true negatives recorded (n=767) 
reflect the diversity of the MRSA252 genome compared with MW2. 
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>1 ernb1BX571856 . 11 mD Staphylococcus aureus subsp . aureus strain MRSA252 , compl ete 
genome 
Length=2902619 
Features in this part of subject sequence: 
exotox~n 5 
Query 1 GCAGAAAGTCAAACTGTAAACGCGAAAGTAAAGTTGGATGAAACACAACG 50 
1111111111 1111 111 11111111 11 111 111 11111 111 111111111 
Sbjct 459424 GCAGAAAGTCAAACTGTAAACGCGAAAGTAAAGTTGGATGAAACACAACG 459473 
>1 dbJ IBA000033 . 21 mD Staphylococcus aureus subsp . aureus ~ DNA, complete genome 
Length-2820462 
Features in this part of subject sequence : 
set24 
Query 2 CAGAAAGTCAAACTGTAAACGCGAAAGTAAAGTTGGATGAAACACAACG 50 
11 I I I I I I 11 I I I I I I 11 I I I 11 I I I I 11 I I I 11 I III 11 
Sbjct 438375 CAGAAAGTAAAGCTGTTCACGCGAAAGTAGAACTTGATGAGACACAACG 438423 
Features in this part of subject sequence : 
~ 
Query 2 CAGAAAGTCAAACTGTAAA 20 
I I I I 11 I 11 II I I 11 I I I 
Sbjct 435144 CAGAAAGTCAAACAGTAAA 435162 
Figure 3.6 BLAST output displaying low level sequence homology between probe 
E16-0469 (encoding exotoxin 5) and similar sequences in the MW2 genomes, causing 
false positive probe results. The top panel shows the expected perfect matching with 
genome sequence MRSA252, from which the probe was designed. The bottom panel 
displays the sequence homology of this same probe with the MW2 genome, indicating 
several areas of sequence dissimilarity (e.g. set24) or homology over only a small section 
of the probe (e.g. set21). 
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> i ~mbIBX57185 6.11 ~ Staphylococcus aureus subsp . aureus strain MRSA252 , complete 
genome 
Length=2902619 
Features in this part of subject sequence: 
alpha-hemolysln precursor (pseudogene) 
Query 1 TGAAAACAAGAAACGGTTCAATGAAAGCAGCAGAGAACTTCCTTGACCCT 50 
"""" " "" """""" " """ " "" " """ " 
Sbjct 1180734 TGAAAACAAGAAACGGTTCAATGAAAGCAGCAGAGAACTTCCTTGACCCT 1180685 
Ji ,dbJIBA000033 . 2I ~ Staphylococcus aureus subsp . aureus MW2 DNA, complete genome 
Length- 28 20462 
Features in this part of subject sequence : 
Alpha-Hemolysin precursor 
Query 1 TGAAAACAAGAAACGGTTCAATGAAAGCAGCAGAGAACTTCCTTGA 46 
""'" "'" "'" """"" "" """"'" Sbjct 1140554 TGAAAACTAGAAATGGTTCTATGAAAGCAGCAGATAACTTCCTTGA 1140509 
Figure 3.7 BLAST output displaying sequence homology between probe E16-1208c 
(encoding an alpha haemolysin precursor) and similar sequences in the MW2 
genomes causing true positive probe results. The top panel shows the expected perfect 
matching with genome sequence MRSA252, from which the probe was designed. The 
bottom panel displays the sequence homology of this same probe with the MW2 genome, 
indicating overall sequence similarity except for a few mismatches within the probe 
sequence. 
3.4.1.2 Transcription profiling data set 
In the transcription profiling experiments, it was not expected that the same expression 
readings could be generated through repeat experimentation. Instead, where replicates 
were performed, it was expected that the list of significant genes in each case should be 
very similar in terms of the genes that are expressed. Yet, the overall degree of up or down 
regulation should be similar, and therefore if the genes are ordered numerically, the 
position of genes in this ordered list should be very similar in replicate experiments. 
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CHAPTER 4.0 COMPARATIVE GENOME HYBRIDISATION 
Comparative genome hybridisation (CGH) using the partial composite micro array was 
exploited to study variation within and between lineages of S. aureus to gain insight into 
their diversity and evolution. Further objectives were to identify strain-specific markers or 
those with possible linkage to pathogenicity or epidemicity, both useful for 
epidemiological studies. This chapter has been subdivided to address these aims. 
The strain collection for this study comprised a panel of internationally recognised 
healthcare-associated (HA-) and community-associated (CA-) strains, representative of the 
most clinically significant lineages in humans. The dominant lineages prevalent in hospital 
environments belong to CCS, CC8, CC22, CC30 and CC4S, whilst those in the community 
setting include CCI, CC8, CC59, CC80, CC88, ST93 and CC97. Five of the sequenced 
MRSA strains (MW2, Mu50, N315, COL and SA252) and two of the sequenced MSSA 
strains (MSSA-476 and NCTC-8325) were also analysed. The results are presented and 
discussed below (see CD for complete data set). 
4.1 Studying variation amongst lineages of S. aureus 
4.1.1 Clonality of S. aureus 
The clonality of S. aureus has long been recognised through traditional typing techniques. 
Feil and colleagues (2004) showed this by performing MLST on clinical S. aureus strains. 
International standardisation of typing and nomenclature was greatly improved through 
MLST, which groups strains into clonal complexes (CC) according to the nucleotide 
sequences of a core set of conserved genes. Despite the fact the design of the array 
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comprises the variable and core-variable genes rather than the standard 'house-keeping' 
genes used for MLST, the data presented here show congruence with MLST (see Table 4.1 
and Figure 4.1). An advantage of the array approach is the additional information afforded 
by this technology (discussed previously, section lA). Presentation of the data in heat map 
format provides a way of analysing the data visually and rapidly. Individual strain profiles 
can be used as a means of discriminating between related strains. The array provides a 
valuable and comprehensive tool based on the determination of virulence-associated 
markers of strains of interest. The data generated can be used as a standard reference when 
analysing further clinical strains on the array. 
As well as detecting differences between strains of a given CC, this technology facilitates 
recognition of putative areas of gene transfer (horizontal or vertical), resulting in variation 
amongst lineages. Furthermore, by studying more strains, recombination events may be 
more easily detected. Of course, this is dependant upon the design of the array and number 
of genes included in the compilation, as well as the strain collection under investigation. 
Table 4.1 displays the heatmap profile of the strain collection when grouped by clonal 
complex. By comparing the black areas, it can clearly be seen that there are many areas of 
similarity within a CC but which differ between CCs. 
With respect to selecting markers for typing purposes, this may be easily achieved. 
However, rather than simply selecting genes present in a group, selecting sets of genes that 
are both present and absent provides a more discriminatory approach. Table 4.2 highlights 
some of those features most noticeable from the array data that may be used to define 
strains within a CC. However, with respect to the singletons (Le. only I strain from a CC), 
more representative strains of these groups would need to be investigated on the array. 
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Table 4.1 Clonal Complexes 
Snapshot profile of CGH results for a subset of the strains used in this study; strains were grouped into clonal complexes based on previous MLST data. 
Each horizontal strip represents one strain, whilst vertical strips represent a single gene profile; red areas mark gene presence, absence is indicated by 
green, and areas of ambiguity are marked in white (this is the same for all similar tables in this chapter to follow). The table shows that CGH similarities 
within a group are congruent with MLST data. 
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Table 4.2 Microarray features specific to the major clonal complexes analysed on the array. These represent the array features that may be used to define isolates 
within a CC. For example, SA2010-2012 are unique to the CCS group, whilst SA0190-97 are found only in CCI and CCS. Clonal complexes 1,5 and 30 generally had 
one consensus profile for this genes list, whilst CC8 and CC22 had several variants. In particular, the ST239 and ST240 strains differed from the consensus CC8 profile 
at several loci. 
CCI CC5 CC30 
CC8 and variants CC22 and variants 
-0\ 
~ 
Oneval neg 
~ f ! I! ! ~ ~ ~ , , !! Strain Identifier MLST -SCCmec MLSTCC I I 
ST772-V ST772-V (PVl+) 1 
USA1000 SE Asia ST59-V (PVl+) 59 
EMRSA 15 var 83 (0414) ST22-1V 22 
EMRSA 15 var 83 (0415) ST22-IV 22 
EMRSA 15 var 83 (0412) ST22-IV 22 
EMRSA-15 var B1 ST22-IV 22 
EMRSA-15 var B7 ST22-IV 22 
EMRSA-15 (NCTC) ST22-IV 22 
EMRSA-15 var B27 5T22-IV 22 
ST22-IV 5T22-IVc (PVl+) 22 
EMRSA-15 var 83 5T22-IV 22 
EMR5A-15 var B5 5T22-1V 22 
Veterinary 5train 5T398 39B 
EMR5A-16 var A1 ST36-11 30 
5A252 5T36-11 30 
EMRSA-16 var A16 5T36-11 30 
EMRSA-16 var A29 (r2) ST36-11 30 
EMRSA-16 var A29 (r1) ST36-11 30 
EMR5A 16 var A2 ST36-11 30 
EMRSA-16 var A14 ST36-11 30 
EMRSA-16 (NCTC) Tk1 ST36-11 30 
EMRSA-16 (NCTC) Tk2 ST36-11 30 
5T39-11 5T39-11 30 
USA1100SWP ST30-IVc (PVl+) 30 
Queensland done ST93-1V (PVl+) 93 
ST86-IV ST66-IVa (PVl+) 88 
EMRSA-12 (NCTC) ST8-IV 8 
EMR5A-2 (NCTC) 5T8-IV 8 
EMRSA-10 (NCTC) ST254-IV 6 
EMR5A-13 (NCTC) 5T8-IV 6 
EMRSA-14 (NCTC) ST6-IV 6 
Irish-2 5T8-IV (var) 6 
EMRSA-17 (NCTC) 5T247-1 6 
EMRSA-5 (NCTC) ST247-1 8 
EMRSA-8 (NCTC) ST250-1 6 
USA300 ST6-IVa (PVl+) 8 
COL ST250-1 6 
Iberian 5T247-1 8 
EMRSA-1(NCTC) 5T239-1I1 8 
EMR5A-11 (NCTC) 5T239-1I1 6 
EMRSA-4 (NCTC) 5T239-111 6 
EMR5A-7 (NCTC) ST239-1I1 6 
EMRSA-9 (NCTC) 5T240-1I1 8 
Irish-1 5T8-11 (var) 8 
NCTC 8325 5T8 8 
SM76 5T1 
WA-MR5A 5T1-IVa (PVl nag) 
MW2 consensus 5T1-IV 
U5MOO ST1-IVa (PVl+) 
European Clone ST80-IVc (PVL +) 80 
5T779-IV 5T779-IV 
ST97 ST97-V 97 
Paediatric (U800) ST5-IV 5 
5T5-IV ST5-IVc (PVL+) 5 
EMRSA-3 (NCTC) 5T5-l 5 
South German ST226-1 5 
NY/Japan ST5-11 5 
Mu50 ST5-11 5 
N315 5T5-11 5 
ST5-IV ST5-IV (PVl nag) 5 
5T886-IV ST886-IV (PVl+) 5 
Figure 4.1 Clustering based on the complete array profiles for all the strains used in 
this study. 
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4.1.2 UK Epidemic HA-MRSA strains: EMRSAI-EMRSAI7 
4.1.2.1 Background 
Epidemic MRSA strains (defined as "those which have been identified in two or more 
patients in two or more hospitals"; O'Neill et al., 2001) have become a significant public 
health problem over recent years. One of the points of discussion and investigation into 
these strains is the reason behind their success within healthcare environments; they spread 
rapidly, and are difficult to control and eradicate. 
EMRSA strains were originally recognised by phage typing characteristics (Marples et al., 
1986) and later confirmed as clonal by molecular typing techniques. The first of the 
epidemic MRSA strains recognised was dubbed EMRSA-l, and was detected in England 
in 1981. This clone became more widespread in the south east of England where it was the 
predominant clone until it began to decline in 1987 (Marples and Cooke 1988. Marples and 
Reith 1992). In this geographic location, EMRSA-1 was able to spread and persist in 
hospitals more successfully than other strain types. In the early 1990s, the national survey 
of MRSA showed EMRSA-1 was declining and the prevalence of EMRSA-3 was 
increasing (Marples and Reith, 1992). Cockfield and colleagues (2007) later noted that in 
any particular hospital, only one or two MRSA lineages predominate. Furthermore, 
international molecular epidemiological studies collected since the late 1980s suggest the 
massive geographic spread of MRSA is due to the dissemination of a relatively few 
epidemic clones (Crisostomo et al., 2001). 
In the late 1990s, EMRSA-15 (ST22-IV) and EMRSA-16 (ST36-II) became the 
predominant clones in UK hospitals and were estimated to account for greater than 95% of 
all MRSA bacteraemias in the UK (Johnson et al., 2001). It seems reasonable to propose 
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that these clones possess genetic features enabling them to be particularly well adapted to 
survive and spread in hospitals compared with other MRSA. From a genomic point of 
view, the search for genes associated with this epidemic phenotype is a primary focus. 
Identification of such genes would be helpful in the identification of 'fit' strains and would 
increase understanding of the mechanisms of strain 'success' and pathogenicity. Almost 
60% of the strains in this study were EMRSA strains of different genetic backgrounds; 
within this, almost half were representatives of EMRSA-15 and -16. The remainder 
included strains of EMRSA types 1 - 17 (except EMRSA-6 which produced poor 
hybridisation results). Analysis of these strains along with non-epidemic HA-MRSA 
sought to identify type-specific markers and to seek common features that might be 
responsible for, or at least correlate with, the EMRSA phenotype. Of the groups, several 
strains belong to the same CC and carry the same SCCmec type. The array profiles 
obtained from these strains are useful as a means of detennining array typeability and 
discriminatory power. The typeability afforded by the array is detennined by the ability to 
distinguish between similar isolates (many of which belong to the same CC). Furthermore, 
regarding the EMRSA-15 and EMRSA-16 PFGE subtypes, array discriminatory power is 
apparent by ability to separate different variants (subtypes) of these two clones (several 
subtypes of these groups were analysed). Finally, the data generated from this EMRSA 
strain collection should provide insights into traits possibly important in their success and 
transmissibility, with particular focus on the clones which have been predominant in the 
UK healthcare setting for the last 2 decades (EMRSA-15 and EMRSA-16). 
4.1.2.2 Determination of array typeability and discriminatory power 
The discriminatory ability of the array is illustrated in figure 4.2 and table 4.3 which show 
a tree diagram and heat map obtained from the profiles of EMRSA strains of CC8 (all 
strains excluding EMRSA -3, -15 and -16 which are not CC8). These show that the related 
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strains cluster well together, but can be distinguished from their near relatives. The 
specificity of the array is illustrated in table 4.4, which shows the ability to discriminate 
between the EMRSA-16 variants and other members of CC30. 
Simple matching (> 5O%MEAN) 
Oneval neg 
. . T ... . 1jI •.. • T ... .T .... T ... . , ... . T ... . , .... ~ .... ~ Strain Identifier 
EMRSA-12 (NCTC) 
EMRSA-2 (NCTC) 
EMRSA-10 (NCTC) 
EMRSA-13 (NCTC) 
'----- EMRSA-14 (NCTC) 
.------- EMRSA-17 (NCTC) 
'------- EMRSA-5 (NCTC) 
'-------- EMRSA-8 (NCTC) 
EMRSA-11 (NCTC) 
EMRSA-1 (NCTC) 
EMRSA-4 (NCTC) 
EMRSA-7 (NCTC) 
EMRSA-9 (NCTC) 
MLST -SCCmec 
ST8-IV 
ST8-IV 
ST254-IV 
ST8-IV 
ST8-IV 
ST247-1 
ST247-1 
ST250-1 
ST239-111 
ST239-1I1 
ST239-1I1 
ST239-111 
ST240-111 
MLSTCC 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
8 
Figure 4.2 Dendogram ofCC8 members ofEMRSAl-EMRSA17. Clustering was based 
on Simple Matching and UPGMA. 
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Table 4.3 EMRSAI-EMRSA17 strains belonging to CC8 
Partial profile of the CGH results of CC8 EMRSA strains. The strains of the same sequence type cluster together (compare vertical strips within a group and between 
groups). 
..... 
0'1 
\0 
STS-IV 
ST254-IV 
ST:M7·1 
ST250-1 
ST239-m 
ST:MO-m 
Table 4.4 CC30 strains 
Comparison of EMRSA-16 variants with the other members of CC30. The top panel represents the EMRSA-16 classified strains; 1-6 correspond to differing 
pulsotypes ofEMRSA-16 termed variants AI , A16, A29, A29 (replicate), A2 and A14 respectively, whilst 7 and 8 are technical replicates of the NCTC EMRSA-16 
strain. The bottom panel denotes the other CC30 members in the following order (9, 10, and 11): USAIOOO (ST30), ST39 and MRSA252 (ST36) respectively. The data 
show the strains display a general similarity, but variation is noted with the NCTC strains (7 and 8) and USA 1000 (9). The complete sequence of MRSA252 (11; an 
EMRSA-16 representative) is known. 
..... 
-....J 
o 
:2 
3 
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8 
f EMRSA-16 
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10 CC30 
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4.1.2.3 Investigating markers associated with success of HA strains 
Moore and Lindsay (2002) studied EMRSA-15 and -16 strains by RFLP analysis (Southern 
blotting) and noted they were markedly different from each other, as well as from other 
EMRSA strains. They also noted EMRSA-3 was distinct from other UK EMRSA. 
Furthermore, EMRSA-l, -4, -7, -9 and -11 were classified as closely related. Similarly, 
EMRSA-2, -5, -6, -8, -10, -12, -13, -14 and -17 were also grouped. In addition, their 
analysis showed that EMRSA-15 and -16 and -3 all carried enterotoxin genes seg and sei 
which form part of the enterotoxin gene cluster (egc) that could play a role in virulence. 
Microarray-based analyses support these observations. 
It can be said that it may be the absence rather than the presence of particular virulence 
genes that determines strain success or selective advantage. In such a case, the advantage 
may come from the reduced burden associated with the absence of these extra genes. The 
microarray data shows that EMRSA-15 and -16 strains differ from other EMRSA in the 
presence or absence of many genes (Tables 4.5 - 4.10). This accounts for the genetic 
distance between these strains and the remaining EMRSAs. The array study was designed 
to investigate whether there were common features of the EMRSA-15 and EMRSA-16 
groups that account for their relative success. To address this, the EMRSA-15 and 
EMRSA-16 strains were compared to the EMRSAI-EMRSAI7 group (Table 4.5). 
Features that differentiated the EMRSA-15/16 strains from the other groups, as well as 
from each other were determined (i.e. genes unique to EMRSA-15 andl-or -16). In the 
original array annotations, many of these genes were classified as 'hypothetical proteins'. 
Therefore, further in silico work was conducted to update these annotations by association 
to more recently sequenced S. aureus strains. The results are summarised in Tables 4.6-
4.10. 
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Features unique to EMRSA-15 and EMRSA-16 strains (compared to the rest) were 
analysed. Table 4.6 & 4.7 show features that define EMRSA-15 strains compared with the 
remaining groups (including EMRSA-16). Few genes were found to be unique to the 
EMRSA-15s; a few lipoproteins and protease/peptidase genes were noted, as well as 
surface proteins. In comparison, the features that uniquely define the EMRSA-16 group 
from the rest were more extensive (Tables 4.8 & 4.9). Several protease genes, as well as 
enterotoxins, exotoxins, lipoproteins and genes associated with S. aureus pathogenicity 
island 1 (SaPlnl) were present (Table 4.8). Furthermore, of those genes that were absent 
from the EMRSA-16 group only, several transcriptional regulators, ABC transporters, 
putative membrane proteins and toxins of the leukocidin family were identified. Of 
particular interest are the transcriptional regulatory genes that are different from those of 
the MW2 and N315 strains used in the oligo probe design. The implication here is one of a 
varied (or partly varied) regulatory network in the EMRSA-16 strains. Furthermore, also 
included are a block of genes encoding lantibiotic synthesis from genomic island nuSaa2. 
Finally, features shared by EMRSA-15 and EMRSA-16 strains but absent from other 
strains were investigated (Table 4.10). The genes constituted purely the accessory 
genome. In particular, genes from bacteriophage <l>Sa2mw (phage genes, but lacking 
MW1401 - large terminase), bacteriophage <l>N315 (enterotoxins), genomic island nuSaa 
(exotoxins), pathogenicity island SaPln3 (enterotoxins) and further enterotoxins from an 
unknown pathogenicity island. In view of the fact the core genomes being compared are 
distinct, EMRSA-16 strains were compared to the other CC30 strains, and EMRSA-15 to 
CC22 strains. These analyses showed <l>Sa2mw genes to be unique to EMRSA-15 and 
EMRSA-16 strains (absent from the other members ofCC22 and CC30 of which the CA-
MRSA strains were included). However, the enterotoxins of SaPln3 were present in all the 
CC30 members; as was the case for the enterotoxins of <l>N315 in CC22 strains, i.e. these 
features were not unique to EMRSA-15. In conclusion, features unique to a particular 
172 
group of strains can be detected and selected from the array. Furthennore, it is apparent 
that the success of a particular clone is probably more to do with subtle differences 
between strains rather than any particular virulence factor since no one factor has been 
identified with certainty to date (although it is important to acknowledge such factors may 
not have been included in the array design). From the microarray data presented, it is 
tempting to speculate that one aspect of EMRSA15/16 success may be attributable to the 
acquisition of extra accessory genes, and in particular the <l>Sa2mw genes. 
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Table 4.5 Comparison ofEMRSAl-EMRSA17. Panel A shows all CC8 members. Panel B shows EMRSA-I5 members (CC22) and panel C shows EMRSA-16 
members (CC30). The blue panels separate the three groups - colours in the top blue panel highlight features specific to EMRSA-I5 compared to the other two groups, 
whereas the lower blue panel highlight features specific to EMRSA-16 compared to the rest; a yellow panel highlights missing feature(s) whereas brown defines 
features unique to EMRSA-15 and/or EMRSA-16. The red areas indicate gene presence, green represent gene absence, and equivocal results remain white. The table 
provides an overview of the degree of similarity/differences between the groups; the details of this are summarised in Table 4.6 - 4.10. 
---.l 
~ 
A 
B 
c 
Table 4.6 CGH probes absent from EMRSA15 but present in EMRSAI-EMRSA16. Using a local BLAST utility, these genes were blasted against all available 
sequenced annotations for S. aureus strains. Homologies to genes of known function have been listed where possible (the same was conducted for Tables 4.7-4.10). 
Additional information obtained from the updated annotations are highlighted in grey. 
Gene ID-
Absent from 
EMRSA-15 
MWOIOS 
SA0377 
SA0378 
MW0400:lp13 
SA0400:lp14 
MW0401:lp14 
SA0404:lp1S 
SAV0416 
SAV0417 
.....:l 
VI 
Original annotation 
[Strain used for oligo design] 
hypothetical protein [MW2] 
hypothetical protein [N315] 
hypothetical protein [N315] 
hypothetical protein (Ip113) [MW2] 
hypothetical protein (Ip14) [N315] 
hypothetical protein (Ip114) [MW2] 
hypothetical protein (IplS) [N315] 
hypothetical protein [MuSO] 
hypothetical protein [MuSO] 
E-value Homology to other genomes [strain] (%homology) 
SAUSA300 0136 cell wall surface anchor family protein 7.00E-22 (100) [USA300-FPRJ7571 
SAR0136 putative surface anchored protein (sasD) 7.00E-22 (100) [MRSA252] 
SAUSA300 0390 conserved hypothetical protein 7.00E-22 (100) [USA300-FPRJ 757] 
SA V0417 hypothetical protein [Mu50] 7.00E-22 (100) 
SAUSA300 0416 staphylococcus tandem lipoprotein 7.00E-22 (100) [USA300-FPR3757] 
SAR0444 putative lipoprotein [MRSA252] 7.00E-22 (100) 
SAUSA300 0411 staphylococcus tandem lipoprotein 7.00E-22 (100) 
ruSA300-FPR3757] 
SAS0400 putative membrane protein [MSSA476] 3.00E-12 (92) 
SACOL04S1 staphylococcus tandem lipoprotein [COL] 3.00E-12 (92) 
SAR0443 putative lipoprotein [MRSA252] 7.00E-22 (100) 
SAUSA300 0417 staphylococcus tandem lipoprotein 3.00E-12 (97.37) [USA300-FPR3757] 
SAUSA300 0418 staphylococcus tandem lipoprotein 4.00E-17 (96) [USA300-FPR3757] 
SAR0444 putative lipoprotein [MRSA252] 4.00E-17 (96) 
SACOL0485 staphylococcus tandem lipoprotein 4.00E-17 (96) [COL] 
SAUSA300 0390 conserved hypothetical protein 7.00E-22 (100) [USA300-FPRJ7S7] 
SA0378 hypothetical protein [N31S] 7.00E-22 (100) 
SAVl811 :splC serine protease (splC) [Mu50] SAUSA300 1756 serine protease SpJC (spJC) [USA300-FPR3757] 
MW1753 serine protease SplC (spIC) [MW2] 
SA2124:fosB fosfomycin resistance protein fotB SAUSA300 2280 metallothiol transferase fosH (fosB) (fosB) [N315] [USA300-FPR3757] 
SAR2419 putative fosfomycin resistance protein (fosB) 
[MRSA252] 
SAV2451 subfamily S9C non-peptidase homologues SAUSA300 2396 para-nitrobenzyl esterase (pnbA) [Mu50] [USA300-FPR3757] 
SAR2541 putative carboxylesterase [MRSA252] 
MW2375 hypothetical protein, similar to para-
nitrobenzyl 
esterase chain A [MW2] 
-- ----
Table 4.7 CGH probes present in EMRSA-15 but absent from EMRSA1-EMRSA16 
Gene ID-
Present in 
EMRSA-15 
SA1208 
SAV2596 
-...l 
0\ 
Homolo 
SA1208 h 
SAS1316 
family SI unassigned peptidases 
7.00E-22 (lOO) 
7.00E-22 (lOO) 
7.00E-22 (100) 
7.00E-22 (J 00) 
7.00E-22 (lOO) 
7.00E-22 (100) 
7.00E-22 (lOO) 
E-value 
7.00E-22 
7.00E-22 
Table 4. 8 CGH probes present in EMRSA-16 but absent fro m EMRSAI-EMRSA15, i.e. unique to EMRSA16 
Gene ID - Present Original annotation Homology to other genomes (strain] E-value 
in EMRSA-16 [St rain used for oligo desif n J (%homolofY) 
Hypothetical protein (lpll) [N315] SAUSA300 0410 staphylococcus tandem lipoprotein SA0396:lpll [USA300-FPR3757] 7.00E-22(100) 
SAR0439 putative lipoprotein [MRSA252] 7.00E-22 (100) 
MW0397:lplO Hypothetical protein (lpll 0) [MW2] SAS0399 putative lipoprotein [MSSA476] 7.00E-22 (100) 
SAR0440 putative lipoprotein (pseudogene) [MRSA252] 3.00E- 12 (92) 
El 6-0475 Exotoxin [MRSA252] SAR0435 exotoxin [MRSA252} 7.00E-22 (1001 
El 6-0776 Putative membrane protein [MRSA252] SAR0686 putative transposase (pseudogene) [MRSA252] 7.00E-22 (100) 
E16-1213c Exotoxin [MRSA252] SAR 1140 exotoxin [MRSA252] 7.00E-22 (lOO) 
SA1819:tsst- l Toxic shock syndrome toxin-l (tst) [N315] SA V20 11 toxic shock syndrome toxin-I (tst) [Mu50] 7.00E-22 (100) 
SAB0360c toxic shock syndrome toxin-I (tsst-l) [RF122] 5.00E-20 (lOO) 
EI6-2042c Enterotoxin [MRSA252] SABI70lc enterotoxin 0 (seo) [RF1221 7.00E-22 (lOO) 
SA V 1830 enterotoxin (soo) [Mu50] 4.00E-08 (89.361 
E16-2024c Enterotoxin [MRSA2521 SAB 170 I c enterotoxin 0 (seo) [RF 122] 7.00E-22 (100) 
SA 1648 enterotoxin seO (seo) [N315] 4.00E-08 (89.36) 
SAY 1830 enterotoxin (soo) [Mu50] 4.00E-08 (89.36) 
EI6-2025c Serine protease (pseudogene) [MRSA252] SAR 1903 serine protease (pseudogene) [MRSA252] 7.00E-22 (100) 
EI62027c Serine protease [MRSA252] SARI905 serine protease [MRSA252] 7.00E-22 (lOO) 
SAB 1670c serine proteinase JspIE)[RF 122] 3.00E-18 (100) 
E16-2979c Putative subtilase family protease [MRSA252] SAR2789 putative subtilase family protease [MRSA252] 7.00E-22 (lOO) 
Hypothetical protein [N3IS] SAB 1896c hypothetical mobile element-associated protein SA1822 [RF122] 7.00£-22 (100) 
SAB0357 bovine pathogenicity island protein om [RF1221 7.00E-22 (lOO) 
SACOL0904 pathogenicity island protein [COL] 7.00E-22 (100) 
Hypothetical protein [N3IS] SAB 1902c hypothetical mobile element-associated protein SA1826 [RFI22] 7.00E-22 (100) 
SAB0353 bovine pathogenicity island protein Orfll [RF 122] 7.00£-22 (100) 
SACOL0900 pathogenicity island protein [COL] 7.00£-22 (lOO) 
SAI828 Hypothetical Qrotein [N315J SAR0375 hYQothetical protein rMRSA2521 7.00E-22 (100) 
-....l 
-....l 
SA1829 
SA1833 
SA1834 
SA1341 
SA2259 
SA2382 
SA2389 
-....l 
00 
Hypothetical protein [N315] 
Hypothetical protein, similar to transcription 
regulator [Pathogenicity [N31S] 
Hypothetical protein [N315] 
Hypothetical protein, similar to export 
protein SpcT [N31S] 
Conserved hypothetical protein [N31S] 
Truncated hypothetical protein, similar to 
glutamyl-endopeptidase [N315] 
Truncated hypothetical protein, similar to 
metalloproteinase mpr [N31SL __ 
SAB 1904c hypothetical mobile element-associated protein 
[RFI22] 7.00E-22 (lOO) 
SAV2022 hypothetical protein [Mu50] 7.00E-22 (lOO) 
SAB 1905c hypothetical mobile element-associated protein 
[RF I 22] 4.00E-17 (96) 
SAB0350 bovine pathogenicity island protein 0rf15 [RF122] 4.00E-17 (96) 
SA V2026 hypothetical protein fMuSOl 7.00E-22 (lOO) 
SA V2027 hypothetical protein [MuSO] 7.00E-22 (100) 
SARIS88 putative membrane protein fMRSA252] 2.00E-19 (98) 
SAV2471 conserved hypothetical protein [MuSO] 7.00E-22 (100) 
SA V2S96 hypothetical protein [MuSO] 7.00E-22 (lOO) 
SA V~S9~oJhetical protein [MuSO] 7.00E-22 (lOO) 
Table 4.9 CGH probes absent from EMRSA-16 but present in other EMRSAI-EMRSA15 
Gene ID -
Absent EMRSA-16 
MW0062 
MW0063 
MW0064 
MW0065 
MW0066 
SA0745 
SA1159 
SA 1320 
MW1742 
MW1744 
--.J 
\0 
Original annotation 
[Strain used for 01i20 design] 
Hypothetical protein, similar to macrolide-efflux 
determinant [MW2] 
Conserved hypothetical protein [MW2] 
Hypothetical protein, similar to transcriptional 
regulator (LysR family) [MW2] 
Hypothetical protein [MW2] 
Hypothetical protein, similar to transcriptional 
regulator [MW2] 
Hypothetical protein, similar to extracellular matrix 
and [N315] 
Hypothetical protein, similar to two-component 
response regulator [N315] 
Hypothetical protein [N315] 
Hypothetical protein [MW2] 
Hypothetical protein fMW21 
Homology to other genomes [strain] 
SAUSA300 0091 putative permease [USA300-FPR3757] 
SAUSA300 0092 conserved hypothetical protein [USA300-
FPR3757] 
SAUSA300 0093 transcriptional regulator, LysR family domain 
protein [USA300-FPR3757] 
SAUSA300 0094 conserved hypothetical protein [USA300-
FPR3757] 
SAUSA300 0095 transcriptional regulator, LysR family domain 
protein [USA300-FPR3757] 
SAS0066 LysR-family regulatory protein [MSSA476] 
SA V0814 hypothetical protein [Mu501 
SAB0747 truncated secreted von WiLlebrand factor-binding 
protein homolog [RFI22] 
MW0768 hypothetical protein, similar to extracellular matrix and 
plasma binding [MW2] 
SAS0755 putative exported protein [MSSA476] 
SAUSA300 1220 DNA-binding response regulator, LuxR family 
[USA300-FPR3757] 
MW 1209 hypothetical protein, similar to two-component response 
regulator [MW2] 
SAUSA300 1380 conserved hypothetical protein [USA300-
FPR3757] 
SAB1349c probable lipoprotein [RF122] 
SAS 1724 hypothetical protein [MSSA4761 
SAUSA300 1747 conserved hypothetical protein [USA300-
FPR3757] __ 
- - --
E-value 
(%homology) 
7.00E-22 (lOO) 
7.00E-22 (lOO) 
7.00E-22 (100) 
7.00E-22 (lOO) 
7.00E-22 (100) 
7.00E-22 (lOO) 
7.00E-22 (lOO) 
2.00E-19 (98) 
4.00E-17 (96) 
4.00E-17(96) 
7.00E-22 (lOO) 
7.00E-22 (lOO) 
7.00E-22 (lOO) 
4.00E-08 
(89.36) 
7.00E-22JIOO) 
7.00E-22 (100) 
SASl726 putative membrane protein [MSSA476] 7.00E-22 (lOO) 
SACOL 1854 hypothetical protein [COL] 7.00E-22 (lOO) 
Hypothetical protein, similar to ferrichrome ABC SAUSA300 2135 iron compound ABC transporter, permease 
MW2102 transporter (permease) [MW21 protein [USA300-FPR3757] 7.00E-22 (100) 
SAB2057c ferrichrome ABC transporter [RF122] 7.00E-22 (100) 
SACOL2166 iron compound ABC transporter, permease protein 
[COL] 7.00E-22 (100) 
SA2272 Hypothetical protein [N315] SA V2484 hypothetical protein [Mu50] 7.00E-22 (100) 
SAUSA300 2427 conserved hypothetical protein, authentic 
frameshift [USA300-FPR3757] 3.00E-21 (100) 
Staphylococcal accessory regulator A homolog SAUSA300 2437 staphylococcal accessory regulator T (sarT) 
SA2286:sarH3 (sarH3) [N315] [USA300-FPR3757] 7.00E-22 (100) 
MW2417 staphylococcal accessory regulator A homolog (sarT) 
[MW2] 7.00E-22 (100) 
Hypothetical protein, similar to ABC transporter SAUSA300 2465 ABC transporter, A TP-binding protein 
SA2314 (A TP-binding [N315] [tLSA300-FPR3 757] 7.00E-22 (100) 
SAB2400 probable ATP-binding ABC transporter [RF122] 7.00E-22 (100) 
Hypothetical protein, similar to ABC transporter SAUSA300 2465 ABC transporter, A TP-binding protein 
MW2446 (ATP-binding protein) [MW2] [USA300-FPR3757] 7.00E-22 (100) 
SAB2400 probable ATP-binding ABC transporter [RF122] 7.00E-22 (lOO) 
MW2447 Conserved hypothetical protein [MW2] SAUSA300 2466 putative membrane protein [USA300-FPR3757] 7.00E-22 (lOO) 
Hypothetical protein, similar to 
synergohymenotropic toxin precursor - SAUSA300 1974 LeukocidinlHaemolysin toxin family protein 
MW1941 S. intermedius [MW2] [USA300-FPR3757] 7.00E-22 (100) 
Hypothetical protein, similar to leukocidin chain SAUSA300 1975 AerolysinlLeukocidin family protein [USA300-
MWl942 lukM precursor [MW2] FPR3757] 7.00E-22 (100) 
SAB1876c probable leukocidin S subunit [RF122] 7.00E-22 (lOO) 
SAI813 hypothetical protein, similar to leukocidin chain lukM 
[N315] 
----- - - ---
7.00E-22 (100) 
-00 
o 
Table 4.10 Genes common to EMRSA-15 and EMRSA-16 but absent from other strains studied 
. Gene ID-
Common to Original annotation Homology to other genomes [strain] E-value 
EMRSA15 & [Strain used for oligo design] (%homology) 
EMRSA16 
E16-1212c SARI 139 exotoxin [MRSA252] SAUSA300 1059 putative exotoxin 1 ruSA300-FPR3757] 1.00E-04 (85.71) 
E1 62040c SAR1919 enterotoxin fMRSA2521 SAB1699c enterotoxin I (sei) fRF122] 7.00E-22 (100) 
E16-2041c SARI920 enterotoxin fMRSA2521 SAB 1700c sem-truncated (sem-truncated) [RF 122] 7.00E-22 (lOO) 
SA 1647 enterotoxin SEM (sem) fN315] 3.00E-09 (91.11) 
I E16-0463 SAR0424 exotoxin [MRSA2521 SAR0424 exotoxin [MRSA252] 7.00E-22 (lOO) 
E16465 SAR0425 exotoxin [MRSA2521 SAR0425 exotoxin fMRSA2521 7.00E-22 (100) 
E16-0467 SAR0427 exotoxin 3 (set3) fMRSA252] SAR0427 exotoxin 3 (set3) fMRSA252] 7.00E-22 (lOO) 
SA1643:sen enterotoxin SeN (sen) fN315] SAV1825 enterotoxin (sen) [Mu50] 7.00E-22 (lOO) 
SA1644:yent2 enterotoxin YENT2 (yent2) fN3151 SAV1826 enterotoxin (vent2) fMu50] 7.00E-22 (100) 
SAB1698c enterotoxin type C variant (sec-variant) [RFI22] 1.00E-14 (95.65) 
SA1646:sei 
extracellular enterotoxin type I precursor SAV1828 extracellular enterotoxin type I precursor (sei) [Mu50] 7.00E-22 (lOO) (sei) [N3151 
SAB 1699c enterotoxin I (seD [RFI22] 2.00E-06 (93.75) 
SA1647:sem enterotoxin SEM (sem) fN315] SA V 1829 enterotoxin (sem) [Mu50] 7.00E-22 (100) 
SAB 1700c sem-truncated (sem-truncated) [RF122] 1.00E-08 (89.58) 
SAV1827:yentl enterotoxin Yentl (yent 1 )fN3151 SA V 1827 enterotoxin (yent 1) fMu50] 7.00E-22 (100) 
SAB l698c enterotoxin type C variant (sec-variant) [RF122] 2.00E-19 (98) 
SA VI 830:seo enterotoxin SeO (seo) fN315] SA V 1830 enterotoxin (seo) Mu50] 7.00E-22 (lOO) 
MW1767:LukD leukotoxin (\ukD) [MW2] SAUSA300 1768 leukotoxin LukD (IukD) [USA300-FPR37571 7.00E-22 (lOO) 
SAS 1748 gamma-haemolysin component B precursor (hlgB) 7.00E-22 (100) fMSSA4761 
MW1768:LukE leukotoxin LukE (IukE) fMW21 SAB 1687c leukotoxin E subunit (IukE) [RF122] 7.00E-22 (100) 
SAS 1749 gamma-haemolysin component A precursor (hlgA) 
IMSSA4761 7.00E-22 (100) 
MW1754:splB serine protease SplB (splB) fMW21 SAUSA300 1757 serine protease SplB (splB) [USA300-FPR3757] 7.00E-22 (lOO) I MW1755:splA I serine protease SplA (sPlA) [MW2] 1 SAUSA300 1758 serine protease SplA (splA) [3.4.21.19] [USA300-
FPR37571 
17.00E-22 (100)1 
-00 
I MW1757 
MW1758:bsaG 
I 
MW1759:bsaE 
MW1760:bsaF 
MW1761 
MW 1762:bsaD 
MW 1763:bsaC 
MW 1764:bsaB 
00 
N 
hypothetical protein, similar to Ear 
protein [MW2] 
hypothetical protein, similar to EpiG 
(bsaG) [MW2] 
hypothetical protein, similar to EpiE 
(bsaE) [MW2] 
hypothetical protein, similar to EpiF 
(bsaF) [MW2] 
hypothetical protein, similar to EpiP 
precursor (bsaP) [MW2] 
hypothetical protein, similar to EpiD 
(bsaD)~2] 
hypothetical protein, similar to EpiC 
(bsaC) [MW2] 
hypothetical protein, similar to EpiB 
(bsaB) [MW21 
SAUSA300 1759 conserved hypothetical protein [USA300-FPR3757] 7.00E-22 (lOO) 
SAS1738 putative exported protein [MSSA476] 7.00E-22 (lOO) 
SAUSA300 1760 lantibiotic epiderm in immunity protein F (epiG) 7.00E-22 (100) [USA300-FPR3757] 
SAS 1739 putative lantibiotic ABC transporter protein [MSSA476] 7.00E-22 (100) 
SAUSA300 1761 lantibiotic epidermin immunity protein F (epiE) 7.00E-22 (100) [USA300-FPR3757] 
SAS1740 putative lantibiotic ABC transporter protein [MSSA476] 7.00E-22 (100) 
SAOUHSC 01947 membrane 2rotein, putative [NCTC 8325] 7.00E-22 (100) 
SAUSA300 17621antibiotic epiderm in immunity protein F (epiF) 7.00E-22 (100) [USA300-FPR3757] 
SAS 1741 putative lantibiotic transport ATP-binding protein [MSSA476] 7.00E-22 (100) 
SAUSA300 1763 lantibiotic epidermin leader peptide processing serine 7.00E-22 (100) protease EpiP (epiP)[USA300-FPR3757] 
SAB 1679c probable serine protease precursor [RF 122] 7.00E-22 (lOO) 
SAS 1742 putative lantibiotic leader peptide processing serine protease 7.00E-22 (lOO) [MSSA476] 
SAUSA300 1764 lantibiotic epidermin biosynthesis protein EpiD (epiD) 
7.00E-22 (lOO) [4.1.1.36] [lJSA300-FPR3757] 
SAS 1743 putative lantibiotic modifying enzyme IMSSA476] 7.00E-22 (100) 
SACOLl875 epiderm in biosynthesis protein EpiD (epiD) [COLl 7.00E-22 (100) 
SAUSA300 1765 lantibiotic epiderm in biosynthesis protein EpiC (epiC) 7.00E-22 (lOO) [USA300-FPR3757] 
SAS 1744 putative lantibiotic biosynthesis protein [MSSA476] 7.00E-22 (100) 
SACOL 1876 epidermin biosynthesis protein EpiC, authentic point 7.00E-22 (100) 
mutation (epiC) [COL] 
SAUSA300 1766 lantibiotic epidermin biosynthesis protein EpiB (epiB) 7.00E-22 (100) [USA300-FPR3 757] 
SAS1745 putative lantibiotic biosynthesis protein [MSSA476] 7.00E-22 (100) 
SACOLI877 epidermin biosynthesi_~protein EpiB (epiB) [COL] 7.00E-22 (lOO) 
, 
, 
MW1765 
MWl766:bsaAl 
MW 1386 
MW1390 
MW 1393 
MW1400 
MW1401 
MW1405 
MW1408 
MW1769 
00 
w 
hypothetical protein, similar to 
gallidermin precursor (bsaA2) [MW2] 
hypothetical protein, similar to 
gallidermin precursor (bsaAl) [MW2] 
hypothetical protein [MW2] 
hypothetical protein [MW2] 
MW1393 major tail protein [MW2] 
hypothetical protein 
MW1400 portal protein [MW2] 
MWI401 tenninase large subunit [MW2] 
MW1405 hypothetical protein [MW2] 
MW1408 hypothetical protein [MW2] 
MWI769 hypothetical protein [MW2] 
SAUSA300 1767 lantibiotic epidermin biosynthesis protein EpiA (epiA) 7.00E-22 (100) [USA300-FPR3757] 
SACOLI8781antibiotic epidermin precursor EpiA (epiA) [COL] 7.00E-22 (100) 
SAOUHSC 01953 Gallidermin superfamily epiA, putative [NCTC 8325] 7.00E-22 (l001 
SAS 1747a lantibiotic precursor [MSSA476] 7.00E-22 (lOO) 
SAB1685c hypothetical protein [RF122] 3.00E-18 (97.92) 
SAUSA300 1389 phiSLT ORF636-like protein[lJSA300-FPR3757] 7.00E-22 (lOO) 
SAR1503 hypothetical phage protein [MRSA252] 7.00E-22 (lOO) 
SAOUHSC 01521 SLT orf636-like protein [NCTC 8325] 7.00E-22 (lOO) 
SAUSA300 1393 phiSLT ORF2067-1ike protein, phage tail tape measure 7.00E-22 (100) protein [USA300-FPR3757] 
SACOL0379 prophage L54a, tail tape meausure protein, TP901 family 7.00E-22 (lOO) [COL] 
SAOUHSC 01525 phage tail tape meausure protein, TP901 family, core 7.00E-22 (100) 
region domain protein [NCTC 8325] 
SAUSA300 1397 phiSLT ORF213-like protein, major tail protein 2.00E-21 (100) [USA300-FPR3757J 
SAS0940 major tail protein [MSSA476] 2.00E-21 (lOO) 
SACOL0375 prophage L54a, major tail protein, putative [COLl 2.00E-2l (lOO) 
SAOUHSC 01529 major tail protein [NCTC 8325] 2.00E-21 (100) 
SAUSA300 1403 phiSLT ORF412-like protein, portal protein [USA300-
2.00E-21 (lOO) FPR3757] 
SAR 1518 portal protein [MRSA252] 2.00E-21 (lOO) 
SAOUHSC 01538 phage terminase, large subunit, putative [NCTC 
7.00E-22 (lOO) 8325] 
SAUSA300 1404 phiSLT ORF 563-like protein, tenninase, large subunit 4.00£-08 (89.36) [USA300-FPR3757] 
SACOL0367 prophage L54a, terminase, large subunit, putative [COL] 4.00£-08 (89.36) 
SAUSA300 1408 phage helicase [USA300-FPR3757] 7.00E-22 (100) 
SAUSA300 1410 virulence-associated protein E [USA300-FPR3757] 7.00E-22 (100) 
SAUSA300 1770 conserved hypothetical protein [USA300-FPR3757] 7.00E-22 (lOO) 
4.2 Investigating recombination events 
4.2.1 Background 
Genetic exchange is an important part of the evolution of any organism, facilitated by 
transformation, transduction and/or conjugation. Transduction, the most common of these 
mechanisms, is mediated by bacteriophage, and can result in the replacement of tens of 
kilobases in vitro (Milkman et al., 1999). Conjugation, also mediated by mobile genetic 
elements. involves cell-to-cell contact. Conjugative plasmids or transposons facilitate the 
movement of host DNA, which can be hundreds of kilo bases in vitro (Lloyd and Buckman 
1995, Milkman et. al. 1999). Transformation on the other hand, involves the uptake of 
DNA from the local environment. by competent bacteria, but results in smaller 
replacements of less than ten kilobases in nature (Feil et. al .• 2000). These mechanisms of 
horizontal gene transfer have played an important role in the genetic diversity and 
epidemiology of pathogenic bacteria. Although not all such genetic events result in 
enhanced fitness, recognition of these events is of great interest (genetic exchange resulting 
in loss of fitness is unlikely to be detected). In the S. aureus genome. the accumulation of 
virulence and antibiotic resistance genes has been mediated via bacteriophage. transposons 
and plasmids alike. However. these genetic changes have not been limited to the accessory 
genome. The microarray was used to probe for recombination events that may have 
occurred during the evolution of successful S. aureus lineages. 
4.2.2 ST239 lineage 
It has been reported (Robinson and Enright, 2004) that ST239 (e.g. EMRSA-l) is a 
recombinant lineage. The evidence for this was derived from MLST -based analysis, but it 
was also revealed using the original version of the virulence-associated microarray 
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(Saunders et al. 2004). ST239 appears to have originated from a large-scale 
recombination event between a CC30 strain (which contributed approximately O.3Mb, 
including the origin of replication) and a CC8 strain (which contributed the remaining 
genes, approx. 2.5Mb). This is illustrated in Table 4.11 which shows heat maps for ST239, 
two CC30 strains and two CC8 strains. Table 4.11 a shows genes around the origin of 
replication and similarity between ST239 and CC30. Table 4.11b shows genes remote from 
the origin and congruence between ST239 and CC8. Strain ST239 has been a significant 
public health problem in terms of its success and transmission, causing many hospital 
infections world-wide. 
Table 4.11 Similarities between ST239 and CCs 8 and 30 indicate recombination. 
Genes present are shown in black, genes absent in grey and no result in white. Each vertical strip 
represents results for a subset of probes (genes) in a single strain. The left (A) and right (B) panels 
represent genes taken from near to the origin of replication and remote from the origin of 
replication respectively. For simplicity results for only five isolates are shown, two different CC30 
strains, two CC8s and one ST239 (CC8). 
CC30 CC30 ST239 CC8 CC8 CC30 CC30 ST239 cca CC8 
B 
. 
-
-
.~ 
1 
0 __ . 
A 
185 
4.2.3 ST22 lineage 
In the same way that the origin of ST239 may be illustrated using heat maps (Table 4.11) 
similarities were identified between the core genome of strains of CC22 and 
representatives of other clonal complexes (data not shown). These relationships are 
represented in the dendrograms shown in figure 4.3. These indicate that CC22, which 
includes the EMRSA-15 lineage prevalent in the UK, evolved via a large scale 
recombination between CC8-like and CC30-like strains. Approximately O.9MB from 
around the origin of replication (between genomic islands nuSa4 and nuSaa, figure 4.4) 
appears to have originated from CC8 with the remainder from CC30. This is illustrated in 
figure 4.3 which shows dendrograms representing similarities between CC8, CC22 and 
CC30 strains based on the two sets of contiguous core genes. Figure 4.3a shows that CC8 
and CC22 cluster based on genes around the origin of replication (nuSa4 to nuSaa) while 
figure 4.3b shows CC22 and CC30 clustering based on the remaining genes. 
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Oneval neg Onevolnog 
;:: I : ;: . ~ Stra WlldenUfter MLST .scCmec MLSTCC 'l' 'l' '!' 'l' 'l' '1' 
MLST-SCCmec MLSTCC 
iI , . EMRSA-16 var Al ST36-11 30 
EMRSA-16 Vir A16 ST36-U 30 
SA252 ST36-U 30 
SA252 ST36-11 30 
EMRSA-16 Vir Al ST36-U 30 
EMRSA-16 var A16 ST36-11 30 
EMRSA-16 Vir A29 (rl) ST36-1 30 EMRSA-16 var A29(r2) ST36-11 30 
EMRSA-16 Vir A29 (r2) ST36-1 30 USA1100SWP ST30-IVc (PVL+) 30 
ST39-11 ST39-K 30 EMRSA-16 var A29 (rl) ST36-11 30 
EMRSA-16 (NCTC) Tltl ST36-1 30 EMRSA-16 (NCTC)Tkl ST36-11 30 
USAll00SWP ST30-lVc (PVL+) 30 ST39-11 ST39-11 30 
EMRSA 16 var A2 ST36-1 30 EMRSA 16varA2 ST36-11 30 
EMRSA-16 Vir A14 ST36-n 30 EMRSA-16 var A14 ST36-11 30 
EMRSA-7 (NCTC) ST239~n 8 EMRSA 15varB3 (0412) ST22-IV 22 
EMRSA-9 (NCTC) ST240~g 8 ST22-1V ST22-IVc (PVL +) 22 
EMRSA-l (NCTC) ST 239-1 U 8 EMRSA-15 var Bl ST22-IV 22 
EMRSA-12 (NCTC) ST~V 8 EMRSA-15 var B5 ST22-IV 22 
Ilelilll ST247-1 8 EMRSA-15 var B3 ST22-IV 22 
EMRSA-l0 (NCTC) ST254-IV 8 EMRSA-15 var 827 ST22-IV 22 
lrish-2 ST~V(var) 8 EMRSA-15 (NCTC) ST22-IV 22 
COl ST250~ 8 EMRSA-15 var 87 ST22-IV 22 
EMRSA-5 (NCTC) ST247~ 8 EMRSA-17 (NCTC) ST247-1 8 
USA300 STSWa (PVL+) 8 EMRSA-5 (NCTC) ST247-1 8 
EMRSA-8 (NCTC) ST250~ 8 EMRSA-l0 (NCTC) ST254-IV 8 
EMRSA-17 (NCTC) ST247-1 8 Iberian ST2H-1 8 
Irish-l ST~I(var) 8 IriSl-2 ST8-IV (var) 8 
NCTC 8325 STB 8 NCTC 8325 STB 8 
EMRSA-15vlrB5 ST22-1V 22 EMRSA-B (NCTC) ST25O-1 8 
EMRSA-15v..-87 ST22-1V 22 COL ST250-1 6 
EMRSA-15 v..- B 1 ST22-1V 22 EMRSA-7 (NCTC) ST239-111 8 
EMRSA 15 var B3 (0412) ST22-1V 22 EMRSA-9 (NCTC) ST240-1N 8 
ST22-IV ST22-lVc (PVl +) 22 EMRSA-l(NCTC) ST239-1H 8 
EMRSA-15v..-827 ST22-1V 22 EMRSA-12 (NCTC) ST8-IV 8 
EMRSA-15 (NCTC) ST22-1V 22 USA300 ST8-IVa (PVL +) 8 
EMRSA-15 v..- B3 ST22-1V 22 IrlSl-l ST8-11 (var) 8 
Figure 4.3 Dendograms indicating that CC22 may have been derived by large-scale recombination. The dendrograms represent similarities derived only from core genes 
for all strains belonging to CCs 8, 22 and 30. Panel A shows the result obtained for genes situated clockwise between genomic islands nuSa4 and nuSaa (including the origin of 
replication); here CC22 clusters with CC8 strains. Panel B shows the result for the remaining genes; CC22 clusters with CC30 group. 
-00 
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Figure 4.4 Chromosomal map of the MW2 genome used to show the location of the genomic 
islands nuSa4 and nuSaa. ST22 is proposed (in this thesis) to be a recombinant strain derived 
from a large scale recombination event between a CC8 and a CC30 background. The area around 
the origin of replication between nuSa4 and nuSaa is proposed to have originated from the CC8 
background, with the remainder from CC30. 
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4.2.4 ST772 lineage: a unique example of clonal diversification 
A further example of genetic exchange can be postulated for the ST772 lineage 
(represented by the Bengal-Bay clone in this data set; Ellington et al. , 2009), which 
belongs to CCl. Its MLST allelic profile shows it to be a single locus variant from the STl 
strains of CC 1 (Table 4.12). From this point of view, these strains should all have a very 
similar genetic background, which in the case of the CCl strains, the array data 
demonstrates this similarity (Table 4.13). However, the CGH data show the ST772 clone 
presents a different profile to the CC 1 strains. In fact, ST772 appears to be more similar to 
USAlOOO (CC59, which has no MLST alleles in common to ST772, Table 4.12) than to 
members of CCl. This overall genetic similarity can be seen in figure 4.1 (tree diagram 
based on the complete genetic profile). Based on prior information, the onJy cornmonality 
between these isolates was carriage of the type V SCCmec element, and geographic 
association with the Asian sub-continent (ST772 Bangladesh, and ST59 S.E. Asia, 
Taiwan). This was investigated further using the heatmaps. Table 4.13 shows ST772 
compared with USAIOOO and members of CC} (MW2 and WA-MRSA) over both the core 
and accessory genomes. In both cases the greater similarity of ST772 to USAlOOO can be 
clearly seen. 
Table 4.12 MLST allelic profiles for S. aureus sequence types STl, 772 and 59. ST772 is a 
single locus variant to STI (at the pta locus). ST59 shares no alleles in common to ST772. 
MLSTtype arcC aroE glpF gmk pta tpi yqiL 
STl 1 1 1 1 1 1 1 
ST772 1 1 1 I 22 I 1 
ST59 19 23 15 2 19 20 15 
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Table 4.13 Similarities between ST772 [3] and ST59 (USAIOOO) [4] suggest recombination. 
ST772 and USA 1000 were compared to members of CCl (MW2 [I] and WA-MRSA [2]) over 
core (panel A) and accessory genes (panel B). ST772 is a member ofCCl, although the array data 
show it to cluster with USA 1 000 (ST59) based on the core and accessory genome. 
A B 
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From prior knowledge of S. aureus evolution, the possibility a lineage with the same 
MLST alle1es as a particular c1onotype (ST772 and CC I) would present such large genetic 
differences over the core and accessory genome, seems unlikely. Had the variation been 
limited to just the accessory genome, this would have been accounted simply by the 
gain/loss of mobile genetic elements. Furthermore, had variation been seen in several 
MLST alleles (instead of 1 allele alone), a recombination event could have been a 
possibility. However, ST772 appears to be a genetically unusual. The array shows that its 
core genome as well as the accessory genome is unlike STl. Additionally, it is not an 
obvious mosaic like the S1'239 or S1'22 lineages. From the perspective of molecular 
typing, this shows that MLST can be misleading in inferring degree of genetic similarity. 
That is to say, this typing method (which has been the framework for studying S. aureus) is 
not always a reliable indication of genotype, and this can only be highlighted by looking at 
the overall genomic profile rather than a few select genes. 
A possible theory for the relationship between ST772 and STI is descent from a common 
progenitor. Additionally, ST59 could have descended from ST772; these relationships are 
summarised in the diagram below (fig. 4.5). Here it is proposed that multiple 
recombination events (involving core non-essential genes and accessory genes) in the STI 
MSSA background (over a short period of time) gave rise to the ST772 group without 
affecting the core-essential genes. Following on from this, the accumulation of point 
mutations in the core-essential genes (including the MLST alleles) in the ST772 
background gave rise to ST59. It is speculated that the acquisition of type V SCCmec 
could have occurred either after the point mutations or during the period of 
recombinational exchanges. Indeed this explanation would explain why ST59 and ST772 
are more similar than to STI, in that they are more genetically linked in their evolutionary 
descent, compared with STI. 
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SCCmec IV 
I MRSA I ST1 
I MSSA I 
sn Point mutations in house-
I MSSA I scc~ V I MRSA I 
8T59 -----~ ST59 
keeping genes 
mUltiple reco~ ~ /,<,.. I MRSA I 
MSSA events involving ST772 ____________ ---+~ ST772 
non-essential genes SCCmec V 
Figure 4.5 Proposed relationship between STl, ST772 and ST59. 
ST772 is proposed to have descended from the STl genetic background which would explain the 
commonality of 6 out of 7 MLST alleles between these two clones. The accumulation of multiple 
recombination events over the non-essential core genes (as well as the accessory genome) over a 
short period of time, followed by point mutations in the core-essential genes could explain the 
linkage between STI, ST772 and ST59. ' *' marks alternative points at which SCCmec type V may 
have been acquired. 
These data show that the analysis of many genes of an organism has more benefit in 
providing a more complete picture of the genomic content of an organism and thus for 
evolutionary studies. In some instances, the MLST framework for analysing evolutionary 
relationships can be misleading. Furthermore, the evolutionary picture of successful S. 
aureus strains (such as ST239 and ST22) may be more complex than originally anticipated. 
Large scale chromosomal exchange, as well as the accumulation of virulence factors could 
be the key to the spread and success of these clones. 
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4.3 Exploring genotypic differences that may explain variation in epidemiology and 
pathogenicity of S. aureus 
4.3.1 Distribution of genes between HA and CA S. aureus 
One of the aims of this study was to identify any patterns of genotypic variation that might 
account for differences between the HA and CA phenotypes. Initially, genotypic ally 
defined groups of HA and CA-strains, belonging to the same clonal cluster and harbouring 
the same SCCmec type were analysed and compared. This strain collection included three 
clusters (Tables 4.14 - 4.16) belonging to CCs 5, 8 and 22. The results showed that the 
core genome was well conserved even between the groups. However, as expected, 
variability was seen with respect to the mobile genetic elements, and in particular the 
bacteriophage genes. Bacteriophage are recognised as key factors in bacterial pathogenesis 
(Boyd et al. 2001, Wagner and Waldor 2002) and bacterial population dynamics 
(Burroughs et al. 2000, Hendrix 2003). Given that the core genome of S. aureus strains are 
relatively similar across clonal complexes, variation in the genomic content of the mobile 
genetic elements (see Appendix I) are likely to be important influences on the 
pathogenicity potential and success of particular strains. 
For the CC5 strains (Table 4.14), none of the CA strains carried the genes for <I>Sa2mw 
(MW1390-MW1405), whereas two of these three strains carried a group of consecutive 
genes for <I>Sa3mw (MWI896-MWI912) which were absent in the HA-strain. 
Additionally, these same two CA-strains carried a set of genes from SaPIl (S. aureus 
pathogenicity island 1), which were also absent in the HA strain. 
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The HA strains of CC8 were represented by four strains, Irish-2 and three EMRSA strains 
(EMRSA-2, -13 and -14). This group of strains were very similar with respect to the core 
genome and most parts of the accessory genome (some differences were noted on To554, 
<l>Sa2mw and nuSaa). Table 4.15 compares these strains with USA300 (CA-strain) and 
NCTC 8325 (MSSA strain). Here USA300 mainly differed with respect to the arcBDAR 
genes (USA62/64-66 respectively, located within the SCCmec region), whereas the MSSA 
strain displayed a different profile over the <I>Sa3mw and <I>N315 loci. 
In the comparison of the CC22 strains, the profiles for the CA-strain and the HA-strains 
(three HA-strains taken from the same cl~ical patient) were clearly distinct over the loci of 
<I>Sa2mw and <I>Sa3mw (Table 4.16). 
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Table 4.14 CC5 HA- versus CA-strains. 
Illustrated are the main features on the array that showed block variation between the profiles of the HA and CA strains of CC5. These were in the mobile genetic 
elements <l>Sa2mw, <l>Sa3mw and SaPlnl. Other subtle differences were observed over the remaining profile (data not shown). 
M'W1393 cons~rv~d hypoth~tical prot~in 
M'W1400 hypoth~tical prot~in 
M'W1401 hypoth~tical prot~in 
Sa2mw M'W1405 
Phag~ phi Sa 3mw M'W189S hypoth~tical prot~in 
Phag~ phi Sa 3mw M'W1897 hypoth~tical prot~in 
Phag~ phi Sa 3mw M'W1898 hypoth~tical prot~in 
Phage phi Sa 3mw M'W1899 hypothetical prot~in 
Phage phi Sa 3mw M'W1900 hypoth~tical prot~in 
Phage phi Sa 3mw M'W1901 hypothetical protein 
Phage phi Sa 3mw M'W1902 hypothetical prot~in 
Phage phi Sa 3mw M'W1903 hypothetical protein 
Phage phi Sa 3mw M'W1904 hypothetical prot~in [Capsid prot~in] 
Phage phi Sa 3mw M'W1905 hypothetical prot~in 
Phage phi Sa 3mw M'W190S portal protein (phage portal protein) 
Phage phi Sa 3mw M'W1907 hypoth~tical protein 
Phage phi Sa 3mw Mld1908 hypothetical protein 
Phag~ phi Sa 3mw M'W1909 hypothetical prot~in 
Phage phi Sa 3mw M'W1910 hypothetical protein 
Phage phi Sa 3mw M'W1911 hypothetical prot~in 
Sa3mw M'W1912 
Plsland SaPln1 SA1819:tsst-l I toxic shock. syndrome toxin-l 
Plsland SaPlnl SA1822 hypothetical protein 
Plsland SaPln2 SA182S 
4 • 
-\0 
Vl HA CA 
Table 4.15 CC8 HA- versus CA-MRSA and MSSA-strains. Illustrated are the main features on the array that showed similarities and/or differences between the 
profiles of MS SA and MRSA (HA and CA) strains ofCC8. These were again localised to the accessory genome. 
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Table 4.16 CC22 HA- versus CA-strains. The di ffe rences between HA (EMRSA-lS strains) and CA stra ins of CC22 were re lated only to 2 loci, <l>Sa2mw and 
<I>Sa3mw. In the original annotation, the putative function for all but four of these genes was unknown. 
tLoci Gene ID Product Description E15-B3 ST22-IV IE15-B3 ST22-IV IE15-B3 ST22-IV S1'22-IV CA 
Phage phi Sa 2mw MW1386 conserved hypothetical protein 1 1 1 0 
Phage phi Sa 2mw MW1390 subfamily M23B unassigned peptidases 1 1 1 0 
Phage phi Sa 2mw MW1393 conserved hypothetical protein 1 1 1 0 
Phage phi Sa 2mw MW1400 hypothetical protein 1 1 1 0 
Phage phi Sa 2mw MW1401 hypothetical protein 1 1 1 0 
Phage phi Sa 2mw MW1405 hypothetical protein 1 1 1 
Phage phi Sa 2mw MW1408 hypothetical protein 1 1 1 
Phage phi Sa 3mw MW1895 subfamily M23B unassigned peptidases 0 0 0 
Phage phi Sa 3mw MW1896 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1897 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1898 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1899 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1900 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1901 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1902 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1903 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1904 hypothetical protein [Capsid protein] 0 0 0 
Phage phi Sa 3mw MW1905 hypothetical protein 0 0 0 
Phage phi Sa 3mw MW1906 portal protein (phage portal protein) 0 0 0 
Phage phi Sa 3mw MW1907 hypothetical protein 0 0 
Phage phi Sa. 3mw MW1908 hypothetical protein 0 0 
Phage phi Sa 3mw MW1909 hypothetical protein 0 0 
Phage phi Sa 3mw MW1910 hypothetical protein 0 0 
Phage phi Sa 3mw MW1911 hypothetical protein 0 0 
Phage phi Sa 3mw MW1912 hypothetical protein 0 0 
till ~ till ~ 
HA CA 
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To summarise, with respect to patterns of genes in the mobile genetic elements of the HA 
and CA strains, variation in the array profiles was noted in two main loci, <I>Sa2 and <I>Sa3. 
Further analysis was carried out to determine whether this was a real association between 
genotype and phenotype. 
A group of CA-strains of CCl were compared, one MSSA strain and two MRSA strains 
(Table 4.17). Only two of the three CA-strains carried genes characteristic of the <I>Sa2 
locus, but all three strains carried genes similar to <I>Sa3. These data suggest there was a 
stronger association between carriage of <I>Sa3mw genes and CA-status. In this group 
(CA-strains of CC1), patterns of variability were also noted for the mobile genetic 
elements <I>N3I5 and Tn554 (unique to USA400). A cluster of genes unique to WA-
MRSA (MW0040, 0042, 0043 and 0047; hypothetical proteins) were also noted. 
To determine whether the presence of the contiguous genes of <I>Sa3mw (seen in only the 
CA-strains) extended to the other strains in the collection, data were analysed for 
presence/absence of the genes at this locus (full dataset not shown). The results showed 
they were unique to the CA-strains (except for one HA-strain. discussed below). However, 
not all CA strains within the collection carried these genes (Table 4.18). That is, the genes 
are carried predominantly by CA-strains, but it is not absolutely carried by all CA-strains. 
Irish-I, a HA-MRSA strain carried a variant form of these genes in which most were 
present, except the MWI898-I900 group. Table 4.18 shows the results obtained for the 
CA strains (including the two CA MSSA strains NCTC 8325 and MSSA476). 
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Table 4.17 CCl Community associated strain comparison: MSSA v MRSA 
The differences between CA-MS SA and MRSA of CC 1 can be found on <DSa2mw, <DN315 and Tn554 loci. Variation in gene carriage is also observed for the block of 
genes in the region MW0040-47, which are located in the SCCmec element. 
Loci 
SCCmec 
SCCmec 
SCCmec 
SCCmec 
SCCmec 
Bacteriophage phi Sa 2mw 
Bacteriophage phi Sa 2mw 
Bacteriophage phi Sa 2mw 
Bacteriophage phi Sa 2mw 
Bacteriophage phi Sa 2mw 
Bacteriophage phi Sa 2mw 
Bacteriophage phi Sa 2mw 
Bacteriophage phiN315 
Bacteriophage phiN315 
Staphylococcus aureus transposon Tn554 
Staphylococc~ aureus transposon Tn554 
\0 
\0 
Gene ID 
MWOO40 
MWOO42 
MWOO43 
MWOO45 
MWOO47 
MW1386 
MW1390 
MW1393 
MWl400 
MWl401 
MWl405 
MWl408 
SA1808 
SA1809 
SA1953:tnpC 
SA1954:tnpB 
Product Description 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
conserved hypothetical protein 
subfamily M23B unassigned peptidases 
conserved hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
probable ss-1,3-N -acetylglucosaminyltransferase 
hypothetical protein 
transposition regulatory protein 
transposition regulatorv protein 
SA476 WA-MRSA USA400 
0 1 0 
0 1 0 
0 1 0 
0 1 1 
0 1 0 
1 0 1 
1 0 1 
1 0 1 
1 0 1 
0 0 0 
1 on 1 o 11 
0 0 1 
0 0 1 
0 0 - I 
0 0 1 
... .... . 
MSSA MRSA 
Table 4.18 <l>Sa3mw CGH results for all CA strains analysed in this study (including Irish 1 - a HA-MRSA). Based on the genes MWJ896-J9J2 (highlighted), 
the strains can be divided into two main groups: those carrying these genes (group I ; grey) and those without the genes (group 2). This pattern of presence/absence is 
not linked to PVL status, neither is it linked to strain lineage. The remaining genes on this phage do not show any particular pattern of association. 
Mwm, 
MW1417 
MWI411 
MW14U 
MW1m 
N 
o 
o 
t-7,.t~.tic" 'r.t .... 
h7,o,h.,i .. , ,'0'." 
h7,o,h.'i .. , "owin 
.. ,ilUift 
I\"attr...tic" ,r.t •• 
h7,oth.,i •• , ,'DWn. 
,wt.I.,et.i. 
.. ,.,.t~ti<" .. ,at.i. 
h,.,oth.li.ol ,_ ... 
h,.,oth.ti.ol , .. t ... 
h7,oth.ti,""ot." 
hypoth.ti." "ot." 
"mttt.tic" !'IIt •• 
h7,oth.ti .. '"ot.i. 
hy,oth.t i •• '"ot.i. 
""a,Jr..tic.'",.'.", 
hy,o,h.li .. '"ot.;" 
""atft..tic.l,rat.ift 
lil\11.·ttr ... 4 DHA·~i",4i"1 ,rllt. il\ 
1\,.,.th.tic41,rat.in 
hy,olh.li'.'"ol.u. 
hrr.th.tic.' "at.;,. 
h7,oth.ti,""ol.;" 
.",il ... S~~ "f'I.,ien.4 ••• ,i441.., 
t.,~ .... ,.,., •• '" ~ 
'e," .fth"ahx;f'I le 
i"'_1'._ fernil, ) 
.: . t,:"t~4;~t~" :1·:i~i:·J~;}~,i~ ;,~ :,,}t 3 , 1 I '1. • . ~ .: t . 
_ ... ,.. ; .... '-
;.~:.. . .'. ~. :-:~,)~~ : '.'" ;;"':~ 
Group 1 
0 0 0 0 
0 0 0 0 
0 0 0 
0 0 0 
01 i 
0 0 
0 0 0 0 
0 oc::::J 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
0 0 0 0 
Group 2 
4.3.2 Putative functions of the <I>Sa3 gene products 
The <I>Sa3mw genes (MW1896-1912) were mostly annotated as 'hypothetical proteins' at 
the original time of oligonucleotide design. To date, this has not been updated extensively, 
which prompted further in silico investigation. The array oligonucleotide sequences were 
compared with available annotations of all the sequenced strains from a local database. 
The BLAST utility was used to uncover similarities to genes with known function to 
provide insights into the putative functions of the prophage genes of interest. The results 
were selected by homology values, where high significance of homology was represented 
by low e-values. Putative functional assignments with respect to significant homologies of 
the <I>Sa3mw genes (on the array) are listed in Table 4.19. 
Of the genes of interest, the function of the original 'hypothetical proteins' could be 
predicted with high probability to functionally known genes only in 5 instances. These 
were the large terminase subunit (MW 1909), the small terminase subunit (MW 1908). the 
portal protein (MWI906). a prohead protease (MW1905) and the capsid protein 
(MW1904), that is, head and tail structural components involved in the phage lifecycle. 
The functions associated with these recognised genes are as follows. The phage terminase 
interact directly with the substrate DNA during DNA packaging into prohead shells 
(Bazinet and King. 1985). This interaction occurs at specified DNA interaction sites (cos 
and pac sites) which are generally located either within or close to the structural genes for 
the terminases (Black, 1989). During the packaging process, the portal protein associates 
with the terminase (Black, 1989). 
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Table 4.19 Putative ORFs for genes of cI>Sa3mw (in silico analysis). Using a local BLAST 
utility, the genes for Sa3mw were blasted against all available sequenced annotations for S. aureus 
strains. Homologies to genes of known function have been listed. The morphology related genes 
have been highlighted. 
Gene Annotation in MW2 Related Proteins (Origin) E value (% homoll 
MW1883 Hypothetical protein SAR2033 putative membrane 2.00E-21 (100) protein[MRSA252] 
MWI885 Staphylokinase SAUSA300 1922 staphylokinase 4.00E-19 (98) precursor (sak) precursor Jsa10[USA3 OO-FPRJ 75TI 
SAR2039 staphylokinase precursor 4.00E-19 (98) (sak)[MRSA252] 
MWI886 Initial annotation: HP SAUSA300 1923 autolysin [USA300- 2.00E-21 (100) FPRJ75TI 
Update: lytic enzyme SAR2040 autolysin IMRSA25~ 2.00E-21 (100) 
SAOUHSC 02173 amidase[NCTC 2.00E-21 (100) 83251 
NWMN 1881, note: amidase for 
bacteriophage phiNM3, phage amidase 2.00E-21 (100) 
[Newman] 
SaurJHI 2038: CHAP domain 2.00E-21 (100) 
containin!tQrotein [JH I] 
SAOUHSC 02173 amidase[NCTC 2.00E-21 (100) 8325] 
MW1887 Initial annotation: HP SAUSA300 1924 holin[USA300- 2.00E-21 (100) FPRJ757] 
Update: holin SAR2041 holin[MRSA252] 2.00E-21 (lOO) homolog 
SAOUHSC 02174 holin, phage phi 2.00E-21 (lOO) LC3 family[NCTC 8325] 
Staphylococcal MW1889 staphylococcal enterotoxin A MW1889 enterotoxin A 2.00E-21 (100) 
precursor (sea) precursor (sea)[MW2] 
SAV1948 enterotoxin P Is~Mu5Ql 2.00E-2 IJ.1 001 
SAVI948 enterotoxin P (sep)LMu50] 2.00E-21 (100) 
SAR2043 enterotoxin type A 4.00E-19 (98) precursorfMRSA252] 
MW1890 Hypothetical protein SAR2045 putative membrane 2.00E-21 (100) protein[MRSA252] 
MWI892 H~thetical protein SAS061 hypothetical protein[N31 51 2.00E-21 110Q} 
MWl893 Hypothetical protein SA V 1953 phi PVL ORF 20 and 21 2.00E-21 (100) homol~uelMu501 
SAUSA300 1928 phi77 ORF002-like 
protein, phage minor structural 3.00E-04 (93.1) 
proteinIUSA300-FPRJ 75TI 
SAOUHSC 02180 phage minor 
structural protein, N-terminal region 3.00E-04 (93.1) 
domain ~otei,![NCTC 8325J 
SAUSA300 1929 phi77 ORFOO4-like 
MWl894 Hypothetical protein protein, putative phage tail 2.00E-21 (100) 
component[USA300-FPRJ75TI 
SAOUHSC 02181 phi PVL orfs 18-19- 2.00E-21 (100) like protein [NCTC 8325] 
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NWMN 1887, note: tail fiber protein 
for bacteriophage phiNM3, phage tail 2.00E-21 (100) 
fiber protein [Newman] 
MW1895 Hypothetical protein SAOUHSC 02182 tail length tape 4.00E-19 (98) 
measure protein[NCTC 8325] 
SAOUHSC 02183 conserved 
MW1896 Hypothetical protein hypothetical phage protein [NCTC 2.00E-21 (100) 
8325] 
MWI897 Hypothetical protein SAOUHSC 02184 phi PVL orf 14-like 2.00E-21 (100) protein[NCTC 8325] 
MW1898 Hypothetical protein SAOUHSC 02185 phi PVL orf 13-like 2.00E-21 (100) protein[NCTC 8325] 
MW1899 Hypothetical protein SAOUHSC 02186 phi PVL orf 12-like 2.00E-21 (100) protein[NCTC 8325] 
MW1900 Hypothetical protein SAOUHSC 02187 phage protein, HK97 2.00E-21 (100) gplO farnily[NCTC 8325] 
MWI901 Hypothetical protein SAOUHSC 02188 phage head-tail 2.00E-21 (100) 
adagtor, putative[NCTC 8325] 
SAOUHSC 02189 conserved 
MWI902 Hypothetical protein hypothetical phage protein[NCTC 2.00E-21 (100) 
8325] 
SAOUHSC 02190 conserved 
MW1903 Hypothetical protein hypothetical phage protein[NCTC 2.00E-21 (100) 
8325] 
MW1904 Capsid protein SAOUHSC 02191 phage major capsid 2.00E-2 J (100) protein, HK97 family[NCTC 8325] 
MW1905 Hypothetical protein SAOUHSC 02193 prohead 2.00E-21 (100) protease[NCTC 8325] 
MW1906 Portal protein SAOUHSC 02194 phage portal protein 2.00E-21 (100) HK97 family/NCTC 8325] 
MWI907 Hypothetical protein SAOUHSC 02195 phi PVL orf3-like 4.00E-19 (98) protein-related protein[NCTC 8325] 
MW1908 Hypothetical protein SAOUHSC 02196 phage terrninase 2.00E-21 (100) large subunit, putative[NCTC 8325] 
MW1909 Hypothetical protein SAOUHSC 02197 phage terrninase, 2.00E-2] (100) 
small subunit, putative[NCTC 8325] 
SAOUHSC 02198 conserved 
MWI910 Hypothetical protein hypothetical phage protein[NCTC 2.00E-21 (100) 
8325] 
MWI911 Hypothetical protein SAOUHSC 02199 phi PVL orf62-like 2.00E-21 (100) protein[NCTC 8325] 
SAOUHSC 02200 conserved 
MW1912 Hypothetical protein hypothetical phage protein[NCTC 4.00E-07 (88) 
8325] 
MWJ913 Hypothetical protein SAUSA300 1945 phi77 ORF071-like 7.00E-22 (100) protein[USA300-FPR3757] 
SAR2068 putative exported 7.00E-22 (lOO) protein[MRSA252] 
MWI914 Hypothetical protein MW1914 hypothetical protein [MW2] 7.00E-22 (100) 
MW1915 Hypothetical protein MW1915 hypothetical protein [MW2] 7.00E-22 (100) 
MW1916 Hypothetical protein MWl916 hypothetical protein [MW2] 7.00E-22 (lOO) 
MW1917 Hypothetical protein SAUSA300 1954 phiPVL ORF050-like 7.00E-22 (100) protein[USAJOO-FPR3757] 
SAOUHSC 02211 phi PVL orf 50-like 7.00E-22 (100) protein[NCTC 8325] 
SAUSA300 1416 phiSLT ORF 81 b-like 4.00E-
protein [USA300-FPR3757] 13(95.45) 
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MW1921 Single-strand DNA- SAUSA300 1958 Single-strand binding 7.00E-22 (100) binding protein protein [USA300-FPRJ7571 
SAR2083 putative single-strand DNA- 7.00E-22 (100) binding protein [MRSA252] 
SAUSA300 1960 putative phage-
MW1923 Hypothetical protein related DNA recombination protein 2.00E-21 (100) 
[USA300-FPRJ 757] 
MWI925 Hypothetical protein SAR2087 hypothetical phage protein 2.00E-14 (94) [MRSA2521 
MW1926 Hypothetical protein SAOUHSC 02223 phi PVL orf 39-like 7.00E-22 (100) proteinlNCTC 8325] 
SAUSA300 1427 phiSLT ORF86-like 2.00E-07 (88) protein[USA300-FPRJ757] 
MWI927 Hypothetical protein SAOUHSC 02224 phi PVL orf 38-like 2.00E-21 (100) protein-related protein [NCTC 8325J 
SAR2091 putative exported protein 4.00E-19 (98) [MRSA252] 
SAUSA300 1429 phiSLT ORF53-like 6.00E-12 (92) protein [USA300-FPR37571 
SAOUHSC 02226 conserved 
MW1929 Hypothetical protein hypothetical phage protein[NCTC 7.00E-22 (100) 
8325] 
MWI931 Hypothetical protein SAR2095 hypothetical phage protein 2.00E-21 (100) [MRSA2521 
SAUSA300 1966 phi77 ORF014-like 
MW1932 Initial annotation: HP protein, phage anti-repressor protein 2.00E-21 (100) 
[USA300-FPR3757) 
Update: phage anti SAR2096 putative anti repressor 2.00E-21 (100) 
repressor [MRSA252] 
SA 180 1 anti repressor [N315J 2.00E-2IJI0<!} 
MW1933 Hypothetical protein SAOUHSC 02232 phi PVL orf 33-like 7.00E-22 (lOO) protein[NCTC 8325] 
MW1934 Hypothetical protein SAOUHSC 02233 phi PVL orf 32-like 2.00E-21 (100) protein [NCTC 8325] 
MW1935 Hypothetical protein SAOUHSC 02234 repressor-like 7.00E-22 (100) protein-related protein[NCTC 83251 
MW1936 Hypothetical protein MWI936 phage repressor[MW2] 7.00£-22 (1001 
SACOL0321 prophage L54a, repressor 2.00E-19 (98) protein, putative[COL1 
SAOUHSC 02084 phage repressor 2.00E-19 (98) protein, putative[NCTC 83251 
Staphylococcal SACOL0887 staphylococcal MWl937 enterotoxin SEG 7.00E-22 (lOO) 
(seg2) enterotoxin type I (sei)[COL] 
Staphylococcal SAUSA300 0800 staphylococcal MW1938 enterotoxin Sek 2.00E-19 (98) 
(sek21 enterotoxin K (sek)[USA300-FPRJ757] 
SACOL0886 staphylococcal 2.00E-19 (98) 
enterotoxin (sek)[COL] 
MW1939:int Integrase (int) SAUSA300 1972 integrase 7.00E-22 (100) (int)[USA300-FPR3757] 
SA 181 0 integrase (int) 7.00E-22 (100) 1N3151 
HP, sim to SAUSA3001974 
MW1941 synergohymenotropic LeukocidinlHaemolysin toxin family 7.00E-22 (100) 
toxin precursor proteinruSA300-FPR3757J 
MW1942 HP, sim to leukocidin SAUSA300 1975 AerolysinlLeukocidin 7.00E-22 (1001 
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chain lukM~ecursor fami~oteinl!LSA300-FPR37S71 
SAB 1876c probable leukocidin S 7.00E-22 (lOO) 
subunitIBF 12~ 
SA 18 I3 hypothetical protein, similar to 7.00E-22 (lOO) leukocidin chain lukM[N3lS1 
SACOL2006 AerolysinlLeukocidin 7.00E-22 (100) fami!yproteinlCOLl 
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Many of the <I>Sa3mw genes shared homology to ORFs of <I>PVL, <I>SLT and <I>77 (see 
Table 4.19). This prompted research into the area of staphylococcal temperate phage. 
Studies into staphylococcal genomes have been extensive and more than 80 phage 
genomes have been completely sequenced (Kaneko et 01.1998, Iandolo et al. 2002, 
O'Flaherty et al. 2004, Kwon et al. 2005). Previous studies analysed the relatedness of S. 
aureus bacteriophage by means of techniques such as DNA hybridisation (pariza and 
Iondolo 1974, Inglis et al. 1987, Stewart et al. 1985), high resolution thermal denaturation 
analysis of DNA (Inglis et al., 1987), restriction endonuclease similarity patterns (Doskar 
et al., 2000) and virion protein profiles (Lee and Stewart, 1985). These data show 
staphylococcal temperate phage can be classified into genotypically defined groups and 
that sequence similarities correlate with serological relatedness rather than host specificity 
(Pantucek et 01.,2004). 
Comparative analysis of <I>Sa3 and <I>PVL variants revealed a high degree of similarity 
over most of their genomes; however, differences in virulence gene content were noted, 
e.g. enterotoxins seg2 and sek2 found only in <I>Sa3 (Brussow et 01.,2004). This was also 
observed in the in silica analysis for this study (data not shown), that showed many of the 
'hypothetical genes' annotated as homologues of <I>PVL phage ORFs in strain NCTC 8325. 
Although, the <I>Sa3 genomic islands are documented to be related to <I>PVL, only the latter 
group (<I>PVL phage) is associated with PVL carriage. One explanation for this 
relationship could be homologous recombination. The genes of <I>Sa3 islands are notable 
for their mosaic structures, comprising not only <I>PVL genes but also elements from <I>SLT 
(another PVL-carrying phage). It has been proposed that the patchwork similarities (and 
therefore high diversity) between S. aureus phage genomes is a result of multiple 
recombination events and horizontal transfer between <I> N315-, <I>PVL-, <I>PV83·, <I>Sa3-, 
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and <D 13-like phages during their evolutionary history (Brussow et al. 2004, Canchaya et 
al. 2003). 
In general, phage genomes are modular. In members of the family Siphoviridae to which 
staphylococcal phage belong (figure 4.6), each module contains a set of genes which carry 
out a distinct biological function (Casjens et af., 1992). Phage evolution proceeds via the 
exchange of modules from the same gene pool (Botstein 1980). This theory was defined by 
Botstein (1980) as the theory of modular evolution that proposes ''joint evolution of sets of 
functionally and genetically interchangeable elements each of which carries out a 
particular biological function" may occur. Genetic exchange in this way has not only 
played a fundamental role in the evolution of the phages, but also in the bacterial host 
(Fitzgerald et al. 2001, Brussow et al. 2004). This molecular organisation and 
conservation of the order of genes is shared by many phages of the same genome-size class 
(K won et al., 2005). 
Figure 4.6 The conserved modular structure of staphylococcal phage 
Conservation of the morphogenesis module (head and tail structural components) in some 
tailed phages was first pointed out in the early 1970s during the comparative analysis of 
the prophage maps of P2, P22 and A which showed that they were partially congruent 
(Dove, 1971). This was later confirmed by sequence comparison of P22 and A (Eppler et 
al., 1991). Desiere and colleagues (1999) in their comparative analysis of the DNA 
packaging and structural modules of Streptococcus thermophyilus phage Sfi21, noted that 
during bioinformatics comparison with other sequenced strains, homologies generally 
corresponded to phage genes with corresponding positions on their respective genome 
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maps. This method of comparison they called comparative sequence 'gazing', and 
highlighted its ability to increase biological understanding of phage genomics (Desiere et 
aI., 1999). Therefore, to assign putative functions to the remaining hypothetical genes of 
the group of interest in this study, where possible they were mapped to genes in related 
staphylococcal bacteriophage (figure 4.7). 
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Figure 4.7 (A) Genetic organisation of <I>PVL genome (adapted from Zou et al. 2000 and Kaneko 
et al. 1998). Schematic representation of <I>PVL genome Iinearized at the att sites. ORF 57 and 
ORF 60-0RF22 were identical to the equivalent region in <l>PV83-pro, i.e. the packaging and 
morphogenesis region. (B) Genetic organisation of the ORF map of the <J>Sa3ms genome. 
A further classification system, the phage proteomic tree classifies phage into taxa based 
on the overall similarity of about 100 completely sequenced phage genomes (Rohwer and 
Edwards, 2002). It addresses phage taxonomy independently of phage phylogeny; the 
former resolves around the naming although it does not need to deal with pbylogeny. "The 
tree is the result of a computer-based (objective) calculation process and is applicable to 
any completely sequenced phage". Using this technique, <l>SLT, <1>12, <l>PVL <1>13, and 
<l>PV83 were all classified as PVL-like Siphoviridae. The confusion regarding the 
established and more recently proposed classification of phage taxonomy has been 
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recognised. Proux and colleagues (2002), and Nelson (2004) have both highlighted this 
dilemma. They concluded that "the real taxonomic value of the different proposals will 
depend on the diversity of the bacteriophage genomes encountered in the environmenf'. 
4.3.3 "'Sa3 locus 
From the data in Table 4.19, the genes of <I>Sa3 included on the array have functions 
associated with the lysogeny module, early gene control, DNA replication (DNA 
replication and transcriptional regulation regions) and toxin genes. Furthermore, the 16-
consecutive genes seen in the CA-strains were possible head- (and/or tail-) structural 
components, as well as genes involved in DNA packaging and late gene control. The 
genes of known function (i.e. small and large terminase, portal, prohead protease, major 
capsid and head-tail adaptor) are all necessary to build a procapsid and package DNA. 
However, whether all the phages of the strains in this study have the necessary tail 
structural proteins to produce infectious particles, is not something that can be commented 
on from this array data set since the genes encoding these structures were not included on 
the array. Comparative sequence gazing revealed that the array genes of <I>Sa2 and <I>Sa3. 
which are mostly components of morphology related modules, varied in their 
presence/absence in this group of strains. This implies that there may be different 
morphotypes of these phages circulating within the staphylococcal population. 
DNA packaging mechanisms can be differentiated into two groups i.e. those used by cos 
site and pac site phages (Le Marrec et al., 1997). Research into the DNA packaging 
mechanisms of the Sti21 (cos) and Still (pac) phages of the Siphoviridae family revealed 
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that two clearly distinct structural gene clusters corresponded to these packaging 
mechanisms (Lucchini et al., 1998). This led to division of the genus Siphoviridae into 
two groups for the Sti21-like and Sfi 11-like phage. Comparative genomics was used to 
find these phage groups in many bacterial genera (Desiere et al., 2001). Conservation of 
head and/or tail structural proteins has been used as a method for assigning phages to 
lineages. Classification of phage genomes based on structural genes has been shown to be 
a discriminatory technique to distinguish bacterial sub species. For example comparative 
genomics of the structural genes of lactococcal phages delineated four species and 
distinguished two genera based on head morphotype (proux et al., 2002). Similarly, 
Brussow and Desiere (2001) in their comparative analysis of Siphoviridae showed the 
relatedness and conserved order of the DNA packaging and head proteins of S. aureus 
phages <I>SLT, <I>PVL and <I>PV83. The evolutionary history of individual phage modules 
(e.g. this structural module) is starting to emerge through such comparative studies 
(Brussowand Desiere, 2001). 
Narita and colleagues (2001) compared the genomes of three PVL-carrying phages, <I>SLT, 
<I>PVL and <I>PV83-pro. The mosaic structure of these phage was shown. For example, 
<I>PV83-pro was shown to have the att site and integrase of <D 11 together with packaging 
and morphogenesis modules from <I>PVL. Thus it seems likely that the <I>SaJ phage are 
mosaics comprised of elements found in other staphylococcal phages. 
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4.3.4 Prophinder software: comparative analysis of staphylococcal prophage genomes 
Genomic analyses of the prophage content of <1> Sa3mw (MW2), <1>Sa3ms (MSSA476) have 
shown that only 14bp difference exists between the sequences (Sumby and Waldor, 2003). 
To investigate the structural relationships between the morphogenesis units of phages 
found in completely sequenced strains that carried the genes of interest (e.g. MW2, 
MSSA476 and NCTC8325) and those that do not (e.g. USAJOO) the Prophinder online tool 
(http://aclame.ulb.ac.belTools/Prophinder/) was used. Prophinder detects prophages in 
sequenced bacterial genomes using BLASTP. This algorithm detects coding sequences that 
are similar to phage proteins stored in the local ACLAME database. Similarities were 
found with six phage Le. <1>13, <1>PVL, <1>PV83, <1>108-PVL, tp310-1 and tp31O-3 (spa-310 
type staphylococcal phages from a pvt strain, MLST22). The region of significant 
homology was present in <1>Sa3mw. In comparison, strain USA300 (which did not harbour 
the block of genes putatively associated with the CA phenotype) showed most homology 
to <1>NM3 (from Newman strain), <1>N315 and <1>77 within this locus. This is further 
evidence that the prophage of NCTC 8325, MSSA 476, and MW2 are related and distinct 
from the prophage of USAJOO. It also supports the suggestion the eleven CA-strains that 
carry the specific head and tail gene unit (Table 4.18) would also show homology to the 
same six phages. Conversely, it appears that the phage ofUSAJOO, and other strains that 
do not carry this block of genes, are of a different morphotype. 
Although there are multiple proposed theories for lineage determination, the following may 
be speculated with respect to these studies. If the head structural components are 
conserved in a proportion of the CA-strains, but are not seen in the hospital strains (except 
a variant in the Irish-l strain), it may be possible that a different 'type' of phage is 
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associated with this group, and therefore associated with comrnunity-acquiredness. It could 
also be speculated that the proposed variant phage is associated with the MSSA strains 
which have gone on to become successful CA-strains. 
A recent study by Ma and co-workers (2008) presented data on the prevalence of PVL 
phage in MRSA and MSSA strains in Japan. In this study, the entire nucleotide sequences 
of two bacteriophage carrying PVL (<I>Sa2958 and <l>108-PVL) were compared. Both 
phage integrate at the site corresponding to <l>Sa2mw on the MW2 genome. By 
comparison to the extant five PVL phages characterised to date (<I>PVL, <l>SLT, <l>Sa2mw, 
<l>108PVL and <l>Sa2usa), <l>Sa2958 displayed conservation over 27 open reading frames 
(ORF) with the phages <l>Sa2mw and <l>SL T. In particular, this included 8 ORFs associated 
with DNA packaging and head and tail formation (Le. the terminase small subunit, 
terminase large subunit, portal protein, prohead protease, capsid protein, major tail protein 
and phage tail tape measure proteins). The phage morphologies of the five characterised 
phages are not identical, but can be assigned to two types: the icosohedral-head type and 
the elongated-head type (Canchaya et al., 2003). In these strain populations they observed 
both the icosohedral-head type (represented by similarity to <l>108-PVL) and the elongated 
head type phages (represented by similarity to <l>Sa2958). Ma and colleagues observed no 
link between SCCmec type and carriage of a particular PVL phage type. However, they 
did observe that most of the PVL positive strains were of sequence type ST30 (or belonged 
to CC30). and produced coagulase type 4. It has therefore been proposed that these two 
groups of phages (or similar phages) were independently acquired by MSSA strains 
(coagulase type 4 ST30) prior to the acquisition of SCCmec elements, and later evolved 
into PVL-positive MRSA strains (Ma et al., 2008). Ma and co-workers concluded that 
phages <l>Sa2958, <l>Sa2mw and «I>SL T belong to a taxon that is associated with the virulent 
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PVL + phenotype in Japan (Ma et al., 2008). The data presented in this study support these 
findings i.e. that a particular phage taxon, in this case <I>Sa3mw, is also associated with the 
CA phenotype. 
Phage head conservation is also deduced from the array data available for the genes of 
bacteriophage <I>N315 and <I>Sa2 (see the following sections). No particular distinction 
between HA- and CA-strains with respect to the pattern of these genes was identified. 
However, it was noted was that CA-strains carrying <I>Sa3 DNA packaging! morphogenesis 
genes, usually lacked the morphogenesis genes of <I>N315 (Table 4.20). 
4.3.5 ~N315locus 
In strain N315, bacteriophage <I>N315 integrates at a locus adjacent to <I>Sa3 of strain 
MW2. Interestingly, the <I>N315 genes were present in the majority of strains tested (HA 
and CA) with the exception of seven CA strains and Irish-l (Table 4.20); these strains all 
carried the <I>Sa3mw gene block or the close variant found in Irish-I. Three isolates (CA-
strains ofSTs 22, 866 and 5 [PVL neg]) carried both <I>Sa3mw and <I>N315 gene blocks. 
213 
Table 4.20 <l»N3I5 CGH profile for a ll the CA-strains (and Irish-I). Most of the group- l strains (carrying <l>Sa3mw morphology genes) lack the equivalent 
morphology genes in <l>N3 15; the opposite is observed for the group-2 strains (most carry <l>N315 genes)_ 
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4.3.6 Bioinrormatics analysis or <IlN315 gene products 
Most of the <l>N315 genes on the array were originally annotated as 'hypothetical protein'. 
Functional assignment of these genes were explored using the methods described 
previously, revealing 11 consecutive ORFs involved in head morphogenesis. Thus it was 
possible to identify the corresponding morphology genes of<l>SaJ and <l>N315 (Table 4.20 
and Table 4.21). 
Several phage integrate into the staphylococcal genome at positions adjacent to <l>SaJmw 
(e.g. <l>Sa3ms). These have been reported to display sequence similarities (Sumby and 
Waldor, 2003). However, in most cases the strains tested either had homologies to 
<l>SaJ mw or to <I> N315 with little evidence for mosaic structures. As discussed above 
Prophinder analysis showed homology between the prophages <l>N315, <l>NM3 and <1>77. 
This group is distinct from that of <l>SaJmw Le. the <1>13, <l>PVL. <l>PV83, <l>108-PVL. 
tp310-1 and tp31O-3 group. Yet, interestingly, CA strains ST22. ST866 and ST5 (PVL 
neg) were unusual in that they carried the morphogenesis genes from both <l>SaJmw and 
<l>N315. It is unclear whether these strains carry a phage intermediate between <l>SaJmw 
and <l>N315 or if both are present. Finally a single unusual CA-strain (ST97 SCCmec type 
V) carried neither set of structural genes. 
Of the HA-MRSA strain collection, four strains did not have structural genes 
corresponding to <l>N315, these were strains COL, Iberian ST247. EMRSA-15 variant B3 
and EMRSA-15 variant B5. Additionally. the animal associated CA-MRSA strain ST398, 
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did not carry these genes. The COL genome (which has been fully sequenced) does not 
have any prophage sequences at this locus (data from Prophinder). Therefore, it may be 
that the other 4 HA-MRSA strains also do not have prophage at this locus. However, this 
cannot be confirmed here. A limitation of the array is that dissimilarity to a present 
prophage and complete absence of a prophage cannot be distinguished. 
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Table 4.21 Putative ORFs for genes of Cl)N315 (in silico analysis). Using a local BLAST utility, 
the genes for <I>N315 were blasted against all available sequenced annotations for S. aureus strains. 
Homologies to genes of known function have been listed. The morphology related genes have 
been highlighted. 
Gene Annotation in N315 Related Proteins [Origin] E value (% homol) 
SA1755 Hypothetical SAUSA300 1920 chemotaxis-inhibiting protein 3.00E-06 
Protein CHIPS (chs) [USA300-FPR3757] (100) 
SAR2036 chemotaxis-inhibiting protein CHIPS 3.00E-06 
(chp) [MRSA252] (100) 
SA1759 Hypothetical SAUSA300 1923 autolysin [USA300-FPR3757] 1.00E-16 Protein (100) 
Update: lytic SAR2040 autolysin [MRSA252] 1.00E-16 
enzyme (100) 
MW1886 lytic enzyme [MW2] 1.00E-16 (100) 
SAOUHSC 02173 amidase [NCTC 8325] 1.00E-16 (100) 
NWMN 1881, phage amidase [Newman] 1.00E-16 (100) 
SAB0781 lytic enzyme [RF122] 6.00E-12 (95.24) 
SA1761 enterotoxin P (sep) MW1889 staphylococcal enterotoxin A 9.00E-05 (86) precursor (sea) [MW1] 
SAV1948 enterotoxin P (sep) [Mu50] 9.00E-05 (86) 
SA1766 Hypothetical SAR2050 putative membrane protein 7.00E-22 
Protein [MRSA252] (100) 
SAUSA300 1930 phi77 ORF001-lIke protein, 
phage tail tape measure protein [USA300- 2.00E-19 (98) 
FPR37S7] 
SAV195S phi PVL ORF 15 and 16 homologue 2.00E-19 (98) [MuSO] 
SA1768 Hypothetical NWMN 1890 : phage major tail protein 2.00E-21 
Protein [Newman] (100) 
SaurJHl 2050 : phage major tail protein, phi13 2.00E-21 
family[JH1] (100) 
SAUSA300 1934 phi77 ORF020-like protein, 4.00E-19 (98) phage major tail protein [USA300-FPR37S7] 
SA1769 Hypothetical SAR2055 hypothetical phage protein 7.00E-22 
Protein [MRSA252] (100) 
SAl770 Hypothetical SAUSA300 1935 phi77 ORF029-like protein 4.00E-17 (96) Protein [USA300-FPR3757] 
SAl771 Hypothetical SAUSA300 1936 conserved hypothetical phage 7.ooE-22 
Protein protein [USA300-FPR3757] (100) 
SAl772 Hypothetical SAR2059 hypothetical phage protein 7.00E-22 
Protein [MRSA252] (lOO) 
SA1773 Hypothetical SAUSA300 1937 phi77 ORF045-like protein 7.00E-22 
Protein [USA300-FPR3757] (100) 
SAl774 Hypothetical SAUSA300 1938 phi77 ORF006-like protein, 7.00E-22 
Protein putative capsid protein [USA300-FPR3757] (100) 
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Hypothetical 2.00E-21 SAl775 Protein sim to SAR2062 putative Clp protease [MRSA252] (100) 
scaffolding protein 
NWMN 1897: phage Clp-like protease 2.00E-21 
[Newman] (100) 
SAUSA300 1939 phi77 ORF015-like protein, 4.00E-19 (98) putative protease [USA300-FPR3757] 
SAl776 Hypothetical SAUSA300 1940 phage portal protein [USA300- 1.00E-14 
Protein FPR3757] (100) 
SAR2063 hypothetical phage protein 3.00E-12 
[MRSA252] (97.37) 
Hypothetical SAUSA300 1941 phi77 ORF003-like protein, 7.00E-22 SA1777 phage terminase, large subunit [USA300-Protein 
FPR3757] (100) 
SAl778 Hypothetical SAUSA300 1942 conserved hypothetical phage 7.00E-22 
Protein protein [USA300-FPR3757] (100) 
SAl779 Hypothetical SAUSA300 1943 phi77 ORF040-like protein 2.00E-21 
Protein [USA300-FPR3757] (100) 
NWMN 1901 :phage HNH endonuclease 2.00E-21 
[Newman] (100) 
SaurJH12062 : HNH endonuclease[JH1] 2.00E-21 (100) 
SA1781 Hypothetical SAUSA300 1945 phi77 ORF071-like protein 2.00E-14 (96) Protein [USA300-FPR3757] 
SAR2068 putative exported protein [MRSA252] 2.00E-14 (96) 
SA1783 Hypothetical 
Protein MW1414 hypothetical protein [MW2] 4.00E-19 (98) 
SA1785 Hypothetical SAOUHSC 02059 phi PVL art 52-like protein 4.00E-19 (98) Protein [NCTC 8325] 
SAR2074 hypothetical phage protein 
2.00E-14 (96) [MRSA252] 
SA1788 Hypothetical SaurJH1 2072 : PVL ORF-50 family protein[JH1) 2.00E-21 Protein (100) 
SAUSA300 1421 phiSLl ORF122-like protein, 6.00E-15 
DNA polymerase [USA300-FPR3757] (100) 
SAR1539 putative DNA-binding protein 6.00E-15 
[MRSA252] (100) 
SA1791 Hypothetical SAUSA300 1957 phiPVL ORF046-lIke protein 7.00E-22 
Protein [USA300-FPR3757] (lOO) 
SAR2082 putative phage regulatory protein 7.00E-22 
(pseudogene) [MRSA252] (lOO) 
SA1792 single-strand DNA- SaurJH9 0322 : single-strand binding protein 2.00E-21 
binding protein [JH9] (lOO) 
MW1921 single-strand DNA-binding protein 4.00E-19 (98) [MW2] 
SA1794 Hypothetical SaurJH9 0320: Reel protein, product: Reel 2.00E-21 
Protein protein, from JH9, complete genome. (lOO) 
SAUSA300 1960 putative phage-related DNA 
1.00E-16 (96) 
recombination protein [USA300-FPR3757] 
SA1795 Hypothetical SAUSA300 1961 phiPVL ORF41-like protein 1.00E-19 (98) Protein [USA300-FPR3757] 
SA1797 Hypothetical SAUSA300 1427 phiSl T ORF86-like protein 3.00E-20 
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Protein [USA300-FPR3757] (100) 
SAOUHSC 02074 phi PVL orf 39-like protein 
4.00E-19 (9S) lNCTC 8325J 
SAB1748c hypothetical phage-related protein 6.00E-1S 
[RF122J (97.92) 
SA1799 Hypothetical SaurJH12084: protein of unknown function 2.00E-21 
Protein [JH1J (100) 
SA1S00 SA1S00 hypothetical protein [N315J 7.00E-22 (lOO) 
SA1802 Hypothetical SAUSA300 1967 conserved hypothetical phage 2.00E-21 
Protein protein [USA300-FPR3757J (100) 
NWMN 1919: conserved hypothetical protein 2.00E-21 
[Newman] (100) 
SA1S04 Hypothetical SAUSA300 1968 putative phage transcriptional 7.00E-22 
Protein regulator [USA300-FPR3757J (100) 
Update: 
hypothetical 
SAR2099 DNA-binding protein [MRSA252J 7.00E-22 transcriptional (lOO) 
regulator 
SAOUHSC 01574 Helix-turn-helix domain 7.00E-22 
protein [NCTC 8325] (100) 
Hypothetical SAUSA300 1969 phi77 ORFOll-like protein, 2.00E-21 SA180S phage transcriptional repressor [USA300-Protein (100) 
FPR3757J 
Update: repressor SAR2100 putative repressor [MRSA2S2J 2.00E-21 homolog (100) 
SAOUHSC 01575 Helix-turn-helix domain 2.00E-21 
protein [NCTC 8325] (100) 
NWMN 1921 :phage cl-like repressor [Newman] 2.00E-21 (100) 
SA1806 Hypothetical SAUSA300 1970 putative exonuclease [USA300- 2.00E-21 
Protein FPR3757J (100) 
Update: probable SAOUHSC 01576 exonuclease family [NCTC 2.00E-21 ATP-dependent 
helicase 8325J (100) 
NWMN 1922 : phage exonuclease [NewmanJ 2.00E-21 (100) 
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4.3.7 Cl>Sa2 locus 
Three main patterns of the <l>Sa2 related genes were observed amongst the strains analysed 
(Table 4.22, top segment). In the first group all the genes were absent, the second group 
displayed carriage of all the genes and the final group carried all but the MW1401 gene 
encoding the terminase large subunit. The ORFs preceding this gene encode proteins 
involved in head and tail formation. Therefore, it seems likely that at least three distinct 
types of phage are represented at this locus. However, no particular pattern was seen with 
respect to the CA-phenotype. 
It was noted that although most of the strains were PVL +, this was not an absolute 
correlation with <l>Sa2mw, a recognised PVL-carrying phage. This was also noted by 
Lindsay and colleagues (2006) in their analysis of PVL positive clinical isolates. Of their 
strain collection, only one isolate carried <I>Sa2. This is unsurprising since the PVL genes 
(i.e. lukF and lukS) may be horizontally transferred between lineages. The degree of 
correlation between PVL and the <l>Sa3 morphogenesis genes (described in this thesis) was 
similar to that between PVL and <l>Sa2. Some PVL+ (and PVL") CA-MRSA carried 
sequences homologous to different <l>Sa3 genes. The <l>Sa3 morphogenesis gene cluster 
seems therefore to represent a useful marker for the community-associated phenotype. 
Although there is currently no evidence for a causative link, Ma and colleagues (2008) 
noted possible associations between phage head morphology and virulence. It may be 
speculated that phage factors are the key to variations in epidemiology and pathogenicity 
noted between HA- and CA-strains. Table 4.22 illustrates the genotypes of the CA strains 
for the <l>Sa2, <l>Sa3 and <l> N315 morphology related genes. 
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Table 4.22 Comparison of the morphology related genes of ~Sa2mw, ~Sa3mw and ~N3I5 loci for all the CA-strains (and Irish-I). The general relationship 
between carriage of <I>N3 J S and <I>Sa3mw morphology genes is evident; that is, presence of one group, with absence of the other. The exceptions to this rule are the 
three isolates ST22, STS-IV (PVL neg) and ST866. There is no particular link with the <I>Sa2mw genes. 
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Sumby and Waldor (2003) analysed the transcription of the toxins of the staphylococcal 
phage <l>Sa3ms in the hypervirulent CA-strain MSSA 476. They showed that prophage 
induction (by mitomycin C treatment) caused the up-regulation of the phage-encoded 
toxins sak, sae, seg2 and sek2 transcripts. However, the authors did not confirm that the 
upregulated transcripts were translated. Other studies have shown that prophage induction 
can occur in vivo (Broudy et al. 2001, Voyich et al. 2003, Wagner and Waldor 2001, 
Waldor and Mekalanos 1996). Thus it is possible that prophage induction initiated by host 
factors plays a role in pathogenesis (Sumby and Waldor 2003). Understanding the biology 
of prophage may provide insights into the roles of phage encoded virulence factors. 
Sequencing of further S. aureus strains and phage genomes will also aid this cause, as will 
experimentation in animal models. 
Finally, Christianson and co-workers (2007) used comparative genomics to study Canadian 
epidemic lineages of MRSA by microarray analysis. In their comparison of 8 HA- and 2 
CA-strains, they identified 1 ORF (of a possible 2,741 ORFs on the array) encoding a 
metallo-beta-Iactamase family protein specific to CA isolates. Although not bacteriophage 
encoded, this ORF was localised to the Jl region of the SCCmec element. This was 
suggested as a putative marker for the differentiation of HA- and CA-M RSA isolates. 
However, they noted no defined virulence factors whose presence or absence could 
differentiate HA- and CA-MRSA defmitively. 
In summary, this analysis of an international panel of HA- and CA-MRSA has highlighted 
a novel putative marker for differentiating isolates in these two groups. The work 
contributes to a growing body of evidence pointing toward the possible role of prophage in 
the emergence of the CA phenotype. 
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4.3.8 The relationship between putative serotype and CA pbenotype 
In a recent study, Goerke and colleagues (2009) described the diversity of prophage in 
dominant S. aureus clonal lineages. Through analysis of polymorphisms within the 
integrase gene, they established a classification system for the Siphoviridae family of 
staphylococcal prophage (fig. 4.8). Virulence gene carriage and inferred serogroup type 
(A, B, Fa or Fb) for each of these phage were also described. Serogroup type was based on 
capsid, tail and tail appendix protein sequences (the F group were sub-divided since the 
DNA packaging, head and tail genes belonged to different modules). The work showed 
that prophage integrating at the Sa2 and SaJ loci are not restricted to a particular 
morphotype (although the integrase gene units are homologous); serogroup A and Fb 
phage integrate at the Sa2 locus, whilst serogroup Fa and Fb integrate at SaJ. By 
extrapolation of this study, their work showed that the CA phenotype-associated genes 
described in this work (MWI896-MWI912), to which homology was assigned (via the 
Prophinder tool) to 6 Siphoviridae prophage (<1>13, <1>tp310-3, <I>PVL, <1>PVLI08, tp31O-1, 
<I>PV83), belong exclusively to the Fb serogroup. This indicates that genes MW1896-
MW1912 of the cI>SaJmw locus are markers for Fb serogroup phage. Similarly, based on 
the data presented by Goerke et al. (2009), the <1>N315 and <1>Sa2mw genes identify the Fa 
and A serotypes respectively (fig. 4.9). The only morphotype not identified by the array 
data is the group B serotype carried by the sequenced Mu50 strain which, based on the 
array data, showed no structural units similar to the A, Fa or Fb serotypes. Using this 
information, the phage serotypes carried by the CA strains (including the HA strain Irish-I) 
and the sequenced HA strains analysed on the array are shown in Table 4.23. The 
assignment was based on the array data for those strains that have not been sequenced, 
whilst the data for the sequenced strains was obtained by Prophinder analysis and from the 
research by Goerke and colleagues (2009). 
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Figure 4.8 In si/ico analysis of the intcgrase groups, serogroups, holin groups, and virulence 
genes of 70 published staphylococcal bacteriophage of the class Siphoviridae. lntegrase 
nucleotide sequences were aligned using the ClustalW algorithm. Identical serogroups and holing 
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groups are colour coded. Integrases of the serine recombinase-type family are shaded in grey. 
Taken from Goerke et al., 2009. 
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Figure 4.9 Comparisons of the morphology relates genes of cf)Sa2mw (representing serogroup A phage type), cf)N315 (serogroup Fa phage type) and cf)Sa3mw 
(serogroup Fb phage type) for all the CA strains analysed on the array. Irish-I, the HA strain that clustered with the CA strains is also included, as are the 
sequenced HA strains analysed on the array. CA-MRSA strains are highlighted in yellow, CA-MSSA in green, and HA-MRSA in blue (Irish-l remains yellow). The 
first two rows indicate carriage of the pvl genes lukFS. The prophage data from Goerke et al (2009) has been mapped to this data, clearly indicating that the genes on 
the array correspond fully with phage serogroup type based solely on head! tail sequences. No sites of integration can be specified from the array data, according to 
Goerke and colleagues (2009) <l>Sa4ms and <l>COL (highlighted in pink) integrate at different loci to the <l>Sa2mw phage but all three are serogroup A phage. 
IV 
IV 
0\ 
Table 4.23 Putative relationship between S. aureus pbenotype and bacteriophage serotype. 
Published sequenced strains are given in bold text. See text for details. 
Strain name HAlCA 
phenotype 
ST22-N (PVL+) CA 
USA] 100 SWP: ST30-N 
CA JPVL+) 
NCTC 8325: ST8lM"SSA) CA 
Irish-I: STS-Il (varl HA 
MW2 consensus CA 
WA-MRSA: STI-IVa(PVL 
CA neg) 
SA476:STl ~SSA) CA 
USA400: STl-N (pVL+) CA 
European Clone: STSO-N CA (PVL+) 
ST5-IV (PVL neg) CA 
STS66-IV (pVL+; tsst+) CA 
ST772-V (PVL+) CA 
USA I 000 SE Asia: ST59-IV 
CA (PVL+) 
STSS-N(PVL +) CA 
Queensland clone: ST93-N CA (PVL+) 
USA300: ST8-IV (pVL+) CA 
ST5-IV (PVL+) CA 
ST97-V CA 
N315 HA 
Mu50 HA 
Mu3 HA 
COL HA 
MRSA252 HA 
Newman HA 
JHl HA 
JH9 HA 
Pbage Serogroup 
at Sa3 locus or 
equivalent 
Fa and Fb 
Part Fa and Fb 
Fb 
Variant of Fb 
Fb 
Fb 
Fb 
Fb 
Fb 
Fa and Fb 
Fa and Fb 
Fa 
Fa 
Fa 
Fa 
Fa 
Fa 
Fa 
Fa 
Fa 
Fa 
np 
Fa 
Fa 
Fa 
Fa 
Phage 
Serogroup 
at Sa2 locus or 
equivalent 
np 
np 
A 
A 
A 
np 
A 
A 
A 
np 
np 
np 
np 
A 
A 
A 
np 
A 
np 
B 
B 
A 
A 
B 
B 
B 
.S 
~ 
<Il 
Carriage of lukFS-pvl is highlighted in Table 4.23 (grey; 'strain name' column). The data 
presented in the Goerke paper describes pvl-carrying phage to be either of the A or Fb 
serogroup. Those of the A serogroup (<I> Sa2 mw, <I>2958PVL, <I>Sa2USA300, <DSLT-
USA300_TCH1516 and <DSLT) and the majority of the Fb serogroup (<I>PVL, <DPVL108 
and <J>tp31O-1) integrate at the Sa2 position (the exception is <J>PV83 which integrates at 
the Sa5 locus). The data for the CA strains is summarised in Table 4.23. The vast majority 
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of the CA strains are pvl-carrying phage-positive with serogroup A and/or Fb phage 
present. Conversely, the HA strains predominantly carry Fa and B serogroup phage. Only 
in two cases (COL and MRSA252) were A serogroup phage noted, but neither was of the 
pvl-carrying type. 
The absence of serogroup Fb phage from the HA strains implies that they may be involved 
in the CA phenotype. It was noted that the CA strains ST22-pvt and USAIIOO (ST30-IV 
pvt), both pvl positive, do not show presence of an A group phage. Therefore, pvl carriage 
in these cases is most likely associated with the Fb phage group. Additionally, with 
respect to W A-MRSA (STI-IV pvr) and STS-IV pvr CA strains, both again did not show 
the presence of an A group phage; the Fb group was still present without the carriage of 
pvl. Since almost all the CA strains carry a PVL-associated phage, either of the A 
serogroup or the Fb serogroup (or possibly a mosaic phage within these divisions), it is 
believed that the carriage of PVL-associated phage, (but not pvl itself, since it is absent 
from some of the CA strains) is necessary for the CA phenotype. That is to say, the genes 
recognised by the array sometimes indicate the presence of an NFb serogroup phage 
carryingpvl, or in some cases, only a pvl-negative Fb phage. In the case of the latter, it is 
conceivable to believe that these strains may either carry a non-pvl associated Fb phage, or 
a mosaic phage of the Fb serotype, lacking the pvl genes. Fb phage could possibly form a 
mosaic phage (via exchange of modules according to the theory of modular evolution) that 
combines the fitness factors of the pvl-carrying Fb phage and the saki chp/ scn carrying Fb 
phage. Thus, to summarise, it seems that it could be the carriage of Fb- and/or A-
serogroup prophage that are associated with CA-status. Since restriction modification play 
a central role in determining the uptake of bacteriophage by a bacterial genome, the 
serogroup NFb taxon phage associated with community-acquiredness may have a system 
by which this may be manipulated. The carriage of most of the morphology related genes 
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of the Fa and Fb serogroups by 3 of the CA strains, ST22 pvt, ST866 and ST5 pvl 
negative (confirmed for the latter two via sequence data; data not shown), provides 
supporting evidence for recombination between phage. Furthermore, detection of pvl 
phage not of the AlFb groups (in strains ST772, USAIOOO and STS-IV PVLl indicates 
that pvl in this case could possibly be associated with a novel morphotype. According to 
the data by Goerke and colleagues, pvl is not associated with the Fa serogroup. That is to 
say, a pvl phage of a novel serotype could be circulating within CA strains. 
The original identification of the unique morphology genes (now known to represent the 
Fb serogroup; MW1896- MW1912) in a subset of the CA strains described in this thesis 
prompted the sequencing of some of these members, including W A-M RSA, ST772, 
USA 1000, ST866 and the Queensland clone ST93. lrish-l was also sequenced to 
investigate its relationship with the CA strains (data not published). The sequenced data 
from these strains was used to confirm the presence of the phage serogroups described in 
Table 4.23 by nucleotide homology using BLAST analysis. Additionally, homology to the 
B serogroup (the only Siphaviridae serogroup not detected on the array) was analysed by 
nucleotide similarity to genes representing the structural units of cp 11 (a group B phage). 
This in silica analysis showed that the data presented in Table 4.23 were correct, and that 
the B serogroup was not present in any of these CA strains. Additionally, lrish-l did carry 
an Fb phage, not a variant as initially described, indicating that further analysis of this 
strain is required to fully understand its clustering with the CA strains. One possibility is 
that, like the other HA strains, a non-pvl type phage is carried by this strain (here a non-pvl 
Fb phage e.g. cp13, cptp310-3, cp Sa3mw or cpSa3ms are possibilities). The evidence from 
this strain suggests that either this was an original CA strain that excelled in the hospital 
environment in which it was detected (where it became classified as a HA strain), or it 
shows the potential of HA strains to become CA-strains by acquiring additional factors. 
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The Sa3 prophage group, the largest group of Siphoviridae phage, are predominantly 
composed of serogroup Fa and Fb phage. Both these serogroups carry recognised 
virulence-associated genes other than pvl, including sak, scn and chps (a few also carry 
sep/sea or seq). From this there is no implication that the Fb phage are more virulent than 
the Fa group. However, it may be the combination of virulence-associated genes carried 
by the PVL-associated phage as well as the virulence-associated genes carried at the Sa3 
position (sale, scn, chps, etc) produce a particularly virulent phenotype in those strains 
carrying phage of this morphotype. This putative link between a particular phage type and 
CA-status has not been previously reported. Analysis of further strains (in a revised 
version of the array) may provide insights into any further patterns between these genes 
and CA status. At present, these genes are a partial marker for the CA phenotype and in 
future it may be possible to establish a phenotype-genotype link. This finding further 
supports the role of the accessory genome, and in particular bacteriophage, in the evolution 
and epidemiology of S. aureus. 
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CHAPTER 5.0 TRANSCRIPTION PROFILING 
The virulence-associated gene microarray was used to investigate gene expression in 
strains of interest. As an analytic technique, transcriptomic analysis provides more 
detailed infonnation about bacterial response to its microenvironment. The results 
acquired purely reflect the transcripts obtained at the time of sampling, and thus the 
response to the experimental conditions at that time. 
In this chapter, comparative analyses of an agr mutant strain are described with the aim of 
measuring changes in gene expression between a parental and mutant strain (see below). 
In addition, a S. aureus isolated from a chronic wound, grown under biofilm-simulating 
conditions, is analysed in the same way. Biofilm grown cells were compared to their 
planktonic counterparts to assess differences between expression levels, and also to 
determine the suitability of this model for further studies. 
5.1 Agr study 
5.1.1 Background 
Agr, as described in the introduction (section 1.3.2.1), is one of the major and most 
thoroughly studied regulators of S. aureus virulence. A strain with a mutation in the agr 
locus (SHI00l), and the progenitor unmodified strain (SHI000) were provided by Simon 
Foster (Horsburgh et al., 2002). SHI000 was derived from the commonly used genetic 
lineage S. aureus 8325-4 (RN6390) and a functional rsbU gene (8325-4 rsbcF) inserted. 
RsbU is the positive regulator of Sigma factor B (section 1.3.3), and is often non-
functional in strain 8325-4 due to a mutation (8325-4 rsbU). For this study, strains were 
analysed for changes in expression levels at the early exponential- (5hr), late exponential-
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(7.5hr) and stationary- (overnight, 21h) phases. The consensus model is that genes 
encoding surface-associated proteins are generally expressed in the early exponential phase 
during cell proliferation (e.g. fibronectin binding protein A), whilst secreted proteins (e.g. 
a-haemolysin) are repressed. Conversely, in the stationary phase the opposite regulation 
effect has been reported (fig. 5.1). That is, secreted proteins (e.g. proteases/toxins), which 
aid spread and colonization, are up-regulated during later stages. 
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Figure 5.1 Growth phase dependent expression of virulence-associated genes observed during 
culture growth. Taken from Cheung et al., 2004. 
Cells were grown under the same conditions, on the same day, and extractions prepared in 
the same batch. The assumption is that genes that have changed response status (up or 
down regulation) between the isogenic strains could potentially be regulated via agr. The 
results obtained are described below. 
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5.1.2 Agr+ strain 
5.1.2.1 Differential expression observed between early exponential (EE) - versus late 
exponential (LE) -growth 
In the agr + strain, comparison of EE- versus LE-phases revealed significant expression 
(>900 fluorescence units, average sum of Cy3 and Cy5 spot pixels) of 500 genes. Genes 
with weak signals in both channels were eliminated from this analysis. Logarithms (base 2) 
of the corrected ratios were recorded, and a crude cut-off threshold for significant 
expression change was set at +2 for down-regulated and -2 for up-regulated. In this study, 
it was often noted that individual gene transcripts were measured at a significant level at 
only one growth phase (EE). This indicates clear regulation of gene transcription, however 
the calculated ratio whilst clearly indicating up or down regulation. was not considered an 
accurate indication of the scale of regulation. 
Based on these criteria, 13 genes were significantly down-regulated in the LE phase (Table 
5.1). These genes were present above the detection threshold at one or both time points. 
Half of the 13 down-regulated genes in Table 5.1 were transporter proteins, mostly with 
iron related functions. that is, genes involved in metabolism. The LE phase represents the 
intennediate phase between actively growing cells and stationary cells. The down 
regulation observed probably reflects the fact that these metabolic genes are expressed less 
in the LE phase. Included also in this list were two transcriptional regulatory proteins, one 
of which is gapR, a protein involved in the glycolysis pathway for carbon metabolism. In 
addition, spaA (the IgG binding protein) was also significantly up-regulated (spaA is a 
gene known to be repressed by agr. 
233 
A greater number of genes (52) were found to be up-regulated between the EE and LE 
phases (Table 5.2). Several of these were related genes (some belonging to the same 
operon and others located next to each other around the chromosome), giving confidence 
in the data observed. These included the capsule genes (14 genes representing types 5 and 
8 capsule groups), two serine proteases (MWI752-54) and several hypothetical proteins 
similar to (I) Ear protein - an exported protein (MWI757) and (il) putative lantibiotic ABC 
transporters (MW1758-60) located adjacent to one another on genomic island nuSa~2. 
Also up-regulated were members of the haemolysin toxin family (hla, hla precursor 
[SARl136], hlb, hlgB, hlgC). The capsule genes represent a host defence mechanism, 
whilst the toxin and protease genes are also involved in the infection process. The 
lantibiotics protect the bacterium against self-produced toxins. As indicated previously the 
generally accepted model is that toxin and protease genes, which facilitate spread and 
colonization, are down-regulated in the early exponential phase and up-regulated post 
exponentially (fig. 5.1). 
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Table 5.1 Genes down-regulated in the agr+strain between the EE and LE growth. 
Genes with significant expression and log2 ratio> +2 are listed. TF (total fluorescence) units are given for each gene. Additional gene descriptions obtained from recent 
in si/ico investigations are given in square parentheses (for this table and all tables to follow). 
Gene ID 
MW2013 
SA1888: rodA 
MW0982:potA 
SA0598:pbp4 
SA2144 
MW2103 
MW0595 
SAV2455 
MW0084:spa 
MW0594 
SA0726:gapR 
MW0698 
MW0593 
N 
\.>l 
Vl 
Product description 
lipoprotein precursor 
hypothetical protein, similar to rod shape determining protein RodA 
[cell division protein, FtsWlRodAlSpoVE family (ftsW)] 
spermidine/putrescine ABC transporter, A TP-binding protein homolog 
penicillin binding protein 4 (pbp4) 
hypothetical protein, similar to transcriptional regulator (TetRlAcrR family) 
hypothetical protein similar to ferrichrome ABC transporter (binding protein) 
hypothetical protein, similar to ABC transporter A TP-binding protein 
family M42 unassigned peptidases (SAV2455 protein) 
[glutamyl-aminopeptidase] 
IgG binding protein A 
conserved hypothetical protein 
[ABC transporter, permease protein] 
glycolytic operon regulator 
[transcriptional regulator] 
lipoprotein, similar to ferrichrome ABC transporter 
lipoprotein, Streptococcal adhesin PsaA homologue 
jiron repressed lipoprotein (mntC)! ABC transporter, substrate-binding protein] 
IOg2 ratios 
(Agr+ 5v7) TF 
2.06 7177.52 
2.17 2779.52 
2.50 1356.02 
2.68 1232.02 
2.78 8193.02 
3.04 3040.52 
3.13 7902.52 
3.28 4316.52 
3.46 39112.52 
3.54 7114.52 
3.73 17808.52 
3.94 2574.52 
4.54 11729.52 
Table 5.2 Genes up-regulated in the agr+ strain between the EE and LE growth. 
Genes with significant levels of expression and lo~ ratios < -2 are listed. Total fluorescence (TF) units are given for each gene. 
Gene ID 
SAV0161 :CapSM 
SAV0155:Cap5G 
MW1874 
MW1872 
SAV0154:CapSF 
MW0764:clfA 
MW1760:bsaF 
SAV0151 :Cap8C 
MW1834 
E161084c SAR1022 
SAV2451 
SAV0150:CapSB 
MW1754:sp1B 
MW2344:hlgB 
MW1759:bsaE 
SAV0157:CapSI 
SAV0160:Cap5L 
SAV0164:Cap5P 
MW1758:bsaG 
SAV0153:Cap8E 
MW1757 
SAV0162:Cap5N 
SA1814 
bbp 
SAV0159:Cap5K 
N 
V-l 
0\ 
Product description 
capsular polysaccharide synthesis enzyme CapSM 
capsular polysaccharide synthesis enzyme Cap5G 
hypothetical protein , similar to ABC transporter, ATP-binding protein 
hypothetical protein , similar to ABC transporter, ATP-binding protein 
capsular polysaccharide synthesis enzyme CapSF 
fibrinogen-binding protein 
hypothetical protein, similar to EpiF (Genomic island nuSal32) 
[putative lantibiotic ABC transporter protein] 
capsular polysaccharide synthesis enzyme Cap8C 
hypothetical protein, similar to ferritin (ftn) 
V8PROTEASE 
subfamily S9C non-peptidase homologues 
[putative carboxylesterase] 
capsular polysaccharide synthesis enzyme CapSB 
serine protease 
gamma-haemolysin component B 
hypothetical protein, similar to EpiE (Genomic island nuSal32) 
[putative lantibiotic ABC transporter protein] 
capsular polysaccharide synthesis enzyme Cap51 
capsular polysaccharide synthesis enzyme Cap5L 
capsular polysaccharide synthesis enzyme Cap5P 
hypothetical protein, similar to EpiG (Genomic island nuSal32) 
[putative lantibiotic ABC transporter protein] 
capsular polysaccharide synthesis enzyme Cap8E 
hypothetical protein, similar to Ear protein 
[putative exported protein] 
capsular polysaccharide synthesis enzyme CapSN 
subfamily M20A unassigned peptidases 
[succinyl-diaminopimelate desuccinylase] 
sdrE homolog (bone sialoprotein binding protein) 024 
capsular polysaccharide synthesis enzyme Cap5K 
1092 ratios TF 
(Agr+ Sv7.S) 
-2.02 20233.52 
-2.03 18497.52 
-2.08 22357.52 
-2.12 22189.52 
-2.14 17S5S.52 
-2.14 39294.52 
-2.19 13542.52 
-2.20 16S98.52 
-2 .21 42398.52 
-2 .22 2995.02 
-2.26 16937.02 
-2.29 24054.52 
-2.30 1337.52 
-2.31 2088.52 
-2.38 8101 .S2 
-2.54 10215.52 
-2.55 10054.52 
-2.S6 12078.52 
-2.57 9447.52 
-2.60 17382.52 
-2.61 1243.02 
-2.62 7946.52 
-2.64 6931 .52 
-2 .67 1579.52 
-2.75 7361 .52 
SAV0163:Cap80 
SAV0156:Cap5H 
MW1753:sp1C 
SA2424 
SAR1902 
MW1752:sp1F 
SAV0158:Cap5J 
SAV1813:sp1A 
MW2590:lip 
MW1032:sdhB 
MW1910 
MW0074 
MW1041 
efb 
MW2553:arc 
MW1040 
MW2431 
MW0167 
MW0297:geh 
MW1881 :hlb 
MW2343:hlgC 
E161208c SAR1136 
MW1044:hla 
MW0396 
SA0211 
N 
W 
-...J 
capsular polysaccharide synthesis enzyme Cap80 
capsular polysaccharide synthesis enzyme O-acetyl transferase Cap5H 
serine protease 
hypothetical protein , similar to transcription regulator Crp/Fnr family protein 
SAR1902 (was splE S.hyicus) 
serine protease 
capsular polysaccharide biosynthesis enzyme Cap5J 
subfamily S1 B unassigned peptidases (exoprotein A) 
[serine protease] 
triacylglycerollipase precursor 
succinate dehydrogenase iron-sulfur protein subunit (MW2) 
hypothetical protein [phage protein] 
hypothetical protein 
hypothetical protein , similar to fibrinogen-binding protein 
fibrinogen-bind ing protein (strain 4074/MW1 040) 
carbamate kinase 
fibrinogen-binding protein 
hypothetical protein , similar to glucarate transporter 
hypothetical protein , similar to transcription regulator 
glycerol ester hydrolase (lipase) 
beta haemolysin 
gamma-haemolysin component C 
BICOMPNTOXIN 
[hla precursor] 
alpha toxin; alpha haemolysin 
hypothetical protein 
[putative exported protein] 
acetyl-CoA acetyltransferase probable 
[thiolasel 
-2 .81 9771 .52 
-2 .82 16743.52 
-2.83 1298.02 
-2.86 2042.52 
-2 .87 1074.52 
-2.89 1282.02 
-2 .96 11567.52 
-3.01 1804.52 
-3.27 2783.52 
-3.56 26220.52 
-3.82 2395.52 
-3.89 1488.02 
-3.94 5849.52 
-3.96 15162.52 
-3.99 12883.52 
-4.10 6602.52 
-4.13 12962.52 
-4.54 9809.52 
-5.06 25134.52 
-5.14 21924.52 
-5.20 5121 .02 
-5.21 8750.52 
-5.57 26600.02 
-5.81 31226.02 
-6.29 16199.52 
5.1.2.2 Differential expression observed between EE - venus overnight (ON) -growth 
Gene expression was also measured after overnight (ON, 21hrs) culture. Changes between 
the EE and ON cells were investigated. Compared with the 5 v 7.5hr phase, 25 of the 52 
genes still had detectable expression levels, but only 7 genes were significantly up-
regulated (Table 5.3, marked by astrix, *). These were the putative lantibiotic ABC 
transporter genes bsaEFG, elf A (clumping factor A. a fibrinogen binding protein). sdhB (an 
iron related enzyme), MW0396 (a hypothetical, possibly exported protein), and SA0211 (a 
probable acetyl coA acetyl transferase ). With the exception of elf A and SA0211, the 
expression levels of the other 5 genes were greater in the ON phase, indicated by the 
expression ratios (compare Table 5.2 and 5.3). The increase in expression ratio between 
the EE to LE and EE to ON phases suggests that these genes are growth phase dependent 
and that they continue to be up-regulated as cell density increases. An additional set of 
genes was not found to be up-regulated in the EE to LE comparison but were noted in the 
EE to ON data (Table 5.3). These included surface binding proteins (e.g. epbS, sdrE), 
ribosomal RNA. the protease clpP, dnaK (a chaperonin) and regulatory proteins including 
sarA. The implied increase in levels of the chaperonin (analogous to hsp70) is likely to be 
indicative of stress responses in the ON cells that result from nutrient depletion and the 
accumulation of extracellular toxins. The increase in transcription of the surface proteins 
was unexpected. 
A larger number of genes (n=106) were significantly down-regulated between the EE and 
ON culture phases (Table 5.4). Here several interesting observations were made. In 
particular, the expression levels of many of the regulatory genes decreased including the 
key regulators agre}, sarH} (sarS) and sarR, sigB (and its regulatory protein rsbU), saeR 
and arlR, as well as lytR. vraR. eepA and several hypothetical proteins with putative 
regulatory functions. Other down-regulated genes included 15 peptidases, the hsd 
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restriction modification operon (hsdR/S/M), two lytic regulatory proteins from transposon 
Tn554, several transport related proteins and house-keeping genes. In order to determine 
which of the observed effects were mediated by agr, these experiments were repeated 
using the isogenic mutant strain (SHIOOO agr). 
239 
Table 5.3 Genes up-regulated in the agr+ strain between EE and ON growth. 
Gene ID 
MW1369:epbS 
MW0111 
MWrRNA02 
MW0985 
SA0573:sarA 
SAV0768:clpP 
SA0857 
MW1032:sdhB * 
MWrRNA05 
MW1760:bsaF * 
MW1758:bsaG * 
MW0518:sdrE 
MW1759:bsaE * 
MW1532:dnaK 
MW0396 * 
SA2308 
MW0764:clfA * 
SA0211 * 
N 
~ 
o 
----
Product description 
cell surface elastin binding protein 
hypothetical protein similar to tetracycline resistance protein 
[putative transport system protein] 
23S ribosomal RNA 
spermidine/putrescine-binding protein precursor homolog, potO 
[ABC transporter] 
staphylococcal accessory regulator A 
peptidase Clp (type 1) 
[ATP-dependent Clp protease, proteolytic subunit ClpP] 
hypothetical protein, similar to negative regulator of genetic competence MecA 
[regulatory protein] 
succinate dehydrogenase iron-sulfur protein subunit (MW2) 
16S ribosomal RNA 
hypothetical protein, similar to EpiF (Genomic island nuSa~2) 
[putative lantibiotic ABC transporter protein] 
hypothetical protein, similar to EpiG (Genomic island nuSal32) 
[putative lantibiotic ABC transporter protein] 
Ser-Asp rich fibrinogen-bind ing bone sialoprotein-binding protein 
hypothetical protein , similar to EpiE (Genomic island nuSal32) 
[putative lantibiotic ABC transporter protein] 
OnaK protein [chaperone protein] 
hypothetical protein 
[putative exported protein] 
hypothetical protein, similar to transcription regulator MarR family 
fibrinogen-binding protein 
L ac_etvl-CoA acetyltransferase probable [thiolase] 
1092 ratios TF 
(Agr+ 5vON) 
-1 .90 11021 .07 
-1 .94 1362.07 
-1 .97 61362.07 
-2.11 3764.07 
-2.16 7282.07 
-2.27 4984.07 
-2 .31 13315.07 
-2 .38 5578.07 
-2.87 52414.07 
-3.54 13834.07 
-3.58 5227.07 
-3.91 18485.07 
-4.17 5639.07 
-4.86 25581 .07 
-4.99 10119.07 
-5.10 3131 .07 
-5.20 23461.07 
-5.64 8593.07 
Table 5.4 Genes down-regulated in the agr+ strain between EE and ON growth. 
Gene ID 
MW0723:lgt 
SA1557:ccpA 
SA1649 
MW1501 
MW0339 
• SA1247 
: SAV1068:purQ 
MW0573 
SAV1384 
SAV1057:fmt 
SA0675 
SA1320 
SA1248 
SA1748 
MW1163 
SA0661 :saeR 
MW0213 
SA1329 
MW1594:obg 
SA1700:vraR 
MW2403 
MW1872 
MW0795 
MW0736:tpi 
MW1874 
SA2272 
N 
~ 
Product description 
prolipoprotein diacylglyceryl transferase 
catabolite control protein A [regulator function also] 
conserved hypothetical protein 
family S54 unassigned peptidases (SAV1549 protein aka MW1501) 
[peptidase, rhomboid family] 
hypothetical protein, similar to GTP-binding protein 
[GTP-binding protein YchF (ychF)] 
truncated (putative two-component response regu lator ArlR (truncated-arIR) 
family C56 non-peptidase homologues 
[phosphoribosylformylglycinamidine synthase] 
hypothetical protein similar to iron-binding protein 
[iron compound ABC transporter, permease protein/lipoprotein] 
oligopeptidase F (pepF) 
family S12 unassigned peptidases (Fmt protein) 
[autolysis and methicillin-resistant-related protein (fmt)] 
hypothetical protein , similar to ABC transporter ATP-binding protein 
hypothetical lipoprotein 
truncated (putative response regulator ArlR [S (truncated-arIR)] 
hypothetical protein , similar to transcription regulator, GntR family 
hypothetical protein, similar to 3-oxoacyl- acyl-carrier protein reductase homolog ymfl 
response regulator 
hypothetical protein, similar to nickel ABC transporter nickel-binding protein 
[putative extracellular solute-binding lipoprotein] 
ferric uptake regulator (fur) homolog 
[transcriptional regulator, Fur family] 
SpoOB-associated GTP-binding protein 
two-component response regulator 
hypothetical protein, similar to oxidoreductase 
hypothetical protein, similar to ABC transporter, ATP-binding protein 
ABC transporter ATP-binding protein homologue 
triosephosphate isomerase 
hypothetical protein, similar to ABC transporter, ATP-binding protein 
hypothetical protein 
1092 ratios TF 
(Ag( 5vON) 
1.93 7240.07 
1.94 8426.07 
1.98 1399.07 
2.01 7340.07 
2.02 9592.57 
2.08 4062.07 
2.10 1321 .07 
2.12 1432.07 
2.14 1811 .07 
2.14 1026.07 
2.14 1769.07 
2.17 1513.07 
2.18 2662.57 
2.20 3372.07 
2.22 2408.07 
2.24 5931 .07 
2.25 1083.57 
2.26 946.073 
2.27 4482.07 
2.30 1902.57 
2.33 2493.07 
2.34 2643.07 
2.34 8330.07 
2.36 10517.07 
2.42 1835.07 
2.47 1087.57 
SAV1279 
SA1666 
SAV2133:hmrA 
SA0702:lIm 
SA2418 
MW0623:vraF 
MW1572 
MW1536:lepA 
MW0558 
MW1547:aroE 
SA0298 
SAV0432:hsdS 
MW2103 
MWOO77 
SA0726:gapR 
MW2013 
MW1988:sigB 
SAV0511 :ftsH 
MW2328 
SA2421 
SA2340 
MW1828:map 
SA0276 
SAV1044 
MW2197:modA 
SA1676 
gil78172212 (agr) 
MW0108 
MW1971 :vga 
MW2409 
N 
~ 
N 
subfamily M16C unassigned peptidases [putative protease] 
two-component response regulator homolog 
[DNA-binding response regulator, LuxR family] 
subfamily M20D non-peptidase homologues (HmrA protein) 
[puative peptidase/ similar to amidase (HmrA)] 
lipophilic protein affecting bacterial lysis rate and methici llin resistance level 
[lipophilic regulator protein] 
hypothetical protein, similar to two-component response regulator 
ABC transporter ATP-binding protein 
iron-sulfur cofactor synthesis protein homolog 
GTP-binding protein 
conserved hypothetical protein [putative membrane protein] 
shikimate dehydrogenease 
hypothetical protein, similar to regulatory protein PfoR (perfringolysin 0 regulator protein (pfoR)) 
probable restriction modification system specificity subunit c 
hypothetical protein similar to ferrichrome ABC transporter (binding protein) 
hypothetical protein , similar to transcription regulator AraC/XylS family 
glycolytic operon regulator 
[transcriptional regulator] 
lipoprotein precursor [membrane protein oxaA precursor (oxaA)] 
sigma factor B 
FtsH-2 peptidase [cell-division protein (ftsH)] 
hypothetical protein similar to Zn-binding lipoprotein adcA 
[ABC transporter, substrate-binding proteinl probable zinc-binding lipoprotein] 
hypothetical protein, similar to transcriptional regulator 
hypothetical protein, similar to transcriptional regulator tetR-family 
methionyl aminopeptidase map 
conserved hypothetical protein, similar to diarrheal toxin yukA [essC protein] 
family S33 unassigned peptidases 
[hydrolase, alpha/beta hydrolase fold family] 
probable molybdate-binding protein 
hypothetical protein, similar to regulatory protein (pfoS/R) 
agr type 1 subset specific 1 12 16 17 20 25 
hypothetical protein [cell wall surface anchor family protein] 
hypothetical ABC transporter ATP-binding protein 
conserved hypothetical protein [putative helicase] 
2.48 3158.57 
2.49 908.073 
2.50 2002.07 
2.51 1209.07 
2.53 998.073 
2.54 1268.07 
2.56 3248.07 
2.62 1782.07 
2.64 971 .073 
2.64 2591 .07 
2.68 2027.07 
2.77 1410.07 
2.80 2407.07 
2.87 1173.07 
2.90 13755.07 
2.90 3469.07 
2.90 15212.07 
2.91 10016.07 
2.99 991 .573 
3.03 4273.07 
3.08 1777.57 
3.08 3748.07 
3.09 906.07 
3.13 4111 .57 
3.13 4296.07 
3.15 987.07 
3.16 11804.07 
3.17 1957.07 
3.20 1040.07 
3.22 997.07 
SAV1113 
SA1956 
SA1139:glgP 
SA1949 
MW1064:pbpA 
MW0543:pta 
MW1092:gmk 
MW1942 
MW0682 
MW2259 
SAV0965:spsB 
MW2336 
SAV1262 
SAV0195:hsdR 
MW2368 
SA0704 
agrC1 
MW0263 
MW0698 
MW2261 
MW0342:ssb 
MW1362:hu 
SAV2051 
SA0509:HCHA 
SA0879:htrA 
MW0085: sarH 1 
MW0552 
MW0574 
MW1991 :rsbU 
MW0323 
MW2195:modC 
MW0919 
MW21 02 
N 
~ 
w 
conserved hypothetical protein 
(cell division protein , FtsW/RodAlSpoVE family] 
lytic regulatory protein truncated with Tn554 
glycerol uptake operon antiterminator regulatory protein 
lytic regulatory protein truncated with Tn554 (truncated-SA) 
[membrane-embedded lytic regulatory protein] 
penicillin-binding protein 1 
phosphotransacetylase 
guanylate kinase 
hypothetical protein similar to leukocidin chain lukM precursor 
[probable leukocidin S subuniU Aerolysin/Leukocidin family protein ] 
hypothetical protein , similar to ABC transporter ATP-binding protein 
conserved hypothetical protein [YnfA family proteinl putative membrane protein] 
signal peptidase SpsB (SpsB protein) 
hypothetical protein , similar to amino acid ABC transporter, periplasmic amino acid-binding protein 
RseP peptidase 
probable type I restriction enzyme restriction chain 
hypothetical protein , similar to integral membrane efflux protein [putative drug transporter] 
conserved hypothetical protein [degV family protein] 
group 1 accessory gene regulator, agr operon (af21 0055) 
conserved hypothetical protein, similar to diarrheal toxin incomplete ORF 
lipoprotein, similar to ferrichrome ABC transporter [also transferrin receptor] 
ATP-binding protein) hypothetical protein, similar to ABC transporter 
single-strand DNA-binding protein of phage phi Sa 2mw 
DNA-binding protein" 
family M22 non-peptidase homologues [similar to glycoprotein endopeptidase] 
family C56 unassigned peptidases [DJ-1/Pfpl family protein] 
subfamily S1C unassigned peptidases [serine protease (htrA)] 
staphylococcal accessory regulator A homologue 
major tail protein [putative membrane protein NOT major tail protein] 
hypothetical protein similar to iron(lIl) ABC transporter permease protein 
sigmaB regulation protein RsbU 
conserved hypothetical protein [putative Sec-independent protein translocase protein] 
molybdenum transport ATP-binding protein 
[molybdenum ABC transporter, ATP-binding protein ModC] 
hypothetical protein, similar to UDP-glucose:polyglycerol phosphate glucosyltransferase 
hypothetical protein similar to ferrichrome ABC transporter (permease) 
3.23 1195.57 
3.24 2334.07 
3.29 2236.07 
3.31 4731 .07 
3.35 2831 .07 
3.36 8621 .07 
3.38 12260.07 
3.39 1059.57 
3.46 959.07 
3.48 1683.07 
3.50 1994.07 
3.56 9466.07 
3.57 3165.57 
3.57 1066.07 
3.59 1406.07 
3.61 1734.07 
3.71 11071.07 
3.71 1270.07 
3.71 3349.07 
3.71 1771.07 
3.74 16296.07 
3.7 17837.07 
3.94 1029.07 , 
3.95 12933.07 
3.95 1491 .07 
4.00 1939.07 
4.00 1679.57 
4.05 1072.07 
4.08 13227.07 
4.09 922.07 
4.13 3632.07 
4.15 2590.07 
4.15 998.07 
SAV0431 : hsdM probable type I site-specific deoxyribonuclease Lldl chain 4.17 2634.57 
SA0641 conserved hypothetical protein, similar to transcriptional regulator 4.25 10974.07 
[probable transcriptional regulator MarR family] 
SA2144 hypothetical protein , similar to transcriptional regulator (TetR/AcrR family) 4.29 2767.07 
MW1280 ABC transporter (ATP-binding protein) homolog 4.30 1840.07 
SAV1529 subfamily M24B non-peptidase homologues [proline dipeptidase] 4.34 8225.07 
SAV1751 subfamily M20A unassigned peptidases 4.38 14684.07 
MW1482 subfamily M24B unassigned peptidases [proline dipeptidase] 4.39 7299.07 
MW0595 hypothetical protein, similar to ABC transporter ATP-binding protein 4.45 4460.07 
MW2273 hypothetical protein , similar to multidrug resistance protein 4.48 1203.07 
[drug resistance transporter, EmrS/QacA subfamily, putative] 
MW1811 hypothetical protein , similar to teichoic acid translocation ATP-binding protein tagH 4.70 966.07 
[ABC transporter] 
SA1360 subfamily M24B unassigned peptidases [proline dipeptidase] 4.75 5982.07 
MW1364 hypothetical protein , similar to GTP binding protein 4.78 5116.07 
[putative GTPasel GTP-binding protein EngA (engA)] 
MW0593 lipoprotein, Streptococcal adhesin PsaA homologue 4.81 2783.07 
SAV1000 oligopeptidase F (pepF) 5.24 2688.57 
SAV1879:ampS aminopeptidase S (aminopeptidase ampS) 5.40 4423.07 
MW1182:glpF glycerol uptake facil itator 5.45 5116.07 
SA0251 : lytR two-component response regulator 5.87 2869.07 
[sensory transduction protein LytR] 
MW2213:sarR staphylococcal accessory regulator A homo\og 5.91 11903.57 
MW0594 conserved hypothetical protein 6.14 2305.07 
[ASC transporter permease protein] 
MWOO84:spa IgG binding protein A 6.47 15225.07 
N 
t 
5.1.3 Agr- (mutant) strain 
The agr mutant strain was grown and sampled at the same time points. Overall, less 
expression at all time phases and comparisons was observed. 
5.1.3.1 Differential expression observed between EE- versus LE-growth 
Only six genes were found to be significantly up-regulated (Table 5.5) between the EE and 
LE cultures. As observed in the agr+ strain, increased expression of hla (MWI044), hla 
precursor (SARl136) and MW0396 (a putative exported protein) were observed in the LE 
phase. As these genes are up-regulated in the agr mutant strain, the up-regulation was 
independent of the agr operon. Two other genes, pyre (dibydro-orotase) and arcC 
(carbamate kinase, the housekeeping gene used in MLSn were also up-regulated between 
these phases. As for hla, the regulation was independent of the presence ofRNAIn. 
Table 5.5 Genes up-regulated in the agr strain between EE and LE growth. 
logz ratio 
Gene ID Product description (Agr- 5v7.5) TF 
MW2553:arc carbamate kinase [arcC] -2.22 3125.53 
MW0396 hypothetical protein [putative e, ported -2.40 17318.53 protein] 
MW I 044:hla alpha toxin; alpha haemolysin -2.40 10994.53 
SAV1201:pyrC dihydro-orotase -2.52 6595.533 
E161208c SARI 136 bicompntoxin Qlla precur or] -2.95 1673.533 
SA0211 acetyl-CoA acetyltransferase probable 
-5.43 17726.53 [thiolase] 
Similarly, comparative data show another six genes were significantly down-regulated 
between the EE and LE phases (Table 5.6). Four of these genes were hypothetical 
proteins, which showed similarity to (i) an ABC transporter (MW2336), (ii) lysR family 
transcriptional regulator (SA2123), (Ui) maltose-binding protein (MW0190) and (iv) a 
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multi-drug resistance protein (MW2273). The other two genes were a peptidase 
(SA0509) and a myosin-cross reactive streptococcal antigen homologue (SAOI02). 
Significant expression of these genes was not detected in the agr + strain although the ABC 
transporter (MW2336) and the regulator gene (SA2123) were detected at low levels. 
Therefore, it was not possible to determine whether expression of these genes was growth 
phase dependent in the agr+ strain. However, the results are evidence that certain genes are 
repressed by the Agr operon in EE cells. It may be that this class of genes are very 
sensitive to RNAlII. 
Table 5. 6 Genes down-regulated in the aK'- strain between EE and LE growth. 
Gene ID Product description logz ratios TF 
(Agr-
Sv7.S1 
SA0509: family C56 unassigned peptidases 3.26 27860.53 
HCHA 
MW2273 hypothetical protein, similar to multidrug resistance 2.13 1236.53 
protein 
SA2123 hypothetical protein, similar to transcription regulator 2.24 2499.53 
SAOI02 
LysRfamily 
67 kDa Myosin-crossreactive streptococcal antigen 2.46 929.53 
homologue 
MW2336 hypothetical protein, similar to ABC transporter, 3.21 11224.53 
periplasmic amino acid-binding protein 
MW0190 hypothetical protein, similar to maltose/maltodextrin- 3.30 1304.53 
binding protein 
5.1.3.2 Differential expression observed between the EE- versus ON-growth 
Comparison of the EE and ON phase RNAs revealed nine genes that were significantly up-
regulated (Table 5.7); c/fA (MW0264), a probable acetyl-coA acetyl transferase (SA021I), 
bsaE (MWI759) and bsaG (MWI7S8; putative lantibiotic epidermin immunity proteins! 
ABC transporters), a peptidase, exotoxin 18 (set18), peptidase SAV1512, intracellular 
adhesin protein C (icaC) and serine proteases splA (MW1755) and splB (MW1754). Those 
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marked by an astrix also displayed up-regulation in the isogenic agr + strain between the 
same time points (Table 5.3). 
Table 5.7 Genes up-regulated in the agr- strain between EE and ON growth. 
Gene ID Product description lo~ ratios TF (Agr-SvON~ 
SAVI512 subfamily M20B unassigned peptidases -1.98 3762.58 
SA V2669:icaC intercellular adhesion protein C -2. 14 1062.08 
MWrRNA05 • 16S ribosomal RNA (RNA05) -2.22 80665.08 
MW1758:bsaG • hypothetical protein, similar to EpiG (Genomic island nuSa~2) -2.57 4063.58 
[putative lantibiotic ABC transporter protein] 
MW1754:splB serine protease -2.86 994.08 
MW1759:bsaE • hypothetical protein, similar to EpiE (Genomic island nuSa~2) -2.88 3904.08 
[putative lantibiotic ABC transporter protein] 
MW0384:set18 exotoxin 18 -3.49 1625.08 
MW0764:c1fA * fibrinogen-binding protein -3.95 25515.08 
MW1532:dnaK * DnaK protein -4.33 21299.08 
MW1755:sp1A serine protease -4.48 868.58 
SA0211 * acetyl-CoA acetyltransferase probable [thiolase] -6.75 10067.08 
As found for the agr+ strain, a larger number of genes were down-regulated between EE 
and ON growth phases. Here 54 genes were noted (Table 5.8), with the highest ratios 
observed for spaA, glpF (glycerol uptake facilitator) and the regulator sarR. 
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Table 5.8 Genes down-regulated in tbe ag,- strain between EE and ON growtb. 
Gene ID 
MW2195:modC 
MW1163 
SA2340 
MW1594:obg 
SA VOS11 :ftsH 
SAVI044 
MW2197:modA 
MW0790 
MW0200 
SAV1384 
SAV2051 
MW0339 
MW1988:sigB 
MW0871 :OppF 
MWI092:gmk 
SAV1279 
SA1248 
SA1247 
MW1572 
SA0879:htrA 
SA V0431 :hsdM 
SA0276 
SAVI068:purQ 
SAVOI95:hsdR 
SAV1398:hipO 
SA1557:ccpA 
SA 1700:vraR 
MWOI08 
MW2261 
MW0342:ssb 
N 
~ 
00 
Product description 
molybdenum transport ATP-binding protein 
hypothetical protein, similar to 3-oxoacyl- acyl-carrier protein reductase homo log ymfl 
hypothetical protein, similar to transcriptional regulator tetR-family 
SpoOB-associated GTP-binding protein 
FtsH-2 peptidase 
family S33 unassigned peptidases 
probable molybdate-binding protein 
ABC transporter A TP-binding protein homologue 
hypothetical protein similar to periplasmic-iron-binding protein BitC 
oligopeptidase F 
family M22 non-peptidase homologues 
hypothetical protein, similar to GTP-binding protein 
sigma factor B 
oligopeptide transport A TP-binding protein 
guanylate kinase 
subfamily M 16C unassigned peptidases 
truncated (putative response regulator ArIR [S (truncated-arIR)] 
truncated (putative response regulator ArlR (truncated-arIR)] 
iron-sulfur cofactor synthesis protein homolog 
subfamily SIC unassigned peptidases 
probable type I site-specific deoxyribonuclease LldI chain 
conserved hypothetical protein, similar to diarrheal toxin 
family C56 non-peptidase homologues (phosphoribosylformylglycinamidine synthase) 
probable type I restriction enzyme restriction chain 
famity M20D unassigned peptidases (hippurate hydrolase) 
catabolite control protein A (regulator function also) 
two-component response regulator 
hypothetical protein 
A TP-binding protein) hypothetical protein, similar to ABC transporter 
single-strandpNA-binding protein of phage phi Sa 2mw (phage protein) 
log2 ratios TF 
(A~r-5vON) 
2.054331173 3163.08 
2.067582897 2462.58 
2.081029416 1965.08 
2.089941575 5809.08 
2.123756399 7353.58 
2.136806483 5115.08 
2.144910727 3081.08 
2.161505009 1351.08 
2.183270352 1191.08 
2.186211334 2491.08 
2.209133559 1029.08 
2.256324463 9048.08 
2.267941227 16231.08 
2.299083297 4382.08 
2.305221603 14291.58 
2.312880849 2287.08 
2.376545244 3884.08 
2.380709953 7388.08 
2.384973489 5390.08 
2.39007265 1269.08 
2.404862071 2438.08 
2.418257877 942.08 
2.457022941 1710.08 I 
2.465547286 1559.08 i 
2.556010903 1709.08 
2.597707603 11970.08 
2.616065258 1644.08 
2.655320538 8422.08 
2.714697528 2804.08 
2.744794791 8317.08 
SAV1262 
MW0543:pta 
SA0641 
MW0795 
MWI044:hla 
MW0870:0ppD 
MW 1362:hu 
MW2336 
SAV0520 
MW0919 
SA 1360 
MW1482 
N 
+>-\0 
SAVlOOO 
MW2431 
SAV1529 
MW1834 
MW1991:rsbU 
SA0661 :saeR 
SAV1751 
SA0509:HCHA 
MWOO84:spa 
MW1182:glpF 
MW2213:sarR 
RseP peptidase 
phosphotransacetylase 
conserved hypothetical protein, similar to transcriptional regulator 
ABC transporter A TP-binding protein homologue 
alpha toxin; alpha haemolysin 
oligopeptide transport system ATP-binding protein OppD homologue 
DNA-binding protein 11 
hypothetical protein, similar to ABC transporter, periplasmic amino acid.binding protein 
family C56 non-peptidase homologues 
hypothetical protein, similar to UDP-glucose:polyglycerol phosphate glucosyltransferase 
subfamily M24B unassigned peptidases 
subfamily M24B unassigned peptidases 
oligopeptidase F 
hypothetical protein, similar to glucarate transporter 
subfamily M24B non-peptidase homologues 
hypothetical protein, similar to ferritin 
sigmaB regulation protein RsbU 
response regulator 
subfamily M20A unassigned peptidases 
family C56 unassigned peptidases 
IgG binding protein A 
glycerol uptake facilitator 
staphylococcal accessory regulator t\._homolog __ 
- --- - -- -
2.769100533 1628.58 
2.837414254 9089.08 
2.840251747 5921.08 
2.860950931 10628.08 
2.88377907 1203.08 
2.90446186 1210.58 
2.961804985 27765.08 I 
2.971148981 9957.08 
3.005459543 1967.08 . 
3.040339866 2731.08 I , 
3.076465764 4785.08 
3.185571518 7706.08 
3.189526652 3002.58 
3.19224756 17977.08 
3.24835505 7075.08 
3.305430881 19237.08 
3.366225659 18825.08 
3.502727232 2496.58 
3.678418791 19358.08 
3.941352888 18603.08 
4.383021426 40797.58 
4.924044687 31560.08 
5.07577239 18945.08 
-- -
5.1.4 Agr summary 
Once all significant measurements were recorded, the data from the isogenic strains were 
compared to determine those genes with possible agr-related effects. The agr gene 
product is known to be centrally involved in quorum sensing, that is, responding to the 
environment in a growth-phase dependent manner. Simplistically, any gene regulated via 
agr would not be expected to show the same effect (either no regulation, or reduced 
regulation) in the mutant strain. However, due to the complexity of the regulatory network 
in S. aureus, further work would be necessary to confirm agr involvement, and the 
mechanisms involved (e.g. direct! indirect agr effect or possibly involving other 
regulators). 
In the first comparison (Table 5.3 versus Table 5.7), the genes upregulated between EE and 
ON growth phases in the isogenic strains were compared. Those genes that appeared in 
both lists were excluded (the presence of these genes in the agr" mutant strain essentially 
eliminates the possibility of agr regulation), and the raw data for those remaining in the 
agr+ strain were re-analysed. The revised list is shown in Table 5.9. The highlighted 
genes appear to be strongly associated with the presence of agr (that is, the isogenic strains 
show opposite effects), whilst the others have a weak association (the presence of agr 
enhances the overall effect). 
In the same way, the isogenic strains were also compared for those genes which could be 
negatively regulated by agr (compare Table 5.4 and Table 5.8). Following the same 
algorithm as above, the results obtained are summarised in Table 5.10. 
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Table 5.9 Genes positively regulated by agr according to the data derived from this study. 
The negative log ratios indicate higher expression in the ON phase; in this case this gives a measure of gene expression in response to quorum sensing. The ratios of -3 
and below suggest stronger responses to quorum sensing. 
i Gene ID 
I MW1369:epbS 
MWOlIl 
MW0985 
SA0573:sarA 
SA Y0768:c\pP 
SA0857 
MWI032:sdhB 
MW 1 760:bsaF 
MW0518:sdrE 
MW0396 
SA2308 
N 
VI 
Product description 
cell surface elastin binding protein 
hypothetical protein similar to tetracycline resistance protein 
[putative transport system protein] 
spermidine/putrescine-binding protein precursor homolog, potD [ABC transporter] 
staphylococcal accessory regulator A 
peptidase Clp (type I) 
[ATP-dependent Clp protease, proteolytic subunit ClpP] 
hypothetical protein, similar to negative regulator of genetic competence MecA 
[regulatory protein] 
succinate dehydrogenase iron-sui fur protein subunit (MW2) 
hypothetical protein, similar to EpiF (Genomic island nuSap2) 
[putative lantibiotic ABC transporter protein] 
Ser-Asp rich fibrinogen-binding bone sialoprotein-binding protein 
hypothetical protein 
[putative exported protein] 
hypothetical protein, similar to transcription regulator MarR family 
log2 ratios TF (Agr+ 5vONl 
-1.90 11021.07 I 
-1.94 1362.07 
-2.11 3764.07 
-2.16 7282.07 
-2.27 4984.07 
-2.31 13315.07 
-2.38 5578.07 
-3.54 13834.07 
-3.91 18485.07 
-4.99 10119.07 
-5.10 3131.07 
Table S.10 Genes negatively regulated by agr according to the data generated from this study. 
Gene ID 
MW0723 :lgt 
SA1649 
MWI501 
MW0573 
SAVI057:fmt 
SA0675 
SA 1320 
SA1748 
MW0213 
SA1329 
MW2403 
MW1872 
MW0736:tpi 
MW1874 
SA2272 
SA1666 
SAV2133:hmrA 
SA0702:lIm 
SA2418 
MW0623 :vraF 
MW1536:lepA 
N 
V't 
N 
Product description 
pro lipoprotein diacylglyceryl transferase 
conserved hypothetical protein 
family S54 unassigned peptidases (SAV1549 protein aka MW1501) 
[peptidase, rhomboid family] 
hypothetical protein simi lar to iron-binding protein 
[iron compound ABC transporter, permease protein/ lipoprotein] 
family S 12 unassigned peptidases (Fmt protein) 
[autolysis and methicillin-resistant-related protein (fmt)] 
hypothetical protein, similar to ABC transporter A TP-binding protein 
hypothetical lipoprotein 
hypothetical protein, similar to transcription regulator, GntR family 
hypothetical protein, similar to nickel ABC transporter nickel-binding protein 
[putative extracellular solute-binding lipoprotein] 
ferric uptake regulator (fur) homolog [transcriptional regulator, Fur family] 
hypothetical protein, similar to oxidoreductase 
hypothetical protein, similar to ABC transporter, A TP-binding protein 
triosephosphate isomerase 
hypothetical protein, similar to ABC transporter, A TP-binding protein 
hypothetical protein 
two-component response regulator homo log 
[DNA-binding response regulator, LuxR family] 
subfamily M20D non-peptidase homologues (HmrA protein) 
[puative peptidase/ similar to amidase (HmrA)] 
lipophilic protein affecting bacterial lysis rate and methicillin resistance level 
[lipophilic regulator protein] 
hypothetical protein, similar to two-component response regulator 
ABC transporter A TP-binding protein 
GTP-binding protein 
log2 ratios 
(Agr+ TF 
SvON) 
1.93 7240.07 
1.98 1399.07 
2.01 7340.07 
2.12 1432.07 
2.14 1026.07 
2.14 1769.07 
2.17 1513.07 
2.20 3372.07 
2.25 1083.57 
2.26 946.07 
2.33 2493 .07 
2.34 2643 .07 
2.36 10517.07 
2.42 1835.07 
2.47 1087.57 
2.49 908.07 
2.50 2002.07 
2.51 1209.07 
2.53 998.07 
2.54 1268.07 
2.62 1782.07 
MW0558 
MW1547:aroE 
SA0298 
SA V0432:hsdS 
MW2103 
MWOO77 
SA0726:gapR 
MW2013 
MW2328 
SA2421 
MW1828:map 
SA1676 
gi178172212 (agr) 
MW1971:vga 
MW2409 
SAV1113 
SA1956 
SA1139:glgP 
SA1949 
MWI064:pbpA 
MW1942 
MW0682 
MW2259 
SA V0965:spsB 
MW2368 
SA0704 
agrCl 
MW0263 
MW0698 
N 
VI 
VJ 
conserved hypothetical protein [putative membrane protein] 
shikimate dehydrogenease 
hypothetical protein, similar to regulatory protein PfoR (perfringolysin 0 regulator protein 
(pfoR» 
probable restriction modification system specificity subunit c 
hypothetical protein similar to ferrichrome ABC transporter (binding protein) 
hypothetical protein, similar to transcription regulator AraClXylS family 
glycolytic operon regulator [transcriptional regulator] 
lipoprotein precursor [membrane protein oxaA precursor (oxaA)] 
hypothetical protein similar to Zn-binding lipoprotein adcA 
[ABC transporter, substrate-binding protein! probable zinc-binding lipoprotein] 
hypothetical protein, similar to transcriptional regulator 
methionyl aminopeptidase map 
hypothetical protein, similar to regulatory protein (pfoSIR) 
agr type 1 subset specific 1 12 16 17 20 25 
hypothetical ABC transporter ATP-binding protein 
conserved hypothetical protein [putative helicase] 
conserved hypothetical protein [cell division protein, FtsW/RodAlSpoVE family] 
lytic regulatory protein truncated with Tn554 
glycerol uptake operon antiterminator regulatory protein 
lytic regulatory protein truncated with Tn554 (truncated-SA) 
[membrane-embedded lytic regulatory protein] 
penicillin-binding protein I 
hypothetical protein similar to leukocidin chain lukM precursor 
[probable leukocidin S subunitl Aerolysin!Leukocidin family protein] 
hypothetical protein, similar to ABC transporter A TP-binding protein 
conserved hypothetical protein 
[YnfA family protein! putative membrane protein] 
signal peptidase SpsB (SpsB protein) 
hypothetical protein, similar to integral membrane efflux protein [putative drug transporter] 
conserved hypothetical protein [degV family protein] 
group I accessory gene regulator, agr operon (af21 0055) 
conserved hypothetical protein, similar to diarrheal toxin incomplete ORF 
lipoI>rotein, similar to ferrichrome ABC transporter ralso transferrin receptorl 
2.64 971.07 
2.64 2591.07 
2.68 2027.07 
2 .77 1410.07 
2.81 2407.07 
2.87 1173.07 
2.90 13755.07 
2.90 3469.07 
2.99 991.57 
3.03 4273.07 
3.09 3748.07 
3.15 987.07 
3.16 11804.07 
3.20 1040.07 
3.22 997.07 
3.23 1195.57 
3.25 2334.07 
3.29 2236.07 
3.31 4731.07 
3.35 2831.07 
3.39 1059.57 
3.46 959.07 
3.48 1683.07 
3.50 1994.07 
3.60 1406.07 
3.61 1734.07 
3.71 11071.07 
3.71 1270.07 
3.71 3349.07 
MW0085:sarH I 
MW0552 
MW0574 
MW0323 
MW2l02 
SA2144 
MW1280 
MW0595 
MW2273 
MW18l1 
MW1364 
MW0593 
SAV1879:ampS 
SA025 I :lytR 
MW0594 
N 
VI 
~ 
staphylococcal accessory regulator A homologue 
major tail protein [putative membrane protein NOT major tail protein] 
hypothetical protein similar to iron(III) ABC transporter permease protein 
conserved hypothetical protein [putative Sec-independent protein translocase protein] 
hypothetical protein similar to ferrichrome ABC transporter (permease) 
hypothetical protein, similar to transcriptional regulator (TetR/ AcrR family) 
ABC transporter (ATP-binding protein) homo log 
hypothetical protein, similar to ABC transporter ATP-binding protein 
hypothetical protein, similar to multidrug resistance protein 
[drug resistance transporter, EmrB/QacA subfami ly, putative] 
hypothetical protein, similar to teichoic acid translocation ATP-binding protein tagH 
[ABC transporter] 
hypothetical protein, similar to GTP binding protein 
[putative GTPasel GTP-binding protein EngA (engA)] 
lipoprotein, Streptococcal adhesin PsaA homologue 
aminopeptidase S (aminopeptidase ampS) 
two-component response regulator [sensory transduction protein LytR] 
_conserved ~ypothetical protein r ABC transporter permease protein] 
4.00 1939.07 
4.00 1679.57 
4.05 1072.07 
4.09 922.07 
4.15 998.07 
4.29 2767.07 
4.30 ] 840.07 
4.45 4460.07 
4.48 1203.07 
4.70 966.07 
4.78 5116.07 
4.81 2783 .07 
5.40 4423 .07 
5.87 2869.07 
6.15 2305.07 
Although these results demonstrate the anticipated involvement of the agr operon in gene 
regulation, the mechanism involving RNAIII-related quorum sensing (usually triggered 
during cellular growth) was not particularly evident in the test strains. The observed 
changes in expression were apparently unrelated to the intracellular concentration of 
RNAIII since this transcript (although present in a relatively high levels) was not noted in 
any of the up- or down-regulated gene lists (see above). Nevertheless, RNAIII involvement 
cannot be ruled out. 
This apparent non-response of RNAIII to quorum sensing may be an adapted feature of 
this common laboratory strain. NCTC 8325-4 has been used in laboratory research for 
many years, and presumably has accumulated genetic changes during repeated sub-culture. 
Some of these changes should confer an advantage status to this strain in this environment 
(e.g. adaptations that favour in vitro growth). One such example may be the constant 
expression of RNAIII such that factors involved in cellular proliferation and attachment 
(controlled via RNAIII) are continuously expressed instead of following traditional trends 
of expression. If this was the case, it would seem that the re-introduction of rsbU into 
strain NCTC 8325 (SHlOOO) has not corrected this lack of RNAlII-mediated quorum 
sensing. Sabersheikh and Saunders (2004) in studies of the virulence-associated gene 
transcripts of S. aureus also noted lack of a clear pattern of RNAIII transcription. 
Fluctuations in RNAIII levels were observed, and thought to be correlated with irregular 
growth patterns. This same irregular growth was also observed for strains SHIOOO and 
SHIOOI in this study (section 3.1.2.1.2). Sabersheikh and Saunders (2004) proposed that 
the mechanism by which RNAIII is induced is more complex than originally anticipated 
and that variations in this mechanism exist between different S. aureus clonotypes. It is 
therefore possible that contiguous expression of RNAIII is a feature of this genetic 
background. Another possibility is that a technical limitation prevented accurate 
quantification of RNAIII i.e. the high RNAIII levels may have been beyond the limit of 
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quantification of the array so that any changes in gene expression were not detected. 
However, pixel saturation was not observed for RNAIII, while this did occur for the rRNA 
probes suggesting that the results were reliable. 
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5.2 Biofilm study 
5.2.1 Background 
Staphylococcus aureus and S. epidermidis present a significant clinical problem in device-
related infections (O'Gara and Humphreys, 2001). S. aureus infections associated with 
implanted microbial devices or foreign bodies, as well as endocarditis and osteomylitis are 
associated with biofilm formation. Biofilms can be defined as a "community of 
microorganisms often adhered to a surface and encased in an extracellular polysaccharide 
matrix or glycocalyx" (Kumamoto and Vinces 2005, O'Toole et al .• 2000). Given that 
hospital inpatients may have foreign devices in situ (e.g. catheters and artificial heart 
valves), colonization and infection with staphylococci (often multi-resistant) can be 
problematic. The challenge associated with these microbial communities is their 
inefficient response to control with standard antibiotics (Ceri et al., 1999) and their 
resistance to targeted host defence mechanisms (Donlan et al. 2002, Leid et al. 2002). 
Recently, it has been shown that these microbial communities often include subpopulations 
harbouring a diverse set of phenotypes (termed 'variants'). The characteristics of these 
subpopulations may have overall beneficial effects on the biofilm community (Yarwood et 
al.2007, Boles et al. 2004). Associated with this finding is the key hypothesis that the 
presence of a diverse population within a biofilm will enable the overall community to 
survive a much broader range of conditions than would a less complex community 
displaying fewer phenotypes (Boles et al. 2004). 
Biofilm formation is a multi stage process dependent on several factors including the type 
of bacterial species present, the surface composition (Le. the material to which attachment 
occurs), environmental stimuli and the expression of genes essential to the process 
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(Carpentier and Cerf 1993, Dunne 2002). The primary stage involves microbial adhesion 
to a surface, which has been recognised to occur via specific molecular mechanisms. Upon 
insertion of a foreign medical device into a patient, the material quickly become coated 
with a conditioning film of primarily host-derived extracellular matrix proteins. It is these 
proteins that may act as receptors for microbial attachment. Staphylococcal attachment to 
extracellular matrix proteins is facilitated by microbial surface components recognising 
adhesive matrix molecules (MSRAMMs) (Foster and Hook, 1998). Following attachment, 
cellular communication occurs resulting in biofilm formation (O'Gara, 2007). Bacteria 
attached to a surface aggregate to form colonies and become encapsulated in an exo-
polysaccharide matrix, termed a gylcocalyx (Costerton et al., 1999). 
Cell-to-cell communication (quorum sensing), a critical component ofbiofilm formation, is 
the process by which cells communicate with their neighbours (lones, 2005). Cellular 
communication within a biofilm community is essential for the coordinated behaviour in 
response to environmental stimuli or stress. A key quorum sensing mechanism in S. 
aureus is mediated by the accessory gene regulator. The Agr system is a key regulator in 
S. aureus pathogenesis, and exerts control over several genes important for biofilm 
development such as surface-associated adhesins e.g. fibronectin binding protein. With 
increasing cell density, agr represses the expression of surface-associated adhesins (that 
mediate cell attachment) and increases the expression of secreted proteins that mediate 
detachment (e.g. delta toxin, a molecule with surfactant-like properties) and tissue-
degrading enzymes (e.g. proteases and haemolysins) to favour bacterial spread. It has been 
observed that agr mutants form more robust biofilms (in vivo and in vitro) compared with 
their wild type counterparts (Vuong et al. 2000, Vuong et al. 2004, and Yarwood et al. 
2004). 
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The ica operon-encoded enzymes are the best understood factors implicated in biofilm 
formation in staphylococci (Mack et al. 1996, Maria-Litran et al. 2002). The mechanism 
involves production of an extracellular polysaccharide adhesin known as polysaccharide 
intracellular adhesin (PIA) or polymeric N-acetyl-glucosamine (pNAG). Control of PIA 
production is mediated by the genes of the icaADBC operon (Heilmann et al. 1996, 
Yazdani et al. 2006). Although strain variation has been documented (Cramton et al. 
1999, Rohde et al. 2001, Beenken et al. 2004), the majority of S. aureus strains contain the 
ica operon (Cramton et al. 1999, Fowler et al. 2001, Rohde et al. 2001). The product of 
icaA is a transmembrane protein with homology to N-acetyl-glucosaminyltransferase. 
Transcription of icaA is controlled by the IcaD protein (Gerke et al. 1998). The icaAD 
produced N-acetyl-glucosamine oligomers (polysaccharide chain) reach a maximal length 
of 20 residues and are only elongated further when icaAD is co-expressed with icaC, a 
putative transmembrane protein (Gerke et al. 1998). It is likely that translocation of the 
growing polysaccharide to the cell surface involves the icaC gene product. Finally, a 
surface attached protein (lcaB) mediates deacetylation of the poly-N-acetyl-glucosamine 
molecule (Vuong et al. 2004) permitting bacterial attachment to the cell surface and 
thereby promoting biofilm development (Vuong et al. 2004, O'Gara et al. 2007). 
Regulation of ica expression and biofilm formation involves multiple regulatory elements 
including agr and sarA (Beenken et al., 2004). In particular SarA mutants have a greatly 
reduced ability to form biofilms (Beenken et al., 2004). 
In the past, research into microbial growth primarily focused on the study of monotypic 
'free growing' or planktonic organisms in liquid media. However, more recently these 
studies have moved towards the analysis of microbial growth in biofilms, that is, multi-
layer cellular communities (Percival and Bowler 2004, Wilson 2001). Such research has 
highlighted the marked differences between cellular behaviour, structure and physiology in 
the two states. 
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5.2.2. Study results 
Biofilm development is thought to be controlled VIa gene expreSSlOn that differs 
significantly between biofilm-associated and planktonic organisms (Be loin and Ghigo, 
2005). In this study, S. aureus cells grown in a continuous culture biofilm were analysed 
in parallel with the same strain grown in suspension. The planktonic cells were isolated in 
the early exponential and stationary phases for comparative analysis. As described in the 
methods (section 2.2.1.2), biofilm growth was supported over a seven day period in the 
CDFF instrument, whilst the planktonic cells were grown continuously for 21 hours, with 
sampling at 5 hours and 21 hours. The data represent RNA transcripts isolated at the time 
of sampling. The biofilms were grown over a period of 7 days, however, it was not 
allowed to expand due to the continuous removal of material protruding above the plane of 
the device and the nutrient medium was maintained. Analysis of the data shows genes 
expressed differentially between the two states. A high cut-off threshold was set such that 
only genes with expression levels above this threshold were analysed. Although this leads 
to the elimination of weak positive results a high threshold was necessary to ensure that the 
results were robust. 
In the analysis of virulence-associated genes, the biofilm state represents a model of 
infection in which attached, densely-packed cells, communicate for collective survival 
against host factors. It is a simplistic model for biofilm growth, reflecting biofilm-
associated genes involved in the colonisation process and cell-to-cell communication. The 
dense packing of cells also means neighbouring cells are affected by each others exo-
enzymes. However, in this particular model, the biofilm layer was maintained at a 
constant thickness. Nutrient availability was maintained through continuous supply, more 
closely reflecting the situation in vivo than batch culture. 
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Planktonic free-living cells are less likely to be affected by the by-products of 
neighbouring cells, at least during the early phase of culture. During early growth, 
planktonic cells grow rapidly due to high nutrient availability. However, during latter 
stages, cell growth rates stall presumably due to restricted nutrient levels i.e. they are in a 
state of relative starvation. Thus, the expression of genes in this state will presumably 
reflect those involved in bacterial survival strategies. The following results describe the 
differential gene expression observed between the different growth models, at different 
time points. 
S.2.2.1 Biofilm (BF) versus planktonic exponential (PE) growth 
BF grown cells were compared to planktonic cells extracted during exponential growth and 
genes expressed in greater amounts in the BF cells (Table 5.11) were identified. A group of 
genes belonging to the gamma haemolysin operon (h/gABC) were highly expressed (h/gA 
is written as hlg/l in the table). These genes are known to function as two component 
cytolytic (pore-forming) toxins in the disruption and lysis of erythrocytes and leukocytes. 
In particular, the killing of leukocytes is a potentially important immune-evasion 
mechanism of the bacteria, which results in the weakening of the immune system of the 
host, and enables the bacteria to gain access to nutrients stored in leukocyte cells 
(Menestrina et a/ 2003). Two further toxins (beta haemolysin and exotoxin 6) were also 
highly expressed. Since these cells were grown over 7 days, the expression of such toxins 
would be expected. The fact that some of the toxins were related (hlg operon) provides 
confidence in the data observed. Furthermore, two further related genes, splA and splB 
(proteases) were also detected with greater expression in the BF cells. As noted previously, 
exo-enzymes are important for biofilm detachment following accumulation and growth. 
261 
Another group of genes, belonging to a single operon, expressed at higher levels in the BF 
phase were bsaGEF (MWI758-60). These encode a set of hypothetical proteins (carried on 
genomic island nuSaap) that are similar to the EpiFEG proteins of the gallidermin 
superfamily, specifically epidermin in this case. Uniprot and KEGG descriptions of the 
bsa genes describes their function as involved in ABC type transport systems. Epidermin 
is a lantibiotic (lanthionine containing antibiotic), that is, a bacteriocin (ribosomally 
synthesized peptide antibiotic) containing lanthionine (or other modified amino acid) 
following post translational modification (Saris et al. 1996. Nissen-Mayer and Nes 1997). 
The EpiFEG transport system is involved in protecting lantibiotic producing bacteria 
against fatality associated with its own product. Although no known lantibiotic was 
detected in this data set. the presence of the bsa genes suggests this is a lantibiotic 
producing strain. 
Type 1 agr transcripts including RNAIII were detected in both data sets but at higher 
levels in the BF cells. RNAIII is thought to be involved in the regulation of the 
haemolysin toxin genes as well as the proteases (Ounman et al .• 2001). Another pair of 
related genes highly expressed in the BF cells were arcC (carbamate kinase) and SA2424 
(hypothetical protein similar to arcR transcriptional regulator according to Uniprot). The 
arcR regulator is known to positively regulate the expression of the arcABDC operon for 
arginine catabolism under aerobic conditions. Expression of arcC with a possible 
regulator indicates actively metabolic cells. Finally, of the classical surface-associated 
proteins involved in attachment, clfA was significantly more highly expressed in the BF 
cells. 
262 
Table 5.11 Biofilm-associated genes (BF v PE). 
The log ratios indicate down regulation between BF and PE cells; that is, expression was higher in BF cells. 
Gene ID 
SA0857 
gi178172212 (agr) 
SAV2451 
MW1798 
MW1959 :RNAIJI 
MW1881:hlb 
SA2119 
MW 1 759:bsaE 
SA2424 
MW1754:splB 
MW1758:bsaG 
MW2343:h1gC 
SA V0422:set6 
MW2553:arc 
MW0764:c1fA 
MW1760:bsaF 
MW2344:hlgB 
MW0396 
SAV1813:splA 
MW2342:hlgIl 
N 
0'1 
W 
Product description log2 ratios (BFvPE) 
hypothetical protein, similar to negative regulator of genetic competence MecA 1.94 
agr type 1 subset specific 1 12 16 172025 1.96 
subfamily S9C non-peptidase homologues 2.49 
glutamate ABC transporter ATP-binding protein 2.49 
from agr (hid) 3.47 
beta haemolysin 3.81 
hypothetical protein, similar to dehydrogenase 3.81 
hypothetical protein, similar to EpiE (Genomic island nuSap2) 4.27 [putative lantibiotic ABC transporter protein] 
hypothetical protein, similar to transcription regulator Crp/Fnr family protein 4.60 
serine protease 4.66 
hypothetical protein, similar to EpiG (Genomic island nuSap2) 4.97 [putative lantibiotic ABC transporter protein] 
gamma-haemolysin component C 5.39 
exotoxin 6 5.48 
carbamate kinase 5.49 
fibrinogen-binding protein 5.53 
hypothetical protein, similar to EpiF (Genomic island nuSa~2) 5.69 [putative lantibiotic ABC transporter protein] 
gamma-haemolysin component B 6.16 
hypothetical protein 6.24 
subfamily SIB unassigned peptidases (exoprotein A) 6.40 
gamma haemolysin chain Il 7.84 
TF 
4258.09 
8503.09 
4003.09 
990.09 
3541.09 
3648.59 
1249.09 
910.09 
2501.59 
1070.59 
1119.09 
1476.09 
2308.09 
9679.09 
6708.09 
1469.09 
4178.59 
4793 .59 
1043.09 
2900.09 
Traditionally, biofilm-grown cells are known to have a heterogeneous phenotype. Anwar 
and colleagues (1992) found that the physiology of cells within a biofilm was determined 
by the position of individual cells within the multi-layered community. In particular, cells 
on the surface of the biofilm were larger in size and more metabolically active compared to 
the base layer cells, probably due to the easier access to oxygen and nutrients. Under these 
experimental conditions, cells grown in the CDFF instrument had constant access to 
oxygen and nutrients. This is dissimilar to a classic biofilm model in that cells were not 
allowed to accumulate. It seems these cells display a distinct phenotype different from 
rapidly growing planktonic cells and from relatively starved planktonic cells. 
The list of genes with higher expression in the PE phase (Table 5.12) included many more 
hypothetical genes. In particular, several genes with regulatory (or putative regulatory) 
functions were detected (putative functions had been assigned to most by sequence 
homology). As before, the expression of co-ordinately regulated genes was detected. 
Firstly, sigma factor B (sigB) and SigB regulatory protein (rsbU) displayed similar 
expression levels. Sigma factor B is a known regulator of several virulence factors, which 
generally, exerts indirect regulation. Other related genes detected include bone 
sialoprotein binding proteins sdrD and bbp (a putative sdrE homolog), both adhesion 
proteins. Others genes in the same category (adhesins) were fibronectin binding protein 
(fnbp), spaA (IgG binding protein A) and sbi (Ig binding protein). 
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Table 5.12 PE associated genes (BF v PE) 
Gene ID 
SA0641 
MW1280 
SA V0526:radA 
MW1988:sigB 
MW0681 
bbp 
MW2341:sbi 
MW0736:tpi 
SAVI044 
MW1991:rsbU 
MW0339 
SA0704 
MW0079 
MW2013 
SA2421 
MW0283 
MW2421:fnb 
MW2217 
SA1949 
MW0342:ssb 
MW0517:sdrD 
MW0595 
MW0084:spa 
SA0726:gapR 
MW2336 
SAV0433:set15 
--- --- -
N 
0'1 
v. 
Product description 
conserved hypothetical protein, similar to transcriptional regulator 
ABC transporter (A TP-binding protein) homolog 
family S 16 non-peptidase homologues 
sigma factor B 
hypothetical protein, similar to anion-binding protein 
sdrE homo log (bone sialoprotein binding protein) 024 
IgG binding protein 
triosephosphate isomerase 
family S33 unassigned peptidases 
sigmaB regulation protein RsbU 
hypothetical protein, similar to GTP-binding protein 
conserved hypothetical protein 
hypothetical protein similar to transmembrane eftlux pump protein 
lipoprotein precursor 
hypothetical protein, similar to transcriptional regulator 
hypothetical protein, similar to branched-chain amino acid uptake carrier 
fibronectin-binding protein homolog (for fnbA) 
secretory antigen precursor SsaA homo log 
lytic regulatory protein truncated with Tn554 (truncated-SA) 
single-strand DNA-binding protein of phage phi Sa 2mw 
Ser-Asp rich fibrinogen-binding bone sialoprotein-binding protein 
hypothetical protein, similar to ABC transporter ATP-binding protein 
IgG binding protein A 
glycolytic operon regulator 
hypothetical protein, similar to ABC transporter, periplasmic amino acid-binding 
protein 
exotoxin 15 
IOgl ratios TF 
, 
(BvPE) i 
-1.96 11159.09 
-2.09 1009.09 
-2.18 1094.09 
-2.24 1515.09 
-2.25 2367.09 
-2.26 1755.09 
-2.48 2010.09 
-2.49 2722.09 
-2.52 1501.59 
-2.57 951.09 
-2.82 4257.59 
-3.05 1726.09 
I 
-3.10 1152.59 
-3.13 6182.09 
-3.29 955.09 
-3.44 1186.09 
-3.46 1679.09 
-3.55 1255.59 
-3.85 1678.09 
-3.89 23821.09 
-4.25 1071.09 
-4.31 2083.09 
-4.68 13121.09 
-5.09 8642.09 
-6.19 7108.09 
-6.87 5847.09 
5.2.2.2 BF versus Planktonic Stationary (PS) growth 
The RNA preparations from cells cultured overnight were dominated by structural RNA 
and contained relatively little mRNA. This result is unsurprising since PS cells are less 
metabolically active than other cells examined in this study. When BF and PS transcripts 
were compared (Table 5.13) the list of genes expressed at higher levels in the BF cells was 
similar to that described in the BF versus PE comparison (Table 5.11). In particular the hlg 
operon genes, hlb. exotoxin 6 and SA0857 were still highly expressed in BF cells. Other 
genes not listed in Table 5.11 were also detected due to lower levels of transcripts being 
present in the PS cells. Firstly, two important regulators saeR and lexA, showed high 
expression levels. LexA is an SOS regulatory protein, whilst saeR is the regulator of the 
Sae locus which is known to be essential for hlb transcription (Giraudo et al., 1997) 
detected here. Furthermore, fisH (SA V0511), a cell division protein, was also detected. 
Others included elastin binding protein (MW1369) and a hypothetical protein associated 
with fibrinogen binding protein function (MW1041). The latter are surface-associated 
proteins (MSCRAMMs) that are expected to be expressed during active growth. The BF 
expression of fisH is further evidence of the presence of actively growing cells. These data 
suggest the cells grown within the CDFF model have an actively growing phenotype. 
The gene list for PE cells (Table 5.14) only contained two genes, a hypothetical protein 
with no associated function and a gene found in type IV SCCmec. The detection of only 
two genes expressed at levels higher than those found in the BF cells is an indication of the 
low mRNA content of the PS cells. 
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Table 5.13 Biofilm-associated genes (BF v PS) 
Gene ID Product description 
MW0986 conserved hypothetical protein 
MW1760:bsaF hypothetical protein, similar to EpiF (Genomic island nuSap2) [putative lantibiotic ABC transporter protein] 
SA0641 conserved hypothetical protein, similar to transcriptional regulator 
SAl 174:LexA SOS regulatory LexA protein 
MW1758:bsaG hypothetical protein, similar to EpiG (Genomic island nuSap2) [putative lantibiotic ABC transporter protein] 
MW1369:epbS elastin binding protein 
SA066l :saeR response regulator 
SA V0511 :ftsH FtsH-2 peptidase 
SA0857 hypothetical protein, similar to negative regulator of genetic competence MecA 
MW1041 hypothetical protein, similar to fibrinogen-binding protein 
MW1834 hypothetical protein, similar to ferritin 
MW2343:hlgC gamma-haemolysin component C 
MW2342:hlgII gamma haemolysin chain IT 
SA V0422:set6 exotoxin 6 
MW1881:hlb beta haemolysin 
MW2344:hlgB gamma-haemolysin component B 
MW0396 hypothetical protei(l 
Table 5.14 PS associated genes (BF v PS) 
Gene ID 
TypelVb-F 
MW1744 
N 
0\ 
-..) 
Product description 
SCCmec IVb 
hypothetical protein 
log2 ratios 
(BvPS) TF 
-2 .62 1653.70 
-2.88 1162.20 I 
log2 ratios TF (BvPS) 
2.09 3199.70 
2.15 1054.70 
2.21 1162.70 
2.57 2197.70 
2.58 1017.20 
3.11 1645.70 
3.23 1164.20 
3.32 1837.70 
3.78 3310.70 
4.01 1044.70 
4.39 1700.70 
4.43 1348.70 
4.54 2164.20 
4.80 1912.70 
4.87 2392.70 
5.07 2593.70 
5.83 2929.20 
5.2.2.3 PE versus PS growth 
PE and PS cells were compared in order to explore growth phase dependent differences in 
this strain. The results are summarised in Table 5.15 (higher expression in PS cells) and 
Table 5.16 (higher expression in PE cells). A few interesting trends were observed from 
which some conclusions may be drawn. Of the PS associated genes described in Table 
5.15, 3 of the genes (marked with *) were also expressed at higher levels in the biofilm-
associated cells described in Table 5.11. Furthermore, of the genes expressed at higher 
levels in the PE cells {Table 5.16),4 were also seen in the BF cells (Table 5.13). These 
results indicate that BF cells grown on the CDFF instrument display a typical phenotype 
with differences from both the actively growing cells (PE) and the stationary (PS) cells. 
The CDFF therefore appears to be a helpful model system for investigating natural 
biofilms. Furthermore, this model is amenable to exploitation in studies designed to 
improve our understanding of the mechanisms underlining biofilm survival and regulation 
after long periods of growth. 
Table S.IS PS associated genes (PE v PS) 
Gene ID Product description lo~ ratios TF (PEvPS) 
SAV2451 subfamily S9C non-peptidase homologues -1.96 1822.85 
MW1744 hypothetical protein -2.21 1236.85 
MW0764:c1fA * fibrinogen-binding protein -3.88 1188.85 
MW2553:arcC • carbamate kinase -5.29 3889.85 
E16-0463 - Bactrltoxin 
-5.76 J682.35 SAR0424 
SA2424 * hypothetical protein, similar to transcription 
-11.24 1335.10 
regulator CrplFnr famiJyQrotein 
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Table 5.16 PE genes (pE v PS) 
Gene ID 
MW0543:pta 
MW0085:sarHl 
MW0681 
MW1942 
MW0518:sdrE 
MW1834 
SAVI044 
MWI092:gmk 
MW2341:sbi 
SAV0520 
MW0339 
SAV0743:pepT 
MW0595 
MW0736:tpi 
SA0641 
MW2013 
SA0661 :saeR 
SA0726:gapR 
MW2336 
MW0342:ssb 
MW0084:spa 
SA V05 11 :ftsH 
SA1949 
N 
0\ 
\0 
Product description 
phosphotransacetylase 
staphylococcal accessory regulator A homologue 
hypothetical protein, similar to anion-binding protein 
hypothetical protein similar to leukocidin chain lukM precursor 
Ser-Asp rich fibrinogen-binding bone sialoprotein-binding protein 
hypothetical protein, similar to ferritin 
family S33 unassigned peptidases 
guanylate kinase 
IgG binding protein 
family C56 non-peptidase homologues 
hypothetical protein, similar to GTP-binding protein 
peptidase T 
hypothetical protein, similar to ABC transporter A TP-binding protein 
triosephosphate isomerase 
conserved hypothetical protein, similar to transcriptional regulator 
lipoprotein precursor 
response regulator 
glycolytic operon regulator 
hypothetical protein, similar to ABC transporter, periplasmic amino acid-binding 
protein 
single-strand DNA-binding protein of phage phi Sa 2mw 
JgG binding protein A 
FtsH-2 peptidase 
lytic regulatory protein tT\1ncllted with Tn554 (truncated-SA) 
log} ratios TF (PEvPS) , 
1.99 1200.85 
2.07 910.85 
2.12 1720.85 
2.24 1001.85 
2.32 2128.35 
2.38 981.35 
2.42 917.35 
2.70 1682.85 
3.03 1158.85 
3.04 980.85 
3.04 3652.85 
3.11 985.35 
I 
3.48 940.35 
3.62 1564.85 
3.63 7489.85 
3.67 3001.85 
4.10 1327.85 
4.27 6134.85 
4.45 5965.85 
4.52 19214.85 
4.59 7604.85 
4.64 4535.85 
5.06 1026.85 
5.2.3 Biofilm summary 
From the point of view of exploring differences in the virulence-associated genes of 
biofilm versus planktonic cells, the following observations were noted. Both Table 5.11 
and Table 5.13 list genes expressed at higher levels in BF. Nine genes appear in both 
tables (the raw data are summarised in Table 5.17) and six (all toxins) were highly 
expressed in both comparisons including BF cells. The remaining three genes were not 
consistently highly expressed between the BF RNA preparations. Based on these data high 
level expression of the haemolysin genes was the strongest feature of the biofilm state. 
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Table 5.17 Biofilm-spec:ific gene list 
Gene ID 
MW0396 
MW2344:hlgB 
MW1881:hlb 
MW2342:hlglI 
SA V0422:set6 
MW2343:hlgC 
MW1760:bsaF 
MW1758:bsaG 
SAOS57 
N 
-....I 
-
-
Product Description 
hypothetical protein 
gamma-haemolysin component B 
beta haemolysin 
gamma haemolysin chain 11 
exotoxin 6 
gamma-haemolysin component C 
hypothetical protein, similar to EpiF (Genomic island nuSa~2) 
hypothetical protein, similar to EpiG (Genomic island nuSa~2) 
hypothetical protein, similar to negative regulator of genetic 
_ somp_etence MecA 
- -
IOgl BvPE 
6.24 
6.16 
3.81 
7.84 
5.48 
5.39 
5.69 
4.97 
1.94 
TF IOgl BvPS TF IOgl PEvPS TF 
4793.59 5.83 2929.20 0.00 1.00 
4178.59 5.07 2593.70 0.00 1.00 
3648.59 4.87 2392.70 -1.29 0.41 
2900.09 4.54 2164.20 0.00 1.00 
2308.09 4.80 1912.70 0.00 1.00 
1476.09 4.43 1348.70 0.00 1.00 
1469.09 2.15 1054.70 -3.18 0.11 
1119.09 2.58 1017.20 -0.79 0.58 
4258.09 3.78 3310.70 1.94 3.S3 
CHAPTER 6.0 CONCLUSION 
Staphylococcus aureus is the most clinically significant member of the Staphylococcus 
genus. Its ability to be associated with asymptomatic carriage as well as cause a wide 
range of infections, from superficial to more life-threatening, has prompted much research 
into its genotypic and phenotypic characteristics. Furthermore, interest in its ability to 
maintain a colonist nature in addition to 'switching' to a virulent phenotype in 
epidemiologic ally diverse niches has partly driven the sequencing of >20 genomes of 
various genetic backgrounds representative of the most successful lineages. These 
initiatives have provided data for comparative studies (Le. sequence comparisons, PCR 
analysis and microarray investigation) that have helped researchers to understand further 
the ever-changing evolutionary landscape of this organism and in particular the potential 
virulence- and fitness-factors that may contribute to its success. In this context, microarray 
analysis provides a rapid method by which bacterial genomes can be interrogated. 
This thesis details the development and use of a partial composite S. aureus microarray for 
the interrogation of S. aureus isolates for putative virulence-associated genes. Protocols 
were subsequently developed for comparative genome hybridisation (COli) and 
transcription profiling studies. The microarray was used to investigate a panel of 
internationally recognised pandemic and sporadic lineages of healthcare-associated (lIA-) 
and community-associated (CA-) S. aureus strains to provide insights into variation within 
and between lineages. The micro array provides a comprehensive tool by which these 
lineages can be either clustered or differentiated based on genetic markers. This work 
supports a clonal population structure for this organism, as described previously (Enright, 
2000). The data presented show congruence with MLST as a method for defining lineages, 
with the advantage of providing information on the virulence-gene content of each test 
isolate. Yet, while MLST focuses on a set of core conserved genes, this work 
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demonstrated similar outcomes based on either core or accessory genes, indicating that 
accessory genome components are partially conserved within and between lineages. 
Profiles specific to each of the main clonal groups could be easily identified and so the 
microarray could fonn the basis of a more infonnative approach for epidemiological typing 
of clinical isolates in future. 
The array was used to explore genotypic differences that may account for variations in 
epidemiology and pathogenicity of recognised successful, epidemic, or pandemic strains. 
In particular, epidemic MRSA (EMRSA; defined as "those which have been identified in 
two or more patients in two or more hospitals"; O'Neill et al., 2001) were interrogated for 
features that may provide insights into traits important in the success, transmission and/or 
pathogenicity of these lineages. The NCTC collection of UK epidemic MRSA strains, 
EMRSA-I to EMRSA-17 (excluding EMRSA-6), were analysed using the array. Features 
unique to a particular group of strains could be detected and selected from the array. 
However, analysis of the array data did not implicate any specific virulence-associated 
gene with the epidemicity potential of these strains. Based on the array data, the success 
of any particular clone appears to result from the complex interplay between factors. With 
respect to the important UK epidemic MRSA strains, EMRSA-IS/-16, success of these 
clones might be attributed to the acquisition of extra accessory genes, and in particular the 
~Sa2mw genes (section 4.1.2.3). Alternatively, it is possible that non-virulence factors 
(not represented on the array) may contribute to the epidemicity of these strains. 
The microarray data were also used to probe for recombination events that may have 
occurred during the evolution of successful S. aureus lineages. Genetic exchange is central 
to the evolution of any organism. The hypothesis was that large-scale recombination events 
may have had an impact on the way epidemic strains survive in hospital environments and 
colonise the human nasopharynx. Such events may only be detected if they are relatively 
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recent in evolutionary terms since they are obscured by subsequent mutations and 
exchanges. A particular large-scale recombination appears to have been involved in the 
origin of the EMRSA-15 lineage (ST22-SCCmecIV), the most prevalent epidemic HA-
MRSA in the UK. This work supports the hypothesis that CC22, which includes the 
EMRSA-15 lineage, evolved via a large scale recombination between CC8-like and CC30-
like strains. 
Notably, the array data also show that the ST772 strain (a member of CC 1 by MLST) is an 
interesting example of clonal diversification. Distance trees built by simple matching of the 
individual probe reactions revealed that the ST772 strain clustered with an ST59 strain 
(USAlOOO) and not with other members of CC 1. This result, which was supported by other 
laboratory data, emphasises the importance of using multiple genetic loci for genotypic 
characterisation and highlights the limitation of MLST in focussing purely on a limited 
number of conserved genetic loci. ST772 is proposed to be an intermediary strain in the 
evolution of the CC59 lineage from a common STl ancestor (section 4.2.4). 
A further objective of this work was to explore patterns of genotypic variation that might 
account for differences in epidemiology and pathogenicity of the HA and CA S. aureus 
strains. A set of marker genes (16 consecutive genes of the bacteriophage ~Sa3 locus) 
associated with phage structural units linked with the CA phenotype were identified. 
These genes were identified in 10 of the 16 CA strains, but only in 1 of the HA strains. A 
recent study by Goerke and colleagues (2009) showed that S. aureus bacteriophage 
morphology genes correlate with phage serogroup type (A, B, Fa or Fb). By extrapolation 
of these data, the morphology related genes of the <I>Sa3 locus identified in this study 
represent phage serogroup type Fb. Similarly, the ~N315 morphology genes on the array 
represent the Fa serotype, whilst the ~Sa2mw genes (also present on the array) represent 
the A type. The only morphotype not identified by the array was the B serotype. 
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However, in silico analysis of the sequenced strains showed that the B serotype was 
exclusive to the HA-strains. The absence of B serotype phage in CA strains was also 
confirmed with the recently sequenced CA strains from this study (ST772, WA-MRSA, 
ST866, USAIOOO and the Queensland clone ST93). 
Goerke and colleagues (2009) also showed that the A serogroup phage comprised of two 
divisions, those that carried the pvl genes (PVL phage) and those that did not 
Additionally, PVL phage were also of the Fb serotype. These PVL associated AIFb phage 
were seen only in the CA strains, whilst the non PVL-associated A group phage were seen 
in only two of the sequenced HA strains (and the two CA MSSA strains). However. the 
non PVL-associated Fb phage were not present in any of the HA strains. That is to say, 
since the genes recognised by the array predominantly indicate the presence of an AlFb 
serogroup phage in the CA strains (or possibly a mosaic phage within these divisions. 
which would be possible via exchange of modules according to the theory of modular 
evolution), it is believed that the carriage of PVL-associated phage (but not pvl itself, since 
it is absent from some of the CA strains), is necessary for the CA phenotype. It is possible 
that a mosaic phage that combines the fitness factors of the pvl-carrying AI Fb phage and 
the saki chp/ scn carrying Fb phage could produce a virulent phenotype in those strains 
carrying phage of this morphotype. Presently, these genes represent a partial marker for 
the CA phenotype. This finding further supports the role of the accessory genome, and in 
particular bacteriophage, in the epidemiology of S. aureus. 
The virulence-associated gene microarray was also used to investigate gene expression in 
transcription profiling studies. As an analytic technique, transcriptomic analysis provides 
more detailed information about bacterial response to its microenvironment In the first 
transcription study, the virulence gene expression profiles of cells of an agr mutant strain 
(SHlOOl) and its unmodified parental strain (SHlOOO) were compared to determine the 
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effect of this mutation on virulence gene regulation. SHIOOO was derived from the 
commonly used genetic lineage S. aureus 8325-4 (RN6390) and a functional rsbU gene 
(8325-4 rsbcF) inserted. RsbU, the positive regulator of Sigma factor B, is often non-
functional in strain 8325-4 due to a mutation (8325-4 rsbU). 
The agr locus of S. aureus encodes a regulatory RNA molecule (RNAIII) known to 
influence the transcription of many virulence-associated genes. The consensus model is 
that genes encoding surface-associated proteins are generally expressed in the early 
exponential phase during cell proliferation (e.g. fibronectin binding protein A), whilst 
secreted proteins (e.g. a-haemolysin) are repressed. Conversely. in the stationary phase the 
opposite regulation effect has been reported. Strains were analysed for changes in 
expression levels between the early exponential- (5hr), late exponential- (7.5hr) and 
stationary- (overnight) phases. Cells were grown under the same conditions. on the same 
day, and extractions prepared in the same batch. Although the results demonstrate the 
anticipated involvement of the Agr operon in gene regulation, the mechanism involving 
RNAIII-related quorum sensing (usually triggered during cellular growth) was not evident. 
The observed changes in expression were apparently unrelated to the intracellular 
concentration of RNAIII since this transcript (although present at relatively high levels) 
was not induced or repressed. Nevertheless, RNAIII involvement could not be ruled out. It 
may be that the non-response of RNAIII to cell density may be an adapted feature of this 
common laboratory strain. For example, constant expression of RNAIII could be a feature 
that favours in vitro growth, conferring an advantage status to this strain in this 
environment such that factors involved in cellular proliferation and attachment (controlled 
via RNAIII) are continuously expressed instead of following traditional trends of 
expression. If this was the case, it would seem that the re-introduction of rsbU to strain 
NCTC 8325-4 (SHI000) was insufficient to re-establish normal environmental responses. 
Sabersheikh and Saunders (2004) in studies of the virulence-associated gene transcripts of 
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s. aureus also noted lack of a clear pattern of RNAIII transcription. Fluctuations in 
RNAIII levels were observed, and thought to be correlated with irregular growth patterns 
(also observed in this study). Sabersheikh and Saunders proposed that the mechanism by 
which RNAIII is induced is more complex than originally anticipated and that variations in 
this mechanism exist between different S. aureus clonotypes. It is therefore possible that 
continuous expression of RNA III is a feature of this genetic background, and consequently 
rendering it an unsuitable model for investigating agr-mediated virulence gene regulation. 
Finally, cells grown under biofilm simulating conditions (in the CDFF instrument) were 
used in comparative transcription studies against their planktonic counterparts to determine 
putative biofilm-associated virulence genes and also to determine the suitability of this 
model for further studies. Biofilm formation is a feature of S. aureus infections associated 
with implanted medical devices, especially within the hospital inpatient community. These 
challenging microbial communities are resistant to host defence mechanisms and respond 
inefficiently to standard antibiotics (Ceri et al. 1999, Donlan et al. 2002. Leid et al. 2002). 
Biofilm development is thought to be controlled via gene expression that differs 
significantly between biofilm-associated and planktonic organisms (De loin and Ghigo. 
2005). In this study, S. aureus cells grown in a continuous culture biofilm were analysed 
in parallel with the same strain grown in suspension. Biofilm growth was supported over a 
seven day period in the CDFF instrumen4 whilst the planktonic cells were grown 
continuously for 21 hours, with sampling at 5 hours (early exponential phase) and 21 hours 
(stationary phase). 
The description and analysis of the differential gene expression observed between the 
different growth models, revealed the predominant feature of the biofilm state to be high 
level expression of the haemolysin genes. These genes are known to function as pore-
fOnning toxins involved in the disruption and lysis of erythrocytes and leukocytes. an 
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important immune-evasion mechanism which results in the weakening of the immune 
system of the host, and enables the bacteria to gain access to nutrients stored in leukocyte 
cells (Menestrina et al., 2003). The CDFF instrument appeared to be a helpful model 
system for investigating natural biofilms. Biofilm cells displayed a typical phenotype 
different from both the actively growing planktonic exponential cells and the planktonic 
stationary cells. This model therefore is amenable to exploitation in studies designed to 
improve our understanding of the mechanisms underlining biofilm survival and regulation 
after long periods of growth. 
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CHAPTER 7.0 FUTURE WORK 
Microarrays offer great potential; the infonnation obtained from such experiments far 
exceeds that of any mUltiplex PCR. As a data mining tool, strain! species-specific features 
can be more easily detennined, reducing hands-on time. Informative array design and 
interpretation is highly dependent on genome sequencing and annotation data. S. aureus 
represents one of the most sequenced organisms, with >20 sequenced genomes (including 
several unpublished genomes described in this thesis). 
• The primary objective in any future work will involve updating the array features to 
include genes from more recently sequenced genomes. 
• Additionally, designing customised arrays in a multi array fonnat would provide a 
rapid method for screening for differential markers. 
This project revealed the potential of phage serogroup typing to distinguish HA and CA S. 
aureus strains. Within the current array design. only three (A. Fa and Fb) of the four 
known serogroups could be identified. The remaining B serogroup could only be sought 
via in silico analysis. The results showed that PVL-associated phage of the A and Fb 
serogroups are strongly associated with CA status. whilst the B serogroup was seen only in 
HA strains. 
• Future work would entail designing further oligos for all known phage serotypes. 
Bacteriophage that integrate at the Sa2 and SaJ loci in particular have been found 
in most of the sequenced strains to date, indicating their potential involvement in S. 
aureus success. 
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• The investigation of this same phenomenon with respect to pathogenicity islands 
(PI) or genomic islands (GI) is warranted. The majority of virulence-associated 
factors and antimicrobial resistance determinants are components of the accessory 
genome, and have been mapped to bacteriophage, PI and 01. The ability to detect 
and characterise these mobile genetic elements in strains that have not been 
sequenced (and in particular in clinical isolates), will greatly enhance our 
understanding of the virulence potential of each strain. 
The approach of characterising the carriage of groups of mobile genetic elements may 
provide insights into recombination events between the various groups. By designing 
probes unique to each Fb serogroup phage (and also other serogroups), recombination 
events may be described with greater certainty. 
The results described in this thesis indicate a novel phage taxon could be associated with 
CA status. If so, identifying phage types associated with CA status should lead to the more 
precise identification of genetic elements associated with CA infections. Thus, by 
pinpointing these genetic elements, control measures and even therapeutics to more 
effectively combat these infections may be developed. 
The array was successfully used to study RNA transcripts to monitor changes in gene 
expression. Analysis of the commonly used SHlOOOISHlOOI strains in agr studies 
revealed them to be an interesting model. RNAIII-related quorum sensing, a key feature of 
virulence-regulation, was not evident. Insertion of a functional rsbU gene (8325-4 rsbcr) 
into the commonly used genetic lineage S. aureus 8325-4 (RN6390) did not lead to 
reconstruction of the expected functionality of the Agr operon. 
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• Future work would entail obtaining additional model strains for the study of agr-
mediated virulence regulation. 
Finally, the array was used to study cells grown under biofilm simulating conditions in the 
CDFF instrument. The biofilm grown cells displayed a characteristic phenotype different 
from planktonic cells. This model may be exploited further in studies designed to improve 
our understanding of the mechanisms underlining biofilm survival and regulation after 
long periods of growth. 
• Future studies may seek to monitor the expression profiles of biofilm cells grown 
on simulated tissues. For example. growing the cells on a layer simulating the 
human basal lamina should increase our understanding of biofilm attachment 
processes. 
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CHAPTER 9.0 APPENDIX 
Appendix I: Chromosomal map of sequenced S. aureus strains 
(Taken from Diep et al., 2006) 
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Appendix 11: Abbreviations 
aa 
ACME 
AFLP 
agr 
aha 
AlP 
Arl 
CA-MRSA 
CA-MSSA 
CC 
CcpA 
CDFF 
cDNA 
CFU 
CGH 
CHIPS 
CMV 
CNS 
Cy 
DLV 
E. coli 
EE 
egc 
EMRSA 
GPhi 
HA-MRSA 
HA-MSSA 
hla 
HPA 
IVT 
LE 
LHCAI 
Luk 
MAD 
MLEE 
MLST 
MRCNS 
mRNA 
MRSA 
MRSE 
MSCRAMMS 
MSSA 
NCTC 
NEB 
OD 
ON 
PBP2a 
PCR 
PE 
PFGE 
amino-allyl 
argenine catabolic mobile element 
amplified fragment length polymorphism 
accessory genome regulator 
amino hexylacrylamide 
autoinducing peptide 
autolysis related locus 
community-associated methicillin-resistant 
Staphylococcus aureus 
community-associated methicillin-sensitive 
Staphylococcus aureus 
clonal complex 
catabolite control protein a 
constant depth film fermentor 
complementary DNA 
colony forming unit 
comparative genome hybridisation 
chemotaxis inhibitory protein of staphylococci 
Cytomegalovirus 
coagulase negative staphylococci 
Cyanine 
double locus variant 
Escherichia coli 
early exponential 
enterotoxin gene cluster 
epidemic methicillin-resistant Staphylococcus aureus 
Genomiphi 
healthcare-associated methicillin-resistant 
Staphylococcus aureus 
healthcare-associated methicillin-sensitive 
Staphylococcus aureus 
haemolysin aJ alpha haemolysin 
health protection agency 
In vitro transcription 
late exponential 
Laboratory of Healthcare Associated Infections 
Leukocidin 
median absolute deviation 
multilocus enzyme electrophoresis 
multilocus sequence typing 
methicillin-resistant coagulase negative Staphylococci 
messenger RNA 
methicillin-resistant Staphylococcus aureus 
methicillin-resistant Staphylococcus aureus 
microbial surface components recognising adhesive 
matrix molecules 
methicillin-sensitive Staphylococcus aureus 
National Collection of Type Cultures 
New England Biolabs 
optical density 
overnight 
penicillin binding protein 2a 
Polymerase Chain Reaction 
planktonic exponential 
pulsed-field gel electrophoresis 
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PS 
PSM 
PTFE 
PVL 
RAP 
RIP 
rot 
rRNA 
RT-PCR 
S. aureus 
Sae 
SaPln1 
Sar 
SCC 
SLST 
SLY 
SNPs 
spaA 
ST 
TRAP 
VISA 
VNTR 
VRSA 
WGA 
Cl>Sa2 
Cl>Sa3 
planktonic stationary 
phenol soluble modulins 
polytetrafluoroethylene 
Panton Valentine Leukocidin 
RNAIII-activating protein 
RNAIII inhibitory protein 
repressor of toxins 
ribosomal RNA 
reverse transcriptase PCR 
Staphylococcus aureus 
Staphylococcal accessory element 
Staphylococcus aureus pathogenicity island 1 
staphylococcal accessory regulator 
staphylococcal chromosome cassette 
single locus sequence typing 
single locus variant 
single nucleotide polymorph isms 
staphylococcal protein a 
sequence type 
target of RNAlll-activating protein 
vancomycin intermediate-resistant Staphylococcus 
aureus 
variable number tandem repeat 
vancomycin resistant Staphylococcus aureus 
whole genome amplification 
Staphylococcus aureus bacteriophage phi 2 
Staphylococcus aureus bacteriophage phi 3 
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Appendix 1111: Planned publications 
Mohamed D, Saberesheikh S, Kearns A and Saunders N. 
Comparison of healthcare-associated and community-associated Staphylococcus aureus 
using a truncated composite microarray. 
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Putative link between bacteriophage serotype and Staphylococcus aureus community-
associated phenotype. 
Mohamed D, Saberesheikh S, Kearns A and Saunders N. 
Global regulation of virulence gene expression in a Staphylococcus aureus agr mutant. 
Appendix IV: Supplementary data (see CD) 
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